- Meeting abstracts
- Open Access
XXXV Brazilian Congress of Rheumatology (SBR 2018)
© The Author(s) 2018
- Published: 21 August 2018
Alexandre Moura dos Santos, Rafael Giovane Misse, Jean Marcos de Souza, Diego Sales de Oliveira, Fernanda Rodrigues Lima, Ana Lúcia de Sá Pinto, Samuel Katsuyuki Shinjo
FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: Systemic autoimmune myopathies (SAM) are a heterogeneous group of diseases that cause chronic muscle inflammation and progressive muscle weakness. Reduced aerobic capacity has been documented in several autoimmune rheumatic diseases. However, few studies have assessed in SAM. Thus, the aim of the present study was to analyze aerobic capacity in SAM.
Materials and methods: This is a cross-sectional study, from 2017 to 2018, that compared 23 female patients with SAM (2017 EULAR/ACR classification criteria: 13 dermatomyositis, 4 polymyositis and also 6 antisynthetase syndrome) with 17 aged, gender and body mass index-matched healthy individuals. Aerobic capacity was evaluated by means of the treadmill maximum (Centurion 200, Micromed, Brazil) cardiorespiratory test, demonstrated through VO2max (mL/kg.min). Disease status was evaluated by International Myositis Assessment and Clinical Studies Group (IMACS) core set measures.
Results: Mean age of the patients was 47.9 years, with mean disease duration of 7.6 years. Patients had low disease activity according of IMACS parameters, using different immunosuppressive drugs and with daily prednisone < 10mg. Median aerobic capacity was lower in patients with SAM, when compared to control group (18.0 vs. 28.5 mL/kg.min, P=0.011, respectively). In additional analysis, the reduced aerobic capacity was independent of type of SAM, disease duration, IMACS parameters and treatment.
Conclusions: Aerobic capacity was significantly reduced in SAM when compared to control group. These findings corroborate with literature data that aerobic capacity is reduced in several systemic autoimmune diseases. Recognition of this information is important in daily practice, as it may reflect in the difficulty of performing daily tasks, increasing level of sedentary lifestyle, besides being a prognosis of cardiovascular diseases.
Support by: FAPESP #2016/23574-0 (RGM), #2016/19771-5 (DSO), #2017/13109-1 (SKS)
Luana Oliveira de Lima, Carlos Alexandre Martins Zicarelli, Andressa Saori Matsumura, Karen Barros Parron Fernandes, Layse Rafaela Moroti, Regina Célia Poli-Frederico
UNIVERSIDADE NORTE DO PARANÁ, LONDRINA, PR, Brasil
Background: Fibromyalgia syndrome (FS) is characterized by chronic generalized musculoskeletal pain also associated with symptoms such as fatigue, sleep disorders and psychological. Regarding its physiopathology, studies have been associating the syndrome with a genetic predisposition related to the serotoninergic, dopaminergic and catecholaminergic systems. The catechol-O-metiltransferase (COMT) enzyme acts inactivating the catecholamines and mutations in the gene encoding this protein have been related to the symptoms of fibromyalgia. The single nucleotide polymorphism (SNP) in this gene most studied is rs4680 G / A, and individuals carrying the allele A have a greater sensitivity to pain. However, other studies did not verify such association, evidencing that this investigation is necessary for a better understanding. The aim of this study was to analyze the relationship between polymorphism of the COMT G/A rs4680 gene in women with and without fibromyalgia.
Materials and methods: Participants in this cross-sectional study were 60 women over 18 years of age, 29 of the fibromyalgia group and 31 of the control group. Demographics and peripheral blood samples were collected for DNA extraction. Genotypic analyzes were performed using the PCR-SSP method followed by 1% agarose gel electrophoresis. Chi-square tests and the Kendall Tau-ḇ correlation test were used for a possible association and correlation between the variables, establishing a 95% confidence interval and significance level of p <0.05.
Results and conclusions: A greater proportion of the study participants had GG genotype (58%) and only 8.3% of the women had the AA genotype. There was a statistically significant association between genotypes and FS. Participants who were carriers of the AA or allele A genotype had FS (p=0.01). In the present study, patients with AA and allele A were 4.07 times more risk to develop FS than those who did not carry this genotype/allele (95% CI 1.37-12.14, p=0.02/95% 1.65-10.27, p=0.03). There was an association between race and FS, demonstrating that the white race was 2.05 times more likely to develop the syndrome (95% CI 0.93-4.53, p=0.03). There was a proportional correlation between age and fibromyalgia patients (rS=0.812; p=0.001). Therefore, the present study found that white women of greater age and carriers of the AA/A genotype/allele are at greater risk of developing FS.
Matheus Vieira Gonçalves1, Gustavo Guimarães Moreira Balbi2, Camila Souto Oliveira1, Ana Beatriz Santos Bacchiega1, Manuella Lima Gomes Ochtrop1
1DEPARTMENT OF RHEUMATOLOGY, HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO, UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, BRAZIL, NITERÓI, RJ, Brasil; 2DEPARTMENT OF RHEUMATOLOGY, HOSPITAL UNIVERSITÁRIO, UNIVERSIDADE FEDERAL DE JUIZ DE FORA, JUIZ DE FORA, MINAS GERAIS, BRAZIL, JUIZ DE FORA, MINAS GERAIS, Brasil
Introduction: Takayasu’s Arteritis (TA) is a large-vessel vasculitis, evolving primarily aorta and its major branches, with an insidious and frequently silent progression. Clinical and laboratorial assessment may be normal during flares, and even imaging modalities are not as sensible as needed to precisely document activity and though guide an accurate management. Routine angiographic evaluations are performed to detect vascular lesions and its accrual over time, with variable interval between imaging assessments. The aim of this study is to investigate vascular damage during follow-up and possible factors associated with its progression.
Materials and Methods: We included 30 consecutive outpatients that fulfilled the 1990 ACR classification criteria for TA and underwent at least two angiography examination over time, such as Doppler, computed tomography angiography or magnetic resonance angiography. Comparisons were made between the same imaging methods. Clinical, laboratorial and imaging data were collected from electronic medical records, since the first imaging modality registered. NIH criteria (Kerr et al., 1994, excluding new vascular damage) for active disease was calculated. Statistical analysis was performed by SPSS 22.0.
Results: Thirty patients were analyzed, with 28 females (93%), mean age at diagnosis 33.9+14.6 years, 63.3% with angiographic type V at diagnosis and mean follow-up period of 87.6+59.5 months. A total of 37 flares were computed, resulting in angiographic progression in 60% of patients. Two patients changed their angiographic type over time to type V. Right subclavian artery involvement was significantly higher among those who progressed (OR 7.54 95% CI 1.05-54.03; p=0.049). Considering activity clinical features, excluding new vascular lesions from the NIH criteria, at least two of these features were present in 79% of patients who progressed vs. 46% of those who remained stable, with an OR 4.43 (95% CI 1.02-19.27; p=0.041).
Conclusion: The presence of 2 or 3 points in the NIH criteria with 3 variables correlated with progression of vascular damage; also, right subclavian artery involvement was more common in vascular progressors.
O04 ANKRD1 EXPRESSION AS MARKER OF SKELETAL MUSCLE REMODELING IN NAIVE TREATMENT POLYMYOSITIS MUSCLE BIOPSIES
Marilda Guimarães Silva1, Sueli Mieko Oba-Shinjo2, Suely Kazue Nagahashi Marie2, Samuel Katsuyuki Shinjo2
1FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SP, Brasil; 2FACULDADE DE MEDICINA DA USP, SAO PAULO, SÃO PAULO, Brasil
Background: ANKRD1 codes for ankyrin repeat domain containing protein 1. It has an important role in myogenesis and myofibrillar assembly and has been considered as a marker of skeletal muscle pathological remodeling. To date, however, no study has assessed the ANKRD1 expression in adult polymyositis muscle biopsies or has correlated with histological changes in situ.
Materils and Methods: RNA was extracted from frozen muscle biopsies samples of 13 patients with untreatment defined polymyositis (Bohan and Peter, 1975; EULAR/ACR 2017 criteria). As a control group, 20 adult muscle biopsies from adult patients with non-inflammatory myopathy diseases and no histological change were included. ANKRD1 transcript expression levels were determined by quantitative real time PCR. A visual analogue scale was included to score global degree of muscle inflammatory and general abnormalities from 0 (no inflammation or no abnormality) to 10 (most inflammation or most abnormal). ANKRD1 protein localization was analyzed by immunofluorescence technique.
Results: Average age of patients was 45.7, with 69.2% of female gender. Median duration between diagnosis and symptom onset was 5.0 months, and all patients had objective, symmetric, predominantly proximal muscle weakness. Initial serum levels of creatine phosphokinase and aldolase were 3065 and 68.0 U/L, respectively. Higher ANKRD1 relative expression levels were observed in polymyositis muscle relative to control group (P<0.001). Additionally, ANKRD1 expression levels correlated with serum level of creatine phosphokinase and aldolase (rho=0.879, P<0.001 and rho=0.681, P=0.030, respectively). ANKRD1 relative expression levels did not correlate with any clinical parameters or histological analysis (muscle inflammatory and general abnormalities). However, in immunofluorescence analysis, ANKRD1 was mainly observed in regenerating fibers.
Conclusions: The present data reinforce that ANKRD1 may be involved in skeletal muscle remodeling, including in muscle biopsies of naïve treatment patients with PM.
O05 ANTI-INFLAMMATORY EFFECT OF RECOMBINANT CYSTATINS FROM FASCIOLA HEPATICA IN ANTIGEN-INDUCED ARTHRITIS MICE MODEL
Thales Hein da Rosa1, Mirian Farinon1, Renata Ternus Pedó1, Martín Cancela1, Henrique Bunselmeyer Ferreira1, Ricardo Machado Xavier2
1UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, RS, Brasil; 2HOSPITAL DE CLÍNICAS DE PORTO ALEGRE, PORTO ALEGRE, RS, Brasil
Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of joints causing pain, edema, bone and cartilage degradation and frequently leading to joint destruction and disability. Fasciola hepatica is a trematode that parasites, in adult form, the bile ducts of different kinds of mammals. In addition, this worm is able to modulate the host immune response to a T helper (Th) 2 profile to survive. A Th2 response can suppress the pro-inflammatory Th1 response generated in several immunopathology, as RA. One of the mechanisms involved in this immune regulation is the secretion of cysteine proteases-inhibitors such as cystatins. In this study, we evaluated the role of recombinant cystatin 1 and 3 from Fasciola hepatica in leukocyte migration and nociception in antigen-inducedarthritis (AIA) mice model.
Material and methods: Forty-two male BALB/C mice were subjected to AIA by subcutaneous injection of an emulsion containing methylated bovine serum albumin (mBSA) and Freund’s complete adjuvant at day 0. After, at days 7 and 14, mice received mBSA and Freund’s incomplete adjuvant. At day 21, animals were challenged by an intraarticular (ia) joint injection of mBSA. Mice were randomized in five groups: vehicle (PBS), cystatin 1 (100μg/dose and 150μg/dose) and cystatin 3 (100μg/dose and 150μg/dose). Treatment was performed by intraperitoneal injections at 24h and 30 min before ia injection of mBSA. Nociception was analyzed at 0, 3h, 6h, and 24h after ia injection and leukocytes migration was analyzed 24h after ia injection. Data are expressed as mean ± SEM. Two-way ANOVA was performed for nociception and one-way ANOVA for leukocytes migration analyzes, both followed by Bonferroni’s post-test.
Results: Treatment with both cystatins were noteffective in reduce nociception. However, cystatin 1 (100μg/dose) was able to reduce leukocytes migration in 60% (51.17 ± 2.94 x 104 leukocytes/cavity) (p<0.05) and cystatin 3 (100μg/dose) in 63% (48.06 ± 10.04x 104 leukocytes/cavity) (p<0.01) compared with vehicle (129.7 ± 31.87x 104 leukocytes/cavity).
Conclusion: Although it was not able to reduce joint nociception, treatment with cystatin 1 and 3 improved acute experimental arthritis by attenuating leukocyte migration to knee joint. Based on this, cystatins 1 and 3 from Fasciola hepatica demonstrated a potential anti-inflammatory activity and this potential will be further investigated through a chronic mice model of collagen-induced arthritis.
O06 ANTI-MI-2 AUTOANTIBODY IN A LARGE SAMPLE OF ADULT PATIENTS WITH DERMATOMYOSITIS: A RETROSPECTIVE COHORT STUDY
Maria Isabel Cardoso dos Passos Carvalho2, Samuel Katsuyuki Shinjo1
1FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SÃO PAULO, SP, Brasil; 2FACULDADE DE MEDICINA, UNIVERSIDADE DE SÃO PAULO,, SÃO PAULO, SP, Brasil
Background. Anti-Mi-2 autoantibody is described in 2-45% of patients with dermatomyositis. This enormous prevalence range is due, in part, to scarcely available studies in the literature, as well as analyses based on a relatively small and/or heterogeneous sample of patients. In addition, most studies were limited to cross-sectional analysis. Therefore, in the present study, the prevalence, reactivity and impact of anti-Mi-2 was assessed in a large and homogeneous sample of patients with dermatomyositis.
Materials and methods. This is a longitudinal inception cohort study that initially included 177 consecutive adult patients with definite dermatomyositis (Bohan and Peter, 1975; 2017 EULAR/ACR classification criteria) from 2001 to 2017. Strict exclusion criteria were applied to achieve a homogeneous sample: overlap syndrome, neoplasia (previous or concomitant to dermatomyositis onset), pulmonary infections, chronic obstructive pulmonary disease, history of chronic smoking, clinically amyopathic dermatomyositis, patients with positivity to antisynthetase, anti-MDA-5, anti-PM/Scl or anti-Ku autoantibodies. Moreover, patients without collected serum/plasma were also excluded. Anti-Mi-2 analysis was performed using a commercial kit according to the manufacturer’s protocol.
Results. After the exclusion criteria, 87 dermatomyositis cases were evaluated: 17 (19.5%) anti-Mi-2(+) vs. 70 (80.5%) anti-Mi-2(-). Mean age at the disease diagnosis onset was 42.4 years, with a predominance of female and white ethnicity. Median follow-up time was 4.3 years. Constitutional symptoms were present in 59.8% of cases, whereas cutaneous lesions in 100%, involvement of gastrointestinal tract (high dysphagia) in 49.4%, joint in 35.6% and pulmonary in 33.3%. During follow-up, disease relapsing was observed in 19.5% of cases, whilst 13.8% of patients died and 4.6% presented neoplasia (post-dermatomyositis diagnosis). At the end of the present study, 31% patients were still receiving glucocorticoid therapy. Moreover, 33.3% had disease remission, 56.3% had complete clinical response and 10.3% had activity disease. In an additional analysis, all these parameters were compared among the patients with anti-Mi-2(+) vs. anti-Mi-2(-). There was no difference between the groups, except for the following parameters in patients with anti-Mi-2(+), all with P<0.05: (a) elevated serum levels of muscle enzymes and lower frequency of pulmonary involvement at disease onset, (b) higher frequency of disease remission during the following up.
Conclusions. Anti-Mi-2 autoantibody was found in 19.5% of patients with dermatomyositis. This autoantibody was associated with lower occurrence of pulmonary involvement, higher frequency of disease in remission, and elevated levels of muscle enzymes. There was also no correlation regarding the frequency of disease relapsing or neoplasia development.
Support by FAPESP #2011/12700-1 (SKS)
Beatriz Ricato Quental, Feranando Augusto Peres, Lilian Tereza Lavras Costallat, Simone Appenzeller
UNICAMP, SP, SP, Brasil
Background:Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that can affect any organ or system. The SLE is triggered by an immunological imbalance associated with inflammation. Several autoantibodies have been described in SLE, including anti-ribossomal P (anti-P) antibody. However, in previous studies disagreement in relation to the association of the presence of anti-P and clinical manifestations was observed, moreover these studies demonstrate a percentage variation in positives patients for this antibody. Despite this fact, others works detected that ethnicity can influence the percentage of positive Anti-P patients. Therefore, the present study aims to correlate some clinic and laboratory manifestations of SLE with the Anti-P, besides analyzing the frequency of this antibody in the patients.
Methods: For this purpose, a group of 143 patients and 166 controls were selected for this research. These groups passed by clinic and neuropsychiatry evaluation, magnetic resonance image and the blood was collected in order to dose the Anti-P, following ELISA method.
Results and discussion: We observed anti-P in 12 (8.39%) patients and in none of the control (p<0.001). The presence of anti-P antibody was associated with higher disease activity (p=0.007), the presence of depressive symptoms (p=0.018) and the presence of anxiety symptoms (p=0.047). No association of anti-P and other clinical, immunological and imaging feature was observed. In conclusion, anti-P is specific for SLE and associated with disease activity and mood disorders.
Maria Carolina Padovani Guerra, Rosa Weiss Telles, Maria Isabel Mendes Guedes, Maria Veloso Rocha Mameluque, Tiago Loredo e Silva, Cristina Costa Duarte Lanna, Fabiana de Miranda Moura dos Santos
UNIVERSIDADE FEDERAL DE MINAS GERAIS, BELO HORIZONTE, MINAS GERAIS, Brasil
Background: Systemic lupus erythematosus (SLE) is an autoimmune and systemic disease with high morbidity and mortality, in which infection is one of the main cause of death in Brazil. Factors associated with the disease and its treatment are related to the higher incidence of infection in this population. Vaccination, in this context, appears to be an important strategy to prevent infection. The aim of this study is to evaluate the knowledge about vaccination in lupus patients.
Material and methods: A cross-sectional study was performed and outpatients followed at the Lupus Clinic were included. The instrument used was a questionnaire developed by medical students on the knowledge about vaccines. The SPSS program was used to perform descriptive statistical analysis.
Results and Conclusions: One hundred and eight patients were included, 104 (96.3%) women. The mean (DP) of age and of the disease duration were 43.6 (13.7) and 12.6 (8.3) years, respectively. Concerning the treatment, 75 (70%) patients used immunosuppressant, 75 (77%) antimalarials, 71 (67%) prednisone and 3 (3%) immunobiologicals. Sixty-nine (63%) of them reported the vaccines were updated. Thirty five (32.7%) out of 108 patients declared they have received orientation towards vaccination from their doctors, 30 (28%) patients knew about special immunizations service of Reference Center for Special Immunobiologicals (Centro de Referência de Imunobiológicos Especiais- CRIE), 23 (21.5%) knew about their right to receive free vaccines by government and 104 (97.2%) accepted to receive the vaccines after the physician assistant recommendation. Our findings suggest that most patients did not receive orientation from his/her assistant physician to update their vaccination card before. The majority of them stated that they would get the vaccines if they have known about indication and rights. In addition, although being a tertiary center, only 28% had known about CRIE. Therefore, provide vaccination orientation during the attendance is a desired attitude of the health team in order to provide integral care.
O09 ARTERIAL EVENTS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS): DON’T FORGET THE TRADITIONAL CARDIOVASCULAR RISK FACTORS
Gustavo Guimarães Moreira Balbi1,2, Flávio Signorelli3, Roger Abramino Levy3
1HOSPITAL UNIVERSITÁRIO DA UNIVERSIDADE FEDERAL DE JUIZ DE FORA, JUIZ DE FORA, MG, Brasil; 2UNIVERSIDADE FEDERAL DE JUIZ DE FORA, JUIZ DE FORA, MG, Brasil; 3UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil
Background: Arterial events are a major concern when treating patients with isolated or primary (pAPS), and traditional cardiovascular risk factors may have an important role in increasing their occurrence. The aim of this study was to detect which of these factors were associated with increased risk of arterial events in our cohort of pAPS patients.
Methods: A cross-sectional study was performed in 114 outpatients who fulfilled thrombotic pAPS classification criteria (Sydney). Clinical and serologic features were compiled during visits and by chart review. Statistical analysis was performed using chi-square, Mann-Whitney U and Spearman’s R tests, when applicable. Multivariate regression analysis included age, sex, ethnicity, and variables with p<0.10 in the bivariate analysis.
Results: Fifty-three (46.5%) patients had arterial events, 43 (81.1%) were female, and 35 (66%) Caucasian. The mean number of episodes of arterial thromboses was 1.72±1.12 per patient. In a bivariate analysis, arterial events correlated with the presence of livedo (p=0.029), dyslipidemia (p=0.007), smoking (p=0.006), and positive anti-ß2-glycoprotein I (aß2GPI) (p=0.027). There was a tendency of higher rates of arterial thromboses in patients with hypertension (p=0.052). Curiously, obese patients were less prone to develop arterial events in our cohort (p=0.039). aGAPSS was higher in patients with arterial thromboses than in those with venous thromboses (median 9 (7-13) vs. 8 (5-12); p=0.010). In a multivariate analysis, dyslipidemia (OR 4.07; 95%CI 1,45-11,4; p=0.008), smoking (OR 2.97; 95%CI 1.08-8.102; p=0.034), and positivity to aß2GPI (OR 2,52; 95%CI 1,03-6,17) remained as risk factors forarterial events. Obesity was protective in our study (OR 0.25; 95%CI 0.085-0.72; p=0.01). Regarding recurrence, 21 patients (40.3% of arterial event patients) had more than one event. Both positive and persistently positive lupus anticoagulant (LA) correlated with thrombotic recurrence (p=0.03 and p=0.039, respectively). There was a trend of higher rates of recurrence in patients with hypertension (p=0.061) and dyslipidemia (p=0.061), however not reproduced in the multivariate analysis. No difference in aGAPSS was found between recurrent and not recurrent groups.
Conclusion: Traditional cardiovascular risk factors increase the risk of arterial events in pAPS patients and, therefore, their proper control should not be neglected. Patients with higher aGAPSS are prone to develop arterial events. The positivity and persistency of LA are associated with arterial thrombotic recurrence.
Sueli Coelho da Silva Carneiro1, Flavia de Freire Cassia2, Luis Cristóvão Porto3
1UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2HOSPITAL FEDERAL DA LAGOA, RIO DE JANEIRO, RJ, Brasil; 3UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil
Introduction: The association of HLA with psoriasis vulgaris and psoriatic arthritis is widely described in the literature. Reports on populations of diverse ethnical origins show different HLA markers in patients with psoriasis when compared to controls.
Objectives: To type HLA classes I (A, B e C) and II (DRB1 e DQB1) of Brazilian patients with psoriatic arthritis, from HUCFF outpatient unit, and compare them to controls pared in respect to ethnical origin, gender and age.
Materials and Methods: Twenty patients with clinical and/or histopathological diagnosis of psoriasis vulgaris and psoriatic arthritis, with at least 5 years of disease duration, were included in the study. They answered a questionnaire on ethnic background, family history, duration of disease, history of erythroderma, hospital internment and treatment. They were clinically evaluated in respect to distribution and morphology of skin lesions, joint involvement and disease activity and were submitted to laboratorial tests. One-hundred thirty four bone marrow donors served as controls after informed consent. Allelic typing of class I and II HLA genes were determined by PCR-SSP and PCR-SSO hybridization. Differences between the two groups were evaluated through chi-square or Fisher exact tests.
Results: The patients mean age was 47,25 years-old. There were 9 females and 11 males. HLA-B*57 and HLA-Cw*18 were significantly present in patients with arthritis (p=0,00104, OR=6,6769 e p=0,00269, OR=16,50, respectively).
Conclusions: HLA-B*57 and HLA-Cw*18 were significantly high in patients with psoriatic arthritis. HLA-C*18:01is a rare allele in the European caucasian population and was associated with difficult-to-treat plaque psoriasis, but not with psoriatic arthritis yet.
O11 ASSOCIATION OF TNF-Α SYSTEM, ADIPOKINES AND ENDOTHELIAL ACTIVATION BIOMARKERS WITH TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE IN FEMALE PATIENTS WITH SLE – PRELIMINARY ANALYSIS
Rosa Weiss Telles1,3, Ana Julia Furbino Dias Bicalho2, Diogo Couto Carvalho2, Ihan Bruno Lopes Rabelo2, Fernanda Oliveira Gomes2, Luísa Lima Castro2, Fabiana de Miranda Moura Santos3, Antonio Lucio Teixeira3, Cristina Costa Duarte Lanna3, Antonio Luiz Ribeiro3
1FACULDADE DE MEDICINA DA UFMG, BELO HORIZONTE, MG, Brasil; 2HOSPITAL DAS CLÍNICAS - UFMG, BELO HORIZONTE, MG, Brasil; 3FACULDADE DE MEDICINA - UFMG, BELO HORIZONTE, MG, Brasil
Background: Atherosclerosis is an inflammatory process with immune cell activation and inflammation-driven plaque formation. Abnormalities in the function and release of cytokines, adipokynes and endothelial activators biomarkers have been identified in patients with SLE. Furthermore, traditional cardiovascular risk factors (RF) are common in SLE patients and the link between inflammation and RF in lupus has been poorly investigated.
Materials and Methods: A cross-sectional study involving 134 women with SLE (ACR 82/97) was developed. TNF-α and their soluble receptors (sTNFR1 and sTNFR2); adipokines (leptin, resistin and adiponectin) and endothelial activators biomarkers (sVCAM, sICAM, E-selectin, E-chaderin, VEGF) were measured. The traditional cardiovascular RF analyzed were body mass index (BMI), waist circumference (WC), systemic arterial hypertension (SAH), diabetes mellitus (DM), dyslipidemia (HDL-c<50mg/dl and/or LDL-c≥130mg/dl and/or total colesterol≥200mg/dl), tryglicerides (TGL), smoking, postmenopausal status and Metabolic Syndrome (MetS). Spearman correlations or U-Mann-Whitney tests evaluated the univariate association between traditional RF and cytokines and endothelial activators biomarkers. Two-sided p values ≤0.050 were considered significant and p values between 0.051 and ≤0.10 were considered borderline.
Results and Conclusion: The mean age (SD) of the patients was 41.6(11.2) years. The median (IQR) disease duration was 121 (91-178) months. There was a positive correlation between obesity markers (BMI and WC) and ICAM, E-selectin and E-cadherin and an expected negative association with adiponectin. Regarding dyslipidemia, there was a significant positive association with sTNFR1, sTNFR2, ICAM and a negative association with adiponectin. HDL-c was directly correlated to adiponectin and inversely correlated to sTNFR1, sTNFR2, ICAM, VCAM, E-selectin and VEGF. TGL levels were positively correlated to resistin, sTNFR1, sTNFR2, ICAM, VCAM, E-selectin and negatively with adiponectin. In addition, hypertrigliceridemia (TGL≥150mg/dl) was associated positively with ICAM and E-selectin and negatively with adiponectin. Patients with DM had a lower level of adiponectin and a borderline higher level of ICAM, E-selectin and E-cadherin probably due to the small sample of diabetics in our study (n=13 patients). Patients with SAH had a higher level of sTNFR1, ICAM, E-selectin and E-cadherin. Smoking was positively related to resistin, E-selectin and E-cadherin and postmenopausal status was positively related to sTNFR1, ICAM and E-cadherin. Considering Metabolic Syndrome, higher levels of leptin, sTNFR1, sTNFR2, ICAM, E-selectin and E-cadherin were observed, while lower levels of adiponectin were found. In conclusion, the panel of TNF system, adipokines as well as endothelial activators biomarkers showed a significant association with many traditional cardiovascular RF in patients with SLE, showing the dysregulation of the inflammation associated with atherosclerosis.
O12 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS PATIENTS WITH CARDIAC INVOLVEMENT
Daniela Aparecida de Moraes3, Juliana Bernardes Elias1, Ana Beatriz Pereira Lima Stracieri1, Luiz Guilherme Darrigo Junior1, Carlos Eduardo Setanni Grecco1, Marilia Cirioli Oliveira2, Vanessa Leopoldo2, Andreia Ferreira Zombrilli2, Belinda Pinto Simões3, Maria Carolina de Oliveira3
1FACULDADE DE MEDICINA DE RIBEIRÃO PRETO-USP, RIBEIRÃO PRETO, SP, Brasil; 2ESCOLA DE ENFERMAGEM DE RIBEIRÃO PRETO- USP, RIBEIRÃO PRETO, SP, Brasil; 3FACULDADE DE MEDICINA DE RIBEIRÃO PRETO- USP, RIBEIRÃO PRETO, SP, Brasil
Introduction: Autologous hematopoietic stem cell transplantation (AHSCT) is recommended as treatment for patients with rapidly progressive systemic sclerosis (SSc). The procedure aims to suppress autoreactivity, through installation of a renewed and tolerant immune system, promoting control of disease progression. High doses of cyclophosphamide (CY) and rabbit anti-thymocyte globulin (ATG) are commonly used. However, some patients who fulfill indication criteria present cardiac alterations secondary to SSc, that may increase cyclophosphamide-related cardiotoxicity.
Objectives: To assess the tolerability and efficacy of AHSCT for patients with severe forms of systemic sclerosis with cardiac involvement using an alternative conditioning regimen with fludarabine + melphalan + ATG (FLUMEL-ATG).
Patients and methods: This study included patients with diffuse skin involvement and/or interstitial lung involvement who had progression of the disease in the last 12 months, under standard treatment, with evidence of cardiac involvement in the pre-transplant evaluation. Patients underwent collection of autologous hematopoietic stem cells from the peripheral blood through leukapheresis. Subsequently, they received Fludarabine 120mg/m2 + Melphalan 140mg/m2 + rabbit anti-thymocyte globulin (ATG), followed by infusion of previously collected autologous stem cells. After transplantation, patients were monitored for disease activity.
Results: From 2012 to 2018, nine patients with median age of 32 years (12-60) were transplanted using FLUMEL-ATG conditioning. Five were females and seven had been previously treated with monthly cyclophosphamide pulses. All patients presented pre-transplant cardiac abnormalities: non-sustained ventricular arrhythmias (3 patients), pulmonary artery trunk dilatation (3), systolic or diastolic ventricular dysfunction (2), and patchy cardiac fibrosis (2). During transplantation, all patients presented febrile neutropenia, and four developed bacterial pneumonia. One patient presented cardiotoxicity and 4, pulmonary congestion. All patients were promptly treated and fully recovered. Five patients had cytomegalovirus reactivation after transplantation without clinical disease. There were no deaths. Median post-transplantation follow-up duration was 24 months (6-47). The mean (SD) of the cutaneous Rodnan score decreased significantly from 29 (11) before transplantation to 17 (9) (p=0.001) at the last post-transplant evaluation. The mean (SD) predicted value of forced vital capacity increased non-significantly after the procedure, from 66% (12.2) to 74% (17.9) (p=0.068).
Conclusions: We believe AHSCT with FLUMEL + ATG transplant conditioning regimen is safe for SSc patients with mild cardiac involvement, with acceptable incidence of severe transplant-related cardiac events. This group of patients achieved long-term control of disease progression. Longer follow-up and larger number of patients are required to fully support these conclusions.
Fabricia Fonseca Simil, Gilda Aparecida Ferreira
UFMG, BELO HORIZONTE, MG, Brasil
Objective To analyze the performance of FDG-PET/CT in the evaluation of the disease in patients with Takayasu's arteritis (TA), comparing clinical, biological and vascular data in angiotomography.
Methods: cross-sectional clinical trial, 19 patients with TA according to ACR/1990, laboratory (angiotomography and FDG); PET /CT with the 18F-FDG radiopharmaceutical). The FDG-PET/TC were used three parameters for mensuration the values of captating: visual scale, intensity of captation and value of captation maximum customized (SUVmax).
Results and Conclusions: Of the 19 patients with TA, 95% were female, with a mean (SD) age of 38 (8.3) years. Patients active according to NIH presented greater thickening in the left subclavian arteries (p = 0.017), ascending aorta (p = 0.038) and abdominal aorta (p = 0.017) and double ring in the abdominal aorta (p = 0.05). Thickness greater than 2.86 mm in the aortic arch showed sensitivity of 75% and specificity of 72.5% (area below the ROC curve = 0.83, 95% CI 0.63-1.0, p = 0.017) for prediction of disease activity, considering ITAS 2010 as a reference. Thickness greater than 2.9 mm in the ascending aorta artery, 100% sensitivity and specificity of 82.4% (the area below the ROC curve was 1, with 95% CI 1.0-1.0, p = 0.02) for predicting AT activity, ITAS VHS as a reference. The max SUV in the celiac trunk greater than 2.83 with 100% sensitivity and specificity 94% (the area below the ROC curve 0.971, 95% CI 0.89-1.0, p = 0.034) for activity prediction of AT, ITAS VHS as a reference. The visual scale of the FDG-PET / CT showed an association with double ring angiotomography in the following arteries: aortic arch (p = 0.001), brachiocephalic trunk (P = 0.001), right subclavian (p = 0.003), right carotid (p = 0.003), left carotid (p = 0.003) and the descending thoracic aorta (p = 0.05). There was a correlation between the median abdominal aortic artery thickening and the median of the SUVmax of this region (1.3mm Var Min-max 0.05-4.4, p = 0.019). Vascular alterations of angiotomography showed good performance to evaluate disease activity in this sample of TA patients compared to clinical criteria and the presence of double ring at angiotomography showed a significant association with FDG-PET/CT activity.
O14 AXONAL DYSFUNCTION, NEURONAL MARKERS AND PROINFLAMMATORY CYTOKINES IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
Renan Bazuco Frittoli, Danilo Rodrigues Pereira, Mariana Postal, Aline Tamires Lapa, Roberto Marini, Gabriela Castellano, Fernando Cendes, Leticia Rittner, Simone Appenzeller
UNICAMP, CAMPINAS, SP, Brasil
Background: Involvement of the central nervous system is frequently observed in childhood-onset SLE patients (cSLE). Proton magnetic spectroscopy (1H-MRS) is an important non-invasive method of quantification of biological metabolites. Abnormalities in brain metabolites may predict future damage, such as lesions and atrophy in adults-onset SLE, however there are few studies in cSLE. The objective is to determine the presence of axonal dysfunction in cSLE and to determine clinical, laboratory and treatment features associated with its occurrence. To associate axonal dysfunction with sera Th1 (IL-12, TNF-α, IFN-γ), Th2 (IL-6 and IL-10), Th17 (IL-17) cytokines levels and antiribosomal P protein antibodies (anti-P) and S100β.
Methods: We included 77 consecutive cSLE patients [median age 16 years (range 7-31)] from the Rheumatology outpatient unit and 66 healthy controls [median age 18 years (8-32)]. We performed multi voxel 1H-MRS using point resolved spectroscopy sequence over the superior–posterior region of the corpus callosum (3T Phillips®scanner) and signals from N-acetylaspartate compounds (NAA), choline-based compounds (Cho); creatine containing compounds (Cr) and lactate (Lac) were measured and metabolites/Cr ratios were determined. A complete clinical, laboratory and neurological evaluation was performed in all subjects. Neurological manifestations were analyzed according to the ACR classification criteria. Mood and anxiety disorders were determined through Beck Depression and Beck Anxiety Inventory. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. Th1 (IL-12, TNF-α, IFN-γ), Th2 (IL-6 and IL-10), Th17 (IL-17) cytokines levels, S100β levels and anti-P were measured by ELISA using commercial kits. Data were compared by non-parametric tests.
Results: NAA/Cr ratio (p=0.017) and Lac/Cr ratio (p=0.014) levels were significantly decreased and Cho/Cr ratio levels (p=0.038) was increased in cSLE patients when compared to healthy controls. We observed that Cho/Cr ratio was associated with symptoms of anxiety (p=0.02), cognitive decline (p=0.03), corticosteroid use (p=0.034) and correlated with IL-6 (r=0.568; p=0.002). NAA/Cr ratio was associated with disease activity (p=0.01) and correlated with IL-4 (r=0.375; p=0.024). Lac/Cr ratio was associated with symptoms of depression (p=0.016), presence of anti-P (p=0.04) and correlated with IFN-γ (r=0.611; p=0.004).
Conclusion: We observed significant axonal dysfunction in cSLE. Decreased NAA/Cr ratio was associated with disease activity and sera IL-4 levels and increased Cho/Cr ratio was associated with neuropsychiatric manifestations, cumulative use of corticosteroids and IL-6, suggesting brain injury.
O16 CLINICAL OUTCOMES OF PATIENTS WITH TAKAYASU ARTERITIS ON BIOLOGIC THERAPY: REAL-LIFE USE AND EXPERIENCE FROM A BRAZILIAN SINGLE-CENTER
Surian Clarisse da Costa Rocha Ribeiro, Mariana Ortega Perez, Leandro Lara do Prado, Samuel Katsuyuki Shinjo, Rosa Maria Rodrigues Pereira
DISCIPLINA DE REUMATOLOGIA, HOSPITAL DAS CLINICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (FMUSP), SÃO PAULO, SP, Brasil
Background: Glucocorticoids and immunosuppressive drugs are the mainstay of therapy for Takayasu arteritis (TAK). However, in a significant proportion of patients, conventional therapies are unable to induce sustained remission. In this setting, biologic agents such as TNFα inhibitors and tocilizumab may be indicated. Our aim is to report the experience from a single-center with the use of biologic therapy in patients with TAK during the first 12 months of treatment.
Methods: We consecutively studied a cohort of patients with TAK treated with TNF inhibitors and tocilizumab using a standard electronic protocol. TAK was classified by the 1990 American College of Rheumatology criteria. Disease activity was assessed according to the National Institutes of Health (NIH), Indian Takayasu’s Arteritis Activity Score (ITAS 2010), Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) at baseline, 6 and 12 months on biologic therapy. Response to treatment was categorized as complete response (CR): NIH<2 and prednisone <10mg/day; partial response (PR): NIH<2 and prednisone dosage decreased ≥50%; or refractory disease (RD) in another situation. Damage was graded by Vasculitis Damage Index (VDI).
Results: Fourteen patients were evaluated, 92.8% women, 61.6% Caucasian, 28.8±10.8 years old and disease duration of 5.2±3.6 years. Biologics agents of choice were infliximab (n = 12, 85.7%), etanercept (n = 1, 7%) and tocilizumab (n = 1, 7%). After 6 months of treatment, CR was observed in 50% of patients, PR in 14.3% and RD in 35.7%. After 12 months, CR in 50% patients, PR in 28.6% and RD in 21.4% (Table 1). Overall, 35.7% had moderate/severe infection during biologic treatment. Due to inadequate response, 3 patients in infliximab and 1 etanercept treatment performed switching to tocilizumab.
Conclusion: Our data show that, after 12 months, TNFα inhibitors and tocilizumab were associated with complete or partial response in a majority of patients (78.6%), with decrease of inflammatory markers and prednisone dose.
O17 COMPARISON OF CLINICAL FEATURES AND TREATMENT OUTCOMES BETWEEN PATIENTS WITH IMMUNE-MEDIATED NECROTIZING MYOPATHY AND OTHER SYSTEMIC AUTOIMMUNE MYOPATHIES
Samuel Katsuyuki Shinjo1,3, Leonardo Santos Hoff2, Jean Marcos de Souza3
1FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SÃO PAULO, SP, Brasil; 2FACULDADE DE MEDICINA FMUSP, UNIVERSIDADE DE SAO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 3FACULDADE DE MEDICINA FMUSP, UNIVERSIDADE SAO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background. Differently from other systemic autoimmune myopathies (SAM), immune-mediated necrotizing myopathies (IMNM) generally present with clinical signs of severe proximal muscle weakness, rapid onset, very high levels of creatine phosphokinase, and usually refractory to conventional immunosuppressive therapies. IMNM is characterized histologically by necrotic and regenerating muscle fibers, in the presence of scarce or absent inflammatory infiltrates. The aim of the present study was to compare clinical features and treatment outcomes between patients with IMNM and other SAM.
Methods. A retrospective, single-center cohort study (2000 to 2017), included 153 consecutive patients with definite SAM: 14 (9.2%) IMNM (10 anti-SRP, 3 anti-HMGCR, 1 seronegative), 89 (58.2%) dermatomyositis, 20 (13.1%) polymyositis and 30 (19.6%) antisynthetase syndrome. Patients with clinically amyopathic dermatomyositis, inclusion body myositis and other myopathies were excluded. Patient data were extensively reviewed from electronic medical records, with pre-standardized and parameterized information.
Results. Comparing to other SAM, patients with IMNM were significantly older (57.0±9.1 vs. 41.0±15.2 years) and had a higher creatine phosphokinase at disease onset (14614±18532 vs. 6252±9719U/L). In contrast, patients with IMNM were less likely to have interstitial lung disease (7.1% vs. 41.2%). Gender distribution, degree of muscle weakness at disease onset, and frequency of upper dysphagia were similar between both groups. Distribution of frequency and time duration of patients that achieved a complete clinical response, time duration to glucocorticoid withdrawal were also comparable between both groups (P>0.05). Severe infections occurred in 35.7% and 26.3% of patients with IMNM and other SAM, respectively (P=0.659).
Conclusion. Our retrospective cohort study, patients with IMNM were older, had a higher creatine phosphokinase and had less interstitial lung diseases at disease onset, when compared to other SAM. However, other clinical manifestations and also treatment and disease outcomes were comparable between both groups. Therefore, in contrast to available studies in the literature, our patients IMNM had relatively a good outcome.
O18 CYCLOPHOSPHAMIDE FOR NEUROLOGICAL MANIFESTATIONS OF BEHÇET DISEASE: PRELIMINARY RESULTS FROM A MONOCENTER COHORT STUDY
Priscila Dias Cardoso Ribeiro1, Rywka Tenenbaum Medeiros Golebiovski2, Flávia Maria Matos Melo Campos Peixoto2, Pedro Matos2, Pedro Paulo de Alcântara Pedro2, Dennise de Oliveira Nogueira Farias2, João Victor Campos de Oliveira2, Eduarda Bonelli Zarur2, Joice Moraes Faria Monteiro Belem2, Alexandre Wagner Silva de Souza2
1UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, SP, Brasil; 2UNIFESP, SÃO PAULO, SP, Brasil
Background. Neurological involvement, although uncommon (4 a 29%), is one of the most serious causes of long-term morbidity and mortality in Behçet’s disease (BD). There is a wide variety of neurological manifestations in BD that can be categorized in two major types: parenchymal (e.g. meningoencephalitis) and non-parenchymal (e.g. dural venous sinuses thrombosis and aseptic meningitis). To date, no controlled trials have assessed therapy for neuro-Behçet’s disease (NBD). For acute or sub-acute parenchymal NBD attacks, 5-10 intravenous pulses of methylprednisolone and a course of high doses glucocorticoids are recommended, usually followed by a slowly tapering course. Azathioprine is the first-line maintenance therapy. Biologic agents such as IFNα or anti-TNF antibodies may be used in NBD patients refractory to immunosuppressive therapy. Cyclosporine A should be avoided as it is neurotoxic and can be considered a risk factor for developing NBD.
Objective. To describe outcomes of patients with NBD treated with intravenous pulses of cyclophosphamide followed by azathioprine compared with other therapeutic modalities including mainly high-dose glucocorticoids and azathioprine.
Methods. A retrospective cohort study included 25 patients who fulfilled the International Study Group criteria for BD and presented neurological manifestations. NBD followed-up for a mean 91.5 ± 51.6 months after the onset of NBD manifestations. Relapses of NBD after starting therapy was the primary endpoint of this study.
Results. The mean age at study was 43.8 ± 11.5 years and 60% of them were females. Neurological manifestations were found at presentation in 52% of the cases, with parenchymal manifestations in 72%. Only 1 patient used cyclosporine A at NBD onset. Intravenous pulses of cyclophosphamide were given as induction therapy for 68% and 12% of them had a failure to cyclophosphamide during induction therapy and had to be treated with a TNFα antagonists. The overall long-term relapse rate of NBD was 40% at a median of 60.0 months, while the NBD relapse rate with cyclophosphamide was 35.5% and 50.0% with other therapies (p = 0.666). Using the Kaplan Meier analysis, no significant differences were found between cyclophosphamide and other therapies regarding NBD relapses using the log-rank test (p = 0.767). The hazard ratio of cyclophosphamide to prevent relapses of NBD was 0.818 (95% confidence interval: 0.217-3.080).
Conclusion. Preliminary data from this small open-label retrospective study do not show any benefit from intravenous pulses of cyclophosphamide to prevent long-term relapses of NBD.
O19 DEVELOPMENT AND SEVERITY OF RHEUMATOID ARTHRITIS IS NOT RELATED TO CIITA (RS3087456) GENE POLYMORPHISM IN BRAZILIAN POPULATION
Isaura Isabelle Fonseca Gomes da Silva3, Suelen Cristina Lima3, Denise Queiroga de Nascimento3, Eliezer Rushansky1, Maria Helena Queiroz de Araujo Mariano1, José Artur Bogo Chies2, Sergio Crovella3, Paula Sandrin Garcia3
1HOSPITAL UNIVERSITÁRIO OSWALDO CRUZ, RECIFE, PERNAMBUCO, Brasil; 2HOSPITAL DAS CLÍNICAS, UFRGS, PORTO ALEGRE, RIO GRANDE DO SUL, Brasil; 3UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil
Background: Rheumatoid arthritis is an immunological disorder with etiology not fully understood. Genetics factors can contribute to development and severity of rheumatoid arthritis (RA) and can be targets of study to personalized medicine. Genes related to immune system as MHC locus has been associated to RA since plays a role in inflammation observed in the disease. Among these, the Class II Major Histocompatibility Complex Transactivator (CIITA) has been highlighted once that plays a role in the activation of the immune system by stimulating MHC II transcription. The polymorphism rs3087456 of CIITA is located at position -168 A/G has attracted attention since it can change your transcriptional level and plays a role in RA inflammation. Some studies in different populations had found controversial results and the relation between this polymorphism and RA in Brazilian population yet is unclear. Thus, our study aims to determine the potential association of rs3087456 CIITA polymorphism in development and severity of RA.
Methods: Blood samples were collected from 429 Brazilian patients with RA and 329 unrelated healthy control volunteers. All subjects were genotyped using TaqMan genotyping assay in ABI 7500 Real Time PCR platform. Statistical analysis was performed using R version 3.2.1 and Statistica version 8.0 softwares and Chi-square test was applied to compare allele and genotypes frequencies and to test their associations with RA severity it was applied one-way analysis of variance (ANOVA) test.
Results: The Chi-square test indicated no significant differences when comparing the allele frequency of RA patients and controls (p > 0.05). Similar outcomes was observed in genotype distribution using AA genotype as reference in a codominant model, suggesting that this polymorphism does not play a role in RA development in Brazilian population. Regarding to RA severity, genotypes were compared with RA disease activity indexes. The statistical analysis showed no difference among genotypes and disease activity indexes, DAS28, CDAI and HAQ (p > 0.05).
Conclusions: The genetic variant rs3087456 of CIITA gene does not appears to influence the RA susceptibility or severity in a Brazilian population.
CAPES, CNPQ, FACEPE.
Gustavo Gomes Resende1, Ricardo da Cruz Lage1, Olivio Brito Malheiro1, Déborah Lobato Guimarães1, Filipe Augusto Carvalho de Paula1, Diogo Couto Carvalho1, Fernanda Oliveira Gomes1, Carlos Alexandre de Souza Bomtempo1, Marco Antonio Parreiras de Carvalho2
1HC UFMG, BELO HORIZONTE, MG, Brasil; 2FACULDADE DE MEDICINA UFMG, BELO HORIZONTE, MG, Brasil
Background: Diagnostic delay, the gap between onset of musculoskeletal symptoms and diagnosis definition, is associated to worse prognostic and represents a major challenge to assistance of spondyloarthritis (SpA) patients. It was historically reported to be 8-10 years. The aim of this study was to compare it between two different periods of inclusion in a same cohort and evaluate possible associations with SpA features.
Methods: Two cross-sectional analysis from the same database were made. The first included patients admitted to the SpA outpatient clinic up to 2002 (group A) and the second one included patients admitted between 2003 and 2013 (group B). ANOVA F-test and Mann-Whitney were used to compare the two different scenarios and to test the association between the dependent and explanatory variables. Effects with p-values ≤ 0.05 were considered as evidence of statistical significance.
Results and conclusions: In group A (N = 156) we found: 65.4% of males; mean age at onset of 27.7 (±11.6) years; 53.8% of HLA-B27 positivity and mean diagnostic delay of 8.1 (±0.68) years. In group B (N = 99) we found: 57.6% of males; mean age at onset of 31.0 (±13.0) years; 59.0% of HLA-B27 positivity; and mean diagnostic delay of 6.9 (±0.76) years. Analyzing all patients (N = 255), the subtype of SpA, gender, HLA-B27 status or presence of radiographic sacroiliitis (mNY criteria) were not associated to longer delay. Conversely, the presence of extra-articular manifestations - EAM (i.e. uveitis, psoriasis and/or inflammatory bowel disease) on admission was statiscally associated (p < 0.0001) with longer delay (Fig. 1) and the age at onset was negatively correlated with diagnostic delay (r = -0.28 p < 0.0001). In conclusion, we have shown a reduction in diagnostic delay (mean difference of 1.3 years) over a decade. Possible explanations for that include the increased awareness amongst health-care professionals, the adoption of new classification criteria (ASAS 2009) and the incorporation of magnetic resonance imaging (MRI) as a diagnostic tool in SpA. The seen association between EAM presence and earlier disease onset with the longer diagnostic delay, could represent a greater difficulty of non-rheumatologists in identify inflammatory-type symptoms and unawareness of the EAM linkage with SpA. As consequence, patients may not be referenced to rheumatologist in appropriate time and may have an inadequate investigation, delaying the diagnosis. Therefore, there is still a need for further targeted education of health-care professionals to address the issue.
Beatriz Leite1, Marcelo de Medeiros Pinheiro2
1ARACAJU, SE, Brasil; 2UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, SP, Brasil
Background: Psoriatic Arthritis (PsA) is associated with multiple comorbidities, particularly metabolic syndrome (MetS). These findings brought up a potential link between adiposity and PsA, highlighting a potential fat-joint-skin axis mediated by oxidative stress and nutritional inadequacy. So, the aim is to evaluate if dietetic patterns changes or antioxidant supplementation or 5-10% weight loss could improve the disease activity in patients with PsA.
Materials and Methods: A total of 97 PsA patients were enrolled in a 12-week randomized, double-blinded, placebo-controlled trial. Patients were randomized into three groups: D – hypocaloric diet + placebo supplementation; D+S – hypocaloric diet + omega-3 supplementation (3 g/day); and P – placebo. Food intake (3-day registry, Healthy Eating Index (HEI), and the Dietary Inflammatory Index (DII), body composition (whole-body DXA, weight and waist of circumference) and disease activity (BASDAI, DAS28-ESR, DAS28-CRP and MDA) were evaluated at baseline and after intervention. Statistical analysis used intention to treat approach. P level was set as below 0.05.
Results and Conclusion: After 12 weeks, there was DAS28-CRP and BASDAI improvement, especially in the D group (-0.6±0.9; p=0.004 and -1.39±1.97; p=0.001, respectively). In addition, higher proportion of patients achieved minimal disease activity in all groups (D: 34.3%; D+S: 34.4%; P: 27.3%; p=0.006). The D+S group had significant weight loss (-1.79±2.4; p=0.004), as well as waist circumference (-3.28±3.5, p<0.001) and body fat (-1.2±2.2, p=0.006) reduction. There was no significant correlation between weight loss and disease activity improvement. Each 1-unit increase in HEI reduced the likelihood of achieving remission in 4%. Also, each 100-calorie daily intake increase caused 3.4-fold DAS28-ESR impairment. In conclusion, a 12-week hypocaloric intervention provided suitable control of joint disease activity in patients with PsA, regardless of weight loss. Adding omega 3 supplementation caused relevant body composition changes.
O22 DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS: EFFECTS ON IMMUNIZATION COVERAGE AND VACCINE EFFICACY
Helena de Almeida Tupinambá1, Laíssa Cristina Alves Alvino2, Pedro Felipe de Almeida Vianna2, Ana Beatriz Vargas-Santos2, Manuella Lima Gomes Ochtrop2
1UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2HOSPITAL UNIVERISTÁRIO PEDRO ERNESTO, RIO DE JANEIRO, RJ, Brasil
Background: The introduction of disease-modifying drugs (DMARDs) in the treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) was responsible for a dramatic change in the natural history of these diseases. However, the use of immunomodulatory agents also leads to increased risk of infections by common and opportunistic germs. Vaccination is the most important preventive action to reduce this risk. It is a worldwide recommendation that the vaccination schedule be updated in all patients who will be submitted to immunosuppression. This study aims to evaluate vaccine coverage and the impact of therapy on the efficacy of vaccination for Hepatitis B in a sample of patients with RA and JIA.
Methods: A cross-sectional study was carried out, with data derived from the review of medical records of patients with RA or JIA treated until March 2018 at the Biologic Outpatient Clinic of Tertiary Teaching Hospital in Rio de Janeiro. A total of 146 patients were selected for analysis. Vaccination coverage was studied using simple frequencies. To test factors related to the vaccine response to Hepatitis B, univariate logistic regressions were performed using Eviews.
Results: Vaccination coverage was 65% for Influenza, 51% for Pneumococcal, 30% Meningococcal, 64% for Tetanus, 3% for Hepatitis A and 64% Hepatitis B. Of the 93 patients vaccinated for Hepatitis B, 40 had Anti Hbs measured after vaccination, with seroconversion in 38%. Logistic regression used to search for relationship of Anti Hbs positivity and use of synthetic or biological DMARDs during vaccination resulted in an Odds Ratio (OR) of 0.17 (95% CI 0.04-0.7) for use of biological DMARDs (bDMARD) and 1,55 (95% CI 0.33-7.23) for synthetic DMARDs (sDMARD).
Discussion: The vaccination coverage was superior compared to data from the US for influenza and pneumococcal, but it’s still not ideal yet. The vaccine response to hepatitis B appears to be negatively influenced by the use of bDMARDs, with a chance of seroconversion of only 1 in every 5.9 immunized found in our study. Conclusions: Increasing attention has been given to vaccination of patients using bDMARDs. It’s important to have in mind, that an attempt to get it done before starting the treatment will probably lead to better results in efficacy.
O23 DISPENSATION OF IMMUNOBIOLOGICALS IN MODEL OF ASSISTED THERAPY IN THE SUS REDUCES COSTS WITH IMMUNOBIOLOGICAL IN ANKYLOSING SPONDYLITIS
Lorenza Rosa Silverio Scomparin, Carla Gonçalves Schahin Saad, Fernando Henrique Carlos de Souza, Renata Miossi, Ana Cristina de Medeiros Ribeiro, Mariana Gioieli Waisberg, Karina Rossi Bonfiglioli, Leandro Lara do Prado, Vanessa Teich, Eloisa Bonfa, Julio Cesar Bertacini de Moraes
FACULDADE DE MEDICINA DA UNIVERSIDADE DE SAO PAULO, SAO PAULO, SP, Brasil
Introduction: In the 2000s, immunobiologicals were introduced as a treatment option in various rheumatologic conditions, including Ankylosing Spondylitis (AS). The incorporation of these medications by the Unified Health System (SUS) brought important clinical advances in the effective control of the inflammatory process and the quality of life of this population. With the increase in indications and the volume of patients attended, the impact on the SUS budget has increased, requiring a rational and efficient dispensation process.
The predominant model in the supply of medication in the SUS is the direct dispensing to the patient. This model presents several weaknesses, given that the immunobiologicals are injectable and thermolabile, it has lead to an important interruption in the proper conservation and transport, and also in the safety of the medication application.
To improve this process, an assisted dispensing model was created in 2007 to ensure safety application, monitor effectiveness, and rationalize use by combating resource wastage.
Objectives: To compare the model of assisted therapy with that of direct dispensing of SUS for immunobiological drugs for, in terms of reducing the volume of use of immunobiological drugs and their financial impact according to the acquisition costs for each medication during the study period.
Methods: All the visits were included in the center responsible for the model of assisted therapy, with medication provided by the Ministry of Health for patients presenting in the year 2015. In each of the consultations were recorded: medication, number of bottles, prescribed dose, dose received, cancellations, faults and estimates of bottles that would have been dispensed by the direct system. The financial value, in Reais, was calculated according to the acquisition value by the Ministry of Health for each immunobiological in 2015.
Results: A total of 1688 consultations were performed for patients with AS in 2015 by the model of assisted therapy. 669 (23.26%) bottles of a total volume of 2876 prescribed vials of all medications intended for the treatment of AED were no longer used, reducing expenses by R $ 470,289.15 (23.78%). Based on the same savings percentage of the model in question for the whole SUS and according to data from DATASUS for AS in 2015, the reduction of immunobiological expenses for the treatment of AS would be R $ 49,467,109, 97.
O24 DISPENSATION OF IMMUNOBIOLOGY IN MODEL OF ASSISTED THERAPY IN SUS REDUCES COSTS WITH IMMUNOBIOLOGICAL IN YOUTH IDIOPATHIC ARTHRITIS
Lorenza Rosa Silverio Scomparin, Carla Gonçalves Schahin Saad, Fernando Henrique Carlos De Souza, Renata Miossi, Ana Cristina De Medeiros Ribeiro, Mariana Gioieli Waisberg, Karina Rossi Bonfiglioli, Leandro Lara Do Prado, Vanessa Teich, Eloisa Bonfa, Julio Cesar Bertacini De Moraes
FACULDADE DE MEDICINA DA UNIVERSIDADE DE SAO PAULO, SAO PAULO, SP, Brasil
Introduction: Immunobiologicals were introduced as a treatment option for several diseases, including Juvenile Idiopathic Arthritis (JIA) by the Unified Health System (SUS), which brought up important advances, especifically as a new alternative capable of modifying the course of the disease. Given this, the number of indications is a growing process, as well as its budget, since such drugs, by the common SUS model, are dispensed directly to the patient. Given the fact that the medications are injectable and thermolabile, there is an important gap in the return, transport and application of the medications. In 2007 a model of dispensation was created, which values the assisted therapy and safety application, thus combating waste and rationalizing the use of medicines.
Objectives: To compare the direct dispensing model of SUS with that of assisted therapy, in terms of volume reduction of immunobiological drugs and their financial impact.
METHODS: All the visits were included in the center responsible for the model of assisted therapy, with medication provided by the Ministry of Health for patients with JIA in the year 2015. In each service were recorded: medication, number of bottles, prescribed dose, dose received, cancellations, shortages and estimation of bottles received by the direct dispensing system. The financial value was calculated according to the acquisition value by the Ministry of Health for each immunobiological in 2015.
Results: A total of 1898 consultations were performed for patients with JIA in 2015 under the model of assisted therapy. 941 (26.19%) bottles of a prescribed total volume of all medications of 3593 bottles were no longer used, reducing expenses by R $ 341,205.63 (25.21%). Extrapolating the percentage of savings of the model in question for the whole SUS, based on the SUS expenditures on data released by DATASUS for the year 2015, the reduction of immunobiological expenses destined for treatment of JIA would be the amount of R $ 6,141.370.1.
Conclusion: The model of assisted therapy considerably reduces the volume of dispensed bottles compared to the model of direct dispensing bringing significant reduction of expenses to the SUS.
O25 DNA COPY NUMBER VARIATIONS AND FAMILIAL RECURRENCE IN PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
Nailu Angelica Sinicato1, Luciana de Oliveira1, Vera L Gil-da-Silva-Lopes1, Iscia Lopes-Cendes1, Roberto Marini1, Timmothy Niewold2, Simone Appenzeller1
1UNICAMP, CAMPINAS, SP, Brasil; 2NEW YORK UNIVERSITY, NEW YORK, NY, Estados Unidos
Background: The genetic predisposition in Systemic Lupus Erythematosus (SLE) encompasses multiple genes that may trigger or increase risks for the development of the disease. Especially in autoimmune diseases, the understanding of the copy number variations (CNVs) in the development of diseases is still little understood. Our main objective was to investigate the familial recurrence of SLE and the profile of CNVs in patients with cSLE.
Materials and methods: We included consecutive patients with cSLE followed up at the Pediatric Rheumatology Unit of UNICAMP between 2013/2016. CNVs were evaluated through the CytoScan HD Affymetrix®. Recurrence analysis was performed using conventional heredograms of three family generations and analyzed visually.
Results: We evaluated 112 patients with cSLE, 96 (85.7%) female, with a mean age of 21 years (SD ± 4.8 years) and had mean disease duration of 7.8 years (SD ± 6.5). Forty patients with cSLE have family members with autoimmune diseases (except SLE), the most common were hypothyroidism 21 (52.5%), hyperthyroidism 9 (22.5%) and rheumatoid arthritis 3 (7.5%). In relation to the SLE family recurrence, we observed 10 first-degree relatives (recurrence rate: 25.3), 10 second-degree relatives (recurrence rate: 8.3), and 3 third-degree relatives (recurrence rate: 1,3) with SLE. We did not observe statistical difference between familial and sporadic SLE in relation to demographic, clinical, laboratorial and treatment data. In the CNVs analysis, we analyzed 107 patients and observed CNV in relevant genes [genes: MECP2 (duplications), BANK1 (deletions), DNASE1 and TRAP1 (deletions), IKBKG (deletions) and CFHR4 (4 deletions and 2 duplications)]. We do not observe association between the presence of CNV and family recurrence of SLE and the clinical, laboratory and treatment profile.
Conclusions: We conclude that there is a greater recurrence of SLE in first-degree relatives and we observed the presence of CNVs in 10 genes previously related to SLE. No association between the presence of CNV and family recurrence was observed. The interest in genetic factors in SLE brings new challenges in order to understand its role in the development and progression of SLE. Founding grants: Fapesp and Capes.
O26 DO PATIENTS REALLY UNDERSTAND THE PRESCRIPTION? ASSESSING LUPUS PATIENT’S COMPREHENSION OF PHYSICIAN PRESCRIPTION - A PILOT STUDY
Mariana Luiza Lewergger Borges, Maurício Petroli, Luiza Andrade Mussi, Lilah Ferreira Fontenelle Ribeiro, Rafael da Cunha Cancela, Sabrina Fausto de Lima, João Pedro Simão de Mello, Nycholas da Costa Tavares, Tamara Felzenszwaibe Waga, Marlon de Carvalho Ferreira Ribeiro, Ricardo Araujo Rauneitti, Mirhelen Mendes de Abreu
UFRJ, RIO DE JANEIRO, RJ, Brasil
Background: Communication skills and patients understanding of the prescription play an important role in adherence to the treatment program and affects the outcome of the disease. Identifying how patients understand the prescription may contribute to develop patient’s education strategies that will be fundamental for shared decision-making process.
Methods: Designed as a cross-sectional study, this survey interviewed SLE patients (ACR, 2012) older than 18 years old, from a tertiary outpatient facility. Data were collected using a questionnaire that consisted of modules on socio-economic characteristics, clinical and therapeutically profile. The interview occurred after the consultation, on a face-to-face interview. Afterwards, questions regarding the prescription received during the patient-physician encounter were applied. Comprehension was defined according to the right answers related to the questions and to the followed score: great comprehension (from 90 to 100%); very good comprehension (from 70 to 89%); good comprehension (from 50 to 69%); weak comprehension (from 30 to 49%) e no comprehension (0 to 29%). Finally, a retrospective analysis of the medical chart (last two years) to add the analysis. Descriptive statistics were employed using central tendency and dispersion measurements. Also, we analyzed the correlation between comprehension’s scores, self-assessment score, educational level, and clinical aspects.
Results and conclusions: Thirty-seven patients were analyzed. Of them, 89% were female, 66% had between 10 to 15 years of disease; and 34% declared 10 to 15 years of schooling. Most of them (65%) were hospitalized at least once a year, and SLEDAI score was 13 (SD ± 8). The average of medicines per day used was 9 (SD ± 4). Patients’ comprehension score was full for 24% of the sample, partial for 43%; weak was found in 20% patients and no comprehension was observed in 13% of them. The variable that influenced most in the comprehension score was level of schooling (p=0.050). SLEDAI score was also relevant but not significant to influence comprehension (p=0.065). We observed that, in this sample, there is a regular prescription’s comprehension. Future studies can help to understand the factors related with the quality of comprehension so that assertive strategies for patient’s education can be outlined.
O27 DOES GENERAL SELF-EFFICACY MODERATE THE RELATIONSHIP BETWEEN KNEE SYMPTOMS AND FUNCTION? THE ELSA-BRASIL MUSCULOSKELETAL STUDY
Rosa Weiss Telles1,3, Daniela Castelo Azevedo3, Luciana Andrade Machado2, Sandhi Maria Barreto3
1FACULDADE DE MEDICINA DA UFMG, BELO HORIZONTE, MG, Brasil; 2ELSA-BRASIL MUSCULOESQUELÉTICO, BELO HORIZONTE, MG, Brasil; 3FACULDADE DE MEDICINA - UFMG, BELO HORIZONTE, MG, Brasil
Background: Self-efficacy is the perceived belief in one’s capabilities to organize and execute the tasks required to achieve a desired outcome. It is a psychosocial construct known to modify pain expression and coping and it also appears to mediate the relationship between pain and physical function in multiple musculoskeletal disorders. The purpose of this study was to investigate whether self-efficacy levels modify the association between chronic knee pain and knee function in Brazillian adults. We hypothesized that this association would be stronger among adults with low self-efficacy, as compared with those with moderate to high self-efficacy.
Material and Methods: This cross-sectional study used data from baseline assessments of ELSA-Brasil Musculoskeletal Study, which consists of an ancilary study from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Knee symptoms were identified by the report of knee pain, discomfort or stiffness in the previous twelve months, lasting for at least six months. Knee function was subjectively and objectively assessed by the WOMAC index (WOMAC-function subscale) and the five-times sit-to-stand test (5T-STS test), respectively. Function outcomes were entered in the models as dichotomous variables (highest quintile, meaning worst function). Low self-efficacy was defined as the lowest quintile of self-efficay measured by the General Self-efficacy scale. An interaction term was included in logistic regressions to assess the influence of low self-efficacy on the relationship between knee pain and both measures of function. All models were adjusted for potential confounders (sex, age, depressive symptoms, body mass index, and occupational nature).
Results and Conclusions: 1735 participants were included in the analysis with mean age equal to 56.0 (8.9) years, 53.4% were women. In univariate analyses, chronic knee symptoms and low self-efficacy were both significantly associated with low knee function (WOMAC-function: OR: 10.32; 95% CI 8.15-13.07 and OR: 1.32; 95% CI 1.05-1.66; 5T-STS test: OR: 1.89; 95% CI 1.54-2.33 and OR:1.27; 95% CI 1.03-1.57, respectively). However, after adjustments, self-efficacy was neither associated with knee function nor altered the association between knee symptoms and function. Using measures of knee function as continuous variables did not change the results in none of the adjusted linear regression models tested. In conclusion, in this cross-sectional study of Brazillian adults low self-efficacy was neither associated, nor dit it moderate the association between knee symptoms and function.
Brazilian Ministry of Health (Science and Technology Department), of Science and Technology (FINEP, CNPq) and of educations (CAPES).
O28 EFFICACY OF A MULTIDISCIPLINARY REHABILITATION SERVICE IN THE TREATMENT OF CHRONIC SEQUELAE AFTER CHIKUNGUNYA FEVER: REDUCTION OF PAIN AND IMPROVEMENT OF FUNCTIONALITY
Denise Leite Dos Santos2, Erika Guerrieri Barbosa2, Fernanda de Oliveira Ferreira1, Raphael Avelar Nunes2, Gulia Delmaschio Cypriano2, Hevilla Souper2
1UNIVERSIDADE FEDERAL DE JUIZ DE FORA, GOVERNADOR VALADARES, MG, Brasil; 2SECRETARIA MUNICIPAL DE SAÚDE, GOVERNADOR VALADARES, MG, Brasil
Background: In 2017 the municipality of Governador Valadares suffered a Chikungunya fever outbreak, presenting 13,000 notifications. This situation demanded a differentiated confrontation to assist users in the chronic phase, since it is estimated that almost 30% of the cases become chronic. A Center for rehabilitation in arboviruses was structured, with the objective of monitoring chikungunya fever chronic users. Given the diversity of clinical aspects, the service was structured with a multidisciplinary team, acting with procedures many times different from the current protocol, since it was clinically necessary to make adjustments to obtain clinical improvement of symptoms.
Objective: to present the effectiveness of the multidisciplinary rehabilitation service in the treatment of chronic sequelae after chikungunya fever in the municipality of Governador Valadares.
Methods: We analyzed the medical records of 181 patients, with chronic sequelae after chikungunya fever, who sought care at the Center for Rehabilitation in Arboviroses. Participants were assessed at the first consultation, before treatment, and after the treatment. We analyzed the pain reported by patients (Visual Analog Pain Scale), functionality and quality of life (HAQ Scale), data that were registered in the medical records. The medical rheumatologist used a standardized protocol of evaluation, identifying the clinical profile of each patient, verifying the presence of symptoms such as fever, skin changes, diarrhea, vomiting, nausea, dizziness, fatigue and neuropathies such as cramps, paresthesias and tingling. The treatment involved a specialist rheumatologist with extensive experience in the field, a physiotherapist who specializes in manual therapies; an occupational therapist and a psychologist with a specialty in cognitive behavioral therapy. The results of the EVA and HAQ scales were compared before and after treatment using the Wilcoxon test, considering 95% confidence.
Results: The clinical profile revealed a high prevalence of neuropathies (77.8%), the most frequent symptom being paraesthesia (87.2%), followed by cramps (12%) and tingling was reported by only 1 (0, 8%) participant. The data revealed a significant decrease in pain levels and improvement of functionality after treatment (p <0.001).
Conclusions: The study demonstrates that the most frequent clinical repercussion of the chikungunya fever was neuropathy, which requires propaedeutics and differentiated rehabilitation. The treatment used was effective to reduce pain and improve functionality for the cases, making necessary the development of more detailed studies to investigate such procedures not yet described in the clinical protocols and literature.
O29 ENDOTHELIAL FUNCTION FEATURES AND STRUCTURAL PROPERTIES OF LARGE ARTERIES IN SYSTEMIC AUTOIMMUNE MYOPATHIES
Rafael Giovane Missé2, Isabela Bruna Pires Borges2, Valéria Aparecida Costa Hong1, Luiz Aparecido Bortolotto1, Samuel Katsuyuki Shinjo2
1INSTITUTO DO CORAÇÃO DO HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 2FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background. High frequency of cardiovascular diseases and theirs risk factors have been described in systemic autoimmune myopathies (SAM). These comorbidities can be the cause of endothelial dysfunction and arterial stiffness, as shown in several other systemic autoimmune diseases. In this aspect, the aim of the present study was to assess the endothelial function and arterial stiffness in patients with SAM.
Materials and Methods. This cross-sectional study included 19 patients with SAM (14 dermatomyositis and 5 anti-Jo-1 antisynthetase syndrome) from 2017 to 2018. As a control group, 14 aged, gender and body mass index-matched were engaged. Flow-mediated vasodilation (FMD) analysis was achieved from brachial arterial above the antecubital fossa (Doppler ultrasound), whereas carotid-femoral vessels pulse wave velocity (PWV) evaluation was performed by Complior system. Disease status was assessed by the International Myositis Assessment & Clinical Studies Groups (IMACS) core set measures.
Results. Mean age of the patients was 45.0 years, with disease duration of 5.0 years. Patients had a median Manual Muscle Testing (MMT-8) of 80, Health Assessment Questionnaire (HAQ) of 0.70, patient Visual Analogue Score (VAS) of 2.4, physician VAS of 1.5, Myositis Disease Activity Assessment VAS of 0.0, serum level of creatine phosphokinase of 97U/L. Patients were using different immunosuppressive drugs plus prednisone <10mg/day. The FMD (%) measurement was 8.3±4.8 vs. 4.1±4.0 (P<0.029) in SAM and control group, respectively. Analyzing individually the diseases, FMD (%) was 8.9±4.3 vs. 4.1±4.0 (P<0.013) in dermatomyositis and control group, whereas FMD (%) was 6.4±5.5 vs. 4.1±4.0 (P=0.432) in antisynthetase syndrome and control group. The PWV was comparable between SAM and control group (7.0±0.8 vs. 7.0±1.0 m/s; P=0.905, respectively).
Conclusion. Although there is no structural properties of large arteries, patients with clinical and laboratory stable SAM (specifically dermatomyositis) have significant endothelial dysfunction when compared to control group. More studies are necessary to confirm our data and to analyze the possible impact of this vessel dysfunction in disease pathogenesis.
Support by FAPESP #2016/23574-0 (RGM), #2016/20371-1 (IBPB), #2017/13109-1 (SKS)
O30 EPIDEMIOLOGICAL ANALYSIS OF DEATHS BY DISSEMINATED INTRAVASCULAR COAGULATION IN BRAZIL BETWEEN 2010 AND 2015
Érica Alves Nascimento, Andressa Borelli Santos, Mariana Bomfim Menezes, Débora Larissa Montarroyos Leite
UNIVERSIDADE TIRADENTES, ARACAJU, SERGIPE, Brasil
Introduction: Disseminated intravascular coagulation is a syndrome in which there is generalized activation of coagulation, with systemic fibrin deposition and consequent consumption of coagulation factors and platelets, with hemorrhage. It is initiated after conditions such as sepsis and trauma and can be acute or chronic, with two different phenotypes, a thrombotic and a hemorrhagic. It is the phenotype that will determine the treatment of the syndrome.
Objectives: To access the prevalence of deaths due to disseminated intravascular coagulation in Brazil, between 2010 and 2015.
Materials and methods:
Retrospective study demonstrating all cases of death due to disseminated intravascular coagulation, from 2010 to 2015, in Brazil. Epidemiological data were collected through the database of the Mortality Information System (SIM).
The relationship between the number of deaths and age does not follow an exponential increase. It is observed a peak in children under one year, which soon decreases progressively, until the age group of 10 to 14 years, increasing exponentially until the age group of 70 to 79 years. In the regions of Brazil, the one that had the highest number of deaths registered was the Southeast, with 40.8% of the cases. The Cento-Oeste was responsible for the fewest cases, with only 7.8% of the cases. The number of deaths was higher in women, but not significantly. They accounted for 51.1% of all deaths. In relation to the number of deaths per year, there was a non-exponential decrease in this number between 2010 and 2015, going from 205 to 185 registered cases.
Conclusion: It was possible to observe that there is a great affection in children under one year, showing that this condition is an important death rate in these children. It is triggered by sepsis, complications in childbirth, hypoxia, hypothermia, acidosis, enterocolitis, among others. Thus, early treatment in both adults and children is of paramount importance. It is also important to remove the triggering factor from this condition.
O31 EPIDEMIOLOGICAL ANALYSIS OF THE PROFILE OF HOSPITALIZED PATIENTS WITH ACUTE RHEUMATIC FEVER, IN BRAZIL, BETWEEN 2010 AND 2017
Érica Alves Nascimento, Andressa Borelli Santos, Mariana Bomfim Menezes, Débora Larissa Montarroyos Leite
UNIVERSIDADE TIRADENTES, ARACAJU, SERGIPE, Brasil
Rheumatic fever is an inflammatory, systemic disease that occurs in genetically predisposed people. It is a consequence of a pharyngotonsillitis caused by Group A β-hemolytic Streptococcus. Rheumatic heart disease is the main consequence of acute rheumatic fever, which also has other manifestations, like arthritis, chorea, subcutaneous nodules and marginate erythema.
To access the prevalence of acute rheumatic fever treated as hospitalization between 2010 and 2017.
Materials and methods:
Retrospective study demonstrating all cases of hospitalization for acute rheumatic fever, from 2010 to 2017, in Brazil. Epidemiological data were collected through the SUS Hospital Information System (SIH/SUS) database.
From 2010 to 2017, there was a 62,5% decrease in the 31,595 registered cases, mainly due to socioeconomic improvement and more investments in health. From 2012 to 2013, however, there was an increase, decreasing again in 2014. The Northeastern region accounts for 40% of cases of hospitalization, contrasting with the South region, responsible for only 8.6% of the cases, which shows socioeconomic and health care differences in the country. The highest incidence occurs in the age groups of 40 to 69 years. There is a higher prevalence in women, accounting for 51.45% of the cases. Regarding the character of hospitalization, 86% were hospitalized as a matter of urgency.
The study shows that there was a decrease in the number of hospitalizations for acute rheumatic fever in Brazil. However, this disease should not be neglected, since improvements, especially in basic care, may prevent some cases of rheumatic fever.
Blanca E R G Bica1, Mauricio Petroli2, Ana Carolina Lopes Santiago2, Gabriel Alves Oliveira De Pinho2, Juliana Carvalho De Mello2, David Hong Kang2, Ricardo Mannato Bolelli2
1UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2UFRJ, RIO DE JANEIRO, RJ, Brasil
Background: Sjögren’s Syndrome (SS) is a chronic autoimmune disease, rare in childhood and adolescence, characterized mainly by xerostomia and xerophthalmia, which compromises exocrine glands causing inflammatory response that leads to glandular hyposecretion. SS is probably underdiagnosed in pediatric range due to differences in presentation regarding adults with this condition, causing low recognition of the disease in children. The authors describe demographic, clinical, laboratory and treatment profiles of a cohort of children with primary SS attended at a university center.
Methods: Retrospective analysis of 30 selected patients’ medical records between 2005 and 2017 allowed collection of various data. Laboratory and additional investigations included documentation of ocular dryness (Schirmer test, Rose-Bengal stain); evidence of parotid involvement (scintiscan, sialometry); and histological evidence of lymphocytic infiltration of the minor salivary glands or other organs.
Results and Conclusions: 30 patients diagnosed with juvenile SS were selected: 22 girls (73%) and 8 boys (27%) with an average age of 11 years. The clinical characteristics were: parotid enlargement as the initial manifestation of the disease in 11 patients (37%), and recurrent episode in 4 patients (13,3%). 12 patients (40%) had xerostomia and 17 (57%) xerophthalmia. One patient (3,3%) presented with leukocytoclastic vasculitis in lower limbs as first manifestation of the disease in association to recurrent parotid swelling. Two (6,6%) patients presented neurological symptoms (1 peripheric sensory neuropathy and 1 with dysautonomic manifestations). Positive Schirmer test was observed in 11 patients (37%), Rose Bengal stain in 10 (33%). 76% of patients had abnormal salivary glands scintigraphy. In 8 patients (30%) the salivary gland biopsy revealed compatible with Sjogren syndrome. 9 patients (30%) presented positive RF, 14 patients (46%) anti-Ro/SSA, 10 patients (33%) anti-La/SSB, 28 patients (93%) had +ve ANA. 50% received glucocorticoid. Hydroxychloroquine was the drug most often used in 25 patients (83%), followed by methotrexate in 12 patients (40%), azathioprine in 4 patients (13%) and cyclophosphamide in 3 patients (10%). Only one patient required the use of human immunoglobulin and one leflunomide (3.3%). Two patients (6.6%) received rituximab. The present study demonstrated the demographic, clinical aspects, laboratory and treatment in a series of patients with primary juvenile Sjögren’s syndrome, a relatively rare condition, presenting an overview of this population in our hospital.
O33 EPIDEMIOLOGY AND MANAGEMENT PRACTICES FOR CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A SURVEY IN LATIN AMERICA
Clovis Artur Silva1, Juliana C. O. A. Ferreira1, Vitor C. Trindade1, Graciela Espada2, Zoilo Morel3, Eloisa Bonfa1, Claudia S. Magalhães4
1FMUSP, SAO PAULO, SP, Brasil; 2HOSPITAL DE NIñOS DR RICARDO GUTIERREZ, BUENOS AIRES, ARGENTINA, SAO PAULO, SP, Argentina; 3HOSPITAL DE CLINICAS, UNIVERSIDAD NACIONAL DE ASUNCION, PARAGUAY, ASUNCION, Paraguai; 4UNESP, SAO PAULO, SP, Brasil
Background: Two groups have reported data focused on epidemiology, clinical and laboratorial features of cSLE patients in LA: BRAC-SLE (Brazilian Childhood-onset SLE Registry Group) and GLADEL (Grupo Latino Americano De Estudio del Lupus). However, to the best of our knowledge, epidemiology and management of cSLE based on LA Pediatric Rheumatologists (LAPR) were not carried out. Therefore, the objective to our study was to assess epidemiology and management practices of LAPR about childhood-onset systemic lupus erythematosus (cSLE).
Methods: A cross-sectional study was performed in 288 LAPR PANLAR members based on online survey about cSLE practices.
Results: The response rate of web-based survey by LAPR was 170/288 (59%) and the majority worked in University Hospitals (63%). The most five countries of surveyed specialists was: Brazil n=85 (52.5%), Argentina n=22 (14%), Mexico n=22 (14%), Colombia n=11 (7%), Chile n=6 (3.7%). The ACR and/or SLICC classification criteria (99%) and disease activity tools (97%) were almost universally used by LAPR, whereas damage index (70%) and CHAQ (58%) instruments were less frequently used. Laboratory exams, diagnostic imaging and biopsies were generally available (>75%), however low availability for densitometry (66%). Drug access was excellent for the most common prescribed medications (>75%), except for belimumab (11%). Emerging mosquito-borne diseases were also reported: dengue (20%), Chikungunya (11%) and Zika (8%). Groups were further divided in two, according to the number of cSLE patients followed by LAPR in the last year: group A (≥25 patients) and group B (<25 patients). Frequencies of condom in combination with other contraceptive methods were significantly higher in group A than B (p=0.01). The frequencies of reported pregnancy (p<0.001) and non-adherence to therapy were significantly higher in group A (p=0.023). Alcohol intake (p=0.004) and illicit drug use (p=0.007) were also reported more frequently by LAPR of group A in at least one cSLE patient.
Conclusion: This first large web-based survey demonstrated an overall excellent access for diagnosis and therapy by LAPR, probably related to their high rate of practices in tertiary care of University Hospitals. Adherence to therapy, pregnancy and substance abuse were identified as major challenges in this population, particularly in larger centers.
O34 EVALUATION OF CORTICAL MICROARCHITECTURE, BONE STIFFNESS AND BONE REMODELING IN PATIENTS WITH ATYPICAL FEMORAL FRACTURE
Mariana Ortega Perez2, Diogo S Domiciano2, Luciene M dos Reis1, Vanda Jorgetti1, Rosa Maria Rodrigues Pereira2
1DISCIPLINA DE NEFROLOGIA, HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (FMUSP), SÃO PAULO, SP, Brasil; 2DISCIPLINA DE REUMATOLOGIA, HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (FMUSP), SÃO PAULO, SP, Brasil
Background: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit cortical thickening in femoral shaft, suggesting that AFF may occur due to cortical stress. Analysis of cortical bone microarchitecture, biomechanical properties of bone, and bone remodeling in AFF are poorly explored in the literature. Simultaneous evaluation of these parameters may be useful in understanding the mechanisms of this type of fracture. Our aim is to evaluate patients with AFF including: 1) cortical bone microarchitecture and bone stiffness by high resolution peripheral quantitative computed tomography (HR-pQCT) and 2) cortical microarchitecture and bone remodeling parameters by bone histomorphometry of iliac crest.
Materials and methods: Eighteen patients with AFF by the American Society of Bone Mineral Research. Cortical bone parameters (cortical volumetric bone mineral density: Ct.vBMD, mgHA/cm3 and cortical thickness: Ct.Th, mm) and bone stiffness (S, kN/mm) were studied in tibia and distal radius by HR-pQCT and compared to healthy controls matched for sex and age. Cortical thickness (Ct.Th, μm) and bone remodeling (bone formation rate; surface, volume and thickness osteoid; eroded surface; osteoblastic surface) were assessment (Osteomeasure software®) and compared with healthy individuals matched for sex and age.
Results: The mean age of the patients was 64.9±13.3 years old, 94.4% women and 72.2% Caucasian. Seventeen used bisphosphonates (5.8±2.7 years) and 83.3% alendronate at the time of fracture. One patient was on denosumab, but had received bisphosphonate for 6 years. Presence of rheumatic disease was observed in 50% of the patients, most of them with rheumatoid arthritis and 44.4% of the patients used oral glucocorticoid. All fractures were diaphyseal, of which 16 (88.8%) were complete and 4 (22.2%) bilateral. HR-pQCT (n=12) in tibia showed decreased/normal Ct.vBMD in 83.3% and decreased/normal Ct.Th in 91.6% of the patients. Similar findings were observed in distal radius. Seventy-five percent of the patients had decreased bone stiffness in tibia and 58.3% in radius. Bone histomorphometry (n=6) exhibited Ct.Th decreased in 66.6% and normal in 33.3% of the cases. All patients had suppressed bone remodeling.
Conclusion: Unlike the femoral diaphysis, most of our patients with AFF presented decrease in the cortical density and cortical thickness in tibia and distal radius. Histomorphometric analysis was concordant with these findings. Our data suggest that impairment of cortical microarchitecture associated with decreased bone stiffness and suppression of bone remodeling would explain bone fragility in these patients.
O36 EVALUATION OF THE EFFECT OF FASCIOLA HEPATICA EXTRACT AS AN ANTI-INFLAMMATORY THERAPY IN EXPERIMENTAL ARTHRITIS
Renata Ternus Pedó1, Mirian Farinon1, Thales Hein da Rosa1, Martín Pablo Cancela Sehabiague1, Henrique Bunselmeyer Ferreira1, Patricia Gnieslaw de Oliveira2, Ricardo Machado Xavier1
1UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, RS, Brasil; 2UNIVERSIDADE DA CALIFÓRNIA, SAN DIEGO, SAN DIEGO, CALIFÓRNIA, Estados Unidos
Background: Rheumatoid arthritis (RA) is an autoimmune disease where the chronic inflammation and subsequent cartilage and bone erosion lead to joint destruction. Fasciola hepatica (F. hepatica) is a parasite that regulates the immune response of its hosts through excretory-secretory products (ESPs) and tegument antigens. ESPs are able to suppress the immune response via T helper 1 (Th1) and both ESPs and tegument antigens of F. hepatica are able to suppress the activation of dendritic cells by toll-like receptors. Based on this, in this study we aimed to evaluate the effect of F. hepatica extract in two animal models of arthritis.
Material and Methods: Male BALB/c mice (n=21) had antigen-induced arthritis (AIA) with methylated bovine serum albumin (mBSA) and were divide into negative control, vehicle (PBS) and F. hepatica extract (200μg/dose) groups. Intraperitoneal treatment was performed 24h and 30min before intraarticular (ia) injection of mBSA. Was evaluated paw nociception in 0, 3, 6 and 24h and leukocytes migration into knee joints 24h after ia injection of mBSA. Male DBA/1J mice (n=8) had collagen-induced arthritis (CIA) with bovine collagen type II and were divided into prophylactic F. hepatica extract treatment (200μg/dose) and vehicle (PBS) groups. During the treatment period (day 18 from 46) was evaluated clinical articular score, nociception, paw edema and body weight. Statistical analysis was assessed with ANOVA, followed by Turkey. The data are presented as mean± SEM.
Results: In AIA, treatment with F. hepatica extract reduced nociception in 3 (7,46±0,34g), 6 (5.7±0.27g) and 24h (6.37±0.37g) compared with vehicle (24h: 3.81±0.44g) (p<0.001) and inhibited leukocytes migration to inflammatory site (40±7.76x10^4 leukocytes/cavity) compared with vehicle (90.90±12.87x10^4 leukocytes/cavity) (p<0.01). In a preliminary CIA, prophylactic treatment did not improve analyzed parameters. However, treatment group presented a later beginning of clinical signs of arthritis (day 33) compared to vehicle (day 25). Additionally, while vehicle group presented a reduction of 3.4% of body weight, treatment group gained 2.4% of body weight at the end of experimental period (p=0.0509).
Conclusions: Treatment with F. hepatica improved acute experimental arthritis attenuating nociception and leukocytes migration to knee joint. In a preliminary experiment, prophylactic treatment with F. hepatica presented no effect over analyzed parameters in chronic experimental arthritis, but delayed the clinical manifestation of arthritis and seemed to prevent the body weight loss observed in this model. Further studies will be performed to clarify the effect of F. hepatica extract in chronic experimental arthritis.
O37 EVALUATION OF THE EFFECTIVENESS OF A PROGRESSIVE RESISTANCE TRAINING PROGRAM FOR PATIENTS WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL
Jamil Natour, Mariana Vassalli, Raphael Vilela Timoteo da Silva, Anamaria Jones
EPM/UNIFESP, SÃO PAULO, SP, Brasil
Background: Fibromyalgia (FM) is a chronic pain syndrome, not inflammatory, characterized by the presence of diffuse pain and painful points. Commonly, it is linked to other symptoms such as fatigue, sleep disorders, morning stiffness; and psychological disorders such as anxiety and depression. The medical treatment of FM brings benefits in the short term. For long-term benefits it is usually associated with non-medicated treatment, such as patient education, physical conditioning, rehabilitation and psychological therapy. In this study, we used the progressive resistance training, which is muscle strengthening performed through the gradual increase of load during the training period.
Objectives: To evaluate the impact of a global progressive resistance training program on pain, quality of life, functional capacity and muscular strength in patients with fibromyalgia
Methods: Sixty patients were randomized into2 groups: experimental group and control group. Patients in the experimental group underwent a progressive resistance training program, performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1RM. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training, the experimental group also received a structured education program in one hour class once a week for five weeks. Patients in the control group received the same education program.
Results: After the intervention, significant improvements were observed in the experimental group in comparison with control group over time for the following parameters: pain (p = 0.004), FIQ (p = 0.021), quality of life (with statistically significant improvement for all the SF-36 domains), functional capacity, assessed by the 6-minute walk test (p = 0.045), and muscle strength (with statistically significant improvement for all muscle groups trained). The intergroup and intragroup comparisons were showed in Table 1.
Conclusions: The progressive resistance training program was effective in improving pain, quality of life, functional capacity and muscular strength of patients with fibromyalgia.
O39 EXPOSURE FACTORS ASSOCIATED WITH SYMPTOMATIC OSTEONECROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Yara Mariana Alvim Santos, Ubiratan Brum de Castro, Wilson Tavares Campos, Cristina Costa Duarte Lanna, Gilda Aparecida Ferreira
UFMG, BELO HORIZONTE, MG, Brasil
Background: The aim of this study was to evaluate the exposure factors associated with symptomatic osteonecrosis (ON) in patients with Systemic Lupus Erythematosus (SLE).
Methods: this is a case-control study, with 139 SLE patients according to ACR/1997 criteria, 33 with symptomatic ON, matched for sex and cumulative dose of glycocorticoid with 106 patients with no known diagnosis of ON. An extensive clinical and laboratory evaluation using a standard protocol established since 2004 was carried out.
Results and Conclusions: Of the 139 patients, 93% were female, the mean (SD) age was 40.8 (12.1) years and the median (min-max) of disease duration was 102 (6-372) months. The SLICC-DI/ACR score (excluding the ON variable at the end of the study) ranged from 0 to 9 (median of 1). Considering the 33 patients with SLE and ON, at the time of ON diagnosis, the mean (SD) age was 33 (11) years, the mean (SD) of the disease duration was 75.7 (62.4) months and the median (min-max) of the prednisone daily dose was 10 (0-60) mg. The median (min-max) of modified SLEDAI-2K prior to the diagnosis of osteonecrosis (mean score of three consecutive appointments per year over a three-year period) was 5 (0-11). The most affected joints were hips (78.8%) and knees (45.5%), bilateral in 48.5% of cases and in multiple sites in 9%. Patients with SLE and ON were younger (p<0.001), had lower age at SLE diagnosis (p=0.021), higher frequency of livedo reticularis (p=0.025), nephritis (p=0.009) and higher score of modified SLEDAI-2K prior to ON diagnosis (p< 0.001) compared to non-ON patients. In the binary logistic regression analysis, disease activity (OR=1.4, 95%CI: 1.187-1.728, p = 0.000) and livedo reticularis (OR = 8.3, 95% CI: 1.305-53.215, p=0.025) were independently associated with ON. The modified SLEDAI-2K in the three previous years of ON diagnosis was a good predictor of ON development (area under the ROC curve= 0.791, 95% CI: 0.697-0.885) and the score >3.5 was the most appropriate cut off for the prediction of ON development. In this group of lupus patients, higher disease activity score was associated with symptomatic ON and was a good predictor of ON development independently of the glycocorticoid use. In addition, younger age at ON diagnosis and at onset of SLE, the presence of livedo reticularis and of nephritis, and a higher damage score after exclusion of ON variable, were other factors associated with symptomatic ON.
O40 HIGHER CUMULATIVE DOSE OF CYCLOPHOSPHAMIDE AND VASCULITIS DAMAGE INDEX AS MAIN RISK FACTORS OF INFECTIONS IN SYSTEMIC VASCULITIS PATIENTS DURING HOSPITALIZATION
Felipe Mendonça De Santana, Carlos Emílio Insfran Echauri, Lorenza Rosa Silvério Scomparin, Maíra Luciana Marconcini de Lacerda, Rafael Pontes Andreussi, Adriana Coracini Tonacio de Proença, Lissiane Karine Noronha Guedes, Eduardo Ferreira Borba Neto, Rosa Maria Rodrigues Pereira
FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SP, Brasil
Background: Systemic vasculitis encompasses a heterogeneous group of diseases distinguished by the presence of an inflammatory response within the vessels wall. Its treatment often requires the use of immunosuppressives. Hence, infections are fairly common in vasculitis patients. However, discerning acute infection from disease relapse is not straightforward. We searched for clinical differences between vasculitis patients admitted due to severe infections and those admitted due to other conditions.
Methods: A cross-sectional study was performed using standard electronic medical records of a rheumatology tertiary center. Data from consecutive inpatients admitted on rheumatology Clinics from 2015 to 2017 were revised. Those with confirmed systemic vasculitis were included. Twenty-six patients (most of them with Granulomatosis with poliangiitis) were considered eligible for analysis, comprising 37 admissions. These were classified regarding the presence or absence of infection at entry. Data collected during hospitalization was used to ascertain whether the baseline clinical condition was indeed confirmed as infection, including cultures and radiologic findings. Baseline variables were compared between patients admitted due to infection (Infection group) and those admitted for other conditions (Non-infection group). The infection group consisted of 14 admissions and the non-infection group of 23 admissions. Respiratory infections were most common (12 of the total of 14). The Non-infection group comprised mainly of patients admitted due to vasculitis activity. χ2 test and Fisher exact test were used for categorical variables and Welch t test, Student t test and Mann-Whitney test for quantitative variables, where appropriate. The alpha level was set at 0.05.
Results: Patients admitted due to infection had significantly higher previous cumulative cyclophosphamide (PCCD) dose (mostly intravenous) (7.4 [IQ 7.0-15.8] vs. 0.0 [IQ 0.0-9.4] g, p=0.038), a higher baseline Vasculitis Damage Index (VDI) (6.07 [SD ± 3.73] vs. 3.52 [SD ± 2.20], p=0.032) and lower Birmingham Vasculitis Activity Score (BVAS) (0.0 [IQ 0.0-2.25] vs. 6.0[IQ 2.0-10.0], p=0.006). No significant differences regarding age, sex, cumulative dose of glucocorticoid during the last year, days of admission and comorbidities were identified. No patients used biologic therapy during the admission. No death was observed.
Conclusions: Infection was closely related with previous damage of the disease but not with activity scores at admission. Supporting this observation, cumulative cyclophosphamide dose was also a main factor for infection. Further studies are necessary to confirm the role of these findings.
O41 IMPACT OF DIFFERENT CLASSES OF LUPUS NEPHRITIS IN MATERNAL AND FETAL OUTCOMES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Evandro Mendes Klumb1,2, Marcela Ignacchiti Lacerda2, Bruna Costa Rodrigues2, Camila Castro Silva2, Camila Pitasi Argueles2, Flavia Cunha dos Santos2, Guilherme Ribeiro Ramires de Jesús2, Nilson Ramires de Jesús2, Roger Abramino Levy2
1UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2UERJ, RJ, RJ, Brasil
Background: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that has variable clinical course, ranging from mild to severe forms. Lupus nephritis (LN) occurs in 60% of patients and is the most common indication for immunosuppression and hospitalization, leading to the highest morbidity and mortality among SLE manifestations. History of LN is associated with increased risk of adverse maternal outcomes such as hypertensive disorders, which are even more frequent when nephritis is active at conception. There is also increased fetal morbidity when LN occurs during pregnancy. The aim of the study was to compare SLE activity during pregnancy, maternal complications and gestational outcomes between SLE patients with LN and without LN, also analysing the differences between LN subclasses.
Materials and Methods: This is a cohort study nested in a Cohort of autoimmune pregnancies followed from 2011 to 2016 with singleton gestations and delivery after 22 weeks. Patients were classified according to the presence of nephritis (including subclasses), SLE non-renal and renal activity, association with antiphospholipid antibodies/syndrome, permanent damage related to SLE and medication at conception and during pregnancy. The main outcomes were SLE non-renal and renal activity; SLICC/ACR damage index (SDI); maternal complications; adverse fetal outcomes; general clinical complications.
Results and conclusions: Patients with LN had more frequently systemic flares (p=0.004), used more often prednisone >20mg/day (p=0.02) and azathioprine (p=0.007), had more hospitalization related to SLE (p=0.01) and not related to SLE (p=0.002). When only patients with proliferative glomerulonephritis (classes III/IV) were compared to patients without LN and other classes of nephritis (II and V), the findings remained similar. History of nephritis and SLE activity at conception were significant risk factors for hypertensive disorders (RR=4.4, p<0.001; RR=4.1, p=0.001, respectively) and placental insufficiency (RR=9.8, p<0.001; RR=2.86, p=0.007, respectively). Patients with LN and permanent damage (SDI≥1) had significantly more disease activity than patients without LN (p=0.02). SLE reactivation during pregnancy, hospitalization and greater need for immunosuppression were more frequent in patients with LN, especially when proliferative nephritis was present. Patients with LN had a higher frequency of permanent damage related to SLE and this was also associated with a higher frequency of adverse maternal and fetal outcomes.
Consent for publication
The authors declare that they have obtained informed written consent from the patient's tutors for publication
O42 IMPACT OF STATINS IN PATIENTS WITH CLINICAL AND LABORATORY STABLE SYSTEMIC AUTOIMMUNE MYOPATHIES
Isabela Bruna Pires Borges, Samuel Katsuyuki Shinjo
FACULDADE DE MEDICINA - USP, SÃO PAULO, SP, Brasil
Background. Recent studies have shown a high prevalence of dyslipidemia and others cardiovascular risk factors in patients with systemic autoimmune myopathies (SAM). However, little is known about impact of statins in these patients, what motivated to assess data to perform the analyses of the present study.
Materials and methods. This is a retrospective study, from 2004 to 2018, in which 440 patients with SAM (2017 EULAR/ACR classification criteria) were initially evaluated. Among them, 22 patients were selected: dyslipidemia (total cholesterol >200, HDL<40, LDL>130 and/or triglyceride >150mg/dL), clinical and laboratory stable MAS, underwent to statins. Patients with clinically amyopathic dermatomyositis and immune-mediated necrotizing myopathies were excluded.
Results. Data form 22 consecutive patients (14 dermatomyositis, 1 polymyositis and 7 anti-Jo-1 antisynthetase syndrome) were assessed. Mean age of cases was 50.4 years and 68.2% were female. Median time between diagnosis and disease symptoms onset was 3.5 months; mean duration of disease of 5.0 years; initial serum levels of creatine phosphokinase was 1406U/L. When statins were introduced, creatine phosphokinase was 116U/L, 50% patients were not using glucocorticoid, whereas the other half used a median dose of 2.5mg/day. Moreover, 2 patients were using any immunosuppressive drugs. Ten patients received simvastatin (10-60mg/day), 11 atorvastatin (20-40mg/day), and 1 atorvastatin (10mg/day) which was later replaced by simvastatin (20mg/day). Median time of statin exposition was 26 months. During the follow-up, in addition to the improvement of the lipid profile, no disease relapsing or clinical and laboratory intercurrence was observed (Table 1). Furthermore, glucocorticoids were totally suspended (P=0.008).
Conclusions. Regardless of the small sample, our data show efficacy and safety of statin specifically in patients with clinical and laboratory stable SAM and with dyslipidemia. Further studies with larger sample and including patients with different disease activity degree are necessary to corroborate our results.
Support by FAPESP #2016/20371-1 (IBPB) and #2017/13109-1 (SKS).
O43 IMPACT OF TREAT-TO-TARGET APPROACH IN THE MUSCLE MAGNETIC RESONANCE IMAGING OF PATIENTS WITH IMMUNE-MEDIATED NECROTIZING MYOPATHIES
Jean De Souza, Samuel Katsuyuki Shinjo
HCFMUSP, SÃO PAULO, SP, Brasil
Background. Immune-mediated necrotizing myopathies (IMNM) are rare autoimmune myopathies usually characterized by muscle disability, atrophy and also fat replacement. Moreover, there is currently no standardized or specific treatment for IMNM. In the present study, the authors assessed thigh magnetic resonance imaging (MRI) of IMNM patients who underwent an early-goal induction of remission with methylprednisolone and/or intravenous human immunoglobulin pulse therapies.
Materials and methods. This inception cohort study, from 2013 to 2018, included 7 consecutive patients with IMNM (4 with anti-signal recognition particle autoantibody and 3 with anti-hydroxy-methyl-glutaryl coenzyme A reductase), according to the Myositis Study Group/119th European Neuromuscular Centre workshop criteria classification. Immediately at diagnosis, patients received methylprednisolone and/or intravenous human immunoglobulin pulse therapies, associated posteriori with immunosuppressant or immunomodulatory drugs (methotrexate, azathioprine, mycophenolate mofetil, isolated or in combination, or also rituximab). After data collection, middle third thigh MRI was assessed to evaluate muscle edema, atrophy and fat replacement, according to a semi-quantitative scale: mild (<25%), moderate (25-50%) or severe (>50% of the cross-sectional area). Disease improvement assessment, evaluated by the International Myositis Assessment and Clinical Studies Group (IMACS) core set measures, was performed before immunosuppression and by the time of MRI acquisition.
Results. Current mean age of patients was 48 years, with female gender predominance (70%). Median duration from symptoms onset to diagnosis was 4 months, whereas from disease diagnosis to MRI was 38 months. The IMACS total improvement score (comparing disease onset to MRI assessment) showed a major response improvement. At the time of MRI, all patients were using at least one immunosuppressive or immunomodulatory drug, but only 3 out of 7 patients were still using prednisone (5-15mg/day). Regarding thigh MRI abnormality features, 3 out of 7 patients had (mild) muscle edema, one (mild) muscle atrophy and 5 fat replacement (4 mild and 1 moderate).
Conclusions. In contrast to scarcely available studies in the literature, our patients had significantly more benign MRI features accompanied with good clinical outcome. This may be a consequence of the treat-to-target induction approach applied in the present study. Although more studies are necessary to corroborate our data, this scenario supports a decisive role of treat-to-target therapy in IMNM.
Consent for publication
The authors declare that they have obtained informed written consent from the patient's tutors for publication
Bruno Camargo Tiseo1, Gabriela Araújo Munhoz2, Eloisa Bonfa2, Eduardo F. Borba2, Guilherme J. A. Wood3, Miguel Srougi3, Clovis A. Silva4, Marcello A. S. Cocuzza3
1DISCIPLINE OF UROLOGY - HOSPITAL DAS CLINICAS DA FACULDADE DE MEDICINA DA USP, SÃO PAULO, SP, Brasil; 2RHEUMATOLOGY DIVISION, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SP, BRAZIL, SÃO PAULO, SP, Brasil; 3DISCIPLINE OF UROLOGY, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SP, BRAZIL, SÃO PAULO, SP, Brasil; 4PEDIATRIC RHEUMATOLOGY UNIT, CHILDREN’S INSTITUTE, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SP, BRAZIL, SÃO PAULO, SP, Brasil
Objective: To evaluate sperm DNA fragmentation analysis in non-azoospermic male SLE (Systemic Lupus Erythematosus) patients.
Methods: Twenty-eight consecutive male SLE patients (ACR criteria) and 34 healthy controls were evaluated for demographic/exposures data, urologic evaluation, hormone profile and sperm analysis (including sperm DNA fragmentation). Clinical features, disease activity/damage scores and treatment were also evaluated.
Results: The median age [33 (20-52) vs. 36.5(25-54) years, p=0.329] and frequency of varicocele (25% vs. 32%, p=0.183) were similar in SLE patients and healthy controls. Sperm DNA fragmentation showed significantly higher levels of cells class III [44 (9-88) vs. 16.5(0-80)%, p=0.001] and cell class IV [10.5(3-86) vs. 7(0-36)%, p=0.039] in SLE. Sperm DNA fragmentation Index was also significantly higher in SLE patients [62 (31-97) vs. 25.5(0-100)%, p<0.001]. Conventional sperm parameters (including sperm count, motility and morphology) were similar in both groups. In SLE patients no correlations were observed between sperm DNA fragmentation index and age, disease duration, SLEDAI-2K and SLICC/ACR-DI scores, and cumulative dose of prednisone, hydroxychloroquine, intravenous cyclophosphamide (IVCYC), methotrexate, azathioprine and mycophenolate mofetil (p>0.05). Further analysis of SLE patients treated with and without IVCYC showed that total sperm motility was significantly lower in the former group [64%(15-83) vs. 72%(57-86), p=0.024]. Sperm DNA fragmentation index was alike in both groups [52.5(31-95) vs. 67.5(34-97)%, p=0.185].
Conclusions: To our knowledge, this is the first demonstration that male non-azoospermic SLE patients have increased sperm DNA fragmentation without evident gonadal dysfunction. IVCYC does not seem to be a major determinant for this abnormality. Future prospective study is necessary to determine the impact of this alteration in these patients’ fertility.
O45 INFLUENCE OF PHYSIOTHERAPEUTIC INTERVENTION ON DISEASE ACTIVITY, FUNCTIONALITY AND PAIN IN SUBJECTS WITH SPONDYLOARTHRITIS: A SYSTEMATIC REVIEW OF LITERATURE
Ana Gabriela De Lima, Mariana Bogoni Budib, Silvio Assis de Oliveira Junior, Izaias Pereira da Costa, Paula Felippe Martinez
UNIVERSIDADE FEDERAL DE MATO GROSSO DO SUL, CAMPO GRANDE, MS, Brasil
Background: Spondyloarthritis are distinct diseases with common characteristics, including clinical aspects (axial pain of inflammatory, association of arthritis of large joints and peripheral enthesopathies), radiological and laboratory findings. This set of diseases include ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthropathy and undifferentiated spondyloarthritis. Conservative treatment has shown to be fundamental for the improvement of disease activity, pain and functionality. In this context, it is necessary to systematize evidence in the search for scientific support on physiotherapeutic methods suitable for the rehabilitation of subjects with spondyloarthritis. The aim of this study is to verify the influence of physical therapy on disease activity, functionality and pain in subjects with spondyloarthritis.
Materials and methods: Systematic search was conducted using PubMed, PEDro and SciELO electronic databases based on the research strategies recommended by the Preferential Reports for Systematic Analysis and Meta-Analysis (PRISMA) items using combinations of Medical Subject Heading descriptors Terms (MeSH): Exercise; Rehabilitation; Exercise Therapy; Physical Therapy Modalities; Spondylarthropathies. As criteria of inclusion, randomized and non-randomized clinical trials published between 2013 and 2018 were considered, which integrated protocols with physical exercises and electrotherapy for the treatment of individuals with spondyloarthritis. First, titles and abstracts of all the articles identified by the research strategy were evaluated in isolation and in duplicate by two reviewers (A.G.L and M.B.B). In the second step, the same reviewers evaluated the full articles, independently and together. Thus, 14 studies were selected.
Results and conclusions: Stretching exercises combined with aerobic exercise reflect on softening pain, improving functionality and activity of the disease. Resistance and aerobic exercises associated with stretching presented positive results for functionality and disease activity. To soften pain and to improve functionality, the use of electrotherapy associated with resistance exercises was more effective than electrotherapy applied in isolation. Alternative methods of exercise, such as exergames and the McKenzie method, have softened the pain, improved functionality and activity of the disease when compared to other therapeutic modalities. In addition, this research revealed the low effectiveness of educational interventions not associated with kinesiotherapy. Similarly, the hydrotherapy presented results similar to the exercises performed in soil for the functionality, pain and activity of the disease. Physical therapy has a significant improvement in pain, function and disease activity. However, there is a gap regarding the type of exercise, volume and intensity appropriate to each stage of the rehabilitation process of subjects with spondyloarthritis.
O47 IS THERE STILL A ROLE FOR NSAIDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS? DATE FROM A LARGE COHORT IN BRAZIL
Ana Paula Monteiro Gomides1, Licia Maria Henrique da Mota2, Geraldo da Rocha Castelar Pinheiro4, Cleandro Pires de Albuquerque3, Ana Beatriz Vargas-Santos4, Manoel Barros Bertolo5, Alisson Aliel Vigano Pugliesi5, Letícia Rocha Pereira4, Eduardo de Almeida Macedo5, Paulo Louzada Filho6, Maria de Fátima L da Cunha Sauma7, Marcel Lobato Sauma7, Júlia Brito de Medeiros8, Claiton Viegas Brenol9, Ivanio Alves Pereira10, Sebastiao Radominski11, Maria Fernanda Resende12, Maria Raquel Costa Pinto12, Gustavo Gomes Resende12, Karina Bonfiglioli13, Henrique Carriço13, Rina Dalva Neubarth Giorgi14, Nathalia de Carvalho Sacilotto15
1UNB/UNICEUB, BRASÍLIA, DF, Brasil; 2BRASÍLIA, DF, Brasil; 3UNB, BRASÍLIA, DF, Brasil; 4UERJ, RIO DE JANEIRO, RJ, Brasil; 5UNICAMP, CAMPINAS, SP, Brasil; 6USP RIBEIRÃO PRETO, RIBEIRÃO PRETO, SP, Brasil; 7UF DO PARÁ, BELÉM, PA, Brasil; 8UF PARÁ, BELÉM, PA, Brasil; 9UFRGS, PORTO ALEGRE, RS, Brasil; 10UFSC, FLORIANÓPOLIS, SC, Brasil; 11UF PARANÁ, CURITIBA, PARANÁ, Brasil; 12UFMG, BELO HORIZONTE, MG, Brasil; 13USP, SÃO PAULO, SP, Brasil; 14HSPE-SP-, SÃO PAULO, SP, Brasil; 15HSPE-SP, SÃO PAULO, SP, Brasil
Introduction: Non-hormonal anti-inflammatory drugs (NSAIDs) have always been used in the treatment of rheumatoid arthritis, but with the emergence of new therapeutic classes, which allow better control of the disease, has been reducing the need for long-term use. In addition, the potential risk in cardiovascular diseases and adverse effects on the gastrointestinal tract, kidneys and possible drug interactions, make the use of this therapeutic class better indicated only in phases of exacerbation and for the shortest possible time. The objective of this study is to evaluate the current use of NSAIDs in RA patients in a large real life cohort in Brazil.
Materials And Methods: A multicenter study was conducted with RA patients from 11 centers in different states of Brazil. Participants should have a written diagnosis of RA and regular follow-up in the referral services of the public network. Clinical and complementary evaluation and registry analysis were performed. The present study is a cross section referring to the initial evaluation of the patients of this project.
Results and Conclusions: A total of 1117 patients with an average disease time of 12.6 years were analyzed. 78.73% had a positive rheumatoid factor. The median DAS was 3.52 and the CDAI of 9,1022 (90.84%) used conventional synthetic MMCDs (isolated or in combination) and 406 (36.09%) used biological MMCDs.
122 patients (10.9%) were currently using NSAIDs at the time of evaluation. The most commonly used NSAIDs were naproxen (54% of all patients). Table 1 shows all types of drugs as well as doses in use.
When questioned about previous use of NSAIDs during RA treatment, 743 patients (66.58) reported having used this class of therapy.
Considering the above, we found a low rate of current use of NSAIDs in this Brazilian population, data that should be confirmed in other studies.
O49 MALIGNANCY IN CHILDHOOD ONSET -SYSTEMIC LUPUS ERYTHEMATOSUS: REAL-LIFE DATA FROM A NATIONWIDE SERIES
Barbara Geane Alves Fonseca1,2, Manuela Pacifico Segredo (FMB-Unesp)2, Glaucia Novak3, Beatriz Molinari3, Ana Paula Sakamoto4, Virginia Paes Leme Ferriani5, Ana Maria Soares Rolim6, Adriana Fonseca7, Adriana Maluf Elias Sallum3, Rosa Maria Rodrigues Pereira8, Maria TeresaTerreri4, Ana Raquel Feitosa9, Eunice Mitiko Okuda10, Eloisa Bonfá8, Clovis A. A. Silva8, Claudia Saad-Magalhaes2
1UNESP, BOTUCATU, SP, Brasil; 2FMB-UNESP, BOTUCATU, SP, Brasil; 3ICR-FMUSP, SÃO PAULO, SP, Brasil; 4EPM-UNIFESP, SÃO PAULO, SP, Brasil; 5FMRP- USP, RIBEIRÃO PRETO, SP, Brasil; 6OBRAS SOCIAIS IRMÃ DULCE, SALVADOR, BA, Brasil; 7IPPMG-RJ, RIO DE JANEIRO, RJ, Brasil; 8FMUSP, SÃO PAULO, SP, Brasil; 9HOSPITAL GERAL DE FORTALEZA, FORTALEZA, CE, Brasil; 10FM - SANTA CASA SP, SÃO PAULO, SP, Brasil
Background: Malignancy surveillance in childhood-onset SLE (c-SLE) is needed and background risk is important for safe treatment planning. A descriptive report of malignancy outcome, in a nationwide series of c-SLE, is presented.
Methods: A retrospective data collection was conducted, looking for rare c-SLE manifestations, in 27 Brazilian pediatric rheumatology centers. Cases fulfilling 1997-ACR criteria, onset before 18 years, who had a comprehensive 3-time-point-clinical assessments, at c-SLE diagnosis, follow up, and last visit and additionallythe results of abiopsy-proven malignancy manifestation, were selected, at any time point of follow up. This was a convenience sample, where the end of follow up was defined as the date of cancer diagnosis, allowing inclusion of young adults.
Results: There was a total of 1,555 valid c-SLE cases reported; of those, 6had cancer diagnosis, seen in the same service during c-SLE follow up. Their mean age was 15.6 y(12-25 years), mean follow up duration 4.6 years (0.5 to 14years). Malignancy diagnoses and clinical presentation were hematologic (n=3) and non hematologic (n=3). Of the hematologic, (n=1) was diagnosed withHodgkin lymphoma, presenting with fever, weight loss and enlarged lymphonodes, 5 month after c-SLE onset;(n=1) had non-Hodgkin lymphoma presenting with anemia, fever and arthritis, all concomitant to c-SLE onset;(n=1) had an orbital mass withproptosis, diagnosed as a MALT lacrimal glands lymphoma, after 2 years of c-SLE onset. Of the other types of malignancy (n=3), (n=1) hadHPV-related anal-carcinoma after genital condyloma, it was diagnosed after 14 years from c-SLE onset; (n=1) had a testicle mass with germinal cells carcinoma, 4-years after c-SLE onset and (n=1) had a brain tumor, oligodendroglyoma type, presenting with headaches and seizures, 1.3 yearafter c-SLE onset All had active disease status, their mean SLEDAI scores were 14 (range 2-32). The SLICC-SDI scored at least 1 point for malignancy. We did not observe multiple malignancies. CONCLUSIONS: Thefrequency estimates of malignancy in our c-SLE population was0.4 %. Despite being a very rare outcome, it is is a challenge, demanding awarenessbecause signs and symptoms of hematologic malignancy may also mimic c-SLE manifestations. Also, this outcome may be related to disease factors or due to the treatment with glucocorticoids and cytotoxic drugs.
O50 MICROSTRUCTURAL CHANGES IN CORPUS CALLOSUM IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: DIFFUSION TENSOR STUDY
Beatriz Lavras Costallat1,2, Aline Tamires Lapa2, Lilian Tereza Lavras Costallat2, Fernando Cendes2, Willian Javier Garcia Herrera3, Letícia Rittner3, Simone Appenzeller2
1UNICAMP, CAMPINAS, SP, Brasil; 2FACULDADE DE CIÊNCIAS MÉDICAS -UNICAMP, CAMPINAS, SÃO PAULO, Brasil; 3FACULDADE DE ENGENHARIA ELÉTRICA E DA COMPUTAÇÃO- UNICAMP, CAMPINAS, SÃO PAULO, Brasil
Background: The aim of this study was to determine the microstructural changes of the corpus callosum in patients with systemic lupus erythematosus by the diffusion tensor technique (DTI).
Material and method: The study evaluated 116 patients with SLE (110 women, mean age 40 years) and 48 healthy controls (40 women, mean age 35.5 years). All patients fulfilled 4 or more American College of Rheumatology (ACR) SLE criteria and neuropsychiatric manifestations were analyzed based on the ACR diagnostic criteria for neuropsychiatric impairment, classified as active, inactive, or absent on the date of inclusion of the study. SLEDAI and SLICC were evaluated. All patients and controls underwent cranial MRI examination using diffusion tensor technique (DTI) and fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial (RA) values were calculated in the corpus callosum (CC).
Results: Patients with SLE presented lower values of AF (0.629±0.0612 vs 0.67781 ± 0.0154, p <0.001) and significantly higher values of MD (0.0023± 0.0036 vs 0.0010±0.0001, p= 0.020), and AD (0.0018±0.0001 vs. 0.0017±0.0002, p= 0.040) and RD (0.0008±0.0006 vs. 0.0005±0.0001, p= 0.024) when compared to controls. Patients with active NPSLE presented lower values of AF and greater MD when compared to inactive NPSLE [FA (0.590±0.072 vs 0.661±0.021) and MD (0.0044±0.005 vs 0.0010±0.0001)]; (0.590±0.072 vs 0.668±0.015) and MD (0.0044±0.005 vs 0.001±0.001) and compared to controls FA (0.590±0.072 vs. 0.668±0.015) and MD (0.0044± 0.005 vs 0.001±0.0001). NPSLE patients had higher AD values when compared to non-NPSLE [FA (0.0018±0.001 vs 0.0017±0.00009)] and also when compared to controls [FA (0.0018 ± 0.001 vs. 0.0017 ± 0.0002)]. The inactive NPSLE patients had higher RD values than controls [FA (0.0006 ± 0.001 vs 0.0011 ± 0.0006)]. The SLEDAI presented a negative correlation with FA (r = -0.346, p <0.001) and positive with MD (r = 0.239, p = 0.010), AD (r = 0.223, p = 0.016) and RD 0.018). The SLICC presented a negative correlation with FA (r = -0.314, p = 0.001) and positive with MD (r = 0.275, p = 0.002) and AD (r =0.193, p = 0.03).
Conclusion: Our study indicates that there is microstructural impairment in patients with active NPSLE and patients with systemic disease activity. The DTI MRI study may provide elements for a more comprehensive analysis of the microstructure of the white matter in patients with NPSLE.
O51 NON-CRITERIA MANIFESTATIONS, ANTIPHOSPHOLIPID PROFILE AND THEIR ASSOCIATION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS)
Gustavo Guimarães Moreira Balbi1,3, Flávio Signorelli2, Roger Abramino Levy2
1HOSPITAL UNIVERSITÁRIO DA UNIVERSIDADE FEDERAL DE JUIZ DE FORA, JUIZ DE FORA, MG, Brasil; 2UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 3UNIVERSIDADE FEDERAL DE JUIZ DE FORA, JUIZ DE FORA, MG, Brasil
Background: Antiphospholipid syndrome (APS) is associated with different clinical and laboratorial manifestations that may impact treatment, but were not included in the current classification criteria (Sydney). The aim of this study is to evaluate the frequency of non-criteria manifestations in our population and their correlation with demographic and antiphospholipid antibodies (aPL) profile.
Methods: We performed a cross-sectional study with 120 outpatients who fulfilled pAPS classification criteria (Sydney). Clinical and serologic features were obtained during visits and by chart review. Statistical analysis was performed using chi-square, Mann-Whitney U and Spearman’s R tests, when applicable.
Results: All patients were included in the analysis (114 thrombotic with or without pregnancy morbidity and 6 obstetric with no thrombotic manifestations). One hundred and three (85.8%) were female and 72 (60%) Caucasian. The mean age at the time of analysis was 42.6土12.9. We found the following frequency of non-criteria manifestations: migraine (47.5%), livedo (24.2%), Raynaud’s phenomenon (24.2%), thrombocytopenia (10%), valvopathy (7.5%), cutaneous ulcers (7.5%), seizures (5.8%), hemolytic anemia (0.8%), nephropathy (0.8%), and white matter lesions (0.8%). Regarding the aPL profile, 94% were positive to lupus anticoagulant, 35.8% to anticardiolipin (aCL) (21% with high titers >80 MPL or GPL), 5% to aCL IgA (N=95), 44% to anti-ß2-glycoprotein I, and 21% were triple positive. In a bivariate analysis, livedo correlated with Caucasian race (p=0.006) and thrombocytopenia with persistently positive aCL (p=0.012), aCL titers >80 (0.027), and triple positivity (p=0.009). Raynaud's phenomenon and migraine were more frequent in women (p=0.013 and p=0.001, respectively). There was a tendency of increased probability of hemolytic anemia in patients with persistently positive aCL (p=0.057) and nephropathy in men (p=0.013), but the number of events was very low in both groups.
Conclusion: Migraine was the most common observed non-criteria manifestation, followed by livedo and Raynaud's phenomenon. Caucasians were more prone to present livedo, as women were more prone to complain of Raynaud's phenomenon and migraine. Thrombocytopenia was associated with persistently positive aCL, high titers of aCL, and triple positivity.
Cecilia Victoria Agapito Tito, Juliana Silvatti, Izabela Negrão Frota de Almeida, Elise Vivan Taniguchi, Augusto Paranhos Junior, Tiago dos Santos Prata, Cristiane Kayser
UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, SP, Brasil
Background: Systemic sclerosis (SSc) is characterized by peripheral vasospasm and structural abnormalities of the microcirculation and small vessels. A number of evidences suggested that vascular abnormalities are involved in the pathogenesis of normal tension glaucoma (NTG), as ocular vasospasm may induce optic nerve head damage. In this study, we investigated the presence of normal tension glaucomatous damage in SSc.
Methods: In this single-center, cross-sectional study, 39 patients (3 male, 36 female) with SSc (2013 ACR/EULAR classification criteria) and 18 age- and sex-matched controls were included. All participants underwent complete ophthalmological examination, including visual acuity, intraocular pressure (IOP) measurement with a Goldmann applanation tonometer, slit-lamp biomicroscopy, and gonioscopy. Retinal nerve fiber and optic disc morphology were evaluated by means of spectral-domain optic coherence tomography (SD-OCT) in which peripapillary retinal nerve fiber layer (pRNFL) thickness and vertical cup-disc ratio (VCDR) were obtained. Visual field examination was performed in all participants. NTG was defined as follows: IOP ≤21 mm Hg, evidence of glaucomatous optic neuropathy (GON) (defined as VCDR ≥0.6, asymmetry of the cup-to-disc ratio ≥0.2 between eyes, presence of localized retinal nerve fiber layer and/or neuroretinal rim defects, and disc haemorrhages), and visual field defects.
Results: A total of 36 eyes of normal subjects, and 72 eyes of SSc patients were evaluated. The mean IOP in SSc patients was of 14.52 ± 2.63 mmHg and of 15.12 ± 2.46 mmHg in controls (p=0.271). The average pRNFL was significantly thinner in SSc patients compared to controls (106.54 ± 11.34 μm versus 113.11 ± 17.71 μm, respectively p < 0.05). An excavated disc with a cup-to-disc ratio ≥0.6 was observed in 31 (43%) eyes of SSc patients and in 17 (47%) eyes of the controls (p=0.774). The average VCDR assessed by SD-OCT was of 0.53 ± 0.19 in SSc patients and of 0.62 ± 0.16 in the control group (p<0.05). Visual field defects were observed in 42% of SSc patients and in 65% controls (p=0.077).
Conclusion: A significant thinning of the pRNFL and decreased VCDR were observed in SSc patients compared with healthy subjects, suggesting that subclinical GON abnormalities are present in SSc. Since reduced pRNFL thickness has been demonstrated in patients with glaucomatous optic neuropathy and might precede visual field loss and optic nerve head defects, prospective studies to detect potential risks for developing glaucomatous damage in patients with SSc are warrant.
O53 OCCURRENCE OF AUTOIMMUNE DISEASES IN RELATIVES OF PATIENTS WITH SYSTEMIC VASCULITIS AT AN UNIVERSITY HOSPITAL: A CASE-CONTROL STUDY
Alessandra De Sousa Braz1,2, João Calvino Soares de Oliveira2, Matheus Vieira Falcão2, Alexia Lavínia Holanda Gama2, Jade Arruda de Carvalho Motta2, Maria Roberta Melo P. Soares2, Karla Valéria M. De Campos2, Eutilia Andrade M. Freire2
1UNIVERSIDADE FEDERAL DA PARAÍBA, JOÃO PESSOA, PB, Brasil; 2UFPB, JOÃO PESSOA, PB, Brasil
Background: Vasculitis is a general term for a group of rare diseases that have in common inflammation of blood vessels. There are many types of vasculitis, and the different diseases may vary significantly in terms of symptoms, severity, and duration. There are very few studies that aim to analyze the occurrence of autoimmune diseases (AID) among relatives of patientes with diagnosis of vasculitis, despite the support of the scientific community affirming that genetics is one of the great responsibles for the origin of autoimune disturbs. The purpose of the research is to verify the occurrence of AID in first-degree relatives of patients diagnosed with vasculitis at an University Hospital.
Materials and Methods: It was performed a case-control study, observational and tranversal, in the rheumatology sector at an University Hospital. The participants were selected by a non-probabilistic way, through active recruit of patients. The control-group were selected at the hematology, endocrinology and pneumology sectors at the same hospital. The inclusion criteria for the case-group were been diagnosed with Systemic Vasculitis (according to the Chapel Hill Consensus Conference) and not having any cognitive deficit, while for the control-group was not been diagnosed with Vasculitis and not having cognitive deficit. At the descriptive statistics, the relative and the absolut frequencies regarding the qualitative variables were determined. Concerning the inferencial statistics, the Mann-Whitney test were applied regarding the ordinal variables. The significance level to all the inferential procedures was 5%. The data was analyzed using the statistician program SPSS version 20.0. Results and
Conclusions: There were 169 participants of the research, 19 from the case-group and 150 from the control-group. Among the patients with Vasculitis, 63% were female and 47,3% had first-degree relatives with AID, presenting Rheumatoid Arthritis – RA (44,4%), Systemic Eritematous Lupus – LES (22,2%), Kawasaki (22,2%) and Hashimoto Thyroiditis (11%). Among the control-group, 58,6% were female and 4,6% had first-degree relatives with AID, presenting RA (71,4%) and LES (28,6%). The occurrence of AID in the case-group has shown statistical significance, when compared to the control-group. It can be noticed that in the case-group occurred a greater frequency of AID, such as RA and LES. The result found shows the need of more research in the field of familiar genetics of vasculitis, since it’s still a subject not very present in scientific studies.
O54 ONE YEAR 24H-PROTEINURIA: SIMILAR RESULTS WITH BOTH CYCLOPHOSPHAMIDE AND MYCOPHENOLATE MOFETIL FOR LUPUS NEPHRITIS INDUCTION IN REAL LIFE SITUATION
Maíra Luciana Marconcini De Lacerda, Gabriela Araujo Munhoz, Luciana Parente Costa Seguro, Eduardo Ferreira Borba Neto, Eloisa Silva Dutra de Oliveira Bonfa
HC FMUSP, SÃO PAULO, SP, Brasil
Background/Purpose: One year 24h-proteinuria is the best single predictor for long term renal prognosis in lupus nephritis, as demonstrted in two trials and also in real life situation. Our aim was to compare one-year 24h-proteinuria in patients with lupus nephritis treated with with low-dose intravenous cyclophosphamide (Euro-lupus) or Mycophenolate mofetil (MMF)-based regime as induction therapy in real life situation.
Methods: Retrospective analysis using an electronic chart database of consecutive lupus patients (SLICC 2012) with active lupus nephritis treated as induction therapy with either Euro-lupus (500 mg, every 15 days for 3 months, followed by MMF or azathioprine) or MMF (3g/day). All patients were followed at the Lupus Outpatient Clinic at the Tertiary University Hospital. Clinical outcomes and laboratory results were evaluated at baseline and after 12 months. Exclusion criteria included pregnancy and creatinine clearance <10 mL/min.
Results: 36 patients received Euro-lupus and 54 patients received MMF. Euro-lupus and MMF groups had comparable age (34.69 ± 10.73 vs. 38.18 ± 11.11 years, p=0.143), female gender (86.1 vs. 85.2%, p=1.0), white race (77.8 vs. 66.7%, p=0.343) and disease duration (6.06 ± 5.95 vs. 6.30 ± 6.33 years, p=0.859). Baseline laboratory parameters, SLEDAI and glucocorticoid therapy data are shown in Table 1. The frequency of previous nephritis (p = 0.514), systolic (p=0.891) and diastolic (p=0.668) blood pressure levels were comparable in the two groups. After 12 months, 24h-proteinuria was similar in both groups (0.71± 0.68 vs. 0.79 ± 0.78 g/day, p=0.525), as also the frequency of patients with proteinuria < 0.8 g/24h (66.6% vs. 61.1%, p 0.659), creatinine levels (0.81 vs. 0.87 mg/dL, p=0.537) and prednisone daily dose (13.3 ± 11.3 vs. 10.7 ± 7.9 mg/day, p=0.195).
Conclusion: Euro-lupus and MMF protocols were effective as induction therapy for active lupus nephritis with a comparable frequency of patients achieving the proteinuria target at 12 months, which is the best single predictor for long term renal prognosis.
Rosa Weiss Telles1,3, Aline Barbara Pereira Costa3, Luciana Andrade Machado2, Sandhi Maria Barreto3
1FACULDADE DE MEDICINA DA UFMG, BELO HORIZONTE, MG, Brasil; 2ELSA-BRASIL MUSCULOESQUELÉTICO, BELO HORIZONTE, MG, Brasil; 3FACULDADE DE MEDICINA - UFMG, BELO HORIZONTE, MG, Brasil
Background: The aim of the study was to investigate the independent association between markers of overweight/obesity and chronic musculoskeletal symptoms in participants of ELSA-Brasil Musculoskeletal Study.
Material and Methods: Overweight (BMI 25-29.9kg/m2) and obesity (BMI≥30kg/m2) were ascertained using data from current height and weight, and weight at age 20 (for overweight/obesity at age 20). Three mutually exclusive overweight (BMI≥25kg/m2) trajectories were identified: absence of excess weight; excess weight at one point in time; excess weight at two points in time. Waist circumference (WC) was used to identify levels of abdominal obesity. Chronic musculoskeletal symptoms (pain, discomfort and/or stiffness ≥6 months during the preceding 12 months) were evaluated in nine body sites, and three dependent variables were used: presence of symptoms; number of sites of symptoms (none, 1-2 sites, ≥3 sites), and region of symptoms (upper limbs, axial skeleton, lower limbs). Associations between each overweight/obesity marker and the dependent variables were investigated with multinomial logistic regressions adjusted by potential confounders.
Results and Conclusions: 2,821 participants, mean age 56.0(8.94), were included in the analysis. At the time of evaluation, 63.4% were overweight, 54.9% have chronic musculoskeletal symptoms and 18.8% reported symptoms in ≥3 sites. Lower limbs were the most prevalent region of symptoms (36.0%). Adjusted analyzes indicated a significantly higher chance of chronic symptoms among those who were obese at age 20 (OR 2.23; 95%CI 1.01-4.91) or currently (OR 1.60; 95%CI 1.30-1.97). The same was observed for symptoms in ≥3 sites: obesity at age 20 OR 2.83; 95%CI 1.11-7.21; current obesity OR 2.06; 95%CI 1.55-2.73. Models on excess weight trajectories indicated a risk-accumulation behavior; i.e. the chance of chronic symptoms was increased by ~30% when excess weight was present at one point in time and by ~50% when it was present at two points in time. The same was observed for the association between symptoms in ≥3 sites and excess weight trajectories: one point in time OR 1.61; 95%CI 1.27-2.04; two points in time OR 1.73; 95%CI 1.11-2.70. Abdominal obesity showed the same pattern of association with chronic symptoms that BMI, adding none explanation to the study. Overweight/obesity markers were found to be independently associated with chronic musculoskeletal symptoms, with stronger effects being observed among adults experiencing symptoms in multiple sites and/or with longer exposures to excess weight during lifetime.
Brazilian Ministry of Health (Science and Technology Department), of Science and Technology (FINEP, CNPq), and of Education (CAPES).
Jaqueline Cristina de Amorim1, Simone Thiemi Kishimoto1, Clovis A Silva2, Roberto Marini1, Lilian Tereza Lavras Costallat1, Paula Teixeira Fernandes1, Simone Appenzeller1
1UNICAMP, CAMPINAS, SP, Brasil; 2INSTITUTO DA CRIANÇA USP, SAO PAULO, SP, Brasil
Background: Validation and use of a computerized battery for cognitive evaluation of patients with systemic lupus erythematosus (SLE) as part of an investigation of neuropsychiatric manifestations is useful and allows multicenter studies.
Materials and methods: This is a quantitative transversal study with control group conducted in pediatric and adult rheumatology clinics. The computer test batteries ANAM (Automated Neuropsychological Assessment Metrics) or PedAnam (Pediatric version) consists of 10 subtests: Sleepiness scale, simple reaction time, procedural reaction time, code substitution (learning phase), logical relations, spatial processing, running memory continuous performance test, mathematical processing matching grids, matching to sample, memory search, code substitution (delayed phase) and simple reaction time (delayed phase). We included 98 SLE patients and healthy age-matched individuals. All individuals underwent an evaluation through the battery tests taking 30 minutes on average to solve the problems.
Results and conclusions: We included 98 SLE patients 69 female and 29 male, the age with a minimum of 6 and a maximum of 68 and mean of 28.6 years. While the control group with 84 people had a mean age of 25 years with a minimum of 6 and a maximum of 65 years, 73 female and 11 male. For the evaluation was used the Performance Validity Index score, that provides a performance indicator, between 0 and 14, for someone with good effort, or above for someone outside the range of that expected for someone providing good effort. Patients presented an average performance of 8.05, with a minimum of 0 and a maximum of 33, while the control group had a mean of 4.4, minimum 0 and maximum of 27. As the smaller score results in a better effort, it is possible to notice meaningful differences between the groups (p<0.05). Cognitive difficulties are often observed in SLE and practical tools like ANAM and PedAnan should be used to measure the cognitive loss that patients may have; these losses should be monitored more closely if there are other neuropsychiatric symptoms.
O57 POLYMORPHISM OF MICRORNA REGION IN THE TNFA GENE IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
Jessica Fernandes Vivaldo1,2, Mariana Postal2, Nailú Angélica Sinicato2, Roberto Marini2, Timothy B. Niewold3, Simone Appenzeller4
1UNICAMP, CAMPINAS, SÃO PAULO, Brasil; 2UNIVERSIDADE ESTADUAL DE CAMPINAS, CAMPINAS, SÃO PAULO, Brasil; 3NEW YORK UNIVERSITY, NOVA IORQUE, NOVA IORQUE, Estados Unidos; 4UNIVERSIDADE DE CAMPINAS, CAMPINAS, SÃO PAULO, Brasil
Background: Studies have implicated microRNAs (miRNAs) in the pathogenesis of systemic lupus erythematosus (SLE). miRNAs regulate approximately 90% of the protein-encoding genes and play a central role in various biological processes, including impairment of cell differentiation and proliferation e apoptosis. Polymorphism in miRNA regions of TNFA gene may account for the variations observed in the clinical. The aim of this study was to investigate the presence of polymorphisms of miRNA regions of TNFA gene associated to clinical and laboratory profile of these SLE patients.
Methods: Consecutive childhood-onset SLE (cSLE) patients followed at Pediatric Rheumatology Unit of the Unicamp were enrolled in study. Healthy volunteers with were included as control group. A complete clinical, laboratory and neurological was performed in all subjects. cSLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current therapy. Total dose of corticosteroids and other immunosuppressant medications used since the onset of disease were calculated by data obtained by careful review of the medical charts. We investigated miRNA region of the TNFA gene in cSLE compared to healthy volunteers using DNA Sequencing by Capillary Electrophoresis. Data were compared by non-parametric tests.
Results: We included 110 cSLE patients [83 women (75.4%)]. The mean disease duration was 13.18±4.32 (1-20 years). We included as a control group 60 healthy individuals [52 women (86.7%)] recruited from the local community. The mean score of cumulative SLEDAI was 2.88±2.20 (0.09-12.52). The mean of total corticosteroid dose was 23437.54±16656.55mg. We identified polymorphism rs3093665 (c.*77 A>C) in 8 (7.3%) cSLE patients, polymorphism rs3093666 (c.*419 C>T) in 3 (2.7%) patients and polymorphism rs3093667 (c.*453 G>T) in 2 (1.8%) cSLE patients. Polymorphism rs3093665 is located in a region of interest, into a miRNA region-binding site of miR-452 and polymorphism rs3093667 into a miRNA region-binding site of miR-19a. In the control group, we identified polymorphism rs3093665 in only 1 control. We observed an association between polymorphism rs3093665 and organic brain syndrome (p=0.001), an association between polymorphism rs3093666 and thrombocytopenia (p=0.02) and an association between polymorphism rs3093667 and hematuria (p=0.024). Conclusion: To our knowledge, this is the first study to evaluate polymorphisms in miRNA regions of TNFA gene in SLE. We identified polymorphism rs3093665 and rs 3093667, both into miRNA region-binding sites. Alterations contribute to the development of pathological conditions and clinical disorders in SLE.
Ana Paula Monteiro Gomides1, Licia Maria Henrique da Mota2, Geraldo Rocha Castelar3, Cleandro Pires de Albuquerque2, Ana Beatriz Vargas-Santos3, Letícia Rocha Pereira3, Manoel Barros Bertolo4, Alisson Aliel Vigano Pugliesi4, Eduardo de Almeida Macedo4, Paulo Louzada Filho5, Maria de Fátima L da Cunha Sauma6, Marcel Lobato Sauma6, Júlia Brito de Medeiros6, Claiton Viegas Brenol7, Ivanio Alves Pereira8, Sebastiao Radominski9, Maria Fernanda Resende10, Maria Raquel Costa Pinto10, Gustavo Gomes Resende10, Karina Bonfiglioli11, Henrique Carriço11, Rina Dalva Neubarth Giorgi12, Nathalia de Carvalho Sacilotto12
1UNB/UNICEUB, BRASILIA, DF, Brasil; 2UNB, BRASÍLIA, DF, Brasil; 3UERJ, RIO DE JANEIRO, RJ, Brasil; 4UNICAMP, CAMPINAS, SP, Brasil; 5USP RIBEIRÃO PRETO, RIBEIRÃO PRETO, SP, Brasil; 6UF DO PARÁ, BELEM, PA, Brasil; 7UFRGS, PORTO ALEGRE, RS, Brasil; 8UFSC, FLORIANÓPLIS, SC, Brasil; 9UF PARANÁ, CURITIBA, PARANÁ, Brasil; 10UFMG, BELO HORIZONTE, MG, Brasil; 11USP, SÃO PAULO, SP, Brasil; 12HSPE-SP, SÃO PAULO, SP, Brasil
Introduction: Polypharmacy is a much-discussed problem in medicine in general. In rheumatology, few studies have evaluated this problem, which may hinder medical treatment with the appearance of drug interactions with altered mechanisms of drug action, new symptoms, poor adherence and treatment abandonment. Some studies in the literature suggest a higher rate of hospitalizations and higher mortality in patients using multiple drugs and probably with multiple comorbidities.
This study evaluated, unprecedented in Brazil, polypharmacy in patients with rheumatoid arthritis (RA).
Material And Methods: A multicenter study was conducted with the participation of public services in different states of Brazil. The patients were evaluated through a complete clinical examination, analysis of complementary exams and records of medical records with a history of the disease since the onset of symptoms. The present study was a cross section with the initial evaluation of the participants.
Results And Conclusions: 1117 RA patients were evaluated in the total, with the majority of women (89% of the total) with a median age of 56.6 years. 78.73% had positive rheumatoid factor and 55.2% had erosive disease. The median ADHD was DAS 28 found was 3.52% and DAS 28 was 3.52.
When the drugs for RA were analyzed, we saw that patients used on average 2.8 and at most 5 drugs of different therapeutic classes. Regarding the medications for comorbidities beyond RA, the mean was 2.7 and the maximum of 9 different types of medications. Evaluating the drugs in total (for RA and comorbidities) the average was 5.5 different drugs and the maximum 11 different drugs.
The most used therapeutic classes in this sample can be seen in Table 1.
Information on this important problem is essential for rheumatologists and discussions on the subject may favor improved management of patients with RA and diverse comorbidities.
Medications used in patients with RA
NUMBER OF PATIENTS
% OF PATIENTS
DRUGS FOR DISLIPIDEMIAS
O59 PREVALENCE AND OUTCOME OF SERIOUS INFECTIONS IN PATIENTS WITH SYSTEMIC AUTOIMMUNE MYOPATHIES: A RETROSPECTIVE COHORT STUDY
Samuel Katsuyuki Shinjo1,2, Leonardo Santos Hoff2
1FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SÃO PAULO, SP, Brasil; 2FACULDADE DE MEDICINA FMUSP, UNIVERSIDADE SAO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background. Serious infections are a major cause of morbidity and mortality in patients with systemic autoimmune myopathies (SAM). Herein, the authors describe the prevalence, outcome, and characteristics of serious infections in our large sample of patients with SAM.
Material and Method. A retrospective, single-center cohort study involving 162 consecutive patients with SAM, followed between 2000 and 2017, was conducted. Serious infections were defined as infections requiring hospital admission, intravenous antimicrobial therapy and/or tuberculosis. Patient data were extensively reviewed from electronic medical records, with pre-standardized and parameterized information.
Results. Forty-four (27.2%) out of 162 patients had serious infections during to mean follow-up of 62 months. Patients had mean age of 45.2 years, with 59.1% female gender. Thirty patients had dermatomyositis, 5 polymyositis, 5 antisynthetase syndrome, and 4 immune-mediated necrotizing myopathy. Thirty-four (77.3%) out of 44 patients had a severe clinical onset, with upper dysphagia, lung disease, vasculitis and/or significant muscle weakness. Sixteen patients had more than one episode of serious infection. Out of 81 episodes of serious infections, 23.5% were aspiration pneumonia, 18.5% bacterial pneumonia, 16% skin infections, 8.6% pyelonephritis, 8.6% herpes-zoster, 7.4% tuberculosis, 3.7% infectious diarrhea, and 13.6% other causes. Ten patients died during to follow-up, and 7 deaths were related to the infection. Infections associated with death included: 2 bacterial pneumonia, 2 skin-related sepsis, 1 aspiration pneumonia, 1 complicated elective cholecystectomy and 1 retropharyngeal abscess. Only 2 patients died in the first 6 months of follow-up; all the 5 remaining infection-related deaths occurred after 1 year of following-up.
Conclusion. Serious infections are observed in 27.2% of patients with SAM. Aspiration pneumonia was the most common type of infection. Therefore patients with dysphagia should be followed carefully. Unfortunately, death is a common complication of infection and usually occurs in patients after 1 year of follow-up.
Tania Caroline Monteiro De Castro, Daniela Gerent Petry Piotto, Simone Andrade Lotufo, Cecilia Harumi Tomizuka, Alessandra Haddad Segato, Fernanda Maria Miyamoto Barreto, Lucila Camargo Lopes de Oliveira, Denise Faria do Amaral, Marcia Wehba Esteves Cavichio
GRUPO FLEURY, SÃO PAULO, SÃO PAULO, Brasil
Background: A non-governamental organization (ONG) Amigos do Bem operates in 115 villages with the lowest levels of human development (IDH) in Brazil through actions that promote access to food, health, education and the generation of employment and income. Since 1993, this ONG acts in order to guarantee medical and dental care of all those assisted by the institution. Monthly, doctors, dentists and other health professionals voluntarily attend the population of this Northeastern community. Arthritis, whether acute or chronic, is a diagnostic challenge, because of the wide variety of pathologies that can occur with arthritis.
The purpose of the study was to determine the prevalence of acute and chronic arthritis in children and adolescents attended at the Catimbau, Buique, Pernambuco.
Materials and Methods: In 2017, during three days, seventeen doctors and health professionals volunteers (radiologists, pediatricians, otorhinolaryngologists and nutritionists) at Fleury Group, performed consultations, clinical, laboratory and diagnostic exams. A total of 676 patients, aged between 2 months and 21 years were attended by pediatricians. The children with rheumatologic complaints were directed to an evaluation with one of the three specialists in pediatric rheumatology who participated in the medical team, on the same day.
Results: A total of 58 (9%) cases of musculoskeletal pain were observed in this community, with the mean age of 9.6 years, 37 (63.8%) female. Thirty-seven children (5.7%), mean age of 9.1 years, and 34 (65%) females reported complaints of arthralgia. Only five children (0.78%) presented arthritis at physical examination. Of these, two were acute monoarthritis and three, chronic arthritis. Among the acute arthritis, one was a teenager with probable septic arthritis in the left knee, the other was a 12-year-old boy with a right shoulder monoarthritis after trauma. He reported having previously dislocated this shoulder (two episodes) and was referred to the orthopedist.
Regarding chronic arthritis, three patients presented with knee arthritis, confirmed by ultrasonography. These patients were referred to the Federal University of Pernambuco for diagnostic investigation: a chronic monoarthritis due to tuberculosis (had a history of tuberculosis in the family), and two juvenile idiopathic arthritis already presenting limitations to the movements. Two children (0.3%) had chronic arthralgia after Chinkungunya.
Conclusion: This work shows the importance of medical care, especially in the most needy communities, in order to reduce the damages resulting from arthritis pathologies that are not diagnosed at an early stage.
O61 PREVALENCE OF ARTICULAR AND PERIARTICULAR ULTRASONOGRAPHIC MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Miriam Kuster Huber1, Érica Vieira Serrano1, José Alexandre Mendonça2, Raquel Ionne Küster1, Valéria Valim1, Maria Bernadete Renoldi de Oliveira Gavi1
1HUCAM/UFES, VITÓRIA, ES, Brasil; 2UNICAMP, CAMPINAS, SP, Brasil
Background Arthritis and periarthritis are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD), however subjective complaints may be non-specific or subclinical manifestations may exist. Detailed anamnesis and clinical examination associated with musculoskeletal ultrasonography (MEUS) may increase this potential diagnostic. The objective of this study was to evaluate the prevalence of musculoskeletal manifestations confirmed by MEUS.
Materials And Methods: Cross-sectional study of patients with IBD from a University Hospital submitted to ASAS classification for axial and peripheral spondyloarthritis. Those patientes with some clinical suspicion were invited to physical examination with MASES search, clinical synovitis screening by DAS 28 and evaluation by MEUS. Two experienced rheumatologists performed independent and blind evaluations. We used Esaote My Lab 70, linear transducer L12-18, power doppler (PD) of 12MHz and PRF 750MHz, wall filter 1. They were analyzed by MEUS: sacroiliac by PD, with resistance index (RI); 12 sites of enthesis by MASEI; vitreous by mode B and PD, clinically symptomatic joints and tendons by mode B and PD.
Results: 118 patients with IBD were interviewed and 40 (33%) presented complaints such as inflammatory arthralgia and / orNarthritis and / or inflammatory low back pain and / or ocular symptoms and / or psoriasis and/or enthesitis. Of this group, 34 patients with IBD Were evaluated clinically and by MEUS: 25 women, mean age of 43 years, mean diagnosis time of 11 years. Of these 59% had inflammatory low back pain, 56% had inflammatory arthralgia, 21% had arthritis and 68% had at least one MASES site. The MASEI sites were clinically palpated and presented positivity in 50%. Of the 442 enthesis of MASES evaluated: 27% with clinical enthesitis. Ocular symptoms occurred in 50%. At MEUS: 24% with sacroiliitis (mean RI: 0.65), 23% with vitreitis, 35% with synovitis (15 joints in mode B and 1 in PD) and 14% with tenosynovitis. At least one ultrasound enthesitis in 100% patients. Mean of MASEI was 17.79. From the 408 enthesis evaluated, 280 (68%) were altered and 14 (41%) patients presented MASEI greater than or equal to 18. Interobserver agreement was statistically significant (p <0.1) in intraclass correlation coefficients - for synovitis (CCI: 0.795), tenosynovitis (CCI: 0.609) and MASEI (CCI: 0.741).
Conclusions Musculoskeletal symptoms were the most common extra intestinal manifestations and the MEUS confirmed enthesitis in 100% of patients with IBD. MEUS is an important complementary method for the diagnosis of spondyloarthritis in IBD.
Cátia Maria Geralda dos Santos Nascimento, Paula Teixeira Fernandes, Lilian Tereza lavras Costallat, Simone Appenzeller
UNICAMP, SP, SP, Brasil
Introduction: Quality of life (QoL) is worse in SLE patients. The objective was to determine if cognitive dysfunction influences QOL life in SLE patients.
Methods: In this cross-sectional study, we included 226 consecutive SLE patients [average age 33.63 years (DP± 11.88); average schooling 11.53 years (DP± 3.9)] from the Rheumatology outpatient unit and 134 healthy controls [average age 33.54 years (DP± 13.6); average schooling 12.6 years (DP± 3.04)]. Cognitive dysfunction was evaluated using the Montreal Cognitive Assessment test (MoCA). Short-Form Health Survey questionnaire (SF-36) evaluated the quality of life. Fatigue Severity Scale questionnaire (FSS) evaluated presence of symptons fatigue. Symptons of depression and anxiety were determined through Beck Depression and Beck Anxiety Inventory. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. Chi-square test was used to compare the categorical variables. Mann-Whitney test was used to compare numerical variables. For correlation between numerical variables, the Pearson correlation test was used. The level of significance adopted for this study was 5%.
Results: In approximately 65% SLE patients were observed dysfunction cognitive and in 41% healthy control (p< 0.001). Presence of anxiety symptoms were observed in 63.3% SLE patients and in 44.8% healthy controls (p =0.004); depression symptoms in 36.7% patients and in 19.4% control group (p=0.003); fatigue symptoms in 61.9% patients and in 30.6% control group (p< 0.001). All SF-36 domains, physical and mental components and total score were significantly lower in the SLE patients compared to healthy controls. Low quality of life was associated with presence symptons depression, anxiety and fatigue. Scores of cognitive dysfunction were significantly correlated only with mental health domain (p=0.021; r=0.153). Scores of depression, anxiety and fatigue symptons apresented inverse correlation with all SF-36 domains. Age at onset of disease and age at diagnosis of the disease were significantly correlated with all domains. However, disease duration apresented inverse correlation with domains: functional capacity (p=0.035; r=-0.14), physical aspects limitation (p=0.026; r=-0.149) and pain (p=0.032; r=-0.143). Presence of damage was associated low physical aspects score domain (p=0.037).
Conclusion: We observed depression, anxiety and fatigue symptons are associated with lower SF-36 physical and mental components in SLE patients. Cognitive dysfunction compromises mental health and, disease damage increases the limitation by physical aspects of patients.
Cátia Maria Geralda dos Santos Nascimento, Paula Teixeira Fernandes, Lilian Tereza Lavras Costallat, Simone Appenzeller
UNICAMP, CAMPINAS, SP, Brasil
Background: SLE patients presented lower scores quality of life than healthy controls. Neuropsychiatric manifestations compromise the quality of life of patients with lupus. Anxiety disorders and mood are commonly reported in lupus. Anxiety when intense presents itself in many ways, becoming anxiety disorders. Among the various anxiety disorders, it has social phobia, which is characterized by intense and persistent fear of social situations. In social phobia, there is functional impairment and quality of life of the subject. The objective is to determine the frequency of social phobia and to avaluate the quality of life in patients with Systemic Lupus Erythematosus (SLE) and to determine the associations with neuropsychiatric manifestations (NPM), disease activity, disease damage, and use of corticosteroids (CE).
Methods: We include 81 SLE consecutive patients [mean age 38.41 years (DP± 9.49) from the Rheumatology outpatient unit and 63 healthy controls [mean age 35.31 years (DP± 10.3)]. Short-Form Health Survey (SF-36) assessed quality of life. Liebowitz Social Anxiety Scale (LSAS) assessed presence of symptoms of social phobia. Mood and anxiety disorders were determined through Beck Depression and Beck Anxiety Inventory. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. NPM were classified according to the criteria established by the American College of Rheumatology (ACR). Data were compared by non-parametric tests.
Results: Social phobia was observed in 52 (64.2%) SLE patients and in 2 (3.2%) healthy controls (p<0.001). Presence of anxiety symptoms were observed in 62 (76.5%) patients and in 20 (31.7%) healthy controls (p<0.001). Depressive symptoms were observed in 39 (48.1%) patients and in 4 (6.3%) healthy controls (p<0.001). There was significant association between social phobia and anxiety disorders (p=0.017) and mood disorders (p=0.004). All SF-36 domains, physical and mental components scores were significantly lower in SLE patients than healthy controls. Pain (p=0.022), vitality (p=0.002) and social aspects (p=0.026) domains were associated with the presence social phobia. There was no significant association between social phobia and cumulative damage, activity disease, current prednisone dose or other neuropsychiatric manifestations.
Conclusion: We observed a high frequency of social fobia related to mood disorders and worse quality of life. Social phobia should be screened routinely it can influence the quality of life of patients.
O64 QUALITY OF LIFE, BODY COMPOSITION AND PSYCHOLOGICAL ASPECTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Simone Thiemi Kishimoto, Catia Maria Geralda dos Santos Nascimento, Lilian Tereza Lavras Costallat, Paula Teixeira Fernandes, Simone Appenzeller
UNICAMP, CAMPINAS, SP, Brasil
Background: In systemic Lupus Erythematosus (SLE) an increase in factors related to physical inactivity, such as obesity, mood swings, anxiety and depression, increasing the risk of mortality and worse patient’s quality of life has been observed. The objective of this study was to evaluate the body composition, psychological and quality of life in SLE.
Methods: For this study we included 250 SLE patients [mean age 24.1 years (SD ± 6.4)], 150 healthy controls [mean age 24.6 years (SD ± 13.5)]. To evaluate the body composition, the vertical electric bioimpedance apparatus (Omron HBF-514C) was used. Quality of life was assessed through the questionnaire SF-36 (Short-Form Health Survey). For the evaluation of the psychological aspects related to the symptoms of anxiety, depression and self-esteem were used the questionnaires: Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI) and Rosenberg Self-Esteem Scale. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity (SLEDAI), damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures.
Results: Related to body composition, we observed better body mass indexes (p <0.0001) and total fat (p = 0.0002) in the control patients compared to the SLE group and the skeletal muscle (p <0.0001) was higher in the control group compared to SLE. Related to psychological aspects, the control group showed better self-esteem indexes (p <0.0001) and lower rates of depressive symptoms (p <0.0001) compared to the SLE group. The anxiety symptoms (p = 0.0383) were better in the control group compared to SLE. Quality of life related to functional capacity (p <0.001), physical aspects (p <0.0001), pain (p <0.0001), general health (p <0.0001), vitality (p <0.0001) and mental (p=0.0002) showed to be better in the control group compared to the SLE group.
Conclusion: In this study we observed better indexes of body composition, psychological and quality of life in the control group in relation to SLE. We emphasize the importance of alternative methods of complementary drug treatment, such as the practice of physical activities, thus helping to control obesity, psychological improvement and quality of life in these patients.
O66 SAFETY AND IMMUNOGENICITY OF THE QUADRIVALENT HPV VACCINE IN GIRLS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS AND DERMATOMYOSITIS
Gecilmara S. Pileggi1, Natalia B. F. Pinto2, Aline L. Oliveira2, Ingrid H. R. Grein3, Flavio R. Sztajnbok4, Juliana O. Sato5, Blanca Bicas6, Rozana G. Almeida7, Luciana Paim8, Nadia E.Aikawa9, Simone Appenzeller10, Melissa M. Fraga11, Aline C. Fraga12, Cássia M. P. L. Barbosa13, Maria C. dos Santos14, Aline Islabão15, Teresa C. M. V. Robazzi16, Marcia Bandeira3, Sheila Knupp Feitosa de Oliveira7, Claudia Saad Magalhães17, Virgínia Paes Leme Ferriani1
1FACULDADE DE MEDICINA DE RIBEIRÃO PRETO – FMRP-USP, Brasil; 2FACULDADE DE MEDICINA DE RIBEIRÃO PRETO – FMRP-USP., Brasil; 3HOSPITAL PEQUENO PRÍNCIPE, CURITIBA, Brasil; 4NÚCLEO DE ESTUDOS DA SAÚDE DO ADOLESCENTE (NESA) – UERJ., Brasil; 5FACULDADE DE MEDICINA DE BOTUCATU - UNESP., Brasil; 6HOSPITAL UNIVERSITÁRIO CLEMENTINO FRAGA FILHO – UFRJ, Brasil; 7INSTITUTO DE PUERICULTURA E PEDIATRIA MARTAGÃO GESTEIRA – UFRJ., Brasil; 8HOSPITAL INFANTIL ALBERT SABIN - HIAS., Brasil; 9INSTITUTO DA CRIANÇA DO HOSPITAL DAS CLÍNICAS DE SÃO PAULO - FMUSP, Brasil; 10UNIVERSIDADE ESTADUAL DE CAMPINAS – UNICAMP., Brasil; 11HOSPITAL DARCY VARGAS DE SÃO PAULO, Brasil; 12HOSPITAL INFANTIL NOSSA SENHORA DA GLÓRIA DE VITÓRIA, Brasil; 13UNIVERSIDADE FEDERAL DE SÃO PAULO – UNIFESP, Brasil; 14FACULDADE DE MEDICINA DA SANTA CASA DE SÃO PAULO, Brasil; 15INSTITUTO DO CÂNCER INFANTIL E PEDIATRIA ESPECIALIZADA DO HOSPITAL DA CRIANÇA DE BRASÍLIA., Brasil; 16HOSPITALAR PROFESSOR EDGARD SANTOS (HUPES) - UFBA, Brasil; 17FACULDADE DE MEDICINA DE BOTUCATU - UNESP, Brasil
Autoimmune diseases, such as systemic lupus erythematosus (SLE) are more prevalent in women in the same age range of higher risk of papilomavírus (HPV) infection. Patients with SLE have a 4-times high risk for developing HPV carcinogenic infection. However, the safety of HPV vaccine in SLE patients are a matter of debate. The aims of this study were to assess the safety and effectiveness of HPV vaccination in girls and adolescents with Juvenile SLE (JSLE) and Dermatomyositis (JDM). It was a multicenter prospective intervention study, involving 14 Brazilian pediatric rheumatology centers. The inclusion criteria: female with age 9-20 years with confirmed diagnosis of JDM or JSLE. Control group: health girls in the same age group. Exclusion criteria: Being or intention to be pregnant at the beginning of the study. The vaccine used was quadrivalent HPV in the 3 doses schedule (0-2-6 months). Safety end points: occurrence of adverse events following vaccination (AEFV) was assessed by a questionnaire handed out to all vaccinated patients and controls, to be filled for 14 consecutive days following each dose of the HPV vaccine; disease activity was assessed before and after each dose, using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) for patients with JSLE, Childhood Myositis Activity Score (CMAS) and Manual Muscle Test (MMT) for JDM, medications and exams were recorded. The algorithm conditional inference trees was used to verify the possible influence of the variables (number of doses, age, disease activity, medication) on the occurrence of AEFV. Luminex immunoassay was used to evaluate the response.
Results: We have included 222 patients with JSLE, 48 with JDM and 41 health controls. The frequency of AEFVs was similar in patients and controls, lasting range 1-5 days; none variable assessed did have showed influence on the occurrence of AEFVs (p> 0.05) and none severe AEFV was reported. Disease remained inactive after vaccination in 73.7% JSLE and 91.5% JDM. In 90% JSLE and 96% JDM continued the therapy and the lab exams remained stable in 84% JSLE and 82% JDM when we compared before and after each dose of the vaccine. Among them 236 patients was vaccinated with the 3 doses, only 26 (11%) not responded to the vaccine, none variable was related to them.
Conclusion: The HPV4 vaccine has shown to be safe, well tolerated and immunogenic in girls and adolescents with JSLE and JDM and should be recommended for this group of patients at high risk to develop carcinogenic lesions of HPV.
Matheus Xavier Guimarães1, Fernanda Pulcheri Ramos2, Andrey Tonetto Barbosa2, Raissa Barbosa de Souza2, Caroline Almeida Oliveira2, Kioko Takei2, Daniela Crema2, Rina Dalva Neubarth Giorgi2, Elaine de Azevedo2
1HOSPITAL DO SERVIDOR PUBLICO ESTADUAL, SÃO PAULO, SÃO PAULO, Brasil; 2HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Introduction: It’s well recognized that vitamin D status in the body is one of the main determinants of bone integrity. The main source of vitamin D is UVB-catalyzed skin synthesis, and it can also be found at low levels of concentration in foods such as eggs and fish. Its deficiency is a prevailing condition in several places of the world, including in tropical countries like Brazil and in big cities like São Paulo (SP). The serum concentration of its metabolite, 25-hydroxyvitamin D (25OH-D), is the method of choice that defines its levels, being little active and stored in adipose tissue, thus directly reflecting the bodies reserves of this vitamin. The objective of this study was to evaluate 25OH-D levels in different age groups and their variation according to the seasons of the year.
Methods: A cross-sectional study that analyzes 25OH-D results collected from January to December 2016 in a tertiary hospital in SP, regardless of socio-cultural habits, historical supplementation, solar exposure and diseases. Groups were established according to the season of the year in which the laboratory was collected. The seasons were divided in autumn (March to June), winter (June to September), spring (September to December) and summer (January to March and December). Statistical analysis included mean and standard deviation, frequencies, chi-square and Fisher exact. It was considered statistically significant p <0.05.
Results: A total of 32.535 vitamin D results were analyzed, 8.529 of which were collected during the autumn, 7.709 during the winter, 5.883 during the spring and 10.408 during the summer. The media of 25OH-D in summer (30,36±11,22ng/dL) was bigger than autumn (28,74±11,07ng/dL), spring (24,4±8,73ng/dL) and winter (25,08±10,10ng/dL) (p<0,0001). Considering the values above 30ng/dL as sufficiency status, we found a higher prevalence of this result in the sum of summer and autumn vs spring and winter (N=8033; N= 3096; p<0,0001, respectively). On the other hand, in all age groups, results below 20ng/dL were more frequent in sum of winter andspring (N=4194p<0.0001) when compared with the other seasons (N=2895).
Conclusion: This study shows lower levels of 25OH-D in the winter and spring months, which is associated with less sun exposure. The data above prove that is necessary to create protocols of adequate 25OH-D supplementation in the months of less sun exposure, whitout the absolute necessity of serial dosing of this hormone, since its seasonal insufficiency or deficiency is known, reducing unnecessary expenses.
O68 SEGMENTATION AND MICROSTRUCTURAL ANALYSES OF CORPUS CALLOSUM IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Beatriz Lavras Costallat1, Beatriz Lavras Costallat2, Aline Tamires Lapa2, Lilian Tereza Lavras Costallat2, Fernando Cendes2, William Javier Garcia Herrerra3, Letícia Rittner3, Simone Appenzeller2
1UNICAMP, CAMPINAS, SÃO PAULO, Brasil; 2FACULDADE DE CIÊNCIAS MÉDICAS - UNICAMP, CAMPINAS, SÃO PAULO, Brasil; 3FACULDADE DE ENGENHARIA ELÉTRICA E DA COMPUTAÇÃO- UNICAMP, CAMPINAS, SÃO PAULO, Brasil
Background: The aim of this study was determine the microstructural changes in each segment of the corpus callosum (CC) in patients with systemic lupus erythematosus by magnetic resonance diffusion tensor technique (DTI).
Material and method: The study evaluated 116 patients with SLE and 48 healthy controls. All patients fulfilled 4 or more American College of Rheumatology (ACR) SLE. SLEDAI and SLICC were evaluated. All patients and controls underwent cranial MRI and the CC was segmented into 5 sub-regions, according to validated classification. The fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial (RA) values were calculated.
Results: Patients with SLE presented lower values of FA (0.5969 ± 0.9569 vs 0.6696 ± 0.3812; p<0.001) and higher of AD (0.0018 ± 0.0002 vs 0.0015 ± 0.0003; p<0.001) in parcel 1 of CC when compared with controls.
In parcel 5 of CC, patient with SLE presented lower values of RD (0.0007 ± 0.0002 vs 0.0008 ± 0.0003; p=0.040) when compared with controls. The SLEDAI score presented a negative correlation with FA in parcel 1 (r = -0.333, p <0.001) and positive with AD (r= 0.235, p= 0.011) and RD (r=0,190; p= 0.042) in parcel 2 and with MD (r=0.276, p=0.003), AD (r=0.327, p<0.001) and RD (r=0.330, p<0.001) in parcel 3. The SLICC score presented a negative correlation with FA (r= -0.184, p= 0.048) and positive with MD (r= 0.188, p= 0.043) and AD (r= 0.246, p = 0.008) in parcel 1. In parcel 3, the SLICC score presented a positive correlation with MD (r= 0.218; p 0,019). In parcel 1, patients with active NPSLE presented lower values of FA when compared to inactive NPSLE (0.533 ± 0.0980 vs 0.619 ± 0.862; p<0.001) and to non-NPSLE (0.533 ± 0.0980 vs 0.619 ± 0.0606; p<0.001). In parcel 3, patients with active NPSLE presented higher values of MD when compared to non-NPSLE (0.0013 ± 0.0002 vs 0.0009 ± 0.0001; p=0.027) In parcel 1, patients with active NPSLE presented higher values of AD when compared to controls (0.0018± 0.0002 vs 0.0014 ± 0.0003; p<0.001). In parcel 3, patients with active NPSLE presented lower values of AD when compared to non-NPSLE (0.0012 ± 0.0003 vs 0.0016 ± 0.0001; p=0.003).
Conclusion: The anterior parcels were those that presented microstructural alteration. The DTI may provide elements for a more comprehensive analysis of the microstructure of the CC in patients with NPSLE.
O69 SENSITIVITY AND SPECIFICITY OF INTERLEUKIN-22 IN DISTINGUISHING RHEUMATOID ARTHRITIS (RA) PATIENTS FROM NON-RA PATIENTS AND HEALTHY INDIVIDUALS
Laurindo Ferreira Da Rocha Jr1, Moacyr Jesus Barreto De Melo Rego2, Adson Belém Ferreira Da Paixão2, Kamila De Melo Vilar2, Andrea Tavares Dantas1, Pablo Ramon Gualberto2, Hugo Deleon De Lima2, Henrique De Ataíde Mariz1, Ivan Da Rocha Pitta2, Maira Galdino Da Rocha Pitta2, Angela Luzia Branco Pinto Duarte1
1HOSPITAL DAS CLÍNICAS - UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PE, Brasil; 2LINAT/NUPIT-SG/UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil
Background: The interleukin (IL)-22 is a member of the IL-10 family and has been implicated in the pathogenesis of rheumatoid arthritis (RA). In the last few years IL-22 has been reported to be higher in RA sera compared to other subjects. This work aimed to evaluate the sensitivity and specificity of IL-22 in distinguishing RA among healthy subjects (HS) and patients with other rheumatic diseases.
Material and Methods: The serum levels of IL-22 was measured by ELISA in 135 patients with RA, 74 with Systemic Lupus Erythematous (SLE), 60 with systemic sclerosis (SSc), 48 with osteoarthritis (OA), 29 with fibromyalgia (FM) and 68 healthy subjects (HS). Associations of serum IL-22 levels among distinct groups were analyzed by univariate comparisons using Mann-Whitney test. Optimum cut-off values were calculated to optimize sensitivity and specificity. Receiver-operating characteristic (ROC) curves were plotted and the areas under the ROC curves (AUC) were calculated to assess the performance of IL-22 to distinguish RA from the subjects studied.
Results and Conclusions: RA patients had significantly increased serum median IL-22 levels 118 (IQR 31.29 – 429.5) pg/ml compared with non-RA patients 31.25 (IQR 31.25 – 108.3) pg/ml and HS, 31.25 pg/ml, p < 0.0001. The sensitivity of IL-22 in differentiating patients with RA from non-RA patients and from healthy controls was of 74,81% (95% CI 66.6 – 81.9). The AUC of IL-22 ability to distinguish RA from all the subjects of the study demonstrated was 0.780 (95% CI 0.736-0.819). The yielded sensitivities, specificities and positive likelihood ratios (LR) of IL-22 to distinguish RA from each disease evaluated as well as the optimal cut-off values found are featured on the Table 1. Serum IL-22 levels might have the potential to be used as a diagnostic biologic marker in RA. Further studies with larger number of patients, early RA and naïve patients are necessary in order to better understand IL-22 role as a diagnostic tool in RA.
Marilda Guimarães Silva1, Walcy Paganelli Rosolia Teodoro2, Samuel Katsuyuki Shinjo2
1FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SP, Brasil; 2FMUSP, SÃO PAULO, SP, Brasil
Background. The increased serum level of the interleukin-17 (IL-17) has been observed in several systemic autoimmune diseases. However, the IL-17 relevance is scarcely described in dermatomyositis, with conflicting data. Therefore, the aim of the present study was to assess the IL-17 serum levels from patients with dermatomyositis in large cohort and to correlate with disease-related clinical data.
Materials and method. This cross-sectional single center study included 81 patients with adult dermatomyositis (Bohan and Peter, 1975; EULAR/ACR criteria, 2017). As a control group, 98 healthy individuals matched by gender, age and ethnicity were included. IL-17 serum levels were assessed by Milliplex Map kit. The disease activity was based on the International Myositis Assessment and Clinical Studies Group (IMACS) core set. The histological analysis was performed using the immunohistochemistry technique, using a monoclonal antibody IL-17.
Results. Mean age of patients was 45.9 years, with predominance of female gender (70.4%) and white ethnicity (69.4%). Median duration of disease was 6 years. Median IMACS core set were: HAQ of 0.90, MMT-8 of 80, patient’s VAS of 3.0, physician’s VAS of 2.0, creatine phosphokinase of 136U/L, aldolase of 4.8U/L. Moreover, 58.0% were using prednisone (median dose of 5mg/day) and 58.0% were in use at least one immunosuppressive drugs. Serum level of IL-17 was 0.49 vs. 0.35pg/mL (P=0.009), respectively, in dermatomyositis and control group. In addition, serum level of IL-17 correlated inversely with MMT-8 (rho=-0.408; Spearman correlation), and positively with MYOACT (rho=0.381), creatine phosphokinase (rho=0.447), aldolase (rho=0.412), patient’ VAS (rho=0.324), physician’ VAS (rho=0.326), P<0.005 for all analysis. In addition, IL-17 was detected in inflammatory cell infiltration around perimysium blood vessels by immunohistochemistry.
Conclusions. IL-17 serum levels of dermatomyositis are not only increased, but also correlate with disease activity parameters of patients. These data suggest that IL-17 may be not only a potential marker of dermatomyositis activity, but also as a possible target for treatment.
O71 SEXUAL FUNCTION EVALUATION BY VALIDATED INSTRUMENT IN FEMALE JUVENILE IDIOPATHIC ARTHRITIS PATIENTS
Gabriela Ribeiro Viola Ferreira1, Renato Bussadori Tomioka2, Ana Claudia Grunspun Pitta1, Daniela Mencaroni Rodrigues Lourenço1, Katia Kozu1, Nadia Emi Aikawa1, Adriana Maluf Elias Sallum1, Lucia Maria Arruda Campos1, Carmita Helena Najjar Abdo2, Rosa Maria Rodrigues Pereira2, Eloisa Bonfá2, Clovis A. Silva1
1ICR-HC-FMUSP, SÃO PAULO, SP, Brasil; 2HC-FMUSP, SÃO PAULO, SP, Brasil
Background: Juvenile idiopathic arthritis (JIA) is a painful and disable disease occurs mainly in females during the adolescence and young adulthood, and may affect sexual performance. There are, however, no studies evaluated sexual function with validated sexual instrument in female adolescent and young adults with JIA.
Material and methods: A cross-sectional study was performed in 21 consecutive JIA (ILAR criteria) and 25 healthy controls from two Pediatric Rheumatology services. The Sexual Quotient Questionnaire for Females (SQQ-F) score was applied and sexual dysfunction was defined with score less then 62 points in SQQ-F. Demographic data, gynecological disturbances, number of sexual activity were also evaluated.
Results and conclusions: The median age [26.5 (17-38.1) vs. 29.3 (19.7-35.8) years, p=0.7)] and SQQ-F score [75.9 (50-92) vs. 78.2 (58-94), p=0.529] were similar in JIA patients and controls. Sexual dysfunction (particularly desire/sexual fantasies and desire/interest disorders) was observed in 14% of JIA patients (RF-negative polyarticular), with median of disease activity score-28 (DAS-28) of 1.36 (1.05-3.41). No differences were evidenced of sexual dysfunction between JIA patients and healthy controls (14.4% vs. 12%, p=1.0). The median of number of intercourses, as well as desire/sexual fantasies, desire/interest, arousal/foreplay, arousal/lubrication, arousal/in tune with partner, penetration/relaxation, pain/penetration, desire/involvement, orgasm and general satisfaction scores were alike in both groups (p>0.05). In conclusion, to our knowledge this was the first study to analyze validated score (SQQ-F), including major domains of female sexual function. In spite chronic disease, sexual function seems to be not affected in young female JIA.
Viviane Cristina Uliana Peterle1, Natalia Mariana Diogenes Silva de Albuquerque2, Amanda Cristina de Souza2, Regina Alice Fontes Von Kirchenheim3, Ana Paula Monteiro Gomides4
1SECRETARIA DE ESTADO E SAÚDE DO DF, BRASÍLIA, DF, Brasil; 2UNICEUB, BRASÍLIA, DF, Brasil; 3SESDF, BRASÍLIA, DF, Brasil; 4UNB/UNICEUB, BRASÍLIA, DF, Brasil
Background: Hip fracture is correlated with high mortality rates. Considering that the fracture risk fluctuate in-between populations, the study’s goal was to analyze the factors associated with in-hospital mortality due to femur fracture and bone fragility when correlating to survival time.
Materials and Method: The sample was analyzed at a public hospital throughout 7 years (January 2010 to January 2017), and it was composed by a cohort of 349 patients older than 60 years with record of hip fractures caused by minimum trauma at the moment of admission. The chosen variables were taken from hospital records of medical charts. In order to evaluate which variables have any impact on the death outcome and the odds ratio of selected predictors, a logistic regression model was built. The R2 of the Nagelkerke model represented 0.80, thus explaining 80% of the answer’s variability. Furthermore, Kaplan-Meier's survivability estimator with log-rank test and Cox regression were made.
Results and Conclusion: The sample had a predominance of women (n = 229) with a mean of 79.7 ± 0.5 years. When observing the logistic regression analysis adjusted for age and sex [IC95%], the variables that explained mortality through the model (p <0.05) were due to the presence of infection OR = 5.7 (p0,026), Respiratory Infection OR = 7.38 (p0.006), time at ICU OR = 1.10 (p0.004) and Arterial Hypertension OR = 4.05 (p0.003). The surgical procedures were also selected by the COX regression model. Patients who underwent osteosynthesis had a lower survival time [HR = 2.1 IC95% 1.03-4.41; p = 0.005] when compared to those who underwent arthroplasty. The Kaplan Meier’s estimator verified that since the patient's hospitalization, the mean survival time was 62.7 days [IC95% 47.8-77.6]. Considering only patients who underwent surgery and the post-operative time, it was observed that the average survival time was 39.2 days. [IC95% 26.34-53.33;]. Therefore, it is noticeable the importance of identifying the factors associated with fracture pre, peri and post-operative and correlate them with the event of mortality. Thereby, Osteoporosis constitute an alarming public health issue because of its association with age-related fractures, thus being vital to incorporate interventions in the health system planning to mitigate the various levels of risk.
O75 SYMPTOMATIC POLYAUTOIMMUNITY AT DIAGNOSIS OF 1,463 CHILDHOOD-ONSET LUPUS: A BRAZILIAN MULTICENTER STUDY
Debora N. Setoue1, Ana Claudia Grunspun Pitta2, Fernanda J. Fiorot2
1HC-FMUSP, SÃO PAULO, SP, Brasil; 2ICR-HC-FMUSP, SÃO PAULO, SP, Brasil
Background: Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune illness with a broad clinical and laboratory spectrum, which may involve any organs and systems. Polyautoimmunity (PA), is defined according to the presence of more than one autoimmune diseases (AD) in each patient and multiple autoimmune syndrome (MAS) was defined as three or more AD. However, to our knowledge the prevalence of PA in cSLE in a large series has not been studied. The objective of study was to evaluate symptomatic PA and MAS at cSLE diagnosis.
Material and methods: A multicenter retrospective study was performed in 1,463 cSLE (ACR criteria) patients from 27 Pediatric Rheumatology services. Symptomatic PA was defined according to the presence of more than one concomitant autoimmune disease (AD) and symptomatic multiple autoimmune syndrome (MAS) was defined as three or more AD. An investigator meeting was held to define the protocol. Demographic data, SLICC classification criteria and SLEDAI-2K were evaluated.
Results and conclusions: At cSLE diagnosis symptomatic PA was observed in 144/1,463 (9.8%) and symptomatic MAS occurred in solely 10/1,463 (0.7%). In the former group the more frequently observed associated AD were Hashimoto thyroiditis n=42/144 (29%), antiphospholipid syndrome n=42/144 (29%), autoimmune hepatitis n=26/144 (18%) and type 1 diabetes mellitus n=23/144 (15.9%). Further comparisons between cSLE patients with and without PA showed a higher median age (p=0.016) and lower mean SLICC criteria (p=0.039) in those with PA. Additionally, these cSLE patients had less renal involvement (35% vs. 44%, p=0.038) and red blood cell cast (6% vs. 12%, p=0.042) and more antiphospholipid antibodies (29% vs. 15%, p<0.0001). Approximately 10% of cSLE had symptomatic PA at diagnosis, particularly endocrine autoimmune disorders and antiphospholipid syndrome. Lupus was characterized by a mild disease onset and MAS was infrequently evidenced. Further studies are necessary to determine if this subgroup of cSLE patients have a distinct genetic background with a less severe disease and a better long-term outcome.
Claudia Diniz Lopes Marques1, Henrique Ataíde Mariz1, Illana Costa2, Camila Lucena2, Lays Martins2, Lilian Valadares3, Eutilia Freire4, Izaias Pereira da Costa5, Jose Fernando Verztman6, Angela Luzia Branco Pinto Duarte2
1UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PE, Brasil; 2HOSPITAL DAS CLÍNICAS - UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PE, Brasil; 3HOSPITAL GETULIO VARGAS, RECIFE, PE, Brasil; 4HOSPITAL UNIVERSITARIO LAURO WANDERLEY- UNIVERSIDADE FEDERAL DA PARAÍBA, JOÃO PESSOA, PB, Brasil; 5UNIVERSIDADE FEDERAL DO MATO GROSSO DO SUL, CAMPO GRANDE, MS, Brasil; 6HSFE-RJ, RIO DE JANEIRO, RJ, Brasil
Background: Virus infection has been implicated in the initiation of autoimmune disease (DAI) through an immune response, critical for viral clearance. Immune regulatory mechanisms may fail, culminating in the breakdown of self-tolerance, resulting in immune-mediated attack directed against both viral and self-antigens. Different viruses have been implicated in systemic lupus erythematosus (SLE) pathogenesis. However, there are no case reports in the literature of SLE development after Chikungunya virus (CHIKV) infection. The aim of this study is to describe the clinical characteristics of patients who evolved with SLE after CHIKV infection.
Material and Methods: A cross-sectional retrospective case series study, of patients diagnosed with SLE after CHIKV infection confirmed by IgM or IgG serology.
Results and conclusions: Nine patients previously healthy were included, all women, with a mean age of 42.3 (± 10.41) years. Regarding Chikungunya (CHIK) symptoms, all had fever and joint pain in the acute phase and 75% had arthritis and rash; 66.7% had used corticosteroids before the diagnosis of DAI. The median time between the acute infection and the onset of autoimmune symptoms was 6 months (IQR = 6), but one patient, it was 7 days after the onset of CHIK symptoms. The SLE criteria observed at the time of diagnosis can be seen in Table 1. The ANA titers ranged from 1/320 to 1/1280, with a homogeneous pattern in 45% of cases. The median time to onset of nephritis after diagnosis was 2 months (IQR = 4.5). All patients used prednisone at the start of treatment; hydroxychloroquine was used for 66.7% of the cases; azathioprine in 55.0% and mycophenolate mofetil in 33.3%., pulsotherapy with methylprednisolone in 44.4% and cyclophosphamide in 22.2%. Although it is not possible to state that CHIKV was a trigger for the development of SLE with this study, it is rational to imagine that, as with other infections, it has been the trigger for autoimmunity, since there is a close temporal relationship with the infection. Unlike patients who develop chronic arthritis similar to rheumatoid arthritis, this would be another form of evolution following CHIKV infection.
SLE criteria observed at the time of diagnosis
Subacute cutaneous lupus
O77 TIME OF USE AND CAUSES OF INTERRUPTION OF SYNTHETIC MEDICATIONS IN RHEUMATOID ARTHRITIS: REAL LIFE DATA IN BRAZIL
Ana Paula Monteiro Gomides 1, Licia Maria Henrique da Mota2, Geraldo Rocha Castelar3, Cleandro Pires de Albuquerque2, Ana Beatriz Vargas-Santos3, Letícia Rocha Pereira3, Manoel Barros Bertolo4, Alisson Aliel Vigano Pugliesi4, Eduardo de Almeida Macedo4, Paulo Louzada Filho5, Maria de Fátima L da Cunha Sauma6, Marcel Lobato Sauma7, Júlia Brito de Medeiros7, Claiton Viegas Brenol8, Ivanio Alves Pereira9, Sebastiao Radominski10, Maria Fernanda Resende11, Maria Raquel Costa Pinto11, Gustavo Gomes Resende11, Karina Bonfiglioli12, Rina Dalva Neubarth Giorgi13, Nathalia de Carvalho Sacilotto13, Henrique Carriço12
1UNB/UNICEUB, BRASILIA, DF, Brasil; 2UNB, BRASÍLIA, DF, Brasil; 3UERJ, RIO DE JANEIRO, RJ, Brasil; 4UNICAMP, CAMPINAS, SP, Brasil; 5USP RIBEIRÃO PRETO, RIBEIRÃO PRETO, SP, Brasil; 6UF DO PARÁ, BELÉM, PA, Brasil; 7UF PARÁ, BELEM, PA, Brasil; 8UFRGS-, PORTO ALEGRE, RS, Brasil; 9UFSC, FLORIANÓPOLIS, SC, Brasil; 10UF PARANÁ, CURITIBA, PARANÁ, Brasil; 11UFMG, BELO HORIZONTE, MG, Brasil; 12USP, SÃO PAULO, SP, Brasil; 13HSPE-SP, SÃO PAULO, SP, Brasil
Background: The treatment of rheumatoid arthritis (RA) has undergone significant changes in the last decade. Despite this, conventional synthetic disease-modifying drugs (cs-DMARD) remain essential and first choice, most often for naive patients. Given the scarcity of epidemiological data in Brazil, knowledge of the practical use of these drugs in the country is of fundamental importance. The objective of this study was to evaluate the frequency and time of use of cs-DMARD in a large Brazilian population with RA, as well as the main reasons for interruption.
Materials and Methods: A multicentric cohort of RA patients from 11 public treatment centers in different regions of Brazil was performed. The participants underwent clinical evaluation, analysis of laboratory tests and medical records from the beginning of their medical care. The present study contains data from the initial evaluation of patients who were followed up for 1 year.
Results and Conclusions: The total sample included 1125 patients, with 89.5% being women. 78.73% had a positive rheumatoid factor. The median DAS was 3.52 and the CDAI was 9.1022 (90.84%) used conventional cs-DMARDs (isolated or in combination) and 406 (36.09%) used biological disease-modifying drugs (bDMARDs). The most used therapeutic regimen was the combination MTX + leflunomide, with or without corticosteroids (142/12.6%). The most used cs-DMARD and their time of use can be seen in Table 1. The general causes of drug discontinuation can be seen in Table 2 and the medical causes of suspension in Table 3. Given these real-life data, we can conclude that there is a high frequency of use of cs-DMARDs in Brazil, both in monotherapy and in combination, which are often used for long periods. Knowledge of drug discontinuation motifs and adequate monitoring of side effects may favor the use of these therapeutic classes, which are known to be effective and low cost.
O80 USE OF PSYCHOTROPICS IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA OF AN IMPORTANT MULTICENTRIC COHORT IN BRAZIL
Ana Paula Monteiro Gomides 1, Licia Maria Henrique da Mota2, Geraldo Rocha Castelar3, Cleandro Pires de Albuquerque2, Ana Beatriz Vargas-Santos3, Manoel Barros Bertolo4, Alisson Aliel Vigano Pugliesi4, Eduardo de Almeida Macedo4, Paulo Louzada Filho5, Maria de Fátima L da Cunha Sauma6, Marcel Lobato Sauma6, Júlia Brito de Medeiros6, Claiton Viegas Brenol7, Ivanio Alves Pereira8, Sebastiao Radominski9, Maria Fernanda Resende10, Maria Raquel Costa Pinto10, Gustavo Gomes Resende10, Karina Bonfiglioli11, Henrique Carriço11, Rina Dalva Neubarth Giorgi12, Nathalia de Carvalho Sacilotto12, Letícia Rocha Pereira3
1UNB/UNICEUB, BRASILIA, DF, Brasil; 2UNB, BRASÍLIA, DF, Brasil; 3UERJ, RIO DE JANEIRO, RJ, Brasil; 4UNICAMP, CAMPINAS, SP, Brasil; 5USP RIBEIRÃO PRETO, RIBEIRÃO PRETO, SP, Brasil; 6UF DO PARÁ, BELÉM, PA, Brasil; 7UFRGS, PORTO ALEGRE, RS, Brasil; 8UFSC, FLORIANOPOLIS, SC, Brasil; 9UF PARANÁ, CURITIBA, PARANÁ, Brasil; 10UFMG, BELO HORIZONTE, MG, Brasil; 11USP, SÃO PAULO, SP, Brasil; 12HSPE-SP, SÃO PAULO, SP, Brasil
Introduction: Indications for use of psychotropic drugs (antidepressants, anxiolytics and mood stabilizers) in rheumatoid arthritis (RA) range from the treatment of psychiatric comorbidities concomitant with the disease (mainly anxiety and depression) to as adjuncts in chronic pain management. If on the one hand they can favor a better balance of patients globally, on the other hand they can trigger new symptoms due to side effects and drug interactions. Data on the actual frequency of use of these therapeutic classes in RA are unknown in the literature and this work, in a pioneering way, intends to analyze the subject in a large “real life” population in Brazil.
Material And Methods: A multicenter study was conducted in Brazil with the participation of 11 public hospitals in different states. Patients should be undergoing treatment for RA and evaluated through clinical examination and analysis of complementary exams. Medical records with a history of the disease since diagnosis were analyzed.
This study was a cross section corresponding to the initial evaluation of the participants.
Results and Conclusions: 1117 RA patients were evaluated in total. 89% were women with a median age of 56.6 years. 78.73% had positive rheumatoid factor and 55.2% had erosive disease. The median DAS 28 was 3.52% and the HAQ median was 0.87.
94 patients (8.4%) used some psychotropic drugs at the time of the evaluation, and 15 (1.34%) used 2 or more drugs of these therapeutic classes concomitantly. Antidepressants were the most commonly used drugs with 86 patients (7.7%), the most used being shown in Table 1. 16 patients (1.4%) reported using anxiolytics and only 1 (0.09%) were using a mood stabilizer.
Changes in mental health are known to be frequent in patients with chronic diseases, especially when there are persistent painful pictures. Rational treatment of psychiatric symptoms is desirable for RA patients and may impact the response to treatment of the underlying disease. The knowledge of how it has been done to approach these patients in medical practice, avoiding excessive use of medications but also underdiagnostics, is of fundamental importance in rheumatology. This paper provides information on a large Brazilian population treated in public referral centers in the treatment of RA. Further studies should be performed to confirm these data.
Antidepressants most used in the sample
Gabriela Amorim Mattos, Raquel de Melo Legal Algusto
UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that is associated with multiple infections due to immune system compromise and/or immunosuppressors (IS) use both causing high morbimortality. Vaccines are the main preventive procedure in this scenario and are strongly recommended by most medical societies. However vaccination coverage has been reported to be insufficient even in developed countries and its reasons are not well defined which comprehension may allow interventions as a window of opportunity to increase immunization coverage.
Methods: This is a cross-sectional observational study performed at a university hospital that included adults patients with SLE (ACR criteria). A semi-structured questionnaire was applied to identify vaccination coverage according to the recommendations of the National Brazilian Immunization Program (PNI-MS) and the Brazilian Society of Immunizations (SBIM). Socioeconomic variables and reasons for not receiving the vaccines were identified.
Results: We studied 174 lupus of whom 147 were receiving steroid and/or imunossupressors (IS) and were classified as immunosuppressed. The vaccinal coverage according to the PNI-MS was found to be 2,7% for SLE patients on IS and of 14,8% among those not receiving these agents. According to the SBIM recommendations, no patient (with or without IS) had a complete vaccinal coverage. There was no association of years of formal education (12 years at school) and vaccine coverage (p>0,05). The main patient referred reason for not having received the vaccines were lack of medical recommendation which varied from 60% (MMR) up to 100% (Meningococcus C). For Pneumococcus, lack of medical recommendation was reported by 88% of patients. Other factors that also negatively influenced vaccination coverage were lack access, fear of adverse events, medical contraindication and not paying attention to medical prescription.
Discussion and Conclusions: In the present study we found a very low vaccination coverage for immunosuppressed patients that is inferior to other previously reported in the general population, and it may contribute for the high rates of infection found among these patients. At the same time, one of the main reasons for not adherence to vaccination protocols seems to be lack of knowledge and/or medical fear of complications that is in fact a paradox, since infections are frequent causes of morbimortality. The present data should stimulate interventions among patients and their physicians to improve immunizations.
Consent for publication
The authors declare that they have obtained informed written consent from the patient's tutors for publication
O82 VITAMIN D DOWNREGULATES PRO-FIBROTIC GENE EXPRESSION: IS IT A POTENTIAL MOLECULE FOR TREATMENT OF SYSTEMIC SCLEROSIS?
Anderson Rodrigues De Almeida1, Andréa Tavares Dantas2, Marina Ferraz Cordeiro1, Michelly Cristiny Pereira3, Rafaela Silva Guimarães Gonçalves2, Moacyr Jesus Barreto De Melo Rego3, Angela Luzia Branco Pínto Duarte2, Maira Galdino Da Rocha Pitta3
1LINAT/NUPIT-SG/UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PE, Brasil; 2HOSPITAL DAS CLÍNICAS - UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil; 3LINAT/NUPIT-SG/UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil
Background: Fibrosis is the major mechanisms of systemic sclerosis (SSc) that contributes to increased mortality and decreased quality of life of patients. Transforming growth factor beta (TGF-β) is the main pro-fibrotic cytokine involved in the development of fibrosis in SSc, promotes the activation of fibroblasts and leads to an increase in the expression of molecules that act favoring the development of pathological fibrosis, mainly type I collagen and alpha smooth muscle actin (α-SMA). Thus, molecules involved in the fibrotic process may represent important therapeutic targets in SSc. This study aimed to evaluate the effects of 1,25-Dihydroxyvitamin D on the gene expression of ACTA2, IL6 and COL1A1 in healthy skin and lung fibroblasts stimulated with TGF-β.
Material and Methods: Healthy fibroblast lines of skin (HFF-1) and lung (MRC-5) were obtained from Rio de Janeiro Cell Bank (BCRJ). Cells were plated in six well plates (1 x 104cells/well), stimulated with 5 ng/mL of recombinant TGF-β1, and treated with 1α,25-Dihydroxyvitamin D3 at the concentration of 100 nM. After six hours of incubation, the total RNA was extracted using TRI Reagen (Sigma-Aldrich, St. Louis, MO, USA) and cDNA synthesis was performed from 500 ng using GoScriptTM Reverse Transcription Mix (Promega, Madison, WI, USA). Quantitative analysis of the ACTA2, COL1A1 and IL6 transcripts was performed by Real Time PCR. The 18S ribosomal gene was used as reference gene. The calculation of relative gene expression was performed using the 2-ΔΔCt methods.
Results and Conclusions: We observed that treatment with vitamin D promoted a significant reduction in the gene expression of ACTA2 (p<0.05), but did not significantly alter the expression of COL1A1 and IL6 in healthy skin fibroblasts (Fig. 1a). Additionally, vitamin D downregulated ACTA2, COL1A1 and IL6 expression in lung fibroblasts, but these results were not statistically significant (Fig. 1b). In conclusion, the results showed that treatment with vitamin D promoted the reduction in the expression of ACTA2 in skin fibroblasts, suggesting an antifibrotic effect. However, further studies are needed to better understand the real role of vitamin D in SSc treatment.
P001 5-YEAR EFFICACY AND SAFETY OF APREMILAST TREATMENT IN SUBJECTS WITH PSA: A POOLED ANALYSIS OF THE 3 PHASE III STUDIES
Priscila Magalhaes Reis Nakasato
CELGENE, Estados Unidos
Long-term efficacy and safety of APR treatment were evaluated up to 5 years in subjects with active psoriatic arthritis (PsA) from the phase III PALACE 1-3 studies.
Subjects were randomized (1:1:1) to placebo (PBO), APR 30 mg twice daily (APR30), or APR 20 mg twice daily (APR20). PBO subjects were re-randomized (1:1) to APR30 or APR20 at Week 16 (early escape) or Week 24. Double-blind APR treatment continued to Week 52; subjects could continue APR during an open-label, long-term treatment phase up to 5 years. Safety was assessed at each study visit.
1,493 subjects were randomized and received ≥1 dose of study medication (PBO: n=495; APR30: n=497; APR20: n=501). Of those randomized to APR30 at baseline, Week 16, or Week 24, 45.9% (331/721) completed 260 weeks of study. At Week 52, ACR20/ACR50/ACR70 response rates were 55.3%/26.1%/11.9% for APR30 subjects, regardless of when APR was started (baseline, Week 16, or Week 24); sustained response rates of 67.2%/44.4%/27.4% were observed with continued APR30 treatment at Week 260. Marked SJC improvements were seen, with mean percent reduction of 82.3% at Week 260; TJC reduction was 72.7%. At Week 260, 62.4% (136/218) of APR30 subjects with baseline enthesitis achieved a Maastricht Ankylosing Spondylitis Enthesitis Score of 0; 80.9% (114/141) with baseline dactylitis achieved a dactylitis count of 0. A HAQ-DI MCID of ≥0.35 was achieved by 52.6% of APR30 subjects at Week 260, and 60.4% achieved low disease activity and remission, defined as a Clinical Disease Activity in Psoriatic Arthritis score ≤13. Sustained responses in psoriatic skin involvement were observed with continued treatment at Week 260 in APR30 subjects with ≥3% psoriasis body surface area involvement at baseline, with response rates of 65.8% (98/149) and 43.6% (65/149) in those achieving PASI-50 and PASI-75 responses, respectively. Consistent efficacy results were seen across the individual studies. No new safety concerns were identified with APR up to 260 weeks. Adverse events (AEs) in ≥5% of APR30 subjects entering the 5th year of APR exposure were nasopharyngitis (6.6%) and upper respiratory tract infection (5.8%); most AEs were mild/moderate in severity. Among APR30-exposed subjects, serious AEs occurred in 5.8% in Weeks >208 to ≤260; 5 subjects discontinued due to an AE.
APR demonstrated sustained, clinically meaningful improvements in PsA signs/symptoms, physical function, and associated psoriasis in subjects continuing treatment over 5 years. APR continued to demonstrate a favorable safety profile and was generally well tolerated at 5 years.
P003 A CASE OF REFRACTORY PSORIATIC ARTHRITIS WITH EXCELLENT RESPONSE TO THE FOURTH IMMUNOBIOLOGICAL DRUG ATTEMPT
Lucas Androczevecz Silva, Diogo Cunha Lacerda, Leonardo Michaelis Schmidt, Rodrigo Zuber Maciel, Rubia Carla Cappellari Tolentino, Leonardo Trovo Zilotti, Giovana Balbinot, Rafaela Sorpile Araújo, Polyana Klomfass Piati, Hugo Ogassawara Bioni
CENTRO UNIVERSITÁRIO FAG, CASCAVEL, PARANÁ, Brasil
Background: Psoriatic arthritis is an inflammatory disease, soronegative, associated to cutaneous psoriasis and has variable presentations and clinical courses. Nowadays, the treatment normally consists by the use of DMARDS and anti-TNF medications. In refractory situations to the conventional therapy with DMARDS, some other drugs must be considered, like the use of anti-TNF drugs, the use of ustequinumabe (which is a human monoclonal antibody that binds to the IL-12 and IL-23 citokynes) and the use of secuquinumabe (which is an antibody against IL-17 citokyne).
Case Report: Female patient, 43 years old, farmer, diagnosed with psoriasis when she was only 8 months old. By the age of 12 her hands and knees started to be affected by arthritis. When she was first biochemically evaluated, inflammatory markers were high, RF was negative and HLAB-27 was positive. Simple radiography showed no sacroiliac involvement. Methotrexate was started 10 years ago and, 2 years ago, was used etanercept, which resulted in secondary failure (arthritis and cutaneous lesions continued to progress). Taking that in consideration, etanercept was exchanged by ustequinumabe (which has a different mechanism of action), but it resulted in a worsening of the cutaneous and joint condition. Therefore, ustequinumabe was exchanged by a third immunobiological drug: infliximab. The clinical response to the induction dose of infliximab was satisfactory, however the disease continued to progress after a while (even after the dose was increased and the space between them was reduced). Motivated by the unsuccessful clinical response of three immunobiological medications, a fourth and last adalimumabe was attempted and the patient showed excellent response. After three months of adalimumabe, the dermatological lesions and the arthritis demonstrated fantastic answer to the treatment.
Conclusion: The way of treating psoriatic arthritis may vary according to presentation and severity that the disease manifests. In cases which the condition is refractory to DMARDS, immunobiological therapy must be considered. The advent of this new therapeutic modality (biological drugs) emerged bringing hope of adequate treatment in situations which DMARDS weren’t enough. In the present case, the expected therapeutic response was only reached after attempts with 1 DMARDS (methotrexate) and 4 biological drugs. Therefore, the exposed situation exalts that the discrepancy between the clinical response to different immunobiological agents may be notable, and the persistence of the therapy on the look out for the right treatment can be of extreme benefit to the patient.
Consent for publication
P006 A CROSS-SECTIONAL EVALUATION OF A BRAZILIAN SPONDYLOARTHRITIS SINGLE-CENTER TERTIARY COHORT: CLINICAL AND TREATMENT DATA
Andrea Shimabuco, Julio Bertacini de Moraes, Percival Sampaio-Barros, Claudia Goldenstein-Schainberg, Celio Roberto Gonçalves, Carla Gonçalves Schahin Saad
DISCIPLINA DE REUMATOLOGIA DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SP, Brasil
Background: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use of immunobiological agents for the treatment of SpA has been further improved by the release of new drugs with other mechanisms than anti-TNF, such as secukinumab (anti-IL17, SEC) and ustekinumab (anti-IL12/23, UST). The objective of our study is to describe clinical and treatment data of a SpA patients cohort followed at the outpatient clinic of a Brazilian single center.
Methods: 516 SpA patients evaluated from January 2017 to January 2018. Data from electronic medical records assessed including diagnosis, disease characteristics, treatment and disease activity at the last visit.
Results: Among all patients 195 (37.8%) were classified as Ankylosing Spondylitis (AS), 198 (38.3%) psoriasis arthritis (PsA), 66 (12.8%) axial non-radiographic or peripheral SpA, 42 (8.1%) SpA related to inflammatory bowel disease and 15 (3.0%) as reactive arthritis patients. From all SpA patients 190 (36.8%) have no axial disease, with isolated peripheral arthritis. Regarding treatment, 321 (62.2%) patients used sDMARDs as monotherapy or in association [156/321 (48.6%) methotrexate (MTX); 125/321 (38.9%) sulfasalazine (SSZ); 53/321 (10.3%) leflunomide (LFN) and 30/321 (9.3%) other sDMARDs] 298 (57.7%) patients used NSAIDs. Concerning biological therapy 204 (39,5%) received biological DMARDs (bDMARDs) [68 infliximab (IFX), 59 adalimumab (ADA), 35 etanercept (ETA), 6 golimumab (GOL), 2 certolizumab pegol (CTZ), 23 secukinumab (SEC), 10 ustekinumab (UST), 1 rituximab (RTX)]. AS patients 43/52 (82.7%) are HLA-B27 positive; 152/195 (77.9%) received NSAIDs; 95/195 (48.7%) used sDMARDs (23.1% MTX and 72.6% SSZ) and 79/195 (40.5%) used bDMARDs (31 INF, 22 ADA, 19 ETA, 3 GOL, 3 SEC, 1 UST). Among the 198 PsA patients 148/198 (74.7%) have solely peripheral involvement; 146/198 (73.7%) were under sDMARDs (78.8% MTX and 26.7% LNF) and 77/198 38.9% were receiving bDMARDs (24 IFX, 18 ADA, 10 ETA, 19 SEC, 6 UST, 1 RTX). Concerning disease activity, 25/125 (20%) of AS patients had ASDAS ≥ 2.1 and 42/198 (21%) of PsA patients had active arthritis in the last visit.
Conclusions: The description of epidemiological and clinical data of this cohort reinforces high prevalence of peripheral disease in Brazilian SpA patients. This fact could explain the wide use of sDMARDs in these patients. The frequency use of bDMARDs is in parallel with literature data including non-antiTNF drugs as SEC and UST.
Guilherme Leví Tres, Ana Laura Didonet Moro, Luiza Rossi, Bruna de Lima Porto, Micheline Sulzbacher Batista, Afonso Papke, Fernando Schmidt Fernandes, Vanessa Hax
HOSPITAL DE CLÍNICAS DE PORTO ALEGRE, PORTO ALEGRE, RS, Brasil
Background: Isotretinoin is a synthetic vitamin A derivative regarded as the most effective agent in the treatment of acne. Despite this, the rheumatic side-effects of this drug are still unknown for many rheumatologists. Our aim is to report a case of isotretinoin mimetizing a rheumatologic disease and its evolution.
Case report: A 16 year old male patient presented at the rheumatologic clinic complaining of severe progressive back pain of sudden onset with inability to walk. Over the last 2 weeks, he had already received 2 doses of intramuscular corticoid with no relief. He was previously healthy, except for moderate acne, which he was treating with isotretinoin. The back pain started 20 days after the beginning of isotretinoin and the drug was discontinued after 6 weeks due persistent pain. At his first rheumatologic visit, he was already 30 days without the medication. Examination revealed limitation of back movement in all planes and no peripheral arthritis or enthesitis. The patient had no other findings for SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome) and had no history or signs of active infection or tuberculosis. Magnetic resonance imaging (MRI) showed evidence of bilateral sacroiliitis and osteitis pubis. Full therapeutic dose of non-steroidal anti-inflammatory drug (NSAID) was prescribed. On the investigation, HLA-B27 antigen was absent, viral serologies were negative, erythrocyte sedimentation rate (ESR) was 68mm and C-reactive protein was 0.7mg/dL. After 2 weeks of NSAID, the pain reduced, and patient ability to walk was completely restored after one month of continuous NSAID. Laboratory control showed normalization of inflammatory markers and the patient no longer had to take NSAIDs.
Conclusion: In our case, acute sacroiliitis could be an adverse effect of isotretinoin that improved with its discontinuation and with NSAID. In another case report, patient had to use biological therapy for a short period of time, remaining asymptomatic after drug cessation. Therefore, the rheumatologist should be aware of the possibility of sacroiliitis caused by isotretinoin before establishing a definitive diagnosis of chronic rheumatologic disease.
Consent for publication
P018 Adherence to yellow fever vaccine (YFV) in patients with rheumatic diseases in Brazil: A Real-World Data
Gecilmara S. Pileggi1, Priscila S. Torres2, Ana Lúcia S. M. Paduelo3, Ana Geórgia S. de Almeida4, Célia Maria Silva5, Eni Maria Silva6, Carlos Eduardo D. Tenório7, Izabel Teresinha S. Oliveira8, Marta Maria S. Azevedo9, Samuel Oliveira10, Selma C. S. Merenlender11, Charlles Heldan M. Castro12, Valéria Valim Cristo13, Blanca Elena R. G. Bica14, Rodrigo Poubel V. Rezende15, Lícia Maria H. Mota16
1HOSPITAL DE MEDICINA DE RIBEIRÃO PRETO – FMUSP-RP, Brasil; 2GRUPO ENCONTRAR, Brasil; 3GRUPO DE APOIO AO PACIENTE REUMÁTICO DE RIBEIRÃO PRETO E REGIÃO - GRUPAR-RP, Brasil; 4A MENINA E O LÚPUS, Brasil; 5ASSOCIAÇÃO DE PACIENTES COM DOENÇAS REUMÁTICAS DO ESTADO DO RIO DE JANEIRO RECOMEÇAR-RJ, Brasil; 6GRUPO DE APOIO AO PACIENTE ARTRÍTICO DE SÃO PAULO – GRUPASP, Brasil; 7ASSOCIAÇÃO BRASILEIRA SUPERANDO O LÚPUS, Brasil; 8INSTITUIÇÃO ALUREL SINOS, Brasil; 9GRUPO DE APOIO AO PACIENTE REUMÁTICO DO CEARÁ - GARCE, Brasil; 10ESPONDILITE BRASIL, Brasil; 11SOCIEDADE DE REUMATOLOGIA DO RIO DE JANEIRO, Brasil; 12UNIVERSIDADE FEDERAL DE SÃO PAULO – UNIFESP, Brasil; 13UNIVERSIDADE FEDERAL DO ESPIRITO SANTO – UBES/ES, Brasil; 14UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ, Brasil; 15UNIVERSIDADE FEDERAL FLUMINENSE, Brasil; 16UNIVERSIDADE DE BRASÍLIA - UNB, Brasil
Since December 2016, Brazil is experiencing an upsurge of yellow fever virus activity. In January 2018, an informative Disease Outbreak News from the World Health Organization (WHO), states the need for control the yellow fever through the Vaccination, since this is the single most important measure for preventing this endemic disease with high mortality rates (40-50%).
However, one of the main contraindications for this YFV is immunosuppression, a common condition among rheumatic patients, what raising many questions and hesitations regarding the safety on application of the YFV for this special group. Both, patients and health professionals had been faced with the dilemma, vaccinated or not?
To Understand the real scenario of adherence to the YFV during the mass vaccination campaign, according to the rheumatic patient's perspective.
A qualitative research, conducted through an electronic survey, between February 25 and April 17, 2018, published by social networks of associations to support rheumatic patients: Alurel Sinos, Encontrar, Garce, Grupar, Grupasp, Superando o Lúpus, RecomeçAR-RJ and bloggers, Blog Artrite Reumatoide, A Menina e o Lúpus e Espondilite Brasil. All the participants were volunteer, which have given their consent by mail and guarantee back to keep the information anonymous. The survey would reflect the real setting of the patients have or not receiving the YFV shot during the campaign.
We have assessed 675 answers from patients from all over Brazil, with a higher prevalence of urban residents (96.5%), such as São Paulo (295), Rio de Janeiro (83), Minas Gerais (70) and Distrito Federal (37). The majority of them were patients with rheumatoid arthritis (RA) (318) and systemic lupus erythematosus (169). A total of 240 patients (35,5%) had already been vaccinated, among them 129 (19%) were vaccinated prior to diagnosis and 111 after it, and 10% had received the fractionated dose. Important to note, 68 patients (58%) reported the decision to take the vaccine was without consulting their rheumatologist and 42% (43) (performed the scheduled vaccine after a decision shared with their doctor, planning the medication withdraw. Thus, 77 (66%) patients had vaccine during immunosuppressive therapy.
Of the 435/675 patients were not vaccinated, 264 (62%) reported having received this guidance from their doctor, 124 (29%) admitted were afraid to take the vaccine and 36 (8%) patients had the vaccination denied at the health unit. Access to rheumatologic treatment comes from private resources for 201 (29.8%), 254 (38%) are cared for by the health plan and 220 (33%) have access through the public health system.
We are presented the biggest survey involving a real patient’s perspective on the YFV facing the actual epidemics settings, where a significant number of patients with rheumatic diseases, living in endemic areas, even at the risk of contracting this fatal disease, remain susceptible and are conflicting on the decision to vaccinate or not. In addition, the number of patients who were vaccinated without consulting the rheumatologist was higher than the number of patients vaccinated with medical planning advising. Highlighting the imminent need of a information regarding a management of vaccination with different approach’s: to health professional of caring patients with rheumatic diseases under immunosuppressive therapy, as well to families and patient’s education about immunization adherence as a protective measure for their health.
P021 ADULT-ONSET STILL DISEASE ASSOCIATED WITH MYOPERICARDITIS AND CARDIAC TAMPONADE -FIRST CASE REPORT IN BRAZIL
Othon Moura Pereira Da Silva1, Eduardo Thadeu De Oliveira Correia2, Leticia Mara Dos Santos Barbetta2, Ronaldo Altenburg Odebrecht Curi Gismondi2, Luis Otávio Cardoso Mocarzel2, Adolpho Xavier De Carvalho Filho2, Evandro Tinoco Mesquita2
1UNIVERSIDADE FEDERAL FLUMINENSE-UFF, NITÉROI, RJ, Brasil; 2UNIVERSIDADE FEDERAL FLUMINENSE, NITERÓI, RIO DE JANEIRO, Brasil
Introduction: Autoimmune diseases can affect the cardiovascular system causing pericarditis and/or acute myocarditis. Adult-Onset Still Disease (AOSD) has an unknown etiology, whose clinical findings are non-pathognomonic. This diagnostic is considered after exclusion of disorders such as neoplasias and seronegative autoimmune diseases, with the help of Yamaguchi et al criteria.
Case report: M.P., male, 40 years old with febrile prodrome, sore throat, chest pain, evolving within 48 hours to symmetrical impairment of the knees and ankles, followed by dyspnea. Admitted with electrocardiogram with signs of acute pericarditis, developing cardiac tamponade. X-ray of the thorax showed inflammatory infiltrate, being treated with antibiotic therapy. A pericardial window drainage was performed, withdrawing 350 ml of pericardial fluid, serosanguinolent, with exudative and negative cytology. Extensive evaluation including blood counts, bacterial and viral studies and screening for rheumatoid and nuclear factor were performed, all resulting negative. Symptoms were ceased with Prednisone and Colchicine. After 3 weeks, the patient was rehospitalized with pleuritic chest pain, fever and odynophagia, with leukocytosis (12800/ mm³) and neutrophilia, C-reactive protein 16 mg /dL and normal troponin I. Magnetic resonance imaging (late-enhancement) showed evidence of myocarditis. At this internation ferritin values were dosed, which were increased (> 1,500 ng/mL). After one month, with attempt to reduce steroid therapy, the patient presented recurrence of fever and odynophagia. Corticoid dose was increased to 40mg and methotrexate and hydroxychloroquine were introduced.
Conclusion: The AOSD is based on clinical criterias and negative serological markers. In that way, an approach between cardiologists and internists/rheumatologists is fundamental for considering the AOSD as a differential diagnosis for miopericarditis and for choosing the best treatment options, specially with the emergence of new treatments such as the immunobiologics.
Consent for publication
P022 ADULT-ONSET STILL’S DISEASE ASSOCIATED WITH MACROPHAGE ACTIVATION SYNDROME WITH GREAT THERAPEUTIC RESPONSE IN THE COMBINATION CYCLOSPORINE AND CORTICOSTEROID: CASE REPORT
Eduarda Maria Schroeder, Jalyson de Freitas Souza, Marina Martinichen Furlaneto, Nycolle Louise Klein Ottoni Guedes, Ana Paula Adame, Marcio Augusto Nogueira
UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ, CASCA, PARA, Brasil
Adult-onset Still’s disease is characterized by severe polyarthritis, intermittent nocturnal fever peaks lasting more than 2 weeks, and extra-articular findings such as non-pruritic maculopapular erythematous rash, myalgia, odynophagia, hepatomegaly, splenomegaly, lymphadenopathy, serositis and hyperferritinemia. The manifestation of Adult-onset Still’s Disease (AOSD) is extremely rare, with an incidence of 0.16/100,000 individuals per year. This disease results from hyperactivation of innate immunity cells, with hypersecretion of pro-inflammatory cytokines and phagocytic proteins, such as S-100 protein. The AOSD may present with complications - an example is the Macrophage Activation Syndrome (MAS) - which is characterized by spontaneous hemophagocytosis, which results in severe pancytopenia, manifested by fatigue, infections and bleeding due to anemia, leukopenia and thrombocytopenia, respectively. It may cause acute liver dysfunction with elevated AST/ALT. Hemophagocytosis also accelerates the catabolism of hemoglobin, aggravating hyperferritinemia. In addition, it is responsible for the destruction of circulating fibrinogen, raising fibrin degradation products (FDPs), extending Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT), and decreasing erythrocyte sedimentation rate (ESR). The decrease in ESR is important to distinguish MAS from an exacerbation of ASD. We describe the case of a patient previously diagnosed with polyarticular JIA in remission for years, who evolved to Adult-onset Still’s Disease associated with Macrophage Activation Syndrome, and obtained a great therapeutic response with the proposed treatment. Initially, corticosteroid pulse therapy was prescribed for 3 days, and after that period oral corticosteroid 60mg per day associated with cyclosporine 6mg/kg per day, both with a progressive reduction scheme, which lasted 14 months. The relevance of the case is due to the rarity and high morbimortality of AOSD complicated by MAS, and, also to the good response of the patient to the proposed immunosuppression. It may, therefore, be a useful aid in the conduct of similar cases.
P025 ALTERATION OF THE INFLAMMATORY PROFILE IN THE GINGIVAL FLUID OF PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS
Hellen De Souza Nascimento, Loreley Carlos Agostinho Bragard, Manuela Rubim Camara Sete, Flávio Roberto Sztajnbok, Marcelo da Silva Figueredo
UERJ, RIO DE JANEIRO, RJ, Brasil
The objective of this study was to evaluate the expression of cytokines in the gingival crevicular fluid (GCF) of patients with juvenile systemic lupus erythematosus (SLE) and to compare them with healthy individuals. Thirty patients with SLE (mean age: 16.2 ± 1.5 years) and 29 without systemic disease (mean age 15.5 ± 2.3 years), both groups with gingivitis, participated in the study. Periodontal and gingival fluid data were collected. For cytokine analysis, fluid samples were collected from three to four sites per patient, and the most inflamed sites were selected. Cytokines were analyzed by the multiplex assay with the Bio-plex Pro TM Th17 panel assay kit. Mann-Whitney U test was used to evaluate numerical variables. The levels of probing depth, clinical insertion level, plaque index and gingival bleeding were significantly higher in the test group when compared to the control group. Immunological analysis revealed that IL-1β, IL-7, IL-8, IL-13, G-CSF, IFN-γ and MCP-1 were significantly higher in the test group than in the control group. Cytokines IL-4, IL-12 (p70) and GM-CSF were significantly lower in the test group. It can be concluded that patients with SLE presented worse periodontal conditions and increased IL-1β, IL-7, IL-8, IL-13, G-CSF, IFN-γ and MCP-1 cytokines when compared to systemic patients suggesting a more aggressive inflammatory profile in the FG of patients with SLE.
P028 AN UNUSUAL CASE OF OVERLAP INVOLVING SCLERODERMA, RHEUMATOID ARTHRITIS AND ANTIPHOSPHOLIPID SYNDROME
Julia Permegiani Vilarinho, Sandra Regina Miyoshi Lopes, Dênis Azuma, Larissa Alves da Silveira, Marcela Paganelli
FACULDADE DE MEDICINA DE CATANDUVA, CATANDUVA, SP, Brasil
Overlap Syndrome is characterized by two or more autoimmune diseases in a patient. We report an overlap of Scleroderma, Rheumatoid Arthritis (RA) and Antiphospholipid Syndrome (APS).
Case report: Woman, 51 years old, with complaint of two Transient Ischemic Attacks 15 days ago. It reports two episodes of Ischemic Stroke being the first six years ago and the last, two years ago. History of arthritis in wrists, PIP of hands, elbows, knees and toes; Raynaud’s phenomenon on hands and feet, diagnosing RA and scleroderma for six years ago. Since then, using methotrexate 15mg/week.
Report recurrent pneumonia and dyspnea on moderate exertion. Pregnancies whithout abnormalities. She denied smoking, alcoholism, liver disease and family history. Physical examination: arthritis in 2nd, 3rd phalangean metacarpal, right wrist and elbow; 2nd, 3rd, 4th phalangean metacarpal, left wrist; vesicular murmur positive with subcrepitant rales in 1/3 lower bilateral, respiratory frequency: 13. (2018): Antinuclear Factor: nucleolar dotted 1: 160, antiScL70: 35, antiCCP: 60, Waaler-rose: 40, CRP: 15, ESR: 62, lupus anticoagulant: 6, acid alpha1-glycoprotein: 150; anticardiolipin, serologies and cryoglobulins negative. CT thorax: reticulated pulmonary parenchyma, traction bronchiectasis, architectural distortion and bilateral sparse mosaic. MRI of the skull: chronic ischemic vascular injury in the left posterior artery. Echocardiogram: PSVD 31mmHg. UGIE: hiatal hernia. Abdominal Ultrasonography: mild hepatic steatosis. MRI: chronic inflammatory arthropathy of phalangean metacarpal and degenerative of proximal and distal interphalangeals. Mammography and spirometry: normal.
Discussion: Autoimmune rheumatic diseases can coexist in the same patient, being able to evolve sequentially or appear simultaneously, configuring Overlap Syndrome. Association of manifestations equivalent to APS, Scleroderma and RA, as reported, is extremely uncommon, and only associations that contemplate two of these pathologies are described. Cases covering all these are not observed in the literature. Most of the reports are of cases of Scleroderma that throughout their evolution have overlapped with Polymyositis, Dermatomyositis, SLE, RA or Sjögren’s Syndrome.
This syndrome stands out due to its clinical diversity, order of manifestation of the diseases and their consequences. This is believed to be due to multifactorial diseases.
Valuing history and physical examination, with the ability to interrelate clinical manifestations, is the best way to deal with rare and varied clinical courses.
Consent for publication
Larissa Cristiane De Oliveira Souza, Marilma Galvão dos Santos Gomes, Francisco Alves Bezerra Neto
UFRN, NATAL, RN, Brasil
Background: Medical prescriptions must be analyzed according to a variety of factors. Drug interaction is one of those factors. When harmful, they may extend hospital stay and heighten treatment costs.
The objective of the present investigation is to present the main drug interactions in admitted patients to a rheumatology infirmary as well as the drugs involved in such events.
Materials and methods: Forty three medical prescriptions from the rheumatology infirmary were analyzed between January and October of 2017. Subsequently, evidence-based medical information databases Micromedex and Uptodate were used for analysing of the possible interactions between the most prevailing drugs. Drug interactions deemed as contraindicated and of major severity were the ones considered for analysis.
Results: 54 pharmacological groups were identified along with 111 varieties of drugs. The mean amount of prescribed drugs per patient was 13. Drug interactions considered contraindicated were not found in prescriptions. However, interactions considered of major severity were found in all 43 analysed prescriptions. 6 prevalent drugs were found in rheumatology prescriptions and its respective therapeutic category (see Table 1). The Glucocorticoid class was found to be the most involved in drug interactions. The most prevailing drug-drug interactions were analysed (see Table 2).
Conclusions: The various comorbidities in rheumatology patients frequently result in polypharmacy and consequently in drug interactions.
There is a growing need for the interaction of medical staff with other areas in health care. Drug interaction analysis in our institution is the result of our multidisciplinary staff’s efficacy, which is composed by medical, clinical pharmacology, psychology, occupational therapy and nutrition professionals.
Thus, the study of prescriptions, and more specifically of the drug-drug interactions by the pharmacology staff contributes to action strategies which have as consequence, the reduction of possible harm inflicted to patients, as well as a reduction of healthcare costs due to the reduction of hospital stay.
Vinicius Costa Vieira, Luiz Felipe Dipe Prates Miranda, Adib Chicre Mansur Neto, Guilherme Salles de Escobar Gonçalves, Mauro Goldfarb, Leonardo Domingues Romeiro
HOSPITAL FEDERAL DOS SERVIDORES DO ESTADO RJ, RIO DE JANEIRO, RJ, Brasil
Introduction: Systemic sclerosis (SS) represents an impact on morbidity and mortality rates and determines lower survival in relation to the general population. Cohort studies published worldwide reaffirm the importance of the cardiopulmonary involvement as the main cause of death in this disease.
Objective: Evaluate the survival, causes of deaths and prognostic factors in a cohort of patients with systemic sclerosis of a tertiary hospital.
Methods: a retrospective cohort study of 97 patients followed from 2010 to 2018 with SS. The analysis was by review of medical records and telephone contact between February to April 2018. It was used an excel spreadsheet to the database. The deaths were obtained and analyzed the survival, the causes of deaths and related factors. It was performed a simple analysis of frequencies by EXCEL and also OPENEPI (openepi.com) bivariate analysis by the program.
Results: The average survival rate was 86.7% in the period. 13 deaths occurred: 6 by cardiopulmonary complications, 2 by neoplasms (pulmonar and large B-cell lymphoma), 3 of infectious complications of skin ulcerations and 2 without a defined cause. Associated with deaths, 10 (76.92%) presented with pulmonary arterial hypertension (PAH), 6 (46.15%), interstitial lung disease, 5 (38.46%), anemia and 1 (7.69%) alteration in renal function. The average age at death was 60.46 years. There was no occurrence of scleroderma renal crisis. In bivariate analysis, PAH was variable associated to death with p-value < 0.001 calculated by Fisher’s exact test (calculated on OpenEPI), but the other variables analyzed (anemia, serum creatinine and lung disease) were not statistically significant.
Fernanda Tavares, Francisco Fellipe Claudino Formiga, Bruna Laiza Fontes Almeida, Ana Karla Guedes de Melo, Maria Roberta Melo Gomes Pereira, Danielle C. S. Egypto de Brito, Alessandra de Sousa Braz, Eutilia Andrade Medeiros Freire
UNIVERSIDADE FEDERAL DA PARAÍBA, JOÃO PESSOA, PB, Brasil
Background: Behçet’s disease (BD) is a systemic vasculitis characterized by recurrent oral and genital ulcers, uveitis and cutaneous lesions, and may develop with arthritis, gastrointestinal, neurological, vascular symptoms and orchiepididymitis. Pathergy test can be positive in 20% to 30% of cases and HLA-B51 is described in 20% of patients. The differential diagnosis of BD includes recurrent oral aphthosis, Crohn’s disease, sarcoidosis, pemphigus, pyoderma gangrenosum, erythema nodosum leprosum, myelodysplastic syndrome, among others. Anaplastic T-cell non-Hodgkin’s lymphoma (NHL) is a rare type of NHL that may have nodal and extranodal involvement (skin). On the skin, clinical signs range from erythematous plaques to pruritus, eczema, hypochromia, ulcers and tumors, and may cause disagreement in the characteristics of the lesions.
Case report: Male patient, 35 years, white, admitted on 07/03/18 with ulcers in the lower extremities and testicular region for 15 days. According to the report, on november 2017, he started cutaneous lesions with erythematous-brownish ascending non-nodular macules associated with daily fever. On December of the same year, he presented melena, anemia and two gastric ulcers were diagnosed. He was treated and released for outpatient follow-up. On march 2018, there was persistance of fever and the spots developed into painful ulcers, some with necrotic crusts, when he was admitted to our service. Examination at admission: cardiorespiratory, neuropsychiatric and abdominal devices without alterations. Skin and appendages: macules and erythematous-brown nodules and necrotic ulcers in lower limbs. Personal background: recurrent sores since the age of 14 years and partial bilateral hearing loss (recurrent otitis media). Initially, diagnostic hypotheses were suggested: BD, Crohn’s disease, leprosy, Cogan’s syndrome and necrotizing pyoderma gangrenosum. Blood count, renal and hepatic function, urinalysis, proteinuria 24h, ANCAs, fecal calprotectin, colonoscopy, chest x-ray, transthoracic echocardiogram, temporal bones computed tomography and lymph baciloscopy were investigated: unchanged. Testicular ultrasonography: orchitis. Upper digestive endoscopy showing the same two gastric ulcers (Grade 2 Los Angeles). Initiated prednisone (40 mg / day) and colchicine (1 mg/day), with no response. Acute phase reactants, slightly elevated initially, got worse. The biopsy of a nodular lesion suggested NHL, classified at immunohistochemistry as anaplastic NHL T cell.
Conclusion: the diagnosis of BD is made through clinical criteria and the exclusion of other diseases. The authors call attention to the occurrence of neoplasias with cutaneous manifestations in the differential diagnosis of BD, especially in cases with atypical clinical evolution and with no response to recommended therapy.
Consent for publication
P033 ANTINUCLEAR ANTIBODIES DENSE FINE SPECKLED AND ASSOCIATION WITH AUTOIMMUNE DISEASES AT A TERTIARY HOSPITAL IN SAO PAULO
Fernanda Pulcheri Ramos, Matheus Xavier Guimarães, Andrey Tonetto Barbosa, Izaura Tereza Silva Guedes, Lisa Mielke de Oliveira, Bernardo Patrício Sequeira Dultra, Rina Dalva Neubarth Giorgi, Renata Ferreira Rosa, Nafice Costa Araujo
HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: The detection of antinuclear antibodies (ANAs) is a hallmark of systemic rheumatic diseases. Therefore, understanding the clinical relevance of various autoantibodies showing different staining patterns is crucial for the accurate diagnosis of ANA associated rheumatic disease. The dese fine speckled pattern (DFS-ANA) is one of the most commonly seen in routine diagnostic laboratories. Some authors point out that the DFS-ANA may be an exclusionary marker for ANA-associated rheumatic disease. OBJECTIVES: The objective of the present study is to evaluate the association of DFS pattern with SLE and other diseases.
Methods: This is a longitudinal retrospective study carried out in 2018 in a tertiary hospital in São Paulo, in which all the patients with FAN-PFD were included in the year 2013. The laboratory evaluation was performed by means of indirect immunofluorescence with Hep cell substrate -2. The medical records were analyzed to evaluate the presence or development of autoimmune disease until 2018. For statistical analysis, mean, standard deviation, frequency (%), fisher test, chi-square tests were used. P <0.05 was considered statistically significant.
Results: A total of 283 patients with DFS-ANA ins 2013 were selected. After excluding incomplete data and patients without follow-up, 136 patients were included for analysis, out of 90.4% were women. 77 patients (56.6%) had clinical association, which corresponds to at least 27.2% of all DFS-ANA. Neoplasia was present in 6.6% of the patients, in which liver and breast were the most affected (N=4 and N=2, respectively). 5.9% presented hepatitis B or C (N=1 and N=4, respectively) or autoimmune (N=3), while hyperthyroidism was the sixth most frequent association (3.7%). 33.8% (N=46) presented a diagnosis of SARD, the most common being SLE (14%), RA (9.6%) and ES (4.4%). Other SARDs included Sjogren’s Syndrome, Gout, Cutaneous Vasculitis, LED, JIA and Reactive Arthritis (6.6%). Patients with SARD presented DFS-ANA in higher titers than the others (p=0.047 for titles greater than 320 and p=0.039 for titles greater than 640).
Conclusions: This paper does not corroborate data that relate DFS-ANA with absence of SARD. In this sample, DFS-ANA was associated with several clinical conditions, including a significant relationship between higher titers and the presence of autoimmune rheumatology disease.
Fernanda Pulcheri Ramos, Andrey Tonetto Barbosa, Matheus Xavier Guimarães, Denise Moraes Horiy, Rina Dalva Neubarth Giorgi, Renata Ferreira Rosa, Nafice Costa Araujo
HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: Laboratory tests have the objective of complementing and/or confirming the clinical suspicion generated from anamnesis and physical examination. The indiscriminate request for complementary tests leads to a greater financial cost, laboratories overload and, mainly, a greater risk of erroneous diagnosis and greater anxiety by patients on a positive result. The antinuclear factor (ANA) test is considered a screening method for various autoimmune diseases. It is often found in patients with a wide variety of rheumatic diseases, including systemic lupus erythematosus, systemic sclerosis, Sjogren’s Syndrome, and myositis. However, despite high sensitivity, it does not characterize sufficient criteria for diagnosis and may even be present in healthy individuals.
Objectives: This study aims to correlate the origin of the FAN request with its positivity or negativity.
Materials and Methods: This is an analytical study conducted in 2018 at a tertiary hospital in São Paulo that included 16,181 FAN exams. The collections were carried out between 2010 and 2013 by means of indirect immunofluorescence with Hep-2 cells substrate. For statistical analysis, mean, standard deviation, frequency (%), t-student and Chi-square tests were used. P <0.05 was considered statistically significant.
Results: Out of the 16.181 exams, 11.354 (70%) were nonreactive and 4.827 were reagents, 12.808 were collected in women (79%). The internal medicine clinic was responsible for the largest number of requests (N=3.469, 21.4%), followed by Rheumatology (N=2.393, 14.7%) and Gastroenterology (N=1.849, 11.4%). Among the tests requested by Internal medicine clinic and Gastroenterology, 73.9% and 74.8% were non-reactive, respectively. On the other hand, Rheumatology had 46.3% of negativity in their requests (p=0.0001). The most common pattern was dense fine speckled (DFS) (N=1.754, 36.3%), followed by fine speckled (N=1.117, 23.1%), centromeric (N=201, 4.2%) and homogeneous (N=195, 4%). The prevalence of DFS pattern was similar among the three clinics (34.3%, 36.4% and 32.5%, respectively).
Conclusions: This high index of non-reagent ANA testing allows us to question the correct indication of this exam. Of course, rheumatology presents a higher clinical pre-test probability than other clinics and, therefore, more reagent results. In this way, continuing education in Rheumatology, specially focused on the major clinical specialties, is necessary to increase the value of the test and reduce indiscriminate requests.
P035 ANTIPHOSPHOLIPID SYNDROME AND THE IMPORTANCE OF DIFFERENTIATING ITS NEUROLOGICAL DISORDERS WITH THOSE FROM MULTIPLE SCLEROSIS: A CASE REPORT
Alana Micaela Araújo Lemos, Jonathan dos Anjos Rangel, Letícia Queiroga de Figueiredo, Evânia Claudino Queiroga de Figueiredo, Marcus Ivanovith Fernandes
UNIVERSIDADE FEDERAL DE CAMPINA GRANDE, CAMPINA GRANDE, PARAÍBA, Brasil
The antiphospholipid syndrome is characterized by thromboembolism, repetitive spontaneous abortion and the antibodies presence. Although the antiphospholipid syndrome diagnostic criteria are different from multiple sclerosis, the white matter subcortical lesions might share the two diseases characteristics. Thus, the present report shows a patient with antiphospholipid syndrome, initially diagnosed with multiple sclerosis. Male patient, 42 years old, divorced and camera operator, presented two compatible episodes with cerebral ischemia occurred within a five-year interval, diagnosed with multiple sclerosis and prescribed interferon beta-1a, with symptomatic impairment. In the second ischemic event, the patient was reevaluated and hyperintense focus were observed in T2/Flair subcortical and deep in the supratentorial white matter, from non-specific nature that possibly indicated ischemic gaps, evidenced in Fig. 1, in addition to other complementary exams. The antiphospholipid syndrome diagnosis was made and the anticoagulation, oxcarbamazepine and ciprofibrate were initiated. The risk of treating antiphospholipid syndrome with interferon-beta is uncertain. The patient improvement with the use of this medication makes relevant the description of this case report and justifies the studies accomplishment that evaluate its interference in this syndrome. The differentiation among ischemic and demyelinating brain lesions is important in order to perform accurate diagnosis and safe treatment.
Consent for publication
Hugo Deleon De Lima1, Pedro Arturo Bismara Carneiro Santos2, Rafael da Rocha Caminha2, Bruna Ferraz Gutierrez Piola2, Flávia Jatobá de Barros2, Laurindo Ferreira da Rocha Junior3
1INSTITUTO DE MEDICINA INTEGRAL PROF. FERNANDO FIGUEIRA, RECIFE, PE, Brasil; 2FACULDADE PERNAMBUCANA DE SAÚDE - FPS, RECIFE, PERNAMBUCO, Brasil; 3INSTITUTO DE MEDICINA INTEGRAL PROF. FERNANDO FIGUEIRA - IMIP, RECIFE, PERNAMBUCO, Brasil
Background: Rheumatoid arthritis (RA) is a chronic systemic disease of autoimmune nature that affects mainly the synovial joints and leads to disability. Little is known about the relationship between RA and appetite. The objective of this study was to evaluate the relation of rheumatoid arthritis clinical characteristics and changes in appetite.
Materials And Methods: Cross-sectional study. Data collection of RA patients was performed through clinical evaluation, interview and review of medical records. To evaluate the occurrence of change in appetite and the intensity of the change we used pattern change scale of appetite of Beck Depression Inventory II (BDI-II). The question to evaluate changes in appetite patterns has seven affirmations with values of 0, 1, 2 and 3 indicating no change, mild, moderate and severe changes for decreased or increased appetite. Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints (DAS28) were calculated to measure the disease activity. Functional capacity was analyzed by the Health Assessment Questionnaire (HAQ). Statistical analysis was performed using Graph Pad Prism 6.01 software.
Results And Conclusions: Ninety-six included patients, thirty (30.92%) presented loss of appetite, twenty-four (24.74%) increased appetite and forty-three (44.34%) had no change. When comparing patients with and without appetite change, there were difference in number of painful joints (p 0.414), visual analogue scale (VAS) for physician global assessment of disease (p 0.0349) and HAQ (0.0004). The dicreased appetite was associated with worse functional capacity median HAQ 2.125 (IQR 1.594 –2.406) when compared to patients who did not have change in appetite and those who had increased appetite median HAQ 1.5 (IQR 0.75-22.25) (p 0.0112). On the other hand, increased appetite had association with swollen joints (p 0.0475). Additionally, the the intensity of increased appetite also correlated with swollen joints (p 0.0367; r 0.2558) and with worse functional capacity (p 0.017; r 0.2906). There was a tendency for significance in the correlations of this group with VAS for physician global assessment of disease (p 0.0751; r 0.2189) and CDAI (p 0.0656; r 0.2263). Dicreased appetite correlated with functional capacity (p 0.0006, r 0.391) and CDAI (p 0.043, r 0.2376). The findings suggest that appetite disorders may influence the inflammatory picture of RA. Understanding the role of these disorders in their relation to the etiology and clinical manifestations of RA can point to new therapeutic approaches.
Luis Henrique Savoi De Almeida1,3, Juline do Prado Paes2, Maria Carolina Coelho Gozzano3, Isabella Guadanhim Guerra3, Melissa Nobrega Vasques de Freitas3, Walace Dorneles Gomes3, Gilberto Santos Novaes3
1PONTIFÍCIA UNIVERSIDADE CATÓLICA DE SÃO PAULO, SOROCABA, SP, Brasil; 2PUC SP, SOROCABA, SAO PAULO, Brasil; 3PUC SP (SOROCABA), SOROCABA, SAO PAULO, Brasil
Background: Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to deformity and destruction of the joints.
Although the inflammatory process of RA activity is responsible for the initiation of pain, studies indicate that its intensity may be disproportionate to the severity of the inflammation. It is believed that this is due to the amplification of pain by the central nervous system, mainly due to the decrease in the modulation of conditioned pain.
Thereby this study has the objective of evaluating the characteristics of the main modulators of central pain, as fatigue, sleep and pain intensity, in RA patients with or without active disease.
Methods: The research was developed from the evaluation of 51 patients with RA according to the criteria of the ACR 2011. Simplified Disease Activity Index (SDAI) was used to evaluate disease activity. Pain was assessed according to the SF-36 body pain item. Fatigue severity scale was used in the fatigue assessment and sleep was evaluated by the Pittsburgh Sleep Quality Index (PSQI).
Statistical analysis was performed using Chi-square test, which was considered significant p<0.05.
Results: For the study 41 women (80.4%) and 10 men (19.6%) were selected.
There was a higher prevalence of pain symptom in the group undergoing active disease (50.98%) than in the patient group in clinical remission (19.61%), p = 0.003.
Likewise, a higher prevalence of fatigue symptoms were observed in the active disease group (39.22%), when compared to the group of patients in remission (19.61%), p = 0.17.
There was a higher prevalence of poor sleep quality in the active disease group (50.98%) than in the remission group (7.84%), p = 0.01.
The 3 parameters were found in 9.52% of the patients in remission and in 66.67% of the patients with the active disease, p <0.05. At least two parameters in 28.57% of the patients in remission and 83.33% of the active patients, p<0.05. An isolated parameter was found in 52.38% of patients in remission and 96.66% in patients with active disease, p <0.05.
Conclusions: Analysis of the results showed an association between the three parameters evaluated and the active RA. None of these parameters were able to discriminate central symptoms, sleep, fatigue and pain from active disease suggesting that central pain sensitization modulators do not apply to RA.
P046 ASSOCIAÇÃO ENTRE DENSIDADE MINERAL ÓSSEA E SÍNDROME METABÓLICA EM HOMENS IDOSOS DA COMUNIDADE: SÃO PAULO AGEING & HEALTH STUDY (SPAH)
João De Mendonça Alho Teixeira1, Diogo S Domiciano2, Luana G Machado2, Jaqueline B Lopes2, Camille P Figueiredo2, Valeria F Caparbo2, Liliam Takayama2, Rosa M R Pereira2
1HC FMUSP, SÃO PAULO, SP, Brasil; 2HOSPITAL DAS CLÍNICAS FMUSP, SÃO PAULO, SP, Brasil
Background: Recent studies have shown a link between metabolic syndrome (MS) and bone mass. These results are uncertain about the effect of the components of MS on bone mineral density (BMD) and risk of fragility fractures. Furthermore, the higher prevalence of MS among subjects with higher body mass index (BMI) is a confounding factor, since previous findings have demonstrated that obesity could be a protective factor against bone loss. The aim of this study was to evaluate the prevalence of MS in a community-dwelling older men with high frequency of overweight/obesity and its association with bone parameters.
Methods: 258 community-dwelling older men were evaluated by specific questionnaire. Lumbar spine, femoral neck and total hip BMD were evaluated by DXA. Laboratory tests, including calcium, phosphorus, creatinine, lipid profile and glucose were performed. X-rays were assessed to identify vertebral fractures. National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria were used to define MS.
Results: Prevalence of MS was high (41.5%). Those with MS had higher BMI (28.0±3.9 vs. 25.4±3.4kg/m2, P<0.001), total body fat (19.1±6.4 vs. 15.1±4.6kg, P<0.001), body fat percentage (25.5±4.9 vs. 22.4±4.6%, P<0.001), serum levels of creatinine (1.2±0.3 vs. 1.1±0.3mg/dl, P=0.04), lumbar spine BMD (1.082±0.202 vs. 1.000±0.190g/cm2, P=0.001) and total hip BMD (0.947±0.137 vs. 0.876±0.319g/cm2, P=0.031), but had lower frequency of use of calcium (24.2 vs. 75.8%, P=0.034) and vitamin D supplements (12.5 vs. 87.5%, P=0.015). After adjustments for BMI, hip BMD (OR:1.42 95% CI:1.04-1.93, P=0.029), creatinine (OR:2.79 95% CI:1.17-6.61, P=0.02) and total body fat (OR:1.12 95% CI:1.06-1.19, P=0.001) remained as independent factors associated with MS. No significant difference concerning the prevalence of fractures was observed between the men with and without MS.
Conclusion: A positive association between total hip BMD and MS was found in our community-dwelling older men. Nevertheless, the frequency of fractures was similar in both groups. It suggests that higher BMI does not explain the positive association between higher BMD and MS, and does not protect against fractures. Further studies are necessary to elucidate the effect of MS on bone mass and fracture risk, possibly related to bone quality.
P047 ASSOCIATION BETWEEN ANTINUCLEAR ANTIBODIES CENTROMERE PATTERN AND DIFFERENTS AUTOIMMUNE DISEASES AFTER FIVE YEARS IN BRAZILIAN PATIENTS
Matheus Xavier Guimarães1, Andrey Tonetto Barbosa2, Fernanda Pulcheri Ramos2, Raissa Barbosa De Souza2, Lisa Mielke De Oliveira2, Kioko Takei2, Daniela Crema2, Rina Dalva Neubarth Giorgi2, Renata Ferreira Rosa2, Nafice Costa Araujo2
1HOSPITAL DO SERVIDOR PUBLICO ESTADUAL, Brasil; 2HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Antinuclear antibodies (ANA) are the first-line autoantibodies in suspicion of mostly autoimmune diseases. ANA are immunoglobulins that recognize a broad spectrum of not only nuclear, but also cytoplasmic components. They occur frequently in the sera of patients with a wide variety of rheumatic diseases, including systemic lupus erythematosus (SLE) and Sistemic Esclerosis (SE). According to the ANA consensus, as well as other studies, the centromeric parttern (CP) is on of the least associated with findings in healthy individuals.
Objectives: To determine the frequency of current and new autoimmune manifestations or autoimmune disease five years after detection of antinuclear antibodies centromeric pattern.
Methods: This is a retrospective study, conducted in 2018, included 132 patients with ANA CP between 2010 and 2013. Only 101 patients followed at Rheumatology clinic or other in a tertiary hospital. Were excluded 31 patients who had no follow-up. The 101 patients were divided into two groups according to ANA titles; greater than or equal to 1/640 (N=81, group 1) and less than or equal to 1/320 (N=20, group 2). In both groups we evaluated the presence of autoimmune diseases or autoimmune manifestations. For ANA detection, indirect immunofluorescence is performed using Hep-2 cells as a substrate. For statistical analysis: mean, standard deviation, frequency (%), t-student, Mann-Whitney and Chi-square tests were used. P<0,05 was considered statistically significant.
Results: Of the group 1 patients, the mean age was 63,62 ± 12,65 years, without statistical difference with group 2 (p=0,153). Forty out of 81 patients in group 1 had already diagnosed some autoimmune disease in the ANA achievement (p=0,0017), of which 15 had SE (p=0,0374), 9 Sjogren, 5 Indifferentiated Connective Tissue Disease and 3 Primary Biliar Cirrosis, SLE and reumatoid arthrits. In both groups there was a predominance of females (N=97, 96,03%). After, at least, five years, the most common symptom related were Raynaud phenomenon (FRY) (N=22, p=0,0056), sclerodactyly (N=15, p=0,0374) and esophagophathy (N=15, p=0,0374). Sixteen patients in group 1 developed some autoimmune disease after five years, of which 14 were SSc (p=0,036).
Conclusion: ANA is more associated with females and titers greater or equal to 1/640 are positively associated with autoimmune diseases, mainly SE and its related manifestations. We propose active investigation of all patients who present this standard of ANA in very high titers, considering the incidence of evolution to autoimmune disease after 5 years of follow-up.
Andrey Tonetto Barbosa, Fernanda Pulcheri Ramos, Raissa Barbosa De Souza, Matheus Xavier Guimaraes, Lisa Mielke De Oliveira, Rina Dalva Neubarth Giorgi, Renata Ferreira Rosa
HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection appropriate for sexual satisfaction and may have multiple causes, such as psychological, vascular, neurological and/or endocrine. Clinical studies have shown that ED shares several risk factors with coronary heart disease, suggesting that ED may be a clinical marker of cardiovascular disease (CVD). Gout correlates with various metabolic comorbidities, including arterial hypertension, insulin resistance, dyslipidemia and obesity. New evidences show that hyperuricemia and inflammation may be independent risk factors for ED in addition to those already established.
Objectives: To determine the frequency of ED in patients with and without gout and define their demographic and laboratory features.
Methods: This cross-sectional study, conducted in 2017, included 66 men aged between 40 and 65 years with gout according ACR/EULAR 2015 criteria followed at Rheumatology clinic in a tertiary hospital. As a control group, 37 healthy volunteers were recruited, matched for age. ED was determined by means of questionnaire (Sexual Health Inventory in Men - SHIM), with scores varying from 1 to 25, and classified ED into one of five categories: absent (22–25), mild (17-21), mild to moderate (12-16), moderate (8-11) and severe (1–7). Patients with pre-existing cardiovascular disease and diabetes mellitus were excluded. For statistical analysis: mean, standard deviation, frequency (%), t-student, Mann-Whitney and Chi-square tests were used. P<0,05 was considered statistically significant.
Results: Of the 66 gout patients, the mean age was 63,20 ± 8,36 years and the most common comorbidities were arterial hypertension (57,6%), dyslipidemia (39,4%) and smoking (34,9%). Fourteen out of 17 patients with tophi had ED (82,8%). In gout group, 50 patients (75,8%) presented ED, while 19 (51,4%) in control group (p=0,0162). The mean SHIM score of patients with gout was significantly lower than in control group (15,85 ± 6,61 versus 20,03 ± 3,37; p<0,001). A significantly greater proportion of gout patients (29,5%) had moderate to severe ED compared with control subjects (p<0,001).
Conclusion: ED is present in most men with gout and is frequently moderate to severe. Increasing awareness of the presence of ED in gout patients may lead to earlier medical attention and treatment as well as evaluation of possible CVD. We propose active investigation of ED in patients with gout in order to anticipate unwanted cardiovascular events
P051 ASSOCIATION OF EPSTEIN BARR VIRUS AND CITOMEGALOVIRUS WITH RHEUMATOID ARTHRITIS AND SJÖGREN’S SYNDROME
Camila Nunes Carvalho Sorgato1, Angela Luzia B1, Tatiany Romão Pompílio De Melo1, Jair Carneiro Leão1, Aysa Cesar Pinheiro1, Paula Regina Toche Dos Santos1, Luiz Alcino Monteiro Gueiros2
1UFPE, RECIFE, PE, Brasil; 2RE, PE, Brasil
Background: The role of viral infections in the pathogenesis of autoimmune diseases has long been suggested, but available evidence is still available. The objective of this study was to evaluate an association between Epstein Barr virus (EBV) and Citomegalovirus (CMV) and the presence of Rheumatoid Arthritis (RA) and its association with Sjögren’s Syndrome (SS).
Material and Method: A sample composed of 256 patients of both gender and older than 18 years, divided into three groups: rheumatoid arthritis (RA, n=108), Sjögren’s syndrome associated with rheumatoid arthritis (RA/SS, n = 20)) and healthy controls (C, n = 128). Patients were submitted to resting sialometry, Schirmer’s test and minor salivary gland biopsy in case of suspected SS. Blood samples were collected for detection and quantification of viral loads of CMV and EBV and glandular tissue samples for the detection of these viruses by in situ hybridization (EBV) and immunohistochemistry (CMV).
Results and Conclusions: EBV was more frequent in patients with RA and SS than in healthy controls (p <0.000007), but no correlation with clinical markers (p>0.05) and no difference between RA and AR/SS (p> 0.05). A higher number of EBV/DNA copies was found in RA (158.52 copies/μL) and RA/SS (99.24 copies/μL) than in C (74.67 copies/μL, p=0.739). A statistically significant association was found between the Schirmer test and an EBV/DNA presence (p= 0.0231). CMV was only found in one patient of RA group. The two viruses were not detected in biopsies of minor salivary glands. The presence of EBV/DNA in peripheral blood but not its viral load is associated with RA but not with SS.
Jhésyca Flávia Sousa Castaman Stédile1, Betânia Longo2, Bárbara Stadler Kahlow2, Juliana Simioni2, Ana Paula Beckhauser de Campos2, Thelma Larocca Skare2
1HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA (PR), CURITIBA, PR, Brasil; 2HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA, CURITIBA, PR, Brasil
Background: HLA-B27 is one of the most well studied genetic factors within spondyloarthritis (SpA). Although ankylosing spondylitis (AS) is the disease most associated with this HLA, its association is also verified, to a lesser extent, in other forms of SpA and its presence can modulate the patient’s phenotype. In this study we sought to verify the clinical variability associated with the presence of HLA B27 in a group of patients with SpA.
Methods: This is a retrospective study of 119 medical records of patients of both sexes, followed in a single university hospital with a diagnosis of SpA. For inclusion, patients should meet the ASAS criteria for SpA and have HLA B27 screening performed.
Results: In this sample, 56.3% had AS, 15.9% had psoriatic arthritis; 10.9% had undifferentiated arthritis, 6.7% had non radiological SpA, and 3.3% had reactive arthritis, juvenile SpA and SpA associated with inflammatory bowel disease each. The prevalence of HLA-B27 positivity was 62.1% (74/119). Comparison of HLA-B27 positive and negative individuals can be seen on Table 1.
Conclusion: The studied sample showed association of HLA-B27 with axial involvement of SpA, with AS being the most related phenotype. It was also observed a negative association of HLA-B27 with skin lesions and inflammatory bowel disease.
1. Lin H. et al. Association of HLA‑B27 with ankylosing spondylitis and clinical features of the HLA‑B27‑associated ankylosing spondylitis: a meta‑analysis. Rheumatol. Intern. 2017; 37:1267-80.
2. Yu DT et al. Overview of the clinical manifestations and classification of spondyloarthritis. UpToDate. 2017. Disponível em: . Acesso em: 11/01/2018.
P057 ATYPICAL FEMORAL FRACTURES - CLINICAL-EPIDEMIOLOGICAL PROFILE OF PATIENTS IN A TERTIARY HOSPITAL
Natália Carneiro Dos Santos, Ana Clara Ribeiro, André Ozela Augusto, Dayrana Alves Lucena, Lais Farrapo De Barros Leite, Marcelo Nora Resende, Elaine De Azevedo, Rina Dalva Neubarth Giorgi
HOSPITAL SERVIDOR PÚBLICO ESTADUAL - SP, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Atypical femoral fractures are a rare complication of chronic therapy with bisphosphonate (BF). The American Society for Bone and Mineral Research (ASBMR) generically estimates a cumulative incidence of 0.9 atypical fractures per 100,000 people per year. They differ from classical osteoporotic fractures in several aspects, but mainly on location, since it involves the strongest regions of the femur, subtrochanteric and diaphyseal, differently to osteoporotic fracture, which commonly occurs in the femoral neck. BF are among the main prescribeds medications worldwide for the treatment of osteoporosis (OP) and its role in reducing the incidence of vertebral and non-vertebral fractures when used in the treatment of senile and postmenopausal OP is already established.
Methods: A cross-sectional observational study, including patients following up at an OP service of a tertiary hospital in the state of São Paulo, from 2008 to 2018, who presented atraumatic, subtrochanteric or diaphyseal femoral fractures, in the use of bisphosphonate, and who did not present other conditions associated with the alteration of bone integrity (N = 10).
Results: It was observed that 100% of the studied population were female, with a mean age of 76.2 years old (65-90). At the time of diagnosis of OP, 50% (n = 5) were younger than 60 years old and only one patient was older than 70 years. Eight patients were taking oral BF while only two were taking zoledronic acid. The average time using BF before fracture was 10.2 years (5-20), and 30% (n = 3) of the patients were in use for just 5 years. The type of atypical fracture most observed was the diaphyseal, in 40% of the cases (n = 4). No patient presented a new atypical fracture after discontinuation of BF, but 70% (n = 7) of them presented fragility fractures, the most prevalent was the vertebral fracture (n = 2).
Conclusion: Patients with a history of prolonged treatment (> 5 years) with BF for OP, in general, with a longer diagnosis time, are more likely to evolve with atypical fractures. Even with the small number of cases, there was an expressive increase of fragility fractures after the suspension of BF. It is inferred, therefore, as already established in the literature, that the risk for atypical fractures is small compared to the benefit of the protection conferred by antireabsorption treatment.
P058 ATYPICAL FRACTURE IN PATHOLOGICAL BONE OF A PATIENT WITH IMPERFECT OSTEOGENESIS AFTER PROLONGED USE OF PAMIDRONATE: CASE REPORT
Beatriz Barbosa Teixeira, Thais Lavareda Nascimento, Igor dos Santos Costa, Matheus Lucas da Silva Santana, Camila Alves do Amaral Silva
UNIVERSIDADE FEDERAL DE RORAIMA, BOA VISTA, RR, Brasil
Imperfect Osteogenesis (IO) is a genetic disease of the connective tissue caused by the synthesis of type 1 collagen of poor quality or in reduced quantity. Consequently, hydroxyapatite crystals do not properly penetrate the gaps of the collagen to mineralize it and the connective tissue becomes brittle. Therefore, the bone will have impaired quality and mineralization, with a high risk of fragility, especially in long bones. In addition, other manifestations of IO include imperfect dentinogenesis, bluish sclera, short stature, triangular face and scoliosis. Diagnosis is usually based on clinical criteria (history of repetitive fractures in children), family history and radiological findings. A case of a 24-year-old patient with IO of a hybrid form is reported, and does not matching types determined by the Classification of Imperfect Osteogenesis proposed by Sillence, it made prolonged use of Pamidronate at a dosege of 90 mg/day for 3 days every 6 months for 10 years. In the tenth year of treatment, there was an atypical fracture in the right femur. The event caused the insertion of a plaque,
10 screws, grafting and realignment in the bone affected 6 months ago.
P059 ATYPICAL INITIAL MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH MYOCARDITIS IN A 62-YEAR-OLD WOMAN
Lucas José Sá Da Fonseca, Lerika Moreira Rêgo, Lais Quintiliano Pedroza, Thiago Sotero Fragoso, Vanessa Miranda Pereira Fausto, Sasha Rodrigues de Vasconcellos Costa
UNIVERSIDADE FEDERAL DE ALAGOAS, MACEIÓ, AL, Brasil
Background: Systemic Lupus Erythematosus is a systemic autoimmune disease virtually capable of compromising all organic systems. More commonly affecting women between 16 and 55 years old, its onset in older persons is much less frequent (about 15 percent of the cases) and usually milder. Furthermore, the women: men ratio tend to be reduced with the advance of age.
Case report: a 62-year-old previously healthy woman presented to the Rheumatology department complaining of dyspnea, alopecia and polyarthralgia initiated in the preceding twelve months. The patient was already under treatment for heart failure prescribed by a cardiologist, without significant symptomatic improvement. Clinical history revealed unintentional weight loss of 48 percent of habitual body weight in the preceding year, recurrent fever without evident infection, and previous full alopecia. Physical examination showed crackles in both lung bases, painful hepatomegaly and notable lower limbs edema, with the laboratorial findings of anemia, leucopenia, lymphopenia, elevated erythrocyte sedimentation rate, renal dysfunction (creatinine levels of 1.36 mg/dL, with clearance of 31 ml/min/1.73m2; previous creatinine of 0.77 mg/dL) and positive antinuclear antibody (ANA; nuclear homogeneous pattern at a titer superior to 1:640). As her echocardiogram showed ejection fraction of 45 percent (while being pharmacologically treated for heart failure), with diffuse hypokinesia of both ventricles, the diagnosis of systemic lupus erythematosus with myocarditis was established, with the prescription of prednisone 0.5 mg/kg/day (higher doses were avoided at first, because of the advanced age and uncontrolled systemic arterial hypertension at that time). Two weeks later, the patient returned for clinical reassessment, without peripheral edema or dyspnea, and with normal breath sounds and abdominal examination. New laboratory findings demonstrated reduced complement levels, as well as high titers of double-strand anti-DNA and anti-Ro antibodies, when corticoid dose was then increased to 1mg/kg/day. Once 24-h proteinuria fulfilled criterion for nephritis (792 mg; renal biopsy showing class IV lupus nephritis), treatment with monthly intravenous cyclophosphamide for six months was initiated. After a five-dose course of cyclophosphamide, the general clinical status dramatically improved, along with normalization of the cardiac ejection fraction (from 45 percent to 74 percent) and reduction in 24-h proteinuria (which was shown to be 406 mg).
Conclusion: the case presented emphasizes the importance of considering systemic autoimmune diseases in the differential diagnosis of cardiac compromise in older women with heart failure of apparently cryptogenic ethiology.
P065 AUTOINFLAMMATORY DISEASES: CLINICAL, LABORATORY, GENETIC FEATURES ANDRESPONSE TO TREATMENT OF A REFERENCE CLINICAL PRACTICE IN RHEUMATOLOGICPEDIATRIC POPULATION
Erica Naomi Naka Matos, Milena Foizer Leite, Carolina Yume Arazawa, Laura Loureiro De Souza Rosa
UNIVERSIDADE FEDERAL DE MATO GROSSO DO SUL, CAMPO GRANDE, SSP/MS, Brasil
BACKGROUND: Autoinflammatory Syndromes (AIS) are a group of rare diseases with genetic alterations characterized by the presence of recurrent or continuous episodes of fever, associated with systemic or localized inflammatory signs that affect mainly the musculoskeletal, cutaneous, gastrointestinal, ocular and neurological systems. The objective of this study was to investigate epidemiological, clinical and laboratory features of patients with AIS followed in our clinical practice and evaluate the difficulties in diagnosis and treatment.
MATERIALS AND METHODS: An observational, descriptive, retrospective study was perfomed. Were analysed data of patients with AIS followed between 2003 and 2017, collected through a form (ethnic group, gender, age of onset symptoms and diagnosis, family history, clinical, laboratory and genetic features, therapeutic response).
RESULTS AND CONCLUSIONS: There was six patients whit AIS, 5:1 males-female ratio. The age in the moment of diagnosis ranged from three to ten yearsold. The averaged time passed since the symptoms onset was 32 months. Two patients had mediterranean progeny. Diagnoses were: Family Mediterranean Fever – FMF (4), Neonatal Onset Multisystem Inflammatory Disease – NOMID (1) and Periodic Syndrome Associated with the Receiver of Tumor Necrosis Factor – TRAPS (1). Fever and abdominal pain were present in 100% and all patients presented arthritis and arthralgia in some time of the diseases evolution. One patient presented delayed neuropsychomotor development (NOMID). Regarding the laboratory tests, were found: anemia (4), leukocytosis (3) and raise in platelets (2), inflammatory tests (6) and ferritin (3). The patient with NOMIDhad radiographic changes (bone rarefaction, enlarged metaphyses and epiphyses, patellar fragmentation and hypertrophy). Three patients had access to the molecular study: one had a mutation in the CIAS1 gene, one had a variant in the NOD2 gene (NM_022162) that is considered a risk modifier, but non-specific and another had negative result. Colchicine was the initial empirical choice therapy, being the first choice for Family Mediterranean Fever. Although they did not gain significant symptom control, nonsteroidal anti-inflammatory drugs and corticosteroids were the most widely used drugs in the different diseases. Immunobiological therapies were reserved for refractory and clinically more exacerbated casas as in NOMID and TRAPS. Therefore, AIS remains a challenge thatshould be recognized by pediatricians treating children with recurrent fever, to be early referred to a rheumatologist for treatment and avoid the perpetuation of the inflammation that affects the patient’s well-being.
Consent for publication
Fernada Del Castanhel, Mariana Sanchez Malagutti, Valderílio Feijó Azevedo, Eduardo Dos Santos Paiva
UFPR, CURITIBA, PR, Brasil
Background: Fibromyalgia (FM) is a syndrome that can mask other rheumatological diseases, such as axial spondyloarthritis (axSpA). Widespread pain, fatigue and stiffness are common symptoms. The aim of this study was to evaluate the prevalence of clinical features of axSpA in patients suffering from FM and chronic back pain, seeking for indicators that could suggest the presence of this underlying condition.
Materials and methods: One hundred FM patients between 18 and 65 years old were assessed. This evaluation consisted of a questionnaire based on the clinical arm (clinical features of axSpA, without HLA-B27 testing) of the ASAS (“Assessment of Spondyloarthritis International Society”) axSpA criteria set and a questionnaire on the impact of FM (Revised Fibromyalgia Impact Questionnaire - FIQR)
Results and conclusion: We found that 80% of the patients met clinical criteria for the diagnostic of axSpA. Inflammatory back pain, good response to non-steroidal anti-inflammatory drugs (NSAIDs), arthritis and enthesitis were significantly more common in these patients than in the ones who did not meet the criteria (Table 1). Patients with FM and positive axSpA criteria also presented with higher CRP (C- reactive protein) levels (p=0.00035) as illustrated in Table 1. FIQR mean value was 63.6 and did not show significant difference between patients that met and did not meet axSpA criteria. The investigation of axSpA in patients suffering from FM and chronic back pain should be pursued, in particular if there is associated enthesitis, arthritis, good response to NSAIDs, inflammatory pain and elevated CRP.
P067 AXONAL MOTOR AND SENSORY ACUTE NEUROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS: RARE VARIANT OF GUILLAIN-BARRÉ SYNDROME: CASE REPORT
Andressa Alexandre de Araujo, Débora Rocha de Moura Rodrigues de Aguiar, Julia Yoneshigue Laranja de Oliveira, Paula Guedes Ferreira da Silva, Elba Sophia Theodoro Santos de Oliveira, Luciana de Abreu e Lima Pamplona, Luiz Felipe Dipe Prates Miranda, Carlos Baptista de Figueiredo
HOSPITAL FEDERAL DE BONSUCESSO, RIO DE JANEIRO, RJ, Brasil
Background: Guillain-Barré syndrome (GBS) is an immune-mediated inflammatory polyradiculoneuropathy usually occurring after infection and is the main cause of acute neuromuscular paralysis. Systemic lupus erythematosus (SLE) has neuropsychiatric manifestations, including GBS, occurring in 0.1% of cases.
Case report: A 19-year-old female patient diagnosed in January 2016 with cutaneous-articular SLE, using hydroxychloroquine 400mg/day and prednisone 10mg/day, immunology with ANA 1/640 nuclear fine dotted dense, consumed complement, positive anti-DNA. Anti-RNP, anti-Sm, anti-Ro, anti-LA and anticardiolipins was negative. Presented in our hospital with nausea and intense myalgia which had started 3 days before admission, including face paresthesia, bilateral conjunctival hyperemia. She denied fever. During hospitalization, she developed urinary retention, intestinal constipation paralytic mydriasis of the left eye, descending paresthesia and paresis, with sensitive level. CSF with only a mild protein increase. Methylprednisolone 1g for 5 days was initiated, however that was a rapid progression to tetraplegia, aphasia, arreflexia and anesthesia in the four limbs.
With this evolution, we started immunoglobulin intravenously 400mg/kg/day for 5 days. She responded well with improvement of paresthesia and partial recovery of strength. However, the symptoms of dysautonomia remain.
Magnetic resonance of the brain and electroencephalogram showed no abnormalities. Otherwise, electroneuromyography showed alteration of the axonal sensory-motor type. These findings lead us to the diagnosis of Acute Motor Sensitive Axonal Neuropathy (AMSAN), a rare variant of SGB.
Although intravenous immunoglobulin led to improved strength and sensory changes, there was no response to dysautonomic symptoms. Then, it was started pulse therapy with methylprednisolone 1g for 5 days, cyclophosphamide 500mg/m2 single dose and 1mg/kg/day prednisone regular, obtaining a better control of nausea and emesis. The patient is followed up in our outpatient clinic, with cyclophosphamide 500mg/m2 and immunoglobulin 400 mg/kg/day for 5 days, monthly.
Comments: Most SLE patients have atypical GBS symptoms. Few studies related AMSAN variant to SLE. Another differential of our case is that the paralysis was descending, which can occur in the variants of GBS. Urinary and intestinal retention, which made the differential diagnosis more difficult, are due to dysautonomia, and may be associated with GBS. AMSAN variant consists in rapid evolution and poor prognosis. In our case, although dysautonomic symptoms remained, we observed a good response to immunoglobulin in strength and sensations.
Consent for publication
The authors declare that written informed consent was obtained from patient’s mother.
Marcia Bandeira, Christina Feitosa Pelajo, Ingrid Herta R Grein, Rafaela Wagner, Luana Ribeiro Carlos, Loris Lady Janz Junior
HOSPITAL PEQUENO PRINCIPE, CURITIBA, PR, Brasil
Background: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood. Childhood-onset SLE is associated with higher morbidity and mortality than adult-onset SLE. Most pediatric patients will require glucocorticoids and often immunosuppressive drugs, with the aim of reducing disease activity while also preventing long-term toxicities from medications.
Belimumab is a human monoclonal antibody that inhibits soluble B-lymphocyte stimulator with small data in pediatric patients.
Methods: Observational study of patients with JSLE diagnosed before their 16th birthday, and treated with belimumab, from a single center in Brazil. Data were collected on demographic and disease characteristics, clinical manifestations requiring treatment, concomitant medications, disease course, and treatment outcomes. The outcome was defined as the physician’s impression of improvement in the initial manifestation (s) being treated without worsening in other organ systems.
Results: 5 children treated with belimumab in addition to standard of care therapy had a follow up of at least 9 months. The median age at diagnosis was 11.3 years old (range 9-14 years old); the median disease duration at initiation of belimumab was 4 years (range 2-6 years). All patients were taking other background medications prior to initiation of belimumab (hydroxychloroquine, prednisone, cysclophosphamide, mycophenolate mofetil and azathioprine). The most common indications for initiation of therapy were inability to taper steroids, arthritis, rash and persistent or worsening serologic activity (increasing anti-dsDNA and hypocomplementemia). All patients had a significant decrease in disease activity as measured by SLEDAI, laboratory improvement and decreased autoantibody levels were noted 4 months after starting treatment. And a significant decrease in the amount of corticosteroid was allowed in 80% of the sample.
Conclusion: With improvement of the survival in JSLE the prevent of accrue organ damage secondary to the disease process itself and to its therapy has become a major goal in the management of pediatric lupus in our era. This serie suggest a important role for belimumab in pediatric-onset SLE in tapering steroids and minimizing damage associated with disease flares.
P074 BILATERAL ANEURYSM OF CAROTID ARTERIES AND INTRACAVITARY THROMBUS IN THE RIGHT VENTRICLE AS RARE VASCULAR INVOLVEMENT IN A PATIENT WITH BEHÇET’S DISEASE – CASE REPORT
Pedro Paulo De Alcantara Pedro12, Priscila Dias Cardoso Ribeiro2, Rywka Tenenbaum Medeiros Golebioviski2, Dennise de Oliveira Nogueira Farias2, Flávia Maria Matos Melo Campos Peixoto2, João Victor Campos de Oliveira2, Pedro Matos2, Edgard Torres dos Reis Neto2
1UNIVERSIDADE FEDERAL DE SAO PAULO, SÃO PAULO, SP, Brasil; 2UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: Behçet’s disease (BD) is a systemic disorder characterized by recurrent bipolar ulcers, cutaneous lesions, ocular, neurological and vascular involvement. Arterial involvement may affect any vessel conferring greater morbidity and mortality and the need for aggressive immunosuppressive treatment due to the high risk of complications, such as rupture of aneurysms.
Case Report: A 25-year-old male patient with history of recurrent oral and genital ulcers during the last 10 years associated with pustular lesions on buttocks was admitted with hemoptysis and dyspnea in the last two weeks. Lung tomography confirmed the diagnosis of pulmonary thromboembolism with multiple acute and chronic thrombosed arterial branches, without pulmonary artery aneurysms. Patient also had previous history of bilateral lower limbs venous thrombosis four years ago and one month before admission he was submitted in another hospital to embolization of left internal carotid artery aneurysm after the diagnosis of ipsilateral abducent nerve palsy. Pathergy test, antinuclear antibody and antineutrophil cytoplasmic antibody were negative. Angiotomography of the aorta and its main branches demonstrated saccular aneurysm in the right common carotid artery and left common carotid thrombosis. Transthoracic echocardiography revealed an intracavitary thrombus in the right ventricle with 5.4 cm of diameter. A diagnosis of BD was performed with severe arterial involvement with multiple thrombosis and aneurysms. Immunosuppressive treatment was initiated with methylprednisolone pulse therapy 1g/day for three consecutive days (followed by oral prednisone 1mg/kg/day) associated with cyclophosphamide 0.5g/m² and anticoagulation. Despite this treatment, patient evolved with right carotidinia and expansion of the aneurysm. He was submitted to surgical aneurysm repair (endarterectomy) without intercurrences and symptom improvement. Vessel biopsy through surgery confirmed the etiology of vasculitis of the aneurysm. There was also a reduction in the right ventricular thrombus size. Patient was referred to the outpatient clinic without complaints, using prednisone 1mg/kg/day and monthly intravenous cyclophosphamide.
Conclusion: Vascular involvement in BD can occur in any vessel, arterial or venous. Arterial involvement of large vessels is a severe manifestation of the disease due to the risk of aneurysms, stenosis or thrombosis. In these cases, immunosuppression is the main therapy with high corticosteroids dose associated with immunosuppressants, such as cyclophosphamide or anti-TNFα. In aneurysms with risk of rupture, surgical treatment should be performed.
Consent for publication
Caroline Almeida Oliveira1, Lisa Mielke de Oliveira2, Laís Farrapo de Barros Leite2, Matheus Xavier Guimarães2, Denise Moraes Horiy2, Bernardo Patrício Sequeira Dultra2, Elaine de Azevedo2, Rina Dalva Neubarth Giorgi2
1HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL, SÃO PAULO, SP, Brasil; 2HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Bisphosphonates (BF) are effective drugs in the treatment and control of conditions related to the loss of bone mineral density. The first description of bisphosphonate-induced osteonecrosis of the jaw (ONJ) occurred in 2003. Recently, it has also been identified in patients who used denosumab (Dmabe), without previous use of BF. ONJ has an incidence between 1 / 10.000 and 1/100.000, being slightly higher than the general population. Although it may happen spontaneously, parenteral use remains the main risk factor for this event, most commonly in the jaw. In addition, it is necessary to exclude other predisposing factors, such as periodontal diseases, poor oral hygiene, smoking, diabetes, presence of malignant neoplasia, type of chemotherapy, chronic use of steroids and advanced age.
Case Study: In the outpatient clinic of osteometabolic diseases of a public tertiary hospital in the city of São Paulo, seven female patients with a previous diagnosis of osteoporosis presented osteonecrosis of the jaw during follow-up in the last six years. The mean age during the event was 69 years, all with more than three years of antireabsorption therapy. Of these, three were using intravenous bisphosphonate (Zoledronic Acid) and four used the oral presentation (Alendronate or Ibandronate). Five patients had other associated risk factors for ONJ: two in prolonged use of steroids, two in diabetic patients and the other in patients with periodontal disease as the initial lesion.
Conclusion: The prevalence of ONJ in patients taking antireabsorbents is close to 0.10%. Even though it is a serious adverse effect, the recommendation is to maintain the use of the medication in cases of high risk for fragility fractures. Attention should be given in cases where, in addition to prolonged use of BF, risk factors such as corticotherapy, dental manipulation with inadequate technique, periodontal disease and diabetes are associated. As seen in our series, these overlapping factors seem to increase the chance of ONJ.
P077 BONE MINERAL DENSITY AS A PREDITOR OF OSTEOPOROTIC FRACTURES IN GROUP OF BRAZILIAN VERY ELDERLY PATIENTS
Lisa Mielke de Oliveira1, Raissa Barbosa De Souza2, Andrey Tonetto Barbosa2, Fernanda Pulcheri Ramos2, Denise Moraes Horiy2, Rina Dalva Neubarth Giorgi2, Elaine De Azevedo1
1HOSPITAL DO SERVIDOR ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 2HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone. The incidence of osteoporotic fractures (OF) increases with age and according to FRAX Brazil, the central risks for OF are: family history of fracture, female, smoking, alcoholism, rheumatoid arthritis and chronic use of glucocorticoids. The global prevalence of OF is growing with the aging of the population, which increases substantially the morbidity, mortality and economic cost. It should be considered that at very elderly (VE) there is a main prevalence of multiple diseases and consequently polypharmacy.
Objectives: To compare risk factors for OF and bone mineral density (BMD) in VE patients with primary osteoporosis and relate to the presence of OF.
Methods: This retrospective study, conducted in 2018 included 91 patients with the diagnosis of osteoporosis aged above 85 years followed at Rheumatology clinic in a tertiary hospital. The subjects were divided in two groups, with and without OF (group 1, N=72, group 2, N=19, respectively). For statistical analysis: mean, standard deviation, frequency (%), t-student, Mann-Whitney and Chi-square tests were used. P<0,05 was considered statistically significant.
Results: Of the 91 VE patients, 89,01% were females (N=81) and the mean age was 87,87±3,43 years. The most prevalent diseases in both groups were hypertension (N=69, 75,82%), osteoarthritis (N=58, 63,74%), chronic kidney disease (N=49, 53,84%) and gastroesophageal reflux (N=39, 42,85%). The main prescribed medicines were zoledronic acid (N=42, 46,15%), denosumab (N=32, 35,16%) and teriparatide (N=5, 5,49%). In group 1 the most commons OF were vertebral (N=34, 47,22%), wrist (N=17, 18,06%), hip (N=15, 16,67%) and others (N=18, 25%), however 33 (45,83%) patients had two or more OF. The menopause age of the group 1 was earlier (p=0,045) being the only clinical risk factor with significance for OF. When compared BMD of the total femur, was observed lower BMD of the densitometry in group 1 (0,668g/cm3) versus group 2 (0,755g/cm3) (p=0,0071). According to ROC curve analysis, the best cutoff value for BMD was 0,768g/cm3, yielding sensitivity and specificity of 50% and 86,96%, respectively, for predicting OF events in this study.
Conclusion: In the present study, it was found that both, comorbidities and clinical risk factors, were not sufficient to determine an increased risk for OF. The complementary exam, bone densitometry, was good predictor for risk of OF after 85 years old. Therefore, we suggest that this test be performed at least once in VE patients.
Luiz Felipe Dipe Prates Miranda2, Gabriela Araújo Campos2, Filipe Kruger2, Larissa Franco Motta de Souza2, Guilherme Nogueira d’Utra1, Débora Rocha de Moura Rodrigues de Aguiar2, Carlos Baptista de Figueiredo2
1HOSPITAL MUNICIPAL MIGUEL COUTO, RIO DE JANEIRO, RJ, Brasil; 2HOSPITAL FEDERAL DE BONSUCESSO, RIO DE JANEIRO, RJ, Brasil
Introduction: Cannabis is the psychoactive substance most consumed by young people. The thromboangiitis obliterans is an inflammatory, segmental and non-atherosclerotic disease, which most commonly affects the arteries and veins of small and medium calibers of the extremities. It is most frequent in men and is strongly associated with tobacco use. The cessation of smoking is important to decrease the risk of amputation. It has also been reported in marijuana users (Cannabis Arteritis).
Case report: Woman, 33 years old, former smoker of 20 packs-year and a regular marijuana user. Deny use of other illicit drugs. She presents ischemic lesions of 10 years evolution in extremities, with a previous history of amputation of her second left pododactyl. In another hospitalization she had negative research for thrombophilia and she stopped smoking because of the thromboangiitis obliterans hypothesis, however the lesions continued to progress. She was admitted for investigation of the lesions in September 2017, when she was submitted to an angio tomography and arterial Doppler of the limbs, without alterations. ANA, ANCA, VDRL, RF and serologies for HIV and hepatitis B and C were negative and there was no monoclonal peak into electrophoresis of serum proteins. Arteriography of the lower limbs showed obstruction of the left anterior tibial artery in the middle and distal thirds and of the microcirculation of the ipsilateral foot. Because of the evolution of the lesions, treatment with alprostadil, acetylsalicylic acid, cilostazol and calcium channel blocker was initiated. During the hospitalization period, the lesions showed improvement, with complete healing. After 3 months of discharge, the patient returned to a routine visit with signs of digital ischemia and with the reappearance of the ulcers, when she admitted having returned the use of marijuana and noticed its correlation with the lesions. We kept the same treatment of the first hospitalization and referred to psychology and psychiatry services for assistance in the treatment of drug withdrawal. The lesions regressed again, reinforcing the suspicion of association with the use of Cannabis.
Comments: Despite currently available reviews do not suggest the use of Cannabis as a cause of arteritis due to the concomitant use of tobacco in most patients, our patient presented worsening of the lesions after cessation of smoking and important improvement after the suspension of marijuana, strengthening the hypothesis of this association.
Consent for publication
The authors declare that they have obtained written informed consent from the patient for publication.
Consent for publication
Jhésyca Flávia Castaman Stédile1, Aiessa Z. Fedrigo2, Betânia Longo2, Carla Luchese de Almeida2, Juliana Delfino2, Deborah Cristyne Colombo2, Thelma Larocca Skare2
1HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA (PR), CURITIBA, PR, Brasil; 2HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA, CURITIBA, PR, Brasil
Background: Systemic lupus erythematosus (SLE) is a chronic, multisystemic and autoimmune disease that may affect all structures of the heart. Valvar involvement, when studied by echocardiography, occurs in almost 60% of the patients. They are usually described as diffuse valvar thickness of mitral or aortic valves. Severe hemodynamic changes requiring cardiac valve replacement are rare. Here, we describe five cases of SLE patients needing cardiac valve substitution.
Cases Report: All five patients filled the ACR classification for SLE diagnosis. In 80% (4/5) of the cases, it was found double mitral lesion (stenosis and insufficiency); only one (1/5) had isolated aortic lesion (stenosis). All patients were female with mean age of 35 years at valvar lesion diagnosis and all were negative for antiphospholipid antibody. In all, but one case, the diagnosis of valvar lesion was done after the lupus diagnosis. In addition, in all patients, metallic prosthesis was used for substitution. In this series, pericarditis was seen in 3/5 cases and 1/5 had myocarditis. Glomerulonephritis was the most commonly associated extra cardiac manifestation.
Discussion: Usually cardiac valvar lesions in SLE are associated with SAA, but this could not be verified in our cases. Interestingly, Gabrieli et al, studying 39 lupus and 20 primary SAA patients concluded that valvular involvement is frequent in SLE but it is apparently unrelated to antiphospholipid autoimmunization. In our series mitral is the most affected valve and the pericardium was the second cardiac structure more involved. Glomerulonephritis was also commonly seen in this series.
1. CORDEIRO A et al. Envolvimento valvular cardíaco em doentes com lúpus eritematoso sistêmico. Correlação com presença de anticorpos anticardiolipina. Acta Reum Port. 2004;29: 97-103.
2. GABRIELLI F et al. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol. 1995;51:117-26.
P090 CAUSES OF INTERNATION AND CLINICAL EVOLUTION OF RHEUMATOLOGICAL PATIENTS IN A INTENSIVE THERAPY UNIT OF THE REGIONAL HOSPITAL OF MATO GROSSO DO SUL
Solino de Matos Neto1, Gláucia Moreira Souza de Queiroz1, Ana Elisa Dantas Modesto1, Laize Guerreiro de Jesus1, Alex Magno Coelho Horimoto1, Patricia Rubini2, Claudnei Menezes de Rezende2
1UNIVERSIDADE FEDERAL DE MATO GROSSO DO SUL, CAMPO GRANDE, MS, Brasil; 2HOSPITAL REGIONAL DE MATO GROSSO DO SUL, CAMPO GRANDE, MATO GROSSO DO SUL, Brasil
Introduction: Patients with systemic autoimmune rheumatic diseases (SARD) may require admission to an intensive care unit (ICU) due to underlying disease, associated infections, complications or new manifestations. Usually these patients present significant morbidity and mortality, with death rates ranging from 16.7% to 64.3%. Patients with disseminated intravascular coagulation or infection have the highest mortality rates. Coma, renal failure and acute abdomen are also predictors of worse prognosis. Mortality rates in patients with SARD exceed those predicted by the APACHE II score, and are higher than those in non-rheumatologic patients admitted to the ICU.
Objectives: To identify the main causes of hospitalizations of rheumatologic patients in the ICU, to describe the epidemiological profile of the patients assisted under this regimen and to determine the rate and cause of mortality of the patients during the period of 56 weeks.
Methods: An observational, analytical and cross - sectional study. All patients admitted to the Intensive Care Unit of the Regional Hospital of Mato Grosso do Sul from July 2015 to June 2016 were prospectively identified and monitored.
Results and Conclusions: A sample of 12 patients was obtained in the period, which had a mean age of 41.33 ± 17.35 years; with a predominance of females (58.3%). Systemic lupus erythematosus (SLE) was the most common rheumatic disease (41.7%) in patients admitted to the ICU, followed by systemic vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in 25% of hospitalizations. The main reasons for the hospitalization of these patients were infections, followed by exacerbations of rheumatologic diseases. Among the patients evaluated, 41% had the first diagnosis of SARD in the ICU and found a mortality rate of 25% in the sample, with alveolar hemorrhage in the context of vasculitis being the main cause of mortality. Although the use of the APACHE II score is contradictory in predicting the outcomes of patients admitted to the ICU, it has shown a significant relationship with evolution for renal failure in our study, considering the importance of this tool in the evaluation of rheumatic patients in the ICU.
P091 CAUSES OF MORTALITY IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS - EXPERIENCE OF A TERTIARY HOSPITAL IN RIO DE JANEIRO
Maurício Petroli, Ana Carolina Lopes Santiago, Jéssica Costa Farias, José Paulo Amoedo Bueno Brandão, Daniely Das Graças Roberto, Blanca Elena Rios Gomes Bica
UFRJ, RIO DE JANEIRO, RJ, Brasil
Background: Juvenile Systemic Lupus Erythematosus (JSLE) is an autoimmune chronic inflammatory disease that affects more girls than boys, with median age of onset at 12 to 13 years old. Its etiology is multifactorial. JSLE generates systemic repercussions that impacts especially pediatric range because of the disease’s and its immunosuppressive therapy’s effects on growth and development.
Methods: Cross-sectional study based on review of 18 dead patients’ medical records within a group of 120 patients diagnosed with JSLE between 1989 and 2016 and followed up in a Rheumatology service of a university hospital in Rio de Janeiro between 2000 and 2017. A retrospective analysis of medical records allowed collection of various data, whose subsequent analysis focused on clinical conditions at time of death and causes of mortality.
Results And Conclusions: Among the 18 (15%) patients who died during follow-up, the ratio between female (15, 83.3%) and male (3, 16.7%) was 5:1. The mean time of disease until death was 101.5 months. The age at death ranged from 195 to 348 months. The mean age was 261.5 months, corresponding to 21.8 years old. 11 (61.1%) patients died of infectious causes. Within infectious causes of death, the primary site of infection was: pneumonia (2, 16.7%), urinary tract infection (1, 8.3%), cutaneous infection (2, 16.7%), central nervous system infection (1, 8.3%), and acute gastroenteritis (1, 8.3%). In addition, 1 case was described as fungal infection (8.3%) and 4 cases had no specific infectious focus (33.3%). Another causes of mortality included: chronic kidney disease (1, 5.5%); refractory hemolytic anemia (1, 5.5%); macrophage activation syndrome (2, 11.1%); transplant-associated graft-versus-host disease (1, 5.5%). 1 (5.5%) patient had both septic shock and macrophage activation syndrome. Cause of death remained unknown in 2 (11.1%) cases. Among reviewed patients, the major death cause was infectious diseases, highlighting septic shock. The immunosuppressive therapy used to control the disease had difficult adherence in pediatric range, besides contributing with undesirable clinical outcomes, especially higher risk of infections. JSLE is an important disease in pediatric context due to its diagnostic difficulty, complex management and impairment in growth and development phase. Early diagnosis, close control and encouragement to therapeutic adherence contribute to the reduction of damage and the control of the disease. Early diagnosis of infections and its prompt treatment can minimize mortality rates secondary to infections in immunosuppressed patients.
Caio Bosquiero Zanetti, Diogo Souza Domiciano
HC-FMUSP, AMERICANA, SÃO PAULO, Brasil
Background: Fibromyalgia (FM) is a chronic syndrome characterized by diffuse musculoskeletal pain and multiple somatic symptoms including functional gastrointestinal disorders. Celiac disease and non-celiac gluten sensitivity (NCGS) frequently evolve in adults with symptoms similar to those found among FM patients. However, prevalence of CD/NCGS vary according to genetic background from different populations. There is no consistent data on frequency of gastrointestinal symptoms as well as no study performed duodenal biopsies to investigate CD/NCGS in Brazilian FM patients.
Objective: to determine the prevalence of CD/NCGS in patients with FM from a tertiary hospital and to verify the association between gastrointestinal manifestations and classical symptoms of FM.
Methods: 62 women (age 54.6±12.5 years) with FM (ACR 2010) were consecutively recruted from FM Outpatient clinics of a tertiary hospital. Patients were excluded if they had other disease than osteoarthritis. Clinical evaluation included Widespread Pain Index (O-19), Severity Symptom Scale (0-12), fibromyalgia survey score (“fibromyalgia-ness”) (0–31) and revised Fibromyalgia Impact Questionnaire, besides presence of gastrointestinal manifestations during at least 3 months in the last year. Subjects were screened for the presence of serum IgA anti-endomysial antibodies and IgA tissue transglutaminase antibodies. An upper gastrointestinal endoscopy with duodenal biopsies was performed and samples were studied by two expert pathologists according to classification for CD (Marsh-Oberhüber). Potential statistical associations between gastrintestinal manifestations and FM symptoms were analyzed by chi-square, likelihood ratio, Student’s t or Mann-Whitney’s tests. Significance was set at P<0.05. Results: 46 (74.2%) women reported at least one digestive symptom: 34 (54.8%) constipation, 35 (56.5%) abdominal distension, 21 (33.9%) loss of weight or inappetence, and 21 (33.9%) nausea or vomiting. The average fibromyalgia survey score and FIQR were 16.9 points and 56.5 (moderate impact on quality of life), respectively. There was an association between presence of any digestive symptom and scores Widespread Pain Index and Severity Symptom Scale (fatigue, waking up tired and cognition). 14 (31.8%) individuals presented macroscopic duodenitis and 2(4.5%) had lymphocytic infiltrates on duodenal tissue, but none met CD criteria. In 1 (2.3%) patient the NCGS was confirmed.
Conclusion: In this sample of FM women from a tertiary hospital, we did not find any case of CD and only subject had NCGS. There was a high prevalence of gastrointestinal symptoms (more than half referring constipation or abdominal distension). A positive association between these manifestations and greater degree of central pain amplification was observed. Nevertheless, no difference was found in the impact of FM on quality of life (FIQR) in patients with and without gastrointestinal symptoms.
Consent for publication
Gabriela Guimarães Moreira Balbi, Iggor Oliveira de Sousa, Jade Dib Fernandez, Annelyse de Araújo Pereira, Melissa Marati Fraga, Claudio Arnaldo Len, Sandro Luiz de Andrade Matas, Maria Teresa Terreri
UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, SP, Brasil
Background: Cerebral pseudotumor or benign intracranial hypertension (BIH) is a syndrome that presents with clinical features of elevated intracranial pressure without radiological evidence of intracranial mass, infection, vascular abnormality, hydrocephalus or changes in level of consciousness. It is rare in childhood. The incidence increases between the ages of 12 to 15 years, and 60% of children who develop the syndrome are over 10 years of age. Several conditions are associated with pseudotumor (secondary pseudotumor), such as systemic diseases and drug exposure. The term idiopathic intracranial hypertension is used when the cause of this condition is not found. There are few studies in the literature, most of them case reports, describing secondary pseudotumor syndrome in pediatrics. Our objective was to report all cases of children and adolescents diagnosed with cerebral pseudotumor, with or without rheumatic disease, who were followed by the pediatric rheumatologists and neurologists of our hospital.
Method: Retrospective study based on medical reports, 29 patients aged up to 18 years and diagnosed with cerebral pseudotumor, registered until December 2016 and followed up in pediatric rheumatology and neurology outpatient clinics of a tertiary hospital.
Results and conclusions: Among the 29 patients diagnosed with cerebral pseudotumor, 51.7% were girls and the mean age at disease onset was 12.3 years. Etiology was found in 18 patients (62%) associated with a rheumatic disease in 4 cases. Among these, two of them had juvenile dermatomyositis undergoing oral glucocorticoid withdrawal. One patient had Henoch-Schönlein purpura also receiving glucocorticoid. The fourth patient presented anti-phospholipid antibody syndrome. The most common symptom was headache (69%) and acetazolamide was the most used medication (69%). Two patients developed blindness and 10 are still in follow-up. Although rare, pseudotumor cerebri should be considered in children with headaches, especially in patients with rheumatic disease.
P097 CHANGES IN CYTOKINE EXPRESSION IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS SUBMITTED TO GINGIVAL INFLAMMATION CONTROL
Loreley Carlos Agostinho Bragard3, Manuerla Rubim Camara1, Carlos Marcelo da Silva Figueredo2, Flavio Roberto Sztajnbok3
1UNVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RIO DE JANEIRO, Brasil; 2UNVIERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RIO DE JANEIRO, Brasil; 3UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RIO DE JANEIRO, Brasil
The aim of this study was to evaluate the impact of treatment of gingival inflammation on the expression of cytokines in serum and gingival crevicular fluid (GCF) in patients with Juvenile Systemic Lupus Erythematosus (SLE). Twenty-four patients with SLE (mean age: 16.1 ± 1.6 years) who had gingivitis participated in the study. Periodontal, rheumatologic, blood and GCF data were collected. Cytokines were analyzed by the multiplex assay with the Bio-plex Pro TM Th17 panel assay kit. The McNemar test was used for qualitative data and the Wilcoxon test was used for numerical data. After treatment of gingival inflammation, there was a decrease in SLEDAI (p = 0.039), IL-4 and IL-5 (p = 0.023 and 0.026) in serum. In the gingival fluid, there was a significant decrease in IL-1β, IL-10 and MCP-1 (p = 0.039; 0.010; 0.025; respectively) and a significant increase in IL-4, IL-12 (p70), IL-17, GM -CSF and INF-v (p = 0.003; 0.025; 0.001; 0.049; 0.004; respectively). After the treatment of gingival inflammation, it was concluded there was no significant difference in SLICC (Systemic Lupus International Collaborating Clinics) values, but there was a significant reduction of absolute SLEDAI and serum IL-4 and IL-5 levels, probably in due to the time of treatment of SLE. The increase of the IL-12, IL-17 and GM-CSF cytokines in the GF analysis demonstrated a possibly unfavorable prognosis, since they are associated with local bone and tissue loss.
P098 CHARACTERISTICS OF CARE GIVEN TO HOSPITALIZED PATIENTS WITH OSTEOARTHRITIS IN THE LAST 9 YEARS IN SERGIPE
Luíza Brito Nogueira, João Victor de Andrade Carvalho, Bruno José Santos Lima, Angela Santos Lima, Henrique Gouveia Borba e Souza, Larissa Sá dos Santos, Juliana Monroy Leite, Nicole Santiago Leite, Meyling Belchior de Sá Menezes, Yasmin Oliveira Santos
UNIVERSIDADE TIRADENTES, ARACAJU-SE, SE, Brasil
Background: The arthrosis is an painful infection of the joints caused by the unbalance between the formation and destruction of cartilage. It has already been classified as the most prevalent rheumatic disease among people over 65 years of age and, for being a chronic multifactorial disease, leading to progressive functional disability, patients with arthrosis present different demands of care - elective or urgent. Then, as the treatment of the condition varies from pharmacological to surgical, the hospitalization profile seems to be directly related to such demands.
Methods: This is an exploratory documentary study with secondary data obtained by DataSUS with the Sistema de Informações Hospitalares (SIH) about the influence of elective or urgent care in patients hospitalized for arthrosis in Sergipe in the interval from October 2008 to October 2017.
Results And Conclusions: In the past years, about 67,6% of the patients admitted with arthrosis were assisted in an elective way. This predominance kept on mostly each year, witch its smallest number was in 2010 with 71,2% for the electives and the biggest, in 2008, reached 100%. However, in the years of 2013 and 2014, not only there was an abrupt variation of this average, it was predominant the urgent stamp of the medical assistance with in-patients. Respectively, the numbers reached only 36,6% and 44,6% for the elective support. In general, from 2008 to 2017, there was an alarming 99,4% increase in the hospitalization by arthrosis and, besides mostly of these have been assisted in an elective way, the urgent stamp of the medical support grew 12,7%. Figure 1 shows this variation over the years. It is concluded that the relationship between the stamp of medical assistance and hospitalization of patients with arthrosis in Sergipe not only exists, but also it does not happen in a regular way throughout the years. The reason remains unknown, but the relationship can be predominant of the in-patients that were electively assisted because of the variety of treatments for arthrosis, like physiotherapy, the non-pharmacological, the pharmacological and the surgical, and their different levels of evolution.
P099 CHARACTERIZATION OF CLINICAL BENEFITS IN SUBJECTS CLASSIFIED AS ACR20 NON-RESPONDERS AT WEEK 104 OF APREMILAST TREATMENT: SUBANALYSIS OF 3 LONG-TERM, PHASE III TRIALS
Priscila Magalhaes Reis Nakasato
CELGENE, Estados Unidos
Background: The PALACE 1, 2, and 3 studies evaluated apremilast (APR) efficacy and safety in subjects with active psoriatic arthritis (PsA) despite prior conventional DMARDs and/or biologics. This analysis further characterizes the clinical benefits associated with long-term APR exposure in subjects failing to achieve an ACR20 response at Week 104.
Material and Methods: Subjects were randomized (1:1:1) at baseline to placebo (PBO), APR 30 mg twice daily (APR30), or APR 20 mg twice daily. Subjects randomized to APR30 at baseline and classified as ACR20 non-responders (ACR20NRs) at Week 104 were considered for this analysis. At Weeks 24, 52, and 104, ACR core components were examined as well as the proportions of subjects achieving PASI-75/PASI-50 among those with psoriasis involvement ≥3% of the body surface area (BSA) at baseline and dactylitis count and Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) of 0 among those with dactylitis or enthesitis, respectively, at baseline. Safety is described for the overall PALACE 1-3 population.
Results: A total of 109 subjects randomized to APR30 at baseline were ACR20NRs at Week 104. Baseline ACR core components were similar for ACR20NRs and ACR20 responders at Week 104. Among these ACR20NRs, several core components of ACR response showed sustained improvements from baseline through Week 104 with continued treatment: swollen/tender joint counts (mean % change, −58.0%/−41.7%) and Physician’s Global Assessment of Disease Activity (visual analog scale) scores (mean % change, −44.3%). Importantly, of those with psoriasis BSA involvement ≥3% at baseline, 50.0% achieved a PASI-50 response and 36.0% achieved a PASI-75 response after continued treatment with APR30 through Week 104. Among ACR20NRs with baseline dactylitis (n=44) or enthesitis (n=74), 68.2% achieved a dactylitis count of 0 and 33.8% achieved a MASES of 0 at Week 104, respectively. More limited improvements in Subject’s Global Assessment of Disease Activity, Subject’s Assessment of Pain, HAQ-DI, and CRP outcomes most commonly had an impact on subjects’ ability to achieve an ACR20 response. In the overall subject population, no new safety concerns were identified through 104 weeks.
Conclusions: ACR20NRs receiving APR30 demonstrated significant improvements in core PsA domains. The data may explain why subjects who failed to achieve an ACR20 response remained on long-term APR treatment. These findings suggest some subjects with PsA may experience meaningful clinical improvements not completely captured by assessment of ACR20 response criteria. Outcome measures specifically designed for PsA subjects may be more suitable to evaluate treatment response in PsA subjects.
Jobson Lopes De Oliveira2, Rafael Alves Cordeiro2, Solange Carrasco1, Célio Roberto Gonçalves2, Julio César Bertacini De Moraes2, Carla Gonçalves Schahin Saad2, Percival Degrava Sampaio-Barros2, Claudia Goldenstein-Schainberg3
1FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SAO PAULO, SP, Brasil; 2DIVISAO DE REUMATOLOGIA, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SAO PAULO, SP, Brasil; 3HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: Psoriatic arthritis mutilans (PsAM) occurs in about 5% patients representing the most serious and uncommon form of psoriatic arthritis (PsA). Data concerning PsAM subtype are scarce. It is characterized by shortening of fingers and/or toes, intense osteolysis of those peripheral joints and digital telescoping. In this study we evaluated the prevalence and clinical characteristics of PsAM patients from our tertiary rheumatology center
Methods: All PsA patients ≥ 18 years according to CASPAR criteria followed at our rheumatology division between 2002 and 2017 were actively searched for PsAM deformity of hands and feet. PsAM was considered in the presence of shortened fingers, digital telescoping, and anteroposterior radiography showing at least one joint with severe erosive arthritis (for example pencil-in-cup or gross osteolysis of the bones) without osteophytes. Demographic, clinical, laboratory and radiographic data were searched.
Results: PsAM was found in 8.2% PsA patients (17/207), 12 males and 5 females with mean age = 59.0 ± 9.9 years and mean age at arthritis onset of 34 ± 12.6 years. According to co morbidities, hypertension occurred in 13 patients (76%), dyslipidemia in 10 (59%), metabolic syndrome in 9 (53%), osteoporosis in 6 (35%), psychiatric disorders in 4 (24%), diabetes in 2 (12%). Of note, 3 (18%) patients had cancer (1 colon, 1 breast, 1 multiple myeloma). Syndesmophytes were evident in 9/16 (56%) patients and radiographic sacroiliitis in 7/16 (44%). Surprisingly 9 of 13 (69%) patients tested for HLA-B27 were positive. Regarding therapy, 9/17 PsAM patients (53%) were on biologic agents (2 adalimumab, 4 infliximab, 2 secukinumab, 1 etanercept,).
Conclusion: We have shown a 8.2% prevalence of PsAM in our PsA patients, slightly higher than previously reported. The enhanced positivity of HLA-B27 and radiographic axial involvement in PsAM demonstrated for the first time is intriguing. Furthermore, biologic therapy use in more than half PsAM patients reinforces the severe nature of PsA mutilans involvement.
P101 CHARACTERIZATION OF THE EPIDEMIOLOGICAL PROFILE OF RHEUMATIC HEART DISEASE IN BRAZIL IN THE LAST 10 YEARS
Mariana Bomfim De Menezes, Érica Nascimento, Andressa Borelli, Debora Montarroyos
UNIT, ARACAJU, SE, Brasil
Introduction: Rheumatic heart disease represents a high cost in health, not only in hospitalization, but also in post-discharge care. Knowing its epidemiology allows the adoption of preventive measures and the choice of the most appropriate therapy. The authors present the epidemiological characterization of the pathology over 10 years in Brazil.
Methods: Retrospective descriptive study that shows all Rheumatic heart disease between 2008 and 2018. Epidemiological data were collected database of System of Hospital Information of the Unified Health System (SIH-SUS).
Results: The present study demonstrated 6,383 cases in Brazil. It is also observed a heterogeneous distribution of the number of cases related to the southeastern region in the leadership with 2,853 reported cases. Infections in women were higher than in men during the period.
Conclusions: Through the data collected it is possible to observe the high index of cases of rheumatic heart disease. The fact that the southeastern region represents the second place for cases of rheumatic fever in the country, but leadership in this pathology demonstrates the local need for better prevention.
Natália Jardim Martins da Silva Brasil1,2, Ruy Sampaio de Siqueira Neto2, Leila Patrícia Fonseca Andrad Oliveira2, Vitor Silva Souza2, Fernanda Nogueira Holanda Ferreira Braga2
1JANSSEN BRASIL, FORTALEZA, CE, Brasil; 2HOSPITAL UNIVERSITÁRIO WALTER CANTÍDIO/UFC, FORTALEZA, CE, Brasil
Introduction: Neuropathic arthropathy, also known as Charcot arthropathy, is a chronic, progressive degeneration of a joint associated with an underlying neurological disorder. It is characterized by pathological fractures, destruction, which eventually leads to debilitating deformities and loss of function.¹ We report a case of Charcot neuroarthropathy, secondary to syringomyelia.
Case Report: A 57-year-old woman with complain of arthralgia on the left shoulder about eight years, evolving with decreased strength, tenderness and left upper limb atrophy. The physical exam showed significant left shoulder atrophy with functional limitation and mild movement pain, decreased strength (Grade 3), hypoesthesia of all limbs with deep reflexes absent. The left shoulder X-ray showed head and proximalhumeral metaphysis with multiple intra-articular bone fragments due to the joint destruction. On this, it was hypothesized of neoplasic or neuropathic arthropathy, and a cervical spine and left shoulder magnetic resonance imaging (MRI) were requested. MRI of the left shoulder confirmed the extensive joint destruction; Cervical spine MRI suggested syringomyelia in cervical and dorsal spine. MRI of the thoracic and lumbar spine was performed to estimate the extent of lesion, however was evidenced only in the thoracic spine. With Charcot’s neuropathic arthropathy secondary to syringomyelia hypothesis, the patient was referred to the neurosurgery and orthopedics to analyze the possibility of surgical intervention.
Discussion: Charcot arthropathy is a rare cause of joint destruction in individuals with various forms of neuropathy. The most common causes include: syringomyelia, diabetes mellitus, peripheral neuropathy and tabes dorsalis. The shoulder is involved in less than 5% of patients, and cervical syringomyelia accounts for 75% of cases. 2,³ There are two theories currently accepted about its pathogenesis. The neurotraumatic theory involves repeated trauma by an insensitive joint and neurovascular theory with osteoclastic activation leading to joint inflammation and bone resorption. 4 Treatment goals are to reduce further articular damage while retaining a functional joint. Initially conservative measures are adopted, including symptomatic treatment, anti-inflammatory, orthotics, weight reduction and patient education to minimize mechanical trauma. Recently, several studies have demonstrated a beneficial effect of bisphosphonates. Failure of conservative measures is an indication for surgical intervention.
Consent for publication
Rafael Coradin, Thiago Willers, Maria Odete Esteve Hilario, Tatiana Freitas Tourinho, Maria Lúcia Lemos Lopes, Eduardo Souza da Rosa, Elisa Pacheco Estima Correa
UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE, PORTO ALEGRE, RS, Brasil
Introduction: Chilblains (CB) is a disease with a eritematous localized purple cutaneous lesion associated with pain or itch. It occurs with after 12 to 24 hours after a cold exposure. It is usually self limited. In the south of Brazil it can appear with a relative frequency.
The objective of this article is to demonstrate our experience with CB in pediatric patients in this case report.
Case reports: From 2014 to 2018 there was 9 cases. 88,8% were female with an average of 15-years-old. The hands (44%) and the fingers (77%) were the most affected, and the symptoms remains for about 4,5 weeks, being the itch and erythema the most common. In the laboratory tests, the Antinucleous Antibody (ANA) were present in 44% of the cases, with Nuclear Fine Dotted pattern in 75% of them. Two patients used Nifedipin and other two used naproxen as treatment, all others didn’t needed any kind of medicine. One patient had a family story of CB and other of Lupus.
Discussion/Conclusion: The CB is a benign disease. The understanding of this pathology is important to rheumatologists, because it can be a differential diagnosis of arthritis. The CB can occur secondary to Lupus, Behçet, malignancy and immunoglobulinopathies, enhancing its relevance. The literature in pediatric cases is scarce, with only few case reports. Differently of them, our children were more affected in the upper limbs (88%). We had a predominance of female adolescents, as seen in previous articles. We had no cases with associated disorders, although almost half of the children had a positive ANA. We did not perform skin biopsy because the cases were mild and self-limiting. Due to the possibility of chronicity, as well the risk of associated diseases, we should be aware of CB in childhood.
Larissa Cristiane De Oliveira Souza, Rodrigo Alencar e Silva, Juliana Maia Marinho, Saulo de França Oliveira, Olivia de Fátima Costa Barbosa, Francisco Alves Bezerra Neto
UFRN, NATAL, RN, Brasil
Background: Movement disorders are rare in patients with systemic lupus erythematosus (SLE). With a prevalence rate of 1.3%, chorea is the most common amongst them. It usually occurs within the first years after the onset of SLE.
Case report: Male, 16 years of age, otherwise healthy, presented with migratory arthritis, anasarca and oral ulcers. Approximately 30 days after the onset of such symptoms, the subject experienced choreic movements, dysarthria and mental confusion. The patient denied recent history of seizures, fever or cutaneous lesions. Upon admission, he was alert, feverless, displaying equal and fotorreactive pupils, affective lability, generalized choreic movements (picture 1), appendicular hypotonia, normal deep tendon reflexes, bilateral flexor plantar reflexes and no meningeal signs. Tongue ulcerations on the inferior portion of the tongue were also observed. Left elbow and right metacarpophalangeal joint arthritis were also present. Lab workup revealed positive ANA 1/1280 (homogeneous nuclear and chromosomal metaphase plate pattern), positive Anti-DNA, leukopenia (3000), lymphopenia (1032) and hypocomplementemia. ESR was 28, 61.3 CRP, positive rheumatoid factor, negative P-ANCA and C-ANCA, negative ASO, hepatitis-related serology, VDRL and HIV. Skull CT scan and cerebrospinal fluid showed no abnormalities. The patient was given a diagnosis of SLE with movement disorder (chorea). He was given 1 g methylprednisolone daily for three days, and then started on prednisone 1mg/Kg, hydroxychloroquine 400mg and azathioprine 50 mg daily, achieving full symptom remission.
The patient is currently asymptomatic under hydroxychloroquine and azathioprine.
Conclusion: Chorea, ataxia, choreoathetosis, dystonia and hemiballismus figure among SLE movement disorders. Out of all SLE patients who develop chorea, 50% will do so after after being diagnosed with SLE, 25% will develop it before and 25% at the time of SLE diagnosis. It is paramount to bear in mind the existing association between Chorea and SLE as well as its differential diagnoses: rheumatic fever, infectious diseases, metabolic disorders. drug-induced and occasionally, other autoimmune disease.
P.S.: Publication with consent of the patient.
Mario Sergio Ferreira Santos1,2, Francisco Leonardo De Oliveira Leal2, Francisco Ewardo Rodrigues Da Silva2, Joyce Reis Costa2, Yane Chaves Martins Resende2, Jozelda Lemos Duarte2, Joelma Moreira De Noroes Ramos2, Ingrid Mayra Pereira De Oliveira2, Gabriela Grabowski Amorim2, Therezinha Dantas Nobre Neta2, Vinicius Leal Veloso2
1TERESINA, PI, Brasil; 2UNIVERSIDADE ESTADUAL DO PIAUÍ, TERESINA, PI, Brasil
Background: Systemic lupus erythematosus (SLE) is a chronic, autoimmune inflammatory disease of unknown cause, and diverse symptomatology. The gastrointestinal tract involvement is common, but chronic diarrhea as the initial manifestation of the disease is rare. We present a patient who started the clinical picture with chronic diarrhea, making the diagnostic suspicion difficult.
Case Report: 38-year-old patient, female. Five months ago, she started with diarrhea, abdominal pain and vomiting. Two months later the diarrhea remained about 5 times a day, without blood or pus. A month ago, she was treated at the Emergency Unit. The medical record of the occasion reports a picture of acute respiratory failure, attributed to acute pulmonary edema. Once the clinical emergency was resolved, she was sent to a main hospital (Getulio Vargas Hospital in the city of Teresina-PI). The patient reported that in the last month she presented skin rash with photosensitivity and wrists and hands edema. In the evaluation, generalized edema was identified, besides increased volume and wrists and hands joints sensitivity. Complementary tests: Hemogram with anemia, leukopenia and thrombocytopenia. Urine summary with proteinuria and granular cylinders (2g in 24h proteinuria). FAN 1/320, homogeneous nuclear pattern, C3 and C4 downgraded, anti-DNA and anti-SM, and non-reagent antiphospholipids, antitransglutaminase, antiendomysium and antigliadin. Negative results for gastrointestinal parasites and coproculture. Subsequent investigation for gastrointestinal disease, including endoscopic examination with biopsy and MRI enterography, revealed diffuse intestinal and colonic loops distension, diffuse thickening of this last one, in addition to mild enanthematous gastritis and severe erosive esophagitis. After SLE diagnosis, therapy with 500 mg of methylprednisolone began once a day for 3 days, followed by predinisone 1mg/kg/day, associated with hydroxychloroquine 400mg/day, plus general clinical support measures such as diuretics and hydroelectrolytic care, plus albendazole 400mg/day for 5 days. In the patient’s evolution, a normalization of clinical and laboratory parameters was observed.
Conclusion: Chronic diarrhea as a manifestation of SLE can be explained by enteritis, either by mesenteric vasculitis and/or by intestinal mucosa inflammation. The possibility of vasculitis was reinforced MRI enterography findings. Since protein loss can be identified by proteinuria, the possibility of protein-losing enteropathy was excluded.
Consent for publication
P112 CHRONIC DISCOID LUPUS ERYTHEMATOSUS (CDLE), WITH ANTIPHOSPHOLIPID SYNDROME (APS) AND CUTANEOUS ULCER
Mario Sergio Ferreira Santos1, Mateus Dutra Batalha Costa3, Therezinha Dantas Nobre Neta3, Ana Luiza Gonçalves Santos2, Késsia Pachêco Leal3, Francisca Daline dos Santos Silva3, Sérgio Augusto de Souza Cavalcante3, Gabriel Lima Jurema3, Lucas Moura Santana3, Beatriz Saraiva Araujo3
1UNIVERSIDADE ESTADUAL DO PIAÚ, TERESINA, PI, Brasil; 2IPEMED, SÃO PAULO, SÃO PAULO, Brasil; 3UNIVERSIDADE ESTADUAL DO PIAUÍ, TERESINA, PIAUÍ, Brasil
Background: CDLE may exist as an independent clinical entity or in association with Systemic Lupus Erythematosus (SLE). Antiphospholipid antibodies (aPL) may appear in the course of different clinical disorders, particularly in SLE. However, the presence of these antibodies in the course of CDLE is rare. Moreover, when associated with thrombotic events and cutaneous ulcer. This is what we present in this case report.
Case Report: A 62-year-old female patient on CDLE treatment for face and scalp in the last 5 years. Interrupted the use of hydroxychloroquine (HCQ) 2 months ago. In the last month, constitutional symptoms appeared with worsening of cutaneous lesions, in the form of deep and painful ulcers, on the face and scalp with secondary infection (Klebsiella and Pseudomona). Hb 10g/dl; PT, platelets, leukocytes, kidney and hepatic functions tests were normal; ESR: 140mm/hr; ANA, anti-SM, anti-native DNA and anti-Ro unreacted; Anticardiolipin IgG: 9U GPL and IgM: 40U MPL; lupus anticoagulant was present; anti-Beta-2-Glycoprotein I: 22 and 6.1 U/mL, IgG and IgM respectively. Wide antibiotic therapy, warfarin, treatment of skin ulcers with alginate, silver and calcium, reintroduction of HCQ, plus prednisone at a low dose were instituted. During hospitalization, the patient presented thrombosis of the axillary and left basal veins, requiring full anticoagulation. aPLs remained positive in moderate to high titers, confirming the presence of APS. The patient received Rituximab, 1g EV, reinfused 15 days later. In the evolution, it was observed a regression of cutaneous ulcers, elevation of hemogobin levels and normalization of inflammatory activity tests.
Conclusion: This is one of the few CDLE records, presenting with APS and cutaneous ulcer (CU). CU is accepted as a non-APS criterion. Rituximab appears as an alternative for cases of APS, with skin ulcer difficult to control.
Consent for publication
P113 CHRONIC MUSCULOSKELETAL PAIN IN RHEUMATIC OUTPATIENTS ATTENDING PHYSICAL THERAPY AT A UNIVERSITY HOSPITAL
Mariana Alonso Monteiro Bezerra, Victor Emmanuel Cavalcanti Zamora, Geraldo da Rocha Castelar Pinheiro
UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil
Background: Chronic pain is considered a conscious experience modulated by neurobiological, environmental and cognitive factors. Mechanisms-based classification of chronic musculoskeletal pain is a useful tool in clinical practice, as it combines self-reported pain characteristics and a physical examination, pointing symptoms and signs and leading professionals in the decision making process [1,2]. The purpose of this study was to provide a musculoskeletal pain profile of rheumatic patients assisted by a physiotherapist from a university hospital in Rio de Janeiro.
Methods: A retrospective descriptive study was conducted between January 2016 and September 2017. Data was collected at the first physiotherapy evaluation session. Chronic musculoskeletal pain was classified as predominantly mechanical or inflammatory “nociceptive” pain, “peripheral neuropathic” pain, or pain related to “central sensitization” based on clinical classification previously described . Sociodemographic, economic and clinical factors were also assessed.
Results and conclusions: Of 176 patients evaluated for physiotherapy treatment, 83% were female, 36% were middle-aged adults, 61% had low education, 60% had no current occupational activity, and about 79% were sedentary. The most prevalent clinical diagnosis was osteoarthritis (25%), followed by rheumatoid arthritis (22.1%), spondyloarthritis (11.4%), soft tissues lesions (10.8%), gout (5.7%), systemic lupus erythematosus (4%), osteoporosis (3.4%), and others (17.6%). Regarding the characteristics of the chronic musculoskeletal pain, 60% reported their pain as intense (VAS>7), 70% were classified as nociceptive pain, 18% as chronic widespread pain associated with central sensitization and 12% as peripheral neuropathic pain. The most affected anatomic areas were the knee (65%) and the lumbar spine (44%). Considering the number of body sites, 28.4% of patients referred pain in only one site, 28.4% referred pain in two sites, 18.8% referred pain in three sites and 24% referred pain in four or more sites of the body. Even with a small number of participants, we found a high occurrence of nociceptive pain and this information is useful to guide the dynamics of our service in terms of human resources and therapeutic approach to rehabilitation of patients with chronic musculoskeletal pain.
1. Smart KM, Blake C, Staines A, Doody C. Clinical indicators of “nociceptive”, “peripheral neuropathic” and “central” mechanisms of musculoskeletal pain. A Delphi survey of expert clinicians. Manual Therapy. 2010;15(1):80–7.
2. Smart KM, Blake C, Staines A, Doody C. The Discriminative Validity of “Nociceptive”, “Peripheral Neuropathic”, and “Central Sensitization” as Mechanisms-based Classifications of Musculoskeletal Pain. The Clinical Journal of Pain. 2011;27(8):655–63.
Marcio Ximendes Espirito Santo
UNIMED COSTA DO SOL, MACAE, RJ, Brasil
Background: Churg-Strauss syndrome, also known as eosinophilic granulomatosis with polyangiitis, is a necrotizing vasculitis that affects small-sized vessels and is associated with severe asthma, blood and tissue eosinophilia and a positive antineutrophil cytoplasmic antibody. People around the age of 50 years are most affected, but can occur in all ages.
Case Report: A male aged 28 years was admitted to the intensive care unit with accute breathing insufficiency, hemoptoic sputum and fever. He complained about weight loss, arthralgia and worsening asthma. Before admission, he has received antiobiotics for pneumonia treatment without any result. On examination he had proximal interphalangeal arthritis, small violaceous nodules in hands and foot and distal asymmetric sensory neuropathy. On investigation the computed tomography showed bilateral pulmonary infiltrate in appearance of budding tree and hilar linfadenopathy, he had eosinophilia in blood test and P- antineutrophil cytoplasmic antibody was positive. At first, he received corticoid pulse with great clinical improvement, but with maintenance of the pulmonary infiltrate. After that, he was submitted to lung biopsy that confirmed small vessel vasculitis with eosinophilic infiltrate compatible to the Churg-Strauss syndrome. Finaly, he was treated with cyclofosfamide and was discharged.
Conclusion: We concluded that Churg-Strauss syndrome is a rare disease that can affect any age, depends on early aggressive immunosuppressive therapy and needs to be searched in pacients that have history of nasal allergies, chronic sinusitis or asthma with hard control.
Consent for publication
Denise de Queiroga Nascimento 3, Suelen Cristina de Lima3, Isaura Isabelle Fonseca Gomes da Silva3, Nadja Maria Jorge Asano1, Gisele Vajgel Fernandes2, Lucila Maria Valente2, Paula Sandrin Garcia3
1HOSPITAL CLÍNICAS DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil; 2HOSPITAL DAS CLÍNICAS DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil; 3UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease and genetic, environmental and immunological factors are involved in this pathogenesis. Patients with SLE present photosensitivity to UV radiation, presenting an abnormal cutaneous response. A large number of genes contribute to SLE pathogenesis. Studies have shown there are considerable evidence that single MHC genes contribute to the SLE development. One of them is the Class II Histocompatibility Complex Transformer (CIITA). It is able to alter the level of transcription of the Class II Major Histocompatibility Complex (MHC II), an important regulator of the adaptive immune response. The polymorphism rs3087456 at position -168 (A/G) in the CITTA gene may be responsible for this change. Only one association study was performed between this polymorphism and SLE. However, to date, no association study was performed between this polymorphism and SLE clinical features. Photosensitivity is a clinical feature that affects about 70% of SLE individuals, and this number increases in patients living in places with high UV radiation incidence, as is the case of the Brazilian Northeast population. Thus, our study aims to evaluate the binding of rs3087456 to photosensitivity in SLE in Northeast Brazilian population.
Methods: We collected 74 individuals with SLE in Recife, from the Rheumatology Outpatient Clinic of the UFPE Hospital das Clínicas. The control group consisted of 180 healthy individuals from the analyzed region. All subjects were genotyped using the TaqMan genotyping assay by the ABI 7500 Real Time PCR platform. Statistical analyzes were performed using Fisher’s exact test by program R.
Results: The chi-square test did not indicate significant differences when comparing patients and controls. Using the codominant model, the G/G genotype showed associated to high susceptibility to photosensitivity in SLE patients (p<0.05). Other clinical features analyzed in the present study did not present significant statistical differences between the allelic and genotype frequencies.
Conclusion: Our findings suggests that the CIITA SNP rs3087456 is associated to high susceptibility to photosensitivity in SLE patients from Northeast Brazilian population.
P117 CLASSIFICATION OF MUCOCUTANEOUS MANIFESTATIONS IN SYSTEMIC ERITEMATOSUS LUPUS (SLE): DE GILLIAM JN & SONTHEIMER RD A RIBERO S & LIPSKER D
Luciano Junqueira Guimarães, Ana Paula Monteiro Gomides, Izelda Maria Costa Carvalho, Leopoldo Luiz Dos Santos Neto
HOSPITAL UNIVERSITÁRIO DE BRASÍLIA, BRASÍLIA, DF, Brasil
Background: The spectrum of mucocutaneous manifestations that occur in the course of SLE is broad and the classification is heterogeneous, such manifestations are among the most prevalent in SLE, the most common being malar rash and photosensitivity.
Methods: Bibliographic review.
Results and conclusions: In 1981 James N. Gilliam and Richard D. Sontheimer proposed the classification of lesions in specific and non-specific lupus erythematosus (LE) based on the histopathological findings of skin biopsies. They defined as specific lesions those presenting dermatitis interface to histopathology. Subsequently, the following findings were added: presence of necrosis and vacuolization of the basal layer of keratinocytes, thickening of the basement membrane, incontinence of pigmentation and lymphocyte infiltration at the epidermal dermal junction. Acute LE (erythema malar, maculopapular and bullous erythema), subacute LE (psoriasiform and polycyclic) and chronic cutaneous LE (discoid, verrucous, tumoid, lupus panniculitis, pernium, discoid/lichen planus and mucosal) are included. Manifestations such as periungual telangectasia, livedo reticularis, occlusive vasculopathy, Raynaud's phenomenon, leukocytoclastic vasculitis and thrombophlebitis are the most frequent non-specific lesions in SLE, but may occur in other diseases. In 2010 Dan Lipsker suggested a new classification for cutaneous lesions, based on clinical signs and findings under microscopy. The lesions were classified according to the level of the cellular infiltrate and the tissue damage in the epidermis, dermis and or subcutaneous. In 2016 Simone Ribero et al, separated the nonspecific lesions between those that indicated the presence of thrombotic vasculopathy and those that presented a high standard neutrophil reaction. The specific lesions, most common in SLE according to the latter classification are: epidermal dermis (acute, subacute, chronic/discoid and bullous LE specific disease), dermal (tummy, papulonodular mucinose, erythematous reticular mucinous syndrome and lymphocytic skin infiltrate of Jessner-Kanof) and hypodermic (lupus panniculitis and lupus). The non-specific LE are indicative of thrombotic vasculopathy (livedo reticular, purpura, cutaneous necrosis and thrombophlebitis), neutrophil cutaneous LE (bullous LE, neutrophilic LE dermatosis, neutrophilic urticaria, urticaria LE vasculitis and pyoderma gangrenosum).
Conclusion: Mucocutaneous manifestations constitute 4 of the 17 criteria established by Systemic Lupus International Collaborating Clinics (SLICC) in 2012 for the classification of SLE, denoting the importance of such manifestations in the course of the disease. A broad knowledge of these manifestations is fundamental for the diagnosis and management of SLE.
P118 CLASSIFICATION OF PHYSICAL ACTIVITY LEVEL OF OSTEOPOROSIS PATIENTS ACCOMPANIED AT A RHEUMATOLOGY SERVICE OF SÃO PAULO IN 2018
André Ozela Augusto, Dayrana Alves Lucena, Natália Carneiro dos Santos, Matheus Xavier Guimarães, Lisa Mielke de Oliveira, Bernardo Patrício Sequeira Dultra, Rina Dalva Neubarth Giorgi, Elaine de Azevedo
HOSPITAL SERVIDOR PÚBLICO ESTADUAL-SP, SÃO PAULO, SÃO PAULO, Brasil
Introduction: For the treatment of Osteoporosis, a comprehensive plan should be proposed, including pharmacological therapy associated with practice of physical activity, a fundamental item as it increases the resistance of the bones and improves muscle performance by reducing the number of falls.
Objective: To identifying the physical activity level among the population served, so that one can try to act in order to generate positive impact on this population’s quality of life.
Method: Data were collected from 66 female patients, accompanied in the osteoporosis ambulatory in a rheumatology service. The nationally validated questionnaire “Physical Activity Level Rank (Short Version) – IPAQ” was used, using the classification suggested by it. The data were computed and analysed using the Excel 2013 software.
Results and discussion: The mean age found among the study population was 71 years, with a minimum of 35 and maximum of 94 years, mode of 62 and median of 71, obtaining the following distribution according to the classification proposed by IPAQ: very active 15.2% (10); active 42.4% (28); irregularly active A 16.7% (11); irregularly active B 13.6% (9) and sedentary 12.1% (8). Comparing the obtained results with the São Paulo’s female population profile in 2011, elaborated by Matsuda et al., which evaluated 1048 women with no age or comorbidities restrictions, a higher proportion of very active women (4.1%) were found, maintaining the same percentage of sedentary patients (8%).
Conclusion: This comparison suggests that the perception of the benefits of physical activity in the Osteoporosis treatment reached positively the groups that were previously active, leading to an increase in the level of physical activity. Unfortunately, the greater understanding about the need to adopt more active habits was not sufficient to reduce the number of sedentary patients (which was unchanged in relation to the general population
Ítalo José Araújo Silveira De Sá1, Fernanda Tavares De Melo Cavalcanti2, Ana Valeska Lisboa Carvalho2, Karla Valéria Miranda De Campos2, Esther Bastos Palitot2, Maria Roberta Melo Pereira Soares2, Alessandra Sousa Braz2, Eutília Andrade Medeiros Freire2
1HOSPITAL UNIVERSITÁRIO LAURO WANDERLEY, JOÃO PESSOA, PB, Brasil; 2HULW, JOÃO PESSOA, PB, Brasil
Systemic Lupus Erythematosus (SLE) is an autoimmune systemic inflammatory disease of multifactorial etiology affecting multiple systems. Although it has been described in association with various autoimmune diseases, there is only minimal data available regarding coexistence of Psoriatic Arthritis (PsA) and SLE. We report the first case of a brazilian patient suffering from both PsA and SLE.
A 53 years old woman presented to a tertiary hospital in 2016 with a 5-year history of polyarthralgia and well-demarcated erythematous and scaly plaques on her scalp (Fig. 1) and hands, that were misdiagnosed and treated as leprosy in 2014 by a infectologist, without any improvement. Physical examination reaveled nail dystrophy and symmetric polyarthritis, which affected several proximal interphalangeal (PIP) joints, wrists, shoulders, knees and ankles. A skin biopsy was performed in July 2016 and histology corroborated the diagnosis of psoriasis. Methotrexate was prescribed orally in a weekly dose of 15 mg with supplementation of folic acid 5 mg/week. Three weeks later she developed bone marrow supression and acute kidney failure requiring dialitic therapy, with complete recovery after discontinuation of methotrexate. In 2017 she presented marked photosensivity and nonscarring hair loss. Laboratory tests included: sedimentation rate of 60 mm in the first hour; negative serology test for rheumatoid factor; presence of Direct Coomb’s test in the absence of hemolytic anemia; serum ANA positive (1:640 – homogeneous staining pattern), anti-dsDNA positive (1/40), Anti-Sm positive (36, 9 U/ml), and serology test for anti-Ro positive (107, 3 U/ml). Serum C3, C4 and CH50 complement components were normal. A subsequent X-ray revealed irregular periosteal bony proliferation resulting in periostitis at the 3rd and 4th PIP joints of the left hand. Those clinical, radiographic and laboratorial findings allowed the diagnosis of SLE (based on the Systemic Lupus International Collaborating Clinics classification criteria) and PsA (based on the Classification of Psoriatic Arthritis–CASPAR – criteria), and the patient improved after therapy with corticosteroids, hydroxychloroquine and leflunomide.
The coexistence of psoriasis and SLE is uncommon, while the association of SLE and PsA has rarely been described in medical literalute. To the best of our knowledge, this is the first brazilian pacient reported as suffering from both conditions.
Consent for publication
Tatiane Bellafronte Betoni, Fernanda de Almeida Said, Silvio Almeida de Lima, Thiago Alberto Fernandes Gomes dos Santos, Barbara Stadler Kahlow, Marilia Barreto Gameiro e Silva, Thelma Laroca Skare
HOSPITAL UNIVERITÁRIO EVANGÉLICO DE CURITIBA, CURITIBA, PARANÁ, Brasil
Background: Cognitive impairment has been observed in rheumatoid arthritis (RA) patients. Chronic pain, depression and glucocorticoid use has been implicated in its etiology. Animal studies have shown that glucocorticoids reduce the plasticity of astrocytesand the volume of the hippocampus, inducing cerebral atrophy. Herein we studied a sample of RA patients for cognitive impairment to see if it was associated with cumulative doses of glucocorticoid.
Methods:The sample had 60 RA patients and 64 controls paired for gender (p=0.9), age (p=0.12) and educational level (p=0.12). Epidemiological data were collected and all were invited to answer the mini-mental and the CES-D (Center for Epidemiological Scale-Depression) questionnaires, and a VAS (from zero to 10) of pain. The charts of RA patients were reviewed for extra-articular manifestations, antibody profile, ESR, CPR, DAS-28-ESR and used medications including cumulative dose of glucocorticoids. Patients with neurological and psychiatric problems and using drugs with SNC action were excluded.
Results: RA patients were more depressed than controls (p=0.03) and had worse mini-mental score (p=0.002). RA patients with altered mini-mental were compared with those with normal mini-mental. The results are on Table 1.
Conclusion: Our results showed that RA patients had more cognitive impairment than controls and that the glucocorticoid cumulative dose did not influence in this result.
1. Zhang H et al. Chronic corticosterone exposure reduces hippocampal astrocyte structural plasticity and induces hippocampal atrophy in mice. Neurosci Lett. 2015; 592:76-81
2. Joaquim AF et al. Neuropsychiatric manifestations in rheumatoid arthritis. Autoimmun Rev. 2015;14(12):1116-22.
Bruno Kusznir Vitturi, Beatriz Rizkallah Alves, Bruno Azeredo Coutinho Nascimento, Felipe Sobolewski Carneiro de Campos, Dawton Yukito Torigoe
FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO, SÃO PAULO, SP, Brasil
Background: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. Extra-articular manifestations of RA can occur in about 40% of patients, either in the beginning or during the course of their disease. Recent studies have suggested that RA may have an important relation in the development of cognitive and neurological dysfunction. However, the bond between RA and the brain is still uncertain.
Objective: The purpose of this study was to assess the frequency and the clinical predictors of cognitive impairment in rheumatoid arthritis (RA) patients.
Methods: A cross-sectional and case-control study was performed including consecutive RA patients seen in a rheumatology outpatient clinic of referral tertiary hospital. The control group included 100 healthy subjects. We registered clinical and demographic data including age, sex, level of education, time of disease, time of diagnosis, drugs in use, cardiovascular risk factors and other comorbidities. Functional capacity was assessed using the Health Assessment Questionnaire (HAQ). Neurological appraisal was made with standardized questionnaires: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) and the Hospital Anxiety and Depression (HAD). Analysis of the data was performed using qui-square and t-tests and a multivariate analysis (SPSS 22.0). Significance level was set as <0.05.
Results: We included 200 patients (166 were female) with a mean age of 57.4 (±11.4) years; Among these patients, 163 (81.5%) used corticosteroids, 148 (74%) methotrexate, 16 (8%) sulfasalazine, 91 (45.5%) leflunomide, 35 (17.5%) chloroquine and 57 (28.5%) biologic therapy. The mean age of RA diagnosis was 43.0 (±13.6) years. In both univariate and multivariate analysis, compared to the control group, patients with RA presented significant lower MMSE (21.9±3.9) and MoCA (17.0±4.4) scores (p<0.05). Adjusting for level of education, just 61 and 50 patients presented normal MMSE and MoCA scores (p<0.01), respectively. Cognitive decline was associated with higher HAQ scores (functional outcome due to RA) and prolonged time of disease (p<0.05). No correlation was found between sex, disease-modifying antirheumatic drugs, rheumatoid factor, C-reactive protein levels and the neurological impairment. The mean HAD score was 17.7 (±7.7) and anxiety and depression were more prevalent in RA patients than in control group (p<0.01).
Conclusions: Patients with rheumatoid arthritis may present with cognitive decline and dementia as extra-articular manifestations of the disease. Neurological impairment is usually disregarded and might be under-diagnosed in RA patients. Future studies are necessary in order to better understand the relationship between RA and the brain.
Iloite Maria Scheibel1, Heloisa Pittoli Silva2, Alvares Alves Ferreira Filho2, Paula Gozzi2
1HOSPITAL CRIANÇA CONCEIÇÃO DO GRUPO CONCEIÇÃO, PORTO ALEGRE, RS, Brasil; 2HOSPITAL CRIANÇA CONCEIÇÃO, PORTO ALEGRE, RS, Brasil
The Henoch-Schönlein purpura (HSP) is the most common vasculitis in children, but there’s still questions regarding the long-term renal vascular performance in those patients. The goal of this study is to describe the demographic profile and the clinical evolution of 100 children who presented HSP from 2010 to 2017. Methodology: anterograde retrospective cohort study evaluating 100 patients that were followed up from 2010 to 2017 in a pediatric rheumatology service of a tertiary hospital at southern Brazil. Results: the average age was 5,42 years; divided in two age groups, equal to or under 5 years old and over 5 years old, thru 16, the number of relapses were not statistically different. 25% of the patients of 5 years old or under relapsed at least once in the following year, whilst the relapse rate in patients over 5 years old was 18,8%. Sixty four percent presented with arthritis, 58% had extra-articular edema, 40% had abdominal pain, 6% had gastrointestinal bleeding and 3% presented with macroscopic hematuria. Of those symptoms, only extra-articular edema was more frequent among the patients of 5 years old and under (68,8% versus 51,7%). Corticosteroid use was more prevalent among those with abdominal pain (p 0,004) and arthritis (p 0,04). Forty five percent presented renal impairment, 18% presented with proteinuria (one of them reaching nephrotic range), 30% with microscopic hematuria. Renal biopsy was performed in 2 patients, one of them with nephrotic syndrome and the other with persistent and abundant hematuria. Only one patient, that had both HSP and post-streptococcic glomerulonephritis, presented altered blood pressure. Of those who started follow-up at the hospital, 71% kept coming to appointments for at least 6 months, 51% for a year and 26% for over 2 years. Conclusion: the demographic data corroborated those found on the literature. Most patients presented with edema and arthritis, but abdominal pain appears to be the most motivating isolated symptom for corticosteroid prescription, along with severe acute complications (GI bleeding). Initial corticosteroid use didn’t seem to have protective effect against relapses. There was no hypertension in this group of patients, but 29% were followed for less than 6 months, being necessary the search of those patients to complement their data.
Ana Paula Monteiro Gomides1, Natália Mariana Diógenes Silva de Albuquerque2, Jeniffer Yumie Sonobe Hable2, Brenda Magalhães Rocha2, Lorenna Alves Bezerra2, Licia Maria Henrique da Mota3, Luciana Feitosa Muniz3, Talita Yokoy de Souza3, Viviane Cristina Uliana Peterle2, Luciano Junqueira Guimarães3, Regina Alice Fontes Von Kirchenheim4, Andressa Junqueira Osório3, Luciana Teófilo Lourençoni3, Isabela de Sousa Russo3, Tassiane Raquel Cunha Martins de Moraes3
1UNB/UNICEUB, BRASILIA, DF, Brasil; 2UNICEUB, BRASÍLIA, DF, Brasil; 3UNB, BRASÍLIA, DF, Brasil; 4SESDF, BRASÍLIA, DF, Brasil
Introduction: Rheumatoid arthritis (RA) is a chronic condition, with potential irreversible bone and cartilage damage. In addition to musculoskeletal impairment, patients with RA can manifest other diseases of autoimmune or non-autoimmune etiology, making it difficult to manage patients and aggravating the condition. The association of different comorbidities in individuals with RA causes a marked decline in the quality of life of these individuals, and it is essential that the diagnosis and appropriate treatment be instituted as early as possible.
Methods: Patients with rheumatoid arthritis were analyzed in a University Hospital, participants of an initial RA cohort. For the present study, a cross-sectional study was performed and the patients’ data were analyzed in the year 2018. Participants underwent a thorough clinical evaluation and medical records analysis. The work was approved by the Ethics Committee and the patients signed the consent form.
Results And Conclusions: We evaluated 107 patients with RA with a mean age of 54.5 years. The female gender (95.3%) and the brown ethnic group (47.7%) predominated. The mean duration of disease was 12.8 years and 75.5% had a positive rheumatoid factor. 12 patients (11.3%) had documented erosive disease. The mean HAQ at the time of the evaluation was 0.6 (median of 0.5). The comorbidities found in this population can be seen in Table 1. Based on the data presented, a high association of comorbidities in the course of RA is observed, with prominence for arterial hypertension, dyslipidemia and fibromyalgia. Thus, the importance of exploring this relationship and its respective prevalences is emphasized due to the potential increase in morbidity and mortality, as well as the loss of functional capacity of the patients.
Comorbidities in patients with RA
Other heart diseases
Chronic obstructive pulmonary diseases
Other chronic lung diseases
Moderate or severe liver diseases
Diabetes without damage to vital organ
Diabetes with damage to vital organs
Osteoporosis by bone densitometry
Metastases without tumor
Connective tissue disease
Chronic low back pain
P128 CORRELATION BETWEEN CAPILLAROSCOPY PATTERNS AND AUTOANTIBODY PROFILES IN SYSTEMIC SCLEROSIS PATIENTS
Laíssa Cristina Alves Alvino1, Gabriela Santiago Brum Marques2, Camilla de Castro Silva2, Verônica Silva Vilela2, Roger Abramino Levy2, Cláudia Henrique da Costa2, Rogério Lopes Rufino2
1UNIVERSIDADE ESTADUAL DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RIO DE JANEIRO, Brasil
Background: Specific autoantibodies were reported to correlate with nailfoldcapillaroscopy morphologic alterations in systemic sclerosis (SSc). This study was performed with the objective to evaluate if specific autoantibodies were associated with corresponding nailfoldcapillaroscopy patterns and morphological alterations in a Brazilian population of patients with SSc.
Methods: We evaluated 61 SSc patients that had videocapillarocopy performed and antinuclear antibodies (ANA) and specific autoantibodies registered. Videocapillaroscopy were graded by the following qualitative method as: (1) normal, with more than 9 capillaries per millimiter, no morphological abnormalities and less than 3 microhemorrages per 8 digits; (2) “Early”, few enlarged/giant capillaries, few capillary haemorrhages, relatively well-preserved capillary distribution, no evident loss of capillaries; (3) “Active”, frequent giant capillaries, frequent capillary haemorrhages, moderate loss of capillaries, mild disorganisation of the capillary architecture, absent or mild ramifi ed capillaries; (4) “Late”, irregular enlargement of the capillaries, few or absent giant capillaries and haemorrhages, severe loss of capillaries with extensive avascular areas, disorganisation of the normal capillary array, ramified capillaries; (5) ES like. ANA were performed by IF and national consensus patterns were reported. Specific SSc autoantibodies measured were Scl-70 and centromere. The nonspecific RNP were also measured and correlated.
Results and conclusions: In this present study we found that the anti-centromere was related with 43,75% of the pattern active scleroderma; 31,25% of early scleroderma; 6,24% of late escleroderm and ES like; and 12% of normal pattern. The anti Scl-70 was associated with 38,09% of the pattern active scleroderma; 4,16% with early scleroderma; 57,14% of late escleroderm and did not show relation with the ES like and normal patterns. The anti-RNP was related with 50 % of the pattern active scleroderma; 12,5% of early scleroderma and late escleroderm; 25% of ES like; and didn’t show correlation with the normal pattern. Furthermore, the patients without autoantibodies showed relation with 25 % of the active, early and late escleroderm patterns; 18,75% of the ES-like pattern and 6,25% of the normal pattern. Therefore, the union of the analysis with nail fold videocapillaroscopy in the association with different phenotypes described by each antibody may be use for suggest about the diagnosis and with the intensity of activity of the disease.
P129 CORRELATION BETWEEN SLICC/ACR-SDI CUMULATIVE DAMAGE INDEX AND MATERNAL-FETAL OUTCOME IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Evandro Mendes Klumb1,2, Bruna Costa Rodrigues2, Marcela Ignacchiti Lacerda2, Camilla de Castro e Silva2, Camila Pitasi Argueles2, Guilherme Ribeiro Ramires de Jesús2, Roger Abramino Levy2, Nilson Ramires de Jesús2
1UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2UERJ, RJ, RJ, Brasil
Background: The presence of at least one point in the SLICC/ACR-SDI cumulative damage index in patients with systemic lupus erythematosus (SLE) is associated with a higher risk of future cumulative damage and increases the mortality was 1.46 times in this group when compared to patients with a score equal to zero. Recent studies have shown that gestation does not contribute to the increase in the SDI index. However, the impact of the presence of cumulative damage on gestational, maternal and fetal outcomes has not been investigated. The objective of this study was to analyze the impact of the presence of permanent damage (SDI) on the maternal-fetal outcome in pregnancies of women with SLE.
Methods: Analysis of the evolution of 152 single pregnancies in SLE patients (≥ 4 ACR criteria) with delivery after 22 weeks in the period of 2011 and 2016. Statistical analysis included the Student t test and chi-square test (χ 2) as indicated with a significance level of 5% (p ≤0.05).
Results and Conclusions: Patients with SDI >1 presented more frequently nephritis (p=0,006), neurologic manifestations (p=0,007), anti DNA (P=0,01) and less frequently positive aPL (p=0,02). In reference to fetal outcomes patients with SDI > 1 presented more frequently peripartum hemorrhage (p=0,01), any infection (p=0,0001) and hospital admissions (p=0,02).
Consent for publication
P130 CORRELATION BETWEEN SLICC/ACR-SDI CUMULATIVE DAMAGE INDEX AND MATERNAL-FETAL OUTCOME IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Camilla De Castro E Silva1,2, Bruna Costa Rodrigues2, Marcela Ignacchiti Lacerda2, Flavia Cunha dos Santos2, Guilherme Ribeiro Ramires de Jesús2, Roger Abramino Levy2, Evandro Mendes Klumb2
1HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO -, Brasil; 2HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO - UERJ, Brasil
Background: The presence of at least one point in the SLICC/ACR-SDI cumulative damage index in patients with systemic lupus erythematosus (SLE) is associated with a higher risk of future cumulative damage and increases the mortality was 1.46 times in this group when compared to patients with a score equal to zero. Recent studies have shown that gestation does not contribute to the increase in the SDI index. However, the impact of the presence of cumulative damage on gestational, maternal and fetal outcomes has not been investigated. The objective of this study was to analyze the impact of the presence of permanent damage (SDI) on the maternal-fetal outcome in pregnancies of women with SLE.
Methods: Analysis of the evolution of 152 single pregnancies in SLE patients (≥ 4 ACR criteria) with delivery after 22 weeks in the period of 2011 and 2016. Statistical analysis included the Student t test and chi-square test (χ 2) as indicated with a significance level of 5% (p ≤0.05).
Results and Conclusions: Patients with SDI >1 presented more frequently nephritis (p=0,006), neurologic manifestations (p=0,007), anti DNA (P=0,01) and less frequently positive aPL (p=0,02). In reference to fetal outcomes patients with SDI > 1 presented more frequently peripartum hemorrhage (p=0,01), any infection (p=0,0001) and hospital admissions (p=0,02).
P131 CORRELATION OF THE PSORIATIC ARTHRITIS IMPACT OF DISEASE SCORE (PSAID) WITH THE MINIMAL DISEASE ACTIVITY (MDA) STATUS: A MULTICENTER STUDY
Elziane Da Cruz Ribeiro E Souza1, Sueli Coelho Da Silva Carneiro2, Michel Alexandre Yazbek3, Rita De Cassia Menin4, Cristiano Barbosa Campanholo5, Jamille Nascimento Carneiro6, Carlos Henrique Martins Da Silva7, Roberto Ranza7
1UNIVERSIDADE FEDERAL DE UBERLANDIA, UBERLÂNDIA, MG, Brasil; 2UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RIO DE JANEIRO, Brasil; 3UNIVERSIDADE ESTADUAL DE CAMPINAS, CAMPINAS, SÃO PAULO, Brasil; 4FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO, SÃO JOSÉ DO RIO PRETO, SÃO PAULO, Brasil; 5FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 6HOSPITAL DE BASE DO DISTRITO FEDERAL, BRASILIA, DISTRITO FEDERAL, Brasil; 7UNIVERSIDADE FEDERAL DE UBERLÂNDIA, UBERLÂNDIA, MINAS GERAIS, Brasil
Background: Psoriatic arthritis (PsA) is a complex and heterogeneous disease, which causes functional impairment and reduction of health-related quality of life. These characteristics represent a real challenge in the evaluation of patients with PsA, and it is essential to add to the medical evaluation the patient's impression of their state of health in order to assess the real impact of the disease and define the target of treatment. The PsAID is a validated patient-reported questionnaire of disease impact in PsA.
Objective: To study the correlation between the PsAID score and the minimal disease activity (MDA) and very low disease activity (VLDA) status.
Methods: 150 patients who fulfilled the Classification for Psoriatic Arthritis (CASPAR) criteria were recruited in a cross-sectional study by 6 Brazilian rheumatology centers. Patients were grouped according to MDA status: MDA (if they met at least 5/7 of the MDA criteria), in VLDA (if they met 7/7 of the MDA criteria) and non-MDA. To compare the domains of PsAID among the MDA groups, the Kruskal-Wallis tests and the Dunn test were applied. The level of significance was set at 5% (p <0.05).
Results: Of the 150 included patients, 76 were men and 74 women, with a mean (SD) age of 54.4 (11.3) years. The median of PsA duration (P25-P75) was 9 years (6-14) and 103 (68.7%) patients were on biological treatment. Overall, 16.7% achieved MDA and 11.3% VLDA vs 72% non-MDA. Interestingly, the MDA criteria less frequently met were patient pain visual analog scale and patient global disease activity. Out of 103 patients on biologic, only 26.2% were MDA status. Analyzing the median (P25-P75) of the PsAID total score between the groups, patients in MDA and VLDA had a significantly lower scores [MDA 1.7 (1-3.6), VLDA 0.6 (0.2-0.9) vs non-MDA 4.6 (2.9-6.8)], p<0.001. Accordingly, statistically significant differences were observed between MDA/VLDA groups and non-MDA patients for all PsAID domains (p<0.001). PsAID score <4 was expressed by 84% of patients in MDA and 100% of patients in VLDA vs 42.6% of non-MDA (p<0.0001). The presence of fibromyalgia did not significantly interfere in the total PsAID score, showing a statistical correlation only with the depression domain.
Conclusions: In our experience, the PsAID score correlated with the MDA status: patients in MDA/VLDA considered they have a significantly lower impact of the disease as measured by PsAID.
Pedro Ming Azevedo1, Patricia Martin2, Estefania Sartorato Sanson2, Thiago Alberto Fernandes Gomes dos Santos2, Thelma Laroca Skare2
1HOSPITAL UNIVERITÁRIO EVANGÉLICO DE CURITIBA, CURITIBA, PR, Brasil; 2HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA, CURITIBA, PR, Brasil
Background: Hand involvement secondary to systemic sclerosis causes disability that can be measured by the Hand Mobility in Scleroderma (HAMIS) questionnaire. The aim of this study is to validate the Brazilian version of HAMIS.
Methods: Translation from English to Brazilian-Portuguese was done by two of the authors, and the consensus was back-translated to English by a native English speaker fluent in Brazilian-Portuguese with no prior knowledge of the questionnaire. After verification of coherence between the back-translated and original English version, the consensus Brazilian-Portuguese version was applied to 10 scleroderma patients, to check their understanding. The final version was applied to 31 stable scleroderma patients. One examiner performed the test on day 1 and day 15. A second examiner applied the test on day 15. Intra and inter reliability for each individual question were evaluated by intraclass correlation coefficient (ICC). Intra and inter reliability between final scores were evaluated by Spearman’s coeficient. Internal consistency was evaluated by Kronbach’s alpha coefficient. Factorial analysis was performed to assess the factorial structure of the questionnaire.
Results: The Brazilian version of HAMIS showed a good intra and inter-reliability for all questions (Table 1). Although the examiners disagreed about the results of question 8 in only two patients, the statistical method was not able to detect inter-observer agreement for the question, because responses were limited to first and second domains. The correlation coefficient for the final score was 0.99 (p<0.0001) for intra observer and 0.97 (p<0.0001) for inter observer evaluation, revealing excellent correlation. The alpha’s Cronbach coefficient was 0.92 showing a good internal consistency. The factorial analysis extracted 3 factors that could be clinically characterized. The first factor aggregated questions 2/5/7/9, second factor aggregated questions 1/3/4 and question 8 stood alone as a factor. All movements tested by questions of the first factor are affected by the extension of the fingers and, similarly, second factor is affected by flexion of the fingers. For instance, supination can be misinterpreted if fingers don’t touch the table because of reduced extension. Therefore, examiners must pay attention to the movement being tested.
Conclusion: The translation and cultural adaptation of HAMIS to Brazilian-Portuguese language is supported by our study.
Eduardo S. Paiva, Salun Coelho Aragao, Maiara Bastiani Bisogni, Luiza Bueno Zeni, Luan Luckmann, Keoma Azevedo Sabiao, Chayanne Natielle Rossetto, Isadora Welter Pioresan, Ana Beatriz Artigas Guimaraes
UFPR, CURITIBA, PR, Brasil
Background: The crowned dens syndrome is characterized by acute cervicalgia associated with a decreased cervical range of motion, mainly rotation, caused by deposition of calcium pyrophosphate or hydroxyapatite crystals around the axis odontoid process. As it may be associated with systemic symptoms, such as fever, it can mimic diseases like infectious meningitis. The radiological diagnosis is made by computed tomography (CT), which is superior to simple radiography and magnetic resonance imaging. We herein present a case of crowned dens syndrome in which there was a dramatic response to the use of corticosteroids.
Case report: Female patient, 47 years old, came to emergency department with acute neck pain, with progressive symptoms in the last few days. Since the day before, she was unable to perform any kind of cervical movement. She also reported low-grade fever and headache. Plain radiographs and magnetic resonance of the cervical spine were performed, with no diagnostic definition. She was initially treated with NSAIDs and muscle relaxants, without any improvement. Blocking of the greater occipital nerve was performed, again with no improvement. A spinal tap was negative. Since there was a suspicion of crowned dens syndrome, a cervical spine CT was performed, which showed calcification around the odontoid process of the axis. She underwent pulse therapy with methylprednisolone 500mg/day for a total of 3 days, along with a full-dose NSAIDs, with improvement of symptoms during the following week. The maintenance treatment was done with colchicine, and she remains symptoms-free for the last few months.
Conclusion: Crowned dens syndrome is a difficult diagnosis that should be thought every time there is a case of acute cervical spine pain. The diagnosis is not always easy since the main findings are common to other diseases. The main imaging modality is computed tomography, since the deposits may be difficult to visualize with plain radiographies and magnetic resonance.
Consent for publication
P137 CRYPTOCOCOSIS: A DIFFERENTIAL DIAGNOSIS FOR EXACERBATION OF PULMONARY INVOLVEMENT BY GRANULOMATOSIS WITH POLYANGIITIS
Mateus De Miranda Moura Cortês1,2, Jacqueline Foelkel Pignatari2, Pamella de Paula Bellini2, Gabriela Miyuki Teodoro Ogawa2, Lara Ribeiro Teixeira Bonfim2, Samuel de Oliveira Andrade2, Alisson Aliel Vigano Pugliesi2, Zoraida Sachetto2
1UNIVERSIDA ESTADUAL DE CAMPINAS - UNICAMP, CAMPINAS, SP, Brasil; 2UNIVERSIDADE ESTADUAL DE CAMPINAS – UNICAMP, CAMPINAS, SP, Brasil
Background: Cryptococcus gattii and Cryptococcus neoformans are encapsulated fungi responsible for the greater part of the cryptococcosis, which manifest most frequently as pneumonia and/or meningoencephalitis. Pulmonary nodules, or cryptococomas, are the manifestation of pulmonary involvement and lead to differential diagnosis with other granulomatous diseases. We report a case of granulomatosis with polyangiitis (GPA) with previous lung involvement, under irregular immunosuppressive treatment, in which pulmonary cryptococcosis developed as an opportunistic infection.
Case Report: A 61-year-old male patient, diagnosed with GPA in 2016 (c-ANCA+, rhino-sinusopathy, rapidly progressive glomerulonephritis pauci-immune to renal biopsy, alveolar hemorrhage, pulmonary nodules). Because of illness severity, he underwent induction treatment with oral prednisone and monthly intravenous cyclophosphamide (CYC), but at suboptimal doses and with irregular frequency due to repetitive infectious complications. In 2017, days after the fifth infusion of CYC, the patient was hospitalized for investigation of dry cough and fever. He presented negative initial infectious screening, absence of leukocytosis or increased inflammatory markers, but with bibasilar crackles on pulmonary auscultation and chest X-rays showing diffuse patchy infiltrates. Tomography of the chest revealed multiple nodules and solid masses distributed diffusely across both lung fields, absent in a previous study (Fig. 1). The patient was treated empirically with broad-spectrum antibiotic therapy for five days, without improvement of the febrile curve, until the end of the infectious investigation with bronchoscopy with bronchoalveolar lavage, whose culture was positive for C. gattii. Serum antigenemia for cryptococcosis was positive (1/128), with screening for fungus at other sites proving negative, including cerebrospinal fluid. Pulmonary cryptococcosis was treated with oral fluconazole 400 mg/day, with fever resolution and cough reduction, the patient being discharged for continuity with antifungal for 12 months.
Conclusion: The clinical manifestations of pulmonary cryptococcosis include nodular lesions with or without cavitations, segmental pneumonic infiltrates, segmental interstitial or alveolar infiltrates, pleural effusions, hilar masses and thoracic lymphadenopathy. These findings, however, require a differential diagnostic approach, since they are part of the clinical spectrum of other diseases, such as GPA. In our case, the pulmonary manifestation appeared to be an exacerbation of the basal vasculitis, requiring immunosuppressive treatment, but it was actually a fungal infection, for which more immunosuppression could have had an aggravating effect.
Consent for publication
P140 CYTOMEGALOVIRUS INFECTION IN A SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT TREATED WITH BELIMUMAB: A CASE REPORT
Andréa Tavares Dantas1, Vanessa Fonseca De Jesus2, Henrique De Ataíde Mariz2, Rafaela Silva Guimarães Gonçalves2, Claudia Diniz Lopes Marques2, Angela Luzia Branco Pinto Duarte2
1UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PE, Brasil; 2HOSPITAL DAS CLÍNICAS - UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PERNAMBUCO, Brasil
Background: Treatment of systemic lupus erythematosus (SLE) with belimumab has been associated with a low risk of infection. Cytomegalovirus (CMV) infection in SLE patients may represent a diagnostic challenge because of the difficulty of differentiation with disease flare and the potential to evolve with severe complications. The aim of this case was to report CMV infection in a SLE patient after initiation of therapy with belimumab.
Case report: A 31-year-old female patient diagnosed with SLE for 5 years with a history of arthritis, lymphopenia, thrombocytopenia, nephritis, complement consumption, antinuclear antibodies (ANA) and anti-DNA positive. She demonstrated good control of nephritis after treatment with corticosteroids and mycophenolate mofetil, which was later switched to azathioprine due to intolerance. Because the difficulty of weaning from the corticosteroid due to the recurrence of joint complaints, treatment with belimumab was chosen in January 2017. At the 5th month of treatment, fever, retroorbital pain, odynophagia, headache and erythematous skin rash began to occur, as well as intense fatigue. Laboratory tests revealed anemia (Hb = 9.8 mg/dl), leukopenia and lymphopenia (later with lymphocytic atypia), decreased complement, anti-DNA 1:20, positive direct Coombs test, hematuria, and increased LDH, transaminases, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). In this moment, it was decided to increase dose of prednisone to 0.5 mg/kg/day and to suspend infusion of belimumab. Serologies were negative for dengue, rubella, zika, parvovirus B19, syphilis, hepatitis A, B and C, but with IgM and IgG positive for Cytomegalovirus. DNA PCR for CMV showed 1660 copies/mL. The patient presented with clinical improvement without the need for ganciclovir therapy. The viral load was negative after 2 months and she resumed the treatment with belimumab 5 months after its suspension.
Conclusion: Although only two cases of CMV infection have been reported in pivotal clinical trials of belimumab, one of which was fatal, this is a common infection in immunosuppressed patients and should be considered in the differential diagnosis of SLE flare. Milder cases may be managed symptomatically with the temporary suspension of the immunobiological therapy.
Consent for publication
P142 DATA ON MORBITY AND MORTALITY DUE TO OSTEOPOROTIC FEMORAL FRACTURE AND EVIDENCE ON PRIMARY AND SECONDARY PREVENTION
Dayrana Alves Lucena2, Caroline de Almeida Oliveira2, Matheus Xavier Guimarães1, Fernanda Pulcheri Ramos2, Laís Farrapo de Barros Leite2, Marcelo Nora Resende2, Natália Carneiro dos Santos2, Rina Dalva Neubarth Giorgi2, Elaine de Azevedo2
1HOSPITAL DO SERVIDOR PUBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 2HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL - SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: Osteoporosis (OP) is characterized by bone fragility and changes in its microarray, with the most important clinical outcome being the occurrence of low impact fractures and affecting more than 200 million people worldwide. In Brazil, OP affects around 10 million people. It is estimated that 50% of women and 20% of men aged 50 years or older will suffer a lifetime osteoporotic fracture. Approximately 5% of individuals with hip fractures die during hospital stay, 12% die within the subsequent 3 months, and 20% die within the first year following fracture.
Objective: To evaluate the evolution after a minimum of 24 months of 66 patients who presented a femoral neck fracture in the year 2015, with emphasis on functional capacity.
Methods: Sixty-six patients attended at a tertiary hospital during the year 2015 after hip fracture were selected. Of these 66, 41 were submitted to an inquiry via telephone contact. Epidemiological data such as: identification, age, sex, date of fracture and its mechanism (excluding cases of traumatic fractures), length of hospital stay, information on OP (knowledge about diagnosis and/or previous previous treatment, specific treatment for OP); and functional capacity after two years of fracture.
Results: Of the 41 patients evaluated, 73.1% were female, with a mean age of 71.1 years. Regarding the cause of the fracture, the fall of the height itself occurred in 38 patients. Surgical treatment was performed in 92.6% of the cases with a mean hospital stay of 11.3 days. The majority of the patients (92.6%) were unaware of having OP prior to fracture and 75.6% had never had treatment for the disease. After one year of the event, the number of deaths was 21.9%, 14 patients were completely restored (100% of post-fracture functional capacity), and 43.9% evolved with some degree of functional disability. Only 24.39% of the cases were referred for secondary cause assessment and treatment for PB.
Conclusion: The population studied presented similar morbidity and mortality described in the literature. A special relevance should be given to the absence of diagnosis and treatment for OP prior to fracture and inefficiency in referring patients for secondary prevention. It is imperative to adopt educational, preventive, diagnostic and early treatment measures in order to minimize the complications of this disease.
P143 DEMOGRAPHIC AND EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH RHEUMATIC DISEASES SERVED AT SUS HEALTH UNIT
Maria Carolina Vasconcelos Fecury1, Regina Alice Fontes Von Kirchenheim2, Ana Paula Monteiro Gomides3, Viviane Cristina Uliana Peterle1, Luciano Junqueira Guimarães3
1HOSPITAL DA REGIÃO LESTE - HRL, BRASÍLIA, DF, Brasil; 2HOSPITAL REGIONAL DA ASA NORTE - HRAN, BRASÍLIA, DF, Brasil; 3CENTRO UNIVERSITÁRIO DE BRASÍLIA - UNICEUB, BRASÍLIA, DF, Brasil
Rheumatology is characterized by a wide variety of diseases. More than 100 different conditions are labeled as rheumatic diseases including rheumatoid arthritis, osteoarthritis, autoimmune diseases such as systemic lupus erythematosus (SLE), scleroderma, osteoporosis, back pain, gout, fibromyalgia and tendinitis. In Brazil, there is a lack of data on the population affected by rheumatic diseases, morbidity, mortality and costs. The present research is a cross-sectional, retrospective, descriptive study with secondary data analysis. It was performed with an electronic records analysis of patients over 18 years-old with a diagnosis of rheumatic diseases treated at a SUS rheumatology outpatient clinic from 2012 to 2017. The variables collected were: age, sex, where they were living, pathologies served by the international classification of diseases (ICD 10). The statistical analysis was performed using Excel, and the results were quantitatively descriptive and presented as percentage. The electronic medical records of 80 patients were analyzed, being 90% (n = 72) females and 10% (n = 8) males. The mean age among the female patients was 55.3 years and the male sex was 66.8 years. Of the total number of patients, 96.25% (n = 77) were from the Federal District and 3.75% (n = 3) were from Goiás. The main rheumatic diseases found in the sample were fibromyalgia, 52.5% (n = 42), Osteoarthritis 37.5% (n = 30), Osteoporosis 31.25% (n = 25), Rheumatoid Arthritis 17.5% (N = 3), Ankylosing Spondylitis 2.5% (n = 2) and Sclerosis (n = 3), Lupus 11.25% (n = 9), Psoriatic Arthritis 3.75% Systemic 1.25% (n = 1). SENNA et al. estimated the prevalence of rheumatic diseases in residents of city of Montes Claros, Brazil. Fibromyalgia in 34.7% (n = 76), Rheumatoid Arthritis in 6.4% (n = 14) and Lupus in 1.4% (n = 3) were observed in 57.5% (n = 126). WONG et al. stated that the prevalence of Ankylosing Spondylitis varies from 0.1 to 0.5% worldwide, Gout in Canada affects 3% of adults and other diseases such as Psoriatic Arthritis, Lupus and Scleroderma present a prevalence ranging from 0.1 to 0.5%. There is a great need for epidemiological studies that serve as a basis for strategies and actions for the development of a health policy aimed at diagnosis and early treatment. In addition, the results of the research are corroborating with literature data found in Brazil and Internationally.
Isadora Carvalho Medeiros Francescantonio, Jéssica Ferreira Souza, Ana Márcia Guimarães Alves, Ana Paula Vecchi
HOSPITAL MATERNO INFANTIL, GOIANIA, GO, Brasil
Background: The painful hip syndrome in children can have many causes, including infectious and inflammatory (1,2). The viral infections can be part of this group and lead to acute arthritis (3). How ever the diagnosis can be hard, that’s why is necessary the association of other signs and symptoms and serologies (3). The arboviruses can be related to articular symptoms, being this more prevalent in the cases of chikungunya and rare in dengue (3). The septic arthritis in children is usually caused by hematogenous dissemination of Staphylococcus aureus (SA). It frequently needs early surgical treatment to reduce complications (4). It is described a case of a patient with dengue associated to septic arthritis of the hip.
Case Report: D.P.M, male, 8 years old, with high fever (39ºC) for 8 days and pain in left hip, which was mild at the beginning and was increasing in intensity until leads to movement limitation. He also complains about abdominal pain, vomit and dyspnea. The parents brought some exams: computed tomography showing right pleural effusion, massive ascites and left synovitis of the hip; hemoglobin 19g/dL, hematocrit 52%, leukocytes 20.000, platelets 107.000. On admission he received oxacilin and ceftriaxone and was submitted to a hip joint puncture. In the puncture was drained a big quantity of pus, which have positive culture for SA. During the hospitalization occurs improvement of the hemoconcentration with venous hydration. Also in the recovery period, he presented some episodes of orthostatic hypotension. Because of these symptoms dengue serologies was requested, and have a positive IgM result. The children presented improvement of the articular symptoms and recovered the movements completely.
Conclusion: Dengue can be presented by a variety of symptoms (2). The joint involvement is unusual and frequently transitional with spontaneous resolution (2). Chikungunya causes tissue damage and leads to an inflammatory process. Is possible that the inflammation causes a deregulation of inflammatory process control mechanisms because of the persistence of viral RNA in macrophages. Therefore is also possible that the dengue virus, could cause a similar inflammatory process, and because of that leads to a secondary bacterial infection, which can progress to septic arthritis of the hip. A case with joint involvement associated to serosite can be related to autoimmune diseases and the diagnosis of infectious diseases may be neglected. Therefore it’s fundamental to make a global analyses of the patient taking into account its epidemiological characteristics to make a early diagnoses and treatment.
Consent for publication
Caroline Almeida Oliveira1, Matheus Xavier Guimarães2, Lisa Mielke de Oliveira2, André Ozela Augusto2, Denise Moraes Horiy2, Fernanda Pulcheri Ramos2, Sônia Maria Alvarenga Anti Loduca Lima2, Rina Dalva Neubarth Giorgi2
1HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL, SÃO PAULO, SP, Brasil; 2HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Major depression is a mental health problem that affects approximately 8% of men and 15% of women in the world population. Some evidence shows that this disease is mediated by an inflammatory disorder caused by the activation of cytokines, such as interleukins (IL-2, IL-6, IL-12) and tumor necrosis factor (TNF-alpha) at high levels in depressed patients. However, we report four cases of patients who progressed with depression after using anti-TNF.
Case Study: Four female patients, aged 35 to 58 years, in regular follow-up at the Rheumatoid Arthritis outpatient clinic of a tertiary hospital in the city of São Paulo, reported a depressive picture or worsening of mood during the use of Infliximab or Etanercept to control articular disease activity. Complaints such as discouragement, fatigue, easy crying, marked depression were reported spontaneously during routine care related to the medication. The mean time of disease was 14 years, with inflammatory polyarticular involvement, which required therapeutic changes during evolution. All of them noticed improvement in mood after anti-TNF suspension, maintaining a good clinical and laboratory response from the joint point of view.
Conclusion: Patients with RA have a prevalence of above-average mood disorders, varying from 13% to 47%, possibly because it is a disabling disease or because of chronic inflammatory activity. Two analyzes of depressed patients using Infliximab concluded that there was no generalized efficacy when compared to antidepressants, but there was less need for prescription in this population. Uguz et al., In 2009, evaluated the impact of Etanercept or Infliximab on the severity of depression and anxiety symptoms in 83 outpatients with RA; those on anti-TNF agents had a lower prevalence of mood symptoms compared to those who were not on treatment. To date, there is no evidence of efficacy of IL-6 blockade in the treatment of major depression. The most likely hypotheses for the unexpected effect reported by the four RA patients would be the fact that only a very limited number of proinflammatory cytokines could be inactivated by the currently available blockers, or the possibility that cytokines involved in the pathophysiology of RA depression may be different from those involved in the more typical autoimmune disorders.
P147 DEPRESSION, INTENSITY OF DEPRESSIVE SYMPTOMS AND CORRELATION WITH CLINICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Paulo Gabriel de Oliveira Cerquinho1, Rafael da Rocha Caminha2, Bruna Ferraz Gutierrez Piola2, Flávia Jatobá de Barros2, Pedro Arturo Bismara Carneiro Santos2, Hugo Deleon de Lima3, Mariana Souza Pessoa de Luna3, Marina de Oliveira Stojanovic Gomes3, Leia Teixeira de Andrade3, Dennys Lapenda Fagundes3, Laurindo Ferreira da Rocha Junior3
1FACULDADE PERNAMBUCANA DE SAÚDE, RECIFE, PE, Brasil; 2FACULDADE PERNAMBUCANA DE SAÚDE -FPS, RECIFE, PERNAMBUCO, Brasil; 3INSTITUTO DE MEDICINA INTEGRAL PROF. FERNANDO FIGUEIRA - IMIP, RECIFE, PERNAMBUCO, Brasil
Background: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that primarily affects the joints. It is well known that RA has a profound impact on the social, economic and psychological aspects of the patients’ lives. The objective of this study is to evaluate the presence of depression and the intensity of depressive symptons in RA patients as well as to correlate these symptons with clinical parameters.
Methods: The data collection was done by interview, clinical evaluation and review of medical records of patients. Evaluation of functional capacity was performed wiht Health Assessment Questionnaire (HAQ). For the clinical diagnosis of depression, the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders - 5th edition) was used, while the BDI-II (Beck Depression Inventory II) was applied to evaluate the intensity of depression symptoms. Thirty-one age and sex-matched healthy individuals were enrolled as controls. Statistical association and correlation were performed using software Graphpad prism 6.0. In the associations, the methods of Mann-whitney and t student were used. Pearson and Spearman tests were utilized in the correlations. Fisher exact test was used for categorical variables.
Results And Conclusions: A total of 98 patients participated in this study of which 95 were women with median age of 55 years (IQR 46.25-62.5). Forty patients (40.82%) and 2 (6.5%) healthy controls were clinically confirmed to have depressive disorder after responding to DSM-5 (p=0.0003). Patients with depression compared to patients with no depression had higher median visual analogue scale (VAS) score for stiffness (55mm [IQR 21.75-85.25] vs. 12mm [IQR 0-52.5], P=0.0005), for fatigue (63.5mm IQR [21.75-89.5] vs. 32mm [IQR 3-69], p=0.0106), for patient global assessment (82.5 mm [IQR 61.25-96.5] vs. 52mm [IQR 8-84.5], p=0.0029) and for Physician Global assessment (45mm [IQR 23.25-66] vs. 22mm [IQR 7.5-50], p=0.0095). Additionally, greater number of painful (p=0.0259) and swollen joints (p=0.0199), greater duration of morning stiffness (p=0.0306), worse disease activity indexes (CDAI with p=0.0036 and DAS28 p=0.0099) and worse functional capacity (p=0.0078) was also associated with depression. Patients had higher BDI scores compared to controls (median 13.5 [IQR 5-21] vs. 6 [IQR 2-9], p=0.0007). The intensity of depressive symptons correlated positively with weight (r=0.2209; p=0.0315), mean arterial pressure (r=0.2681; p=0.0098) and functional capacity (r=0.3883; p<0.0001). These results suggest that patients with depression have more severe clinical features of RA. Patients with RA had more intense depressive symponts than healthy subjects.
Eduardo S. Paiva, Ana Beatriz Artigas Guimaraes, Salun Coelho Aragao, Maiara Bastiani Bisogni, Luiza Bueno Zeni, Luan Luckmann, Keoma Azevedo Sabiao, Chayanne Natielle Rossetto, Isadora Welter Pioresan
UFPR, CURITIBA, PR, Brasil
Background: Gout is a metabolic disease caused by monosodium urate crystals deposits leading to a classic picture of acute arthritis and periarthritis that occurs asymmetrically and episodically. The main diagnostic procedure is to proceed with an arthrocentesis of the affected joint. Although described in the literature, the involvement of the spine by the disease is not easy to prove, given the difficulty of performing any kind of puncture at that site. Dual-energy tomography has emerged in recent years as a method for the detection of joint and periarticular deposits of urate, and also serving as a way to differentiate between these kinds of deposits from those of calcium pyrophosphate. Due to its clinical application, it can be a valuable tool for the rheumatologist, helping him differentiate among the causes of episodic arthropathies. We herein describe a case in which the dual energy tomography was useful for the diagnosis of the spinal cord involvement by gout.
Case report: A 57-year-old male patient had a 15-year history of gout. His last crisis occurred one year ago and he was being treated with an inadequate dose of allopurinol. He presented to the emergency department with a recent history of acute dorsal pain followed by arthritis in his left knee and foot, with no response to low-dose over-the-counter NSAIDs. Because there was a strong suspicion of thoracic spine gout, a double energy tomography was requested, which confirmed the diagnosis. There were deposits in the left T8/T9 facet joint and in the T1 vertebral body. He was treated with a combination of a prescription NSAID and moderate-dose prednisone. There was a quick resolution of the spine pain after 2 days of treatment an in the following days he had complete resolution of the foot and knee arthritis.
Conclusion: Dual energy tomography may be useful in the diagnosis of gout patients, especially when there is any kind of diagnostic doubt, or when there is involvement of sites that are hard to access.
Consent for publication
P154 DRUG TREATMENT ADHERENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A LONG TERM ANALYSIS OF ADHERENCE AND A POST-HOC ANALYSIS OF MORISKY MEDICATION ADHERENCE SCALE MODIFIED BY DELGADO AND LIMA
Karen Sanae Takehara Vieira1, Gisele Veiga Guimarães1, Felipe Silva Medeiros1, Pedro Felipe De Almeida Vianna2, Laíssa Cristina Alves Alvino2, Elisa Martins Das Neves De Albuquerque2, Marise Oliveira Dos Santos2, Evandro Mendes Klumb2
1UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil; 2HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO - UERJ, RIO DE JANEIRO, RJ, Brasil
Background: SLE is an autoimmune disease with a variable clinical course and severity. Drug treatment adherence (DTA) is frequently low, especially in undeveloped countries, as in other chronic diseases. However DTA may be influenced by the method employed for its measurement, the reason why this study was developed.
Materials and methods: This study included 246 lupus patients followed at a university hospital in Rio de Janeiro and was designed to investigate DTA in 2009. Adherence was primarily evaluated using the Morisky Medication Adherence Scale modified by Delgado and Lima (MMAS), which was set as a dichotomous variable (adherent or not). Patients were considered adherent whenever they answered “rarely” or “never” to the four questions of MMAS. However, possibly due to cultural characteristics of Brazilian population, the term “sometimes” is commonly used to specify an event that occurs with similar frequency of “rarely” which justified its inclusion as adherence. For this purpose, the 246 questionnaires were reviewed and those with “sometimes”, “rarely” or “never” for the 4 questions were considered adherents (MMAS remodified). A second interview was performed for 123 among the 246 patients previously selected in 2017 and data was analyzed using MMAS and MMAS remodified.
Results: The DTA for the 246 patients was of 31.7% (MMAS), which turned out to be 67.1% when adherence scale included “sometimes” as a positive adherence answer (MMAS remodified). For the 123 patients interviewed in 2017, MMAS showed DTA of 30.1% (2009) and 51.2% (2017). With the employ of MMAS remodified, DTA was 61.7% in 2009 and 79.7% in 2017. The intensity of concordance for DTA between the tests performed (MMAS and MMAS remodified) was moderate (kappa value: 0.37 – for 246 cases), or strong (kappa value: 0.42 – for 123 cases) which indicates a high variability of adherence percentage depending on the scale employed and patient interpretation of terms used.
Discussion and Conclusion: The present study showed that the amount of DTA percentage depends on the method employed. The DTA determination remains a complex issue and its variability is influenced not only by patient compliance but also by methodology employed to analyze data. More accurate methods for DTA determination are needed and they should ideally include patient subjectiveness.
Igor André Telles Da Cunha1, Fernando César Duarte1, Leandro Bonecker Lora1, João Renato Cardoso Mourão1, Priscilla Souza da Cruz2, Leonardo Motta Ramos1, Paula Sampaio Azevedo1, Laura Pessanha Nunes1, Bruna Sande Miguel1, Camilla Meira Riccioppo1, Alessandra Cardoso Pereira1
1UNIGRANRIO, RIO DE JANEIRO, RJ, Brasil; 2ESTÁCIO, RIO DE JANEIRO, RIO DE JANEIRO, Brasil
Mixed Connective Tissue Disease (MCTD) is an overlapping syndrome associated with the presence of anti-U1 RNP antibodies, which incorporates clinical manifestations of systemic lupus erythematosus, sclerodemia and poliomyositis. Definitive diagnosis of MCTD is often complicated by the fact that overlapping features tend to occur sequentially. This confusion arises because of the concomitance of various diffuse connective tissue diseases, as well as changes in the underlying disease pathology. Pulmonary hypertension appears as a late manifestation and appears to be the leading cause of death in MCTD.
We report the case of a female patient, 33 years old, black, who initially had an anastarch, chest pain, dyspnea on minor exertion. She was admitted to a referral hospital in cardiology, with a suspected diagnosis of pulmonary thromboembolism. A chest CT angiography showed no abnormalities, and transthoracic echocardiography revealed significant pulmonary hypertension (mPAP 73mmHg) associated with dilatation and right ventricular systolic dysfunction. He was discharged with prescribed anticoagulant medication. She reported a return of symptoms after three days and a new search for hospital care, and was then referred to the Rheumatology outpatient clinic. In the consultations that occurred between February 2017 and April 2018, alopecia, painful subcutaneous nodules in the lower limbs, visual turbidity, xerostomia, oral ulcers, thoracic pain, cramp, abdominal pain, Raynaud's phenomenon, arthralgia of the metacarpophalangeal joints of both hands, finger edema and sclerodactyly, as well as an episode of pericardial effusion. Laboratory tests revealed thrombocytopenia, elevated CPK (1.482 U /L), anti-Ro and anti-RNP (greater than 240 Elia U/ml), anti-LA transiently positive. Before the findings, the diagnosis of MCTD was made.
The relevance of this case is the atypical clinical evolution of the young patient, who presented pulmonary hypertension in an early form of her disease. This fact is unusual because this complication is related to a longer time of illness and a more advanced age. It is worth mentioning also that anti-Ro positive in the MCTD happens in only 25% of the cases.
Consent for publication
Leticia Fonseca Favarato, Wildner Mardegan Sardenberg, Maria Carmen Lopes Ferreia Silva Santos, Larissa Carvalho Caser, Letícia Fonseca Favarato, Sabrina Zanardi Machado, Valéria Valim
UNIVERSIDADE FEDERAL DO ESPÍRITO SANTO, VITÓRIA, ESPÍRITO SANTO, Brasil
Background: We studied clinical and epidemiological variables that could be related to greater severity and damage in primary Sjögren’s syndrome (pSS).
Methods: Cross-Sectional study including patients with pSS (AECG 2002 or ACR/EULAR 2017). EULAR Sjögren’s syndrome Disease Index (ESSDAI) was calculated at diagnosis and currently. Patients have performed EULAR Sjögren’s syndrome Patient Report Index (ESSPRI) and Sjögren’s syndrome Disease Damage Index (SSDDI). Non-parametric statistics and logistic regression were applied with p-value of 0.05.
Results: 104 patients with pSS were included, 51.49 ± 12.13 years, 95,2% (n=99/104) were women. Disease duration was 65,44 ± 41.89 months. Anti-Ro was positive in 68% (n=70/103), FAN in 82% (n=82/100), FR in 37.4% (n=37/99) and anti-La in 30.3% (n=30/99), focal lymphocytic sialoadenitis in 73% (71/91). The ESSPRI was 5.62 ± 2.56 and the ESSDAI 3.63 ± 18.104.22.168%(n=56/104) was using hydroxychloroquine and 51% (n=53/104) immunosuppressant. The higher damage score was associated with disease duration (0.270; p=0.007), high disease activity at the onset of the disease (initial ESSDAI) (0.226, p= 0.021), respiratory evolvement at the onset of the disease (0.283, p=0.004) and impairment of the peripheral nervous system (0,273, p=0,005), at some point. After multiple regression analysis, the initial involvement of the respiratory system was confirmed to be a risk factor for damage (SSDDI > 3) independent of disease duration and current disease activity (ESSDAI) (OR=8.94, 1.44-55.64CI95%; p<0.05). The respiratory domain was also associated with higher mortality (66.7% vs. 5%, p=0.011).
Conclusion: Early respiratory disease activity is associated with death and predicts damage in primary Sjögren’s syndrome
P157 EARLY-ONSET HELLP SYNDROME AND HEPATIC INFARCTIONS RELATED TO PRIMARY ANTIPHOSPHOLIPID SYNDROME (APS)
Rafael Alves Cordeiro, Jobson Lopes De Oliveira, Camila Nobre Bulhões, Steeven Shu Kai Yeh, Danieli Castro Oliveira De Andrade
DIVISAO DE REUMATOLOGIA, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, SAO PAULO, SP, Brasil
Background: Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. We report a case of a pregnant woman with previously known primary APS who developed early onset hemolysis, elevated liver enzymes, low platelets syndrome (HELLP) and multiple liver infarctions during the 18th week of gestation.
Case Report: A 25-year-old female patient has had a diagnosis of primary APS for 8 years based on the presence of deep venous thrombosis associated with anticardiolipin and lupus anticoagulant positivity. At the time of the diagnosis (another service), she was prescribed enoxaparin, warfarin and aspirin. However, she presented retroperitoneal hemorrhage which led to suspension of the anticoagulation. She remained without anticoagulant treatment until starting follow-up in a high-risk prenatal service in 2017, where she was introduced enoxaparin at a prophylactic dose (40 mg SC/day) and ASA 100 mg/day. At the eighteenth week of gestation, she went to emergency department with abdominal pain in the right quadrant pain. She denied arthralgia, photosensitivity, alopecia, cutaneous lesions, oral or nasal ulcers, dyspnea, chest pain, hematuria and fever. Physical exam: arterial hypertension (140/100 mmHg) and livedo reticularis in the lower limbs. Laboratory evaluation: anemia (9.9 g/dL), elevation of LDH, elevated transaminases (AST: 814 and ALT: 678), thrombocytopenia (98000/mm3) and proteinuria (2.34 g/L). Immunological profile: ANA 1/320 (homogeneous nuclear pattern) with anti-dsDNA negative; absence of complement consumption (C3: 89 and C4: 16); anti-cardiolipin IgG (112.9 GLP) and lupus anticoagulant positive. Obstetric USG: increased resistance of the umbilical and uterine arteries. Abdominal tomography: enlarged liver, multiple hypovascularized and poorly delimited areas in all hepatic segments, compatible with ischemia and tissue necrosis. Hypertension was initially controlled with amlodipine, but fetal death was observed at 19 weeks and 5 days. After pregnancy termination, the patient progressed with resolution of laboratory abnormalities and with no need for antihypertensive drugs. Due to clinical and laboratory evolution (lupus and sepsis were excluded), the diagnosis of early-onset HELLP syndrome and hepatic infarctions associated with the antiphospholipid syndrome was confirmed.
Conclusion: HELLP syndrome is a relatively rare pregnancy-related thrombotic microangiopathic disorder, usually observed during the third trimester. The occurrence of HELLP syndrome before 20 weeks of gestation is extremely rare. However, clinicians should be aware to the diagnosis of early-onset HELLP syndrome and hepatic infarctions associated with APS.
Consent for publication
P159 EFFECTIVENESS OF NIGHT-TIME ORTHOSES IN THE PAIN FOR WOMEN WITH HAND OSTEOARTHRITIS: RANDOMIZED AND CONTROLLED TRIAL
Paula Gabriel Silva, Fabiana de Carvalho Silva, Artur da Rocha Correa Fernandes, Jamil Natour
UNIFESP, SÃO PAULO, SÃO PAULO, Brasil
Objective: To evaluate the effectiveness of night-time orthoses in women with symptomatic osteoarthritis (OA) diagnosis in the second or third fingers of the dominant hand.
Methods: Design: A randomized controlled trial, masked assessor and intention to treat analysis. Setting: the outpatient clinic of the rheumatology department, referral center. Financial support: Support in the grant#13/14460-3 process and grant#13/221591, São Paulo Research Foundation (FAPESP). Participants: Seventy-seven patients with a diagnosis of hand OA were contacted, fifty-two were eligible and allocated randomly to 2 groups. Interventions: The intervention group (IG) N26 used a night-time orthosis starting at baseline and the control group (CG) N26 did not. However, both groups participated in educational group discussions about hand OA. Participants were evaluated at baseline and at 45, 90, and 180 days after inclusion in the study. Main Outcome Measure: Numerical Rating Scale for pain; the Jamar dynamometer for grip strength; a pinch gauge for pinch strength; Cochin and AUSCAN questionnaires for function, and the Moberg pick-up test for manual performance.
Results: The IG showed a statistically significant improvement versus the CG in relation to pain and function; the IG had decreased pain resting at 2.1 cm (p = 0.002) and had decreased pain during activity at 4.3 cm (p <0.001). The improvement in pain had a correlation with the Cochin questionnaire and absence of Bouchard’s node in the third finger, as well as a thin pinch performed without difficulty; these are predictors of the best prognosis for treatment with the night-time orthoses.
Conclusion: The use of night-time orthoses reduces pain and leads to improvement in hand function in women with hand OA.
Cleandro Pires Albuquerque, Ana Paula Faria Carvalho, Luciana Teófilo Lourençoni, Andressa Junqueira Osorio, Isabela de Sousa Russo, Tassiane Raquel Cunha Martins de Moraes, Talita Yokoy de Souza, Ana Carolina Emy Vicente Hidaka, Sandra Maximiano de Oliveira
HOSPITAL UNIVERSITÁRIO DE BRASÍLIA, BRASÍLIA, DF, Brasil
We describe an atypical case of aggressive psoriatic arthritis, refractory to nearly every attempt of treatment, including multiple biologics, but then achieving an excellent response after initiating secukinumab.
Female, 26 years old, diagnosed with axial and peripheral psoriatic arthritis at the age of four. Psoriasis had started only months after birth. The disease followed an aggressive and relentless course through childhood and adolescence, despite every attempt of treatment with DMARDs. At the age of 15, she was submitted to hip arthroplasty. By that time, she had some deformities in hands and feet. She also developed asthma and corticosteroid-induced osteoporosis, with a pelvic fracture.
Throughout the course of the disease, she maintained cutaneous and articular inflammatory activity, refractory to methotrexate, sulfasalazine, leflunomide, cyclosporine, adalimumab, etanercept, infliximab, and ustekinumab. Biologics were always used in combination with conventional DMARDs. She had an anaphylatic shock with infliximab, which was discontinued. For a while, she achieved a good response with the combination of adalimumab and cyclosporine, but eventually this also had to be discontinued due to acute kidney injury. At last, when she was 24 years old, we initiated secukinumab in combination with methotrexate.
Soon after induction therapy, she developed a community acquired pneumonia, requiring hospitalization, and demanding suspension of immunosuppressants. By the time of recovery from the infection, the cutaneous and articular disease was already inactive, and so persisted even after six months of discharge. For that reason, methotrexate was not reinstituted, and she stayed with secukinumab monotherapy.
To this date, two years after starting secukinumab, the patient maintains remission from articular and cutaneous symptoms. BASDAI 0.4, ASDAS-ESR 0.69, ASDAS-CRP 1.1, PASI 0.4.
This case suggests the potential usefulness of secukinumab for highly refractory psoriatic arthritis, even within a monotherapy scenario. Nevertheless, it also points to the possibility of severe infectious complications, associated with the treatment, requiring careful monitoring for prompt intervention throughout.
Consent for publication
P161 EFFECTS OF EXERCISE TRAINING PROGRAM ON ENDOTHELIAL FUNCTION AND STRUCTURAL PROPERTIES OF LARGE ARTERIES OF SYSTEMIC AUTOIMMUNE MYOPATHY
Rafael Giovane Missé2, Diego Sales De Oliveira2, Alexandre Moura Santos2, Jean Marcos Souza2, Bruno Gualano1, Ana Lúcia De Sá Pinto2, Valéria Aparecida Costa Hong3, Luiz Aparecido Bortolotto3, Samuel Katsuyuki Shinjo2
1ESCOLA DE EDUCAÇÃO FÍSICA E ESPORTES DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 2FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil; 3INSTITUTO DO CORAÇÃO DO HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, SÃO PAULO, Brasil
Background: Significant impairment in vascular structure and function has been described in several rheumatic diseases, including in a unique cross-sectional study with systemic autoimmune myopathies (SAM). These vascular abnormalities closely linked to cardiovascular diseases and their risk factors. Exercise training has useful tool for promotes reduction and control in these risks. In this context, the purpose of this study was to evaluate the effect of chronic exercise training in vascular structure and function in patients with SAM.
Methods: This quasi-prospective study included 5 adult female with SAM (2017 EULAR/ACR classification criteria: 3 dermatomyositis and 1 polymiositis). All patients underwent to carotid-femoral pulse wave velocity (PWV) and flow-mediated vasodilation (FMD) analysis achieved from brachial arterial above the antecubital fossa. Disease status was assessed with International Myositis Assessment & Clinical Studies Group (IMACS) core set measures. These exams were applied at baseline and after 12-week, twice weekly, exercise training program that was composed of 60 minutes of aerobic training and strength training composed of 7 exercises (leg press, bench press, leg extension, pulley, leg flexion, seated cable rows and abdominal exercises).
Results: Mean age of the patients was 48 years, whereas median disease duration was 8 years. All patients were clinically and laboratory stable, according to IMACS core set measures, using different immunosuppressive drugs and prednisone dose <10 mg/day. After exercise training, there was an increase in aerobic capacity and muscle strength (P<0.05). In vascular parameters, a reduction tendency with a high effect size was observed in endothelial function parameters (P=0.057; ES: 0.90), but not in arterial stiffness parameters (P=0.438; ES: 0.40).
Conclusion: In patients with clinical and laboratory stable SAM, exercise training promoted a reduction tendency in endothelial function, but not sufficient in arterial stiffness. Further studies with large sample are necessary to confirm these findings.
Support by: FAPESP #2016/19771-5 (DSO), #2016/23574-0 (RGM), #2017/13109-1 (SKS)
P165 EOSINOPHILIC FASCIITIS: DIAGNOSTIC USEFULNESS OF MAGNETIC RESONANCE IMAGING IN A SCLERODERMA-LIKE DISORDER
Bruna Giusto Bunjes, Marília Ambiel Dagostin, Douglas Amaral Moreira, Ana Paula Luppino Assad, Henrique Carriço da Silva, Percival Degrava Sampaio Barros
FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO FMUSP, SÃO PAULO, SÃO PAULO, Brasil
Background: Eosinophilic fasciitis (EF) is a rare disease characterized by symmetrical induration of the skin and inflammation of deep muscle fascia. The onset is typically acute and the clinical findings include erythema, swelling and thickening of the extremities, usually accompanied by peripheral blood eosinophilia, hypergammaglobulinemia and elevated erythrocyte sedimentation rate. Although the affected skin is somewhat similar to that observed in other scleroderma spectrum disorders, the skin of the hands and feet is generally spared.
Case Report: The authors describe the case of a 45-year-old woman who was referred to the Rheumatology Division of our institution due to symmetrical and progressive stiffness, induration and swelling of forearms and legs. As the patient also presented concomitant inflammatory arthralgia and dyspnea on moderate exertion, the diagnosis of systemic sclerosis (SSc) was initially considered. Laboratory tests presented peripheral eosinophilia, positive antinuclear antibodies (ANA), with negative antitopoisomerase I (antiScl70) and anticentromere antibodies. Deep skin biopsy showed a lymphomononuclear infiltrate associated with moderate thickening in fascia, compatible with EF. Magnetic resonance imaging (MRI) of lower and upper limbs showed diffuse thickening with hyperintense signal on T2 fascia, involving all muscle groups, sparing muscle belly. The initial treatment was with oral glucocorticoids with significant improvement.
Conclusion: EF should be considered as a differential diagnosis in fibrosing disorders. The early suspicion is important because, different from others scleroderma-like disorders, EF presents a good response to glucocorticoids. In our patient, MRI showed a good correspondence with anatomopathological data. Therefore, in cases with typical clinical findings, we can presume that MRI findings could possibly substitute deep skin biopsy.
Consent for publication
P166 EPIDEMIOLOGICAL CLINICAL PROFILE OF PATIENTS WITH SPONDYLOARTHRITIS IN THE CENTER-WEST REGION OF BRAZIL
Fabiana Pompeo De Pina, Lucas Carvalho Velloso De Oliveira, Lucas Alves Oliveira, Kleverton Augusto de Castro Siqueira
UNIVERSIDADE FEDERAL DE GOIÁS, GOIÂNIA, GO, Brasil
Background: The epidemiological, demographic and clinical characteristics of spondyloarthritis are variable according to the affected population. There are few studies conducted in the brazilian population. This study carries out a survey of the epidemiological clinical profile of patients diagnosed with spondyloarthritis in a university hospital in the center-west region of Brazil.
Methods: A retrospective analytical-descriptive study was carried out with a cross-sectional design, in which data in medical records from patients with established diagnosis of spondyloarthritis of the spondyloarthritis ambulatory of the Rheumatology Service of a University Institution in central-western region of Brazil were analyzed. The analyzed data were: gender, age, color, occupational disability, signs and symptoms of spondyloarthritis, extra-articular disorders, use of drugs to treat the disease, physical characteristics and metric (Schober, Occiput-to-wall), HLA-B27, evidence of ESR and CRP, functional assessment (BASFI) and disease activity (BASDAI), type of diagnosis and clinical form.
Results and Conclusions: Of the 49 medical records analyzed, 61.22% presented the diagnosis of ankylosing spondylitis, followed by 36.73% of cases with Psoriatic Arthritis and 2.04% with Enteropathic Arthritis. Of the total, 69.39% were male and 30.61% female. Mean age was 49.73 years. The patients most affected by some spondyloarthritis were the self-reported white with 46.81%, followed by the browns with 42.55% and blacks with 10.64%. Of these, 38.78% presented exclusively axial involvement; 34.69% axial and peripheral involvement; and 26.53% were exclusively peripheral. 38.78% of the analyzed patients reported work disability due to the disease. The Schober Test average for the total group analyzed was 13.84 cm; those of occiput-wall distance 24.33 cm; the number of inflamed joints had an average of 1.79; the number of inflamed entheses had an average of 1.05. Of the 42 patients in whom the functionality was assessed by BASFI, the mean was 4.83. Of the 41 patients in whom the disease activity was assessed by BASDAI, the mean was 4.83.26 patients underwent HLA-B27, 57.69% of whom were positive for the test. From the analysis of the data of these medical records, a greater prevalence of ankylosing spondylitis is observed than of the other forms. There is a slight prevalence of axial involvement. The male was the most affected, as were the white group. The important functional impact was also observed in these patients. This is an unpublished study in this federative unit of the center-west region of Brazil. The original data obtained, justify the importance of its accomplishment.
Érica Alves Nascimento, Andressa Borelli Sandos, Mariana Bomfim Menezes, Débora Larissa Montarroyos Leite
UNIVERSIDADE TIRADENTES, ARACAJU-SE, SE, Brasil
Introduction: Leprosy is a chronic and infectious disease caused by the Mycobacterium leprae, which has a high infective power but low pathogenicity and affects the skin and regions of the peripheral nervous system. It is transmitted directly from an infected person to another through the upper airways. In Brazil, it is an endemic disease and has compulsory notification. It is also classified as paucibacillary, when the patient has 1 to 5 lesions, showing a lower bacilli load and in multibacillary, when the patient has more than 5 lesions, showing a greater bacilli load.
Objective: To analyze the epidemiological profile of patients infected with Mycobacterium leprae between 2010 and 2017 in Brazil.
Methodology: Retrospective descriptive study that shows all leprosy cases presents in Brazil between 2010 and 2017. Epidemiological data were collected through the database of the Notification of Injury Information System (SINAN).
Results: There was a decrease in the number of Mycobacterium leprae infections between 2010 and 2015. From 2010 to 2015, the number of cases dropped from 42,433 to 35,131. In 2014, there was a small increase to 38,562 cases. In 2016, the number increased to 64,545, decreasing again in 2017, with 22,495 registered cases. Infections in men were higher than in women in all regions during the period analyzed. It is also observed a heterogeneous distribution of the number of cases recorded in the different Brazilian regions, which expose the socioeconomic differences of the country. Of the 323,182 cases registered, approximately 42% are in the Northeast region. The region with the lowest number of registered cases was the South, representing only 3.5% of the total. Infected patients, aged 20-64 years (economically active age group), represent the majority of the cases occurring between 2010 and 2017.
Conclusions: The study shows that there was a decrease in the number of leprosy cases registered in Brazil, however, this disease should not be neglected, since it affects mainly the economically active population. It is a disease, which, although incapacitating, is easily diagnosed and treated, as long as it occurs early. Because of this, the active search and compulsory notification by family health teams of suspected cases is so important.
Renata Lopes Francisco De Andrade, Aline Maria de Oliveira Rocha, Liana Soido Teixeira e Silva, Vânia Schinzel, Yuslay Fernández Zamora, Cristina Muccioli, Maria Teresa de Sande e Lemos Ramos Ascensão Terreri
UNIFESP, SÃO PAULO, SP, Brasil
Background: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic arthropathy in childhood. Among the extra-articular manifestations, the most frequent is chronic anterior uveitis. We aim to describe the cases of chronic anterior uveitis associated with JIA and the epidemiological characteristics, presence of autoantibodies, follow-up, complications and treatment.
Materials and methods: Retrospective analysis based on chart reviews of 329 JIA patients at the Pediatric Rheumatology outpatient clinic. The ophthalmologic evaluation was performed using a slit lamp with biomicroscopy by a specialized ophtalmologist.
Results and Conclusions: Among the analyzed patients, 32 (9.7%) presented uveitis. Of these, 26 (81.3%) were female, mean age at symptoms onset was 5.4 years (ranged from 8 months to 15 years), mean age at the diagnosis was 6.6 years (ranged from 2 to 15 years) and the mean time of disease follow-up 9.2 years. The mean time between the diagnosis of JIA and uveitis was 8.3 years (between 4 years before and 3.7 years after). FAN Hep2 positive was identified in 21 (65.6%) patients. No patient presented positive rheumatoid factor. According to the ILAR criteria, 20 (62.5%) patients belonged to the oligoarticular group and 12 (37.5%) to the rheumatoid factor negative polyarthritis. All patients received methotrexate as their initial DMARD, 16 oral prednisone, 8 cyclosporine, and 9 leflunomide. Fourteen patients (43.8%) were treatment refractory and needed biological drugs: 4 etanercept, 3 infliximab, 11 adalimumab and 1 had abatacept. Four of the 14 patients (28.6%) took more than one biological drug. In the follow-up, recurrent uveitis occurred in 23 patients (71.9%); of these, 11 presented only 1 recurrence, while the other 12 recurred between 2 and 9 times. Five (15.6%) patients had sequelae lesions, being 4 cataract (one with partial loss of vision), and one corneal opacity. FAN positivity, early age at diagnosis and female sex were related to uveitis development, although not predictors of severity. We concluded that our ocurrence of uveitis was similar to that found in the international literature and treatment refractoriness and recurrence were frequent.
P174 EVALUATION OF BODY COMPOSITION THROUGH BONE DENSITOMETRY IN PATIENTS SUBMITTED TO IMMUNOBIOLOGICAL THERAPY WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
Manuela Amoedo Cox1, Rafaela Amoedo Cox1, Ana Teresa Amoedo2
1UNIFACS, SALVADOR, BA, Brasil; 2UEFS, FEIRA DE SANTANA, BAHIA, Brasil
Background: The present study aims to establish a body mass analysis through double emission bone densitometry (BMD) in patients with rheumatoid arthritis (RA) and spondylarteritis (SPS) using assisted immunobiological therapy.
Materials And Methods: For this, the method of collecting data from the medical records of these patients was used in a private clinic in Feira de Santana. Through the study of scientific articles on the subject and the data collection, it is expected to better understand the relationship between body composition (BC) and these patients. These data have relevance, since it allows to know the health of the patients with RA and SPS in use of this therapy. All patients with RA and SPS, who uses the immunobiological therapy from January 2018 to March 2018, were included in this study.
Results And Conclusion: Twenty patients with RA and SPS, equally distributed, were evaluated, being 17 women and 3 men. The study of BC demonstrated normal bone mass (NBM) in the majority of patients, 85% in both pathology groups. 65% of the patients shown high fat percentage, 45% with overweight, 40% with normal BMI and only 5% of obesity. Concluding that in the present study, there was no change in BMD in the majority of patients in both groups; although AR and SPS are diseases with potential risk factors for bone loss, it can be explained by many other factors like drugs use or sedentary lifestyle. Other studies are needed to establish cause-effect change in the BC in patients using immunobiological therapy.
P175 EVALUATION OF BONE MASS THROUGH BONE DENSITOMETRY IN PATIENTS SUBMITTED TO IMMUNOBIOLOGICAL THERAPY WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
Rafaela Amoedo Cox1, Manuela Amoedo Cox1, Ana Teresa Amoedo2
1UNIFACS, SALVADOR, BAHIA, Brasil; 2UEFS, FEIRA DE SANTANA, BAHIA, Brasil
Background: The present study aims to establish a bone mass analysis through double emission bone densitometry (BMD) in patients with rheumatoid arthritis (RA) and spondylarteritis (SPS) using assisted immunobiological therapy. These data have relevance, since it allows to know the bone health of the patients with RA and SPS in use of this therapy.
Methods: This is a cross-sectional study, based on the collection of data from patients’ medical records with RA and SPS, submitted to immunobiological therapy at a private clinic in Feira de Santana-BA in the year 2018. Through the study of scientific articles on the subject and the data collection, it is expected to better understand the relationship between bone mass and these patients. All patients with RA and SPS, who uses the immunobiological therapy from January 2018 to March 2018, were included in this study.
Results And Conclusion: Twenty patients with RA and SPS, equally distributed, were evaluated, being 17 women and 3 men. The study of BMD in the lumbar spine and femur (total femoral neck) demonstrated normal bone mass (NBM) in the majority of patients, with 60%, 80% and 85%, respectively. The radio evaluation of 33% showed bone loss in 60% of the patients, with a predominance in the RA group. Concluding that in the present study, there was no change in BMD in the majority of patients in both groups; although they are potential risk factors for bone loss. Radio 33% demonstrated a greater alteration of BMD in patients with RA, which may be justified by the high frequency of wrist involvement in this pathology. Other studies are needed to establish cause-effect change in bone mass in patients using immunobiological therapy.
Francielle Santana Santos, Jussara Mathias Netto Khouri, Greice Nascimento Pires
UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, MACAE, RJ - RIO DE JANEIRO, Brasil
Multiple sclerosis (MS), as well as classical autoimmune diseases, predominate in women and there is evidence that heredity may influence the occurrence of these diseases. They also have in common the facts that sometimes the diagnosis of these conditions is difficult, mainly due to the variety of symptoms, involving one or multiple organs, demanding clinical criteria and specific complementary tests. One of the severity parameters of an autoimmune disease is determined by impairment of the central nervous system. Neurological manifestations in autoimmune diseases require investigating the existence of comorbidities with multiple sclerosis. Patient AF, 38 years old, female, Caucasian, coming from Aracaju. Multiple sclerosis diagnosed at age 32 and psoriasis. The treatment offered to this patient was made with Dimethyl Fumarate, derived from fumaric acid. The immunomodulatory properties of dimethyl fumarate in MS were extrapolated from the fumaric acid results in psoriasis. Dimethyl fumarate (DMF), the methyl ester of fumaric acid, is a new agent that was recently (2013) approved by Food and Drug Administration (FDA) and European Medicine Agency (EMA) for the management of relapsing forms of multiple sclerosis. Being an orally available agent with a favourable safety profi le, DMF has become one of the most commonly prescribed disease-modifying agents in the USA and Europe. DMF induces apoptosis of T cells. It was greater for CD8+ vs CD4+, as well as for memory vs naive, and conventional vs regulatory T-cell subsets. In addition, DMF infl uenced dendritic cells by a reduction in their IL-12 and IL-23 synthesis. This attenuation of myeloid antigenpresenting cells in turn reduced the differentiation of CD4+ Th cells into proinfl ammatory Th1 and Th17 cells, and increased the expression of the Th2 cytokine IL-4. A potential neuroprotective role of DMF has been postulated and is currently thought to be mediated by its action on nuclear factor NRF-2 in astrocytes, oligodendrocytes, and neurons. The binding of NRF-2 to its target genes leads to a transcription of ROS (reactive oxygen species) protective genes. At the moment there is still no consensus in the literature regarding the ideal treatment for patients with psoriasis, so it is important to individualize the treatment based on the clinical picture. There is a need for studies/research associating these diseases.
Consent for publication
Lettícia Cristina Santos Cardozo Roque1, Andréa Tavares Dantas2, Victória Pimentel Jatobá3, Rafaela Silva Guimarães Gonçalves2, Angela Luzia Branco Pinto Duarte2
1DEPARTAMENTO DE FISIOTERAPIA - UFPE, RECIFE, PE, Brasil; 2SERVIÇO DE REUMATOLOGIA - HC/UFPE, RECIFE, PE, Brasil; 3UNIVERSIDADE FEDERAL DE PERNAMBUCO, RECIFE, PE, Brasil
Background: Systemic sclerosis (SSc) is a chronic and severe disease, characterized by cutaneous and visceral involvement, presenting a high morbidity and mortality rate. The repercussions of the disease in the various systems are responsible for important functional impact and quality of life impairment. The objective of this study was to evaluate the functional disability in individuals with SSc and their association with clinical manifestations of the disease.
Methods: Descriptive and transversal study, with evaluation of 73 patients with SSc diagnosis. The data were obtained from the interview and review of the medical records. The disability was assessed using the Scleroderma Health Assessment Questionnaire (SHAQ), which contains questions about activities of daily life, as well as five additional domains assessing clinical manifestations of the disease through visual analog scale (VAS). Results were categorized into mild to moderate difficulty (score of 0 to <1), moderate to severe disability (score of 1 to <2) and severe to very severe disability (score of 2-3).
Results and Conclusions: Of the patients evaluated, 95.9% were female, at the average age of 46.0 (± 13.2) years and a median time of diagnosis of 60.5 months. Most of the patients had a limited cutaneous form (54.8%). The median of HAQ and SHAQ scores were 1.38 (0.25-1.88) and 1.13 (0.52-1.52) respectively, indicating moderate to severe disability. Regarding the clinical manifestations, the median values of VAS were: 5.0 cm for Raynaud's phenomenon, gastrointestinal complaints and digital ulcers, 3.0 cm for pulmonary symptoms and 6.0 cm for the general disease. About 43.8% of the patients were in the mild to moderate difficulty SHAQ category, 48.0% in the moderate to severe category and 8.2% in the severe to very severe category. Patients with the diffuse cutaneous form of the disease had a worse SHAQ score when compared to the limited form (1.38 and 0.91, respectively, p = 0.02). Patients with microstomia, arthralgia, myalgia, dysphagia, regurgitation, dyspepsia and dyspnea presented higher SHAQ scores compared to those without these clinical manifestations. In conclusion, patients with SSc have a significant impairment of functional capacity, especially those with diffuse cutaneous form, microstomia, musculoskeletal and gastrointestinal complaints. Measures to improve disability must be emphasized in SSc treatment protocols.
P179 EVALUATION OF HEALTH-RELATED QUALITY OF LIFE, SELF-ESTEEM, ANXIETY AND DEPRESSION IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING SCARS OF CUTANEOUS LUPUS
Rosa Weiss Telles1, Fernando Afrânio Palmeira de Oliveira2, Fabiana de Miranda Moura Santos2, Maria Veloso Rocha Mameluque2, Thiago Loredo e Silva2, Maria Isabel Menezes Guedes2, Maria Carolina Padovani Guerra2, Vinicius Ornela Bicalho2, Claudia Santoro Neiva3, Ana Flavia Madureira de Pádua Dias3, Rosa Weiss Telles2, Cristina Costa Duarte Lanna2
1FACULDADE DE MEDICINA DA UFMG, BELO HORIZONTE, MG, Brasil; 2FACULDADE DE MEDICINA - UFMG, BELO HORIZONTE, MG, Brasil; 3SANTA CASA DE MISERICÓRDIA, BELO HORIZONTE, MG, Brasil
Background: Few studies have analyzed health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) and cutaneous manifestations in the Brazilian population. Although it is known that active skin disease is related to poor HRQoL, it is not well defined if the indexes are maintained in inactive patients. The aim of this study was to describe HRQoL, self-esteem, anxiety and depression in inactive women with SLE and cutaneous scars on the face.
Methods: This is a cross-sectional, descriptive study with SLE women patients according to the ACR/1997 and/or SLICC/2012 criteria, included from September/2015 to March/2018. Patients were 18 years or older and had scars of cutaneous lupus on the face. Patients were excluded if they had moderate to severe systemic activity (SLEDAI 2k-modified>4), did not understand the questionnaires or had started psychological and/or psychiatric treatment within four weeks prior to inclusion. The following validated Brazilian-Portuguese questionnaires were applied: SLE-Quality of Life (SLEQOL), with scores varying from 40 to 280, and Dermatology Life Quality Index (DLQI), with scores varying from 0 to 30, of which higher values identify higher effect on HRQoL for both questionnaires; the Rosenberg Self-esteem Scale with scores varying from 10 to 40, of which higher scores identify higher self-esteem; and Hospital Anxiety and Depression scale (HADs) with scores varying from 0 to 21 for each disorder (scores above seven identify patients with signs of anxiety and/or depression separately).
Results and Conclusions: The mean (SD) age of the 56 outpatient women was 46.3 (11.6) years and the median (IQR) of modified SLEDAI-2k was 2 (2). The SLEQOL scores ranged from 53 to 216 with a median (IQR) of 111 (68.5), the DLQI scores ranged from 0 to 28 with a median (IQR) of 7 (11). The Rosenberg scale scores ranged from 22 to 40 with a median (IQR) of 29 (4). The HADs scores were higher than seven for depression in 48.3% of the patients and for anxiety in 60.7%, identifying cases of doubt and/or presence of signs of depression/anxiety. The study has shown in this group of SLE women presenting scars of cutaneous manifestations and low systemic disease activity an impairment in the HRQoL, in the self-esteem and in the mood/anxiety. This preliminary analysis indicates the need of strategies that could interfere positively in lupus patients’ quality of life.
P180 EVALUATION OF SENSITIVITY AND SPECIFICITY OF BECK DEPRESSION INVENTORY (BDI-II) TO DIAGNOSIS DEPRESSION IN HEALTHY INDIVIDUALS AND PATIENTS WITH RHEUMATOID ARTHRITIS
Rafael da Rocha Caminha2, Paulo Gabriel de Oliveira Cerquinho2, Flávia Jatobá de Barros2, Bruna Ferraz Gutierrez Piola2, Hugo Deleon de Lima1, Pedro Arturo Bismara Carneiro Santos1, Amanda Fernandes Vieira Mendes da Silva2, Leia Teixeira de Andrade1, Dennys Lapenda Fagundes1, Laurindo Ferreira da Rocha Junior1
1INSTITUTO DE MEDICINA INTEGRAL PROFESSOR FERNANDO FIGUEIRA - IMIP, RECIFE, PERNAMBUCO, Brasil; 2FACULDADE PERNAMBUCANA DE SAÚDE - FPS, RECIFE, PERNAMBUCO, Brasil
Background: The Beck Depression Inventory (BDI-II) is an instrument used worldwide to measure the severity of depressive episodes in clinical and non-clinical populations. The aim of this study is to evaluate the ability of BDI-II to diagnosis depression and calculate sensitivity and specificity of this instrument in identifying depression among healthy individuals and patients with Rheumatoid Arthritis (RA).
Methods: BDI-II was applied in two populations: RA patients and healthy individuals. For the calculation of associations of BDI-II values between the groups the Mann-Whitney test was used (software Graphpad prism 6.0). Optimum cut-off values were calculated to optimize sensitivity and specificity (i.e. the Young Index). Receiver-operating characteristic (ROC) were plotted (sensitivity against 100-specificity) and the areas under the ROC curves were calculated to assess the performance of BDI-II to distinguish individuals with depression from individuals with no depression. The gold standard method used for diagnosis of depression was the diagnosis criteria of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
Results And Conclusions: Ninety-eight patients with RA were included, of whom 40 (40.82%) were considered with depression according to DSM-5. Out Of the 31 healthy subjects who participated in the study, 2 (6.45%) were diagnosed with depression. We Stratified the participants in three groups: 1) RA patients 2) healthy subjects 3) RA patients and healthy subjects. The optimal cut-off value for BDI-II to distinguish subjects with depression was > 13 for all the three groups analyzed. With this optimal cut-off the yielded sensitivity of BDI-II to diagnosis depression was 100% (95% CI 92.6-100%) and specificity was 100% (95% CI 92.9-100%) in RA patients. For healthy controls the sensitivity was 100% (95% CI 39.8 – 100%) and specificity was 100% (95% CI 87.2 - 100%). For all the participants the yielded sensitivity was 100% (95% CI 93.2-100%) and specificity was 100% (95% CI 95.3-100%). The ability of BDI-II to distinguish depression from all subjects in the study demonstrated an AUC of ROC analysis of 1,000 (95% CI 0.972-1000) (Fig. 1). Numerical values of BDI-II may have the potential to be used as diagnostic markers in depression. Studies with a greater number of RA patients (with and without depression) and healthy controls are needed to better understand the role of BDI-II as a diagnostic tool for this purpose.
P181 EVALUATION OF THE CLINICAL AND DEMOGRAPHIC PROFILE OF PATIENTS WITH TERIPARATIDE THERAPY IN A TERTIARY HOSPITAL IN SÃO PAULO
Bernardo Patricio Sequeira Dultra, Denise Moraes Horiy, Andre Ozela Augusto, Dayrana Alves Lucena, Laís Farrapo de Barros Leite, Marcelo Nora Resende, Elaine de Azevedo, Rina Dalva Neubarth Giorgi
HOSPITAL SERVIDOR PÚBLICO ESTADUAL - SP, SÃO PAULO, SÃO PAULO, Brasil
Introduction: Teriparatide ((PTH[1-34]rh), fraction 1-34 of human recombinant parathyroid hormone, directly stimulates osteoblastic activity, restoring bone microarchitecture and promoting bone mass gain in the lumbar spine and femoral neck, with a consequent reduction in the risk of vertebral fractures in patients with osteoporosis, both men and women, whether or not glucocorticoid users. Objectives: Describe the demographic and clinical profile of patients with osteoporosis in current or previous treatment with PTH[1-34]rh in a tertiary hospital in the State of São Paulo.
Methods: An analytical-descriptive study, conducted in 2018, which included 42 patients with Osteoporosis in current or previous use of PTH[1-34]rh. Results: Among those included, 95.2% (N = 40) were women, with a mean age of 70.2 ± 10.8 years. The indication of the use of PTH[1-34]rh due to therapeutic failure with antireabsorbents (oral bisphosphonate, parenteral or Odanacatib) occurred in 59.5% (N = 25) of the patients; In 22.2% (N = 10) it was indicated because of Corticosteroid-induced osteoporosis; in 12.8% (N = 5) the exchange was performed after complication of the prolonged use of Bisphosphonate (Osteonecrosis of Jaw) and in another 4.8% (N = 2) was already used as first line therapy. Regarding the identified fractures, 90.5% (N = 38) of the patients had a history of at least one fragility fracture. The most prevalent fractures were vertebral 35.7% (N = 15) and femoral neck 31% (N = 13). About 1/3 of the cases (28.6%, N = 12) had a history of more than one fracture. The majority of cases, 76.2% (N = 32) are in current use of PTH[1-34]rh, while 23.8% (N = 10) already receive sequential post anabolic treatment: 14.3% (N = 6) with Denosumab and 9.5% (N = 4) with Zoledronic Acid. No cases of osteosarcoma were identified.
Conclusion: The profile of patients for whom anabolic therapy was indicated is compatible with the recommendations in the literature. It was observed that the most severe cases and those at high risk for fracture (patients already fractured, at high risk of falls or with very low bone mineral density), as well as who met criteria for therapeutic failure and those with adverse events to previous therapy, are the cases with most benefit from this type of treatment
P183 EVALUATION OF THE SERUM 25-HYDROXYVITAMIN D LEVEL IN DIFFERENT AGE GROUPS WITH EMPHASIS ON INFANTS AND ELDERLY OVER 60 YEARS
Fernanda Pulcheri Ramos, Matheus Xavier Guimarães, Andrey Tonetto Barbosa, Bernardo Patrício Sequeira Dultra, Kioko Takei, Daniela Crema, Rina Dalva Neubarth Giorgi, Elaine de Azevedo
HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL - SP, SÃO PAULO, SP, Brasil
Background: Vitamin D plays an important role in bone formation and reabsortion. The serum concentration of 25-hydroxyvitamin D (25OHD) is used to monitor. Among the risk groups for hypovitaminosis D, the following stand out: elderly (over 60 years), infants, pregnant women, individuals with osteoporosis and other osteometabolic diseases, chronic kidney disease, and disabsorptive syndrome. The recommended level in these groups should be between 30 and 60ng/dL, while for healthy people under 60 years levels above 20ng/dL are recommended. Adequate monitoring and supplementation of 25OHD should be performed in risk groups, since its deficiency is related to certain conditions such as rickets, osteomalacia and secondary hyperparathyroidism, thus increasing the risk of fractures. The objective of this study was to evaluate vitamin D levels in patients with different ages attended in a public tertiary hospital in São Paulo, focusing on two age groups at greatest risk for disability: infants (<2 years) and the elderly over 60 years.
Methods: This is a cross-sectional and analytical study where the results of 32.535 patients residing in the state of São Paulo, Brazil, who underwent 25OHD dosing between January and December 2016, regardless of socio-cultural habits, supplementation, solar exposure or diseases. Laboratory tests were performed on the Architect with Abbot 25-OH-VitaminaD kit 5P02 by the competitive immunoassay technique. The reference values for normality were based on the Official Positioning of the Brazilian Society of Clinical Pathology/Laboratory Medicine and the Brazilian Society of Endocrinology and Metabology published in December 2017.
Results: The overall calculated mean of all patients selected in the study, regardless of age, was 27.6 ± 9.0ng / dL. In infants (N = 92), the mean was 34.1 ± 12.7ng / dL, while in subjects older than 60 years (N = 16,667) it was 28.5 ± 9.5ng / dL. In this group over 60 years, 38.7% had adequate levels above 30ng / dL, most of them with levels between 21-30ng / dL (40.9%). Most infants had vitamin D levels above 30ng/dL (57.6%).
Conclusions: The data presented in the present study can conclude that in this population, unlike that described in the literature, infants had adequate levels of vitamin D, while the elderly, although not fully complying with the recommendation of the new guideline, are close to ideal, perhaps reflecting greater disclosure in recent years of the role of vitamin D among health professionals and the general public.
P185 EXERCISE TRAINING ATTENUATES INSULIN RESISTANCE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE MYOPATHIES
Diego Sales De Oliveira, Jean Marcos de Souza, Rafael Giovani Misse, Isabela Bruna Pires Borges, Alexandre Moura dos Santos, Marilda Guimarães Silva, Samuel Katsuyuki Shinjo
UNIVERSIDADE DE SÃO PAULO, CAMPO LIMPO PAULISTA, SP, Brasil
Background. Recently studies have demonstrated increase metabolic syndrome and insulin resistance in patients with systemic autoimmune myopathies (SAM). Exercise training has been reported as a coadjuvant in improve metabolic parameters in several autoimmune diseases, but not specifically in SAM. Therefore, the aim of the present study was to evaluate the effects of exercise training in insulin resistance in SAM.
Materials and Methods. This prospective cohort study engaged 7 patients (6 female and 1 male gender) with definite SAM (4 dermatomyositis, 2 antisynthetase syndrome and 1 polymyositis) to a 12-weeks, twice-a-week, exercise training program. All sessions started with strength training that was composed by 6 exercises using machines or assisting devices (horizontal leg press, horizontal bench press, let pull down, narrow-grip seated rows, weighted knee extensions and seated hamstring curl). After strength training, the patients performed aerobic exercises on a treadmill in a 30-50 min of moderate-intensity walk/running period. Baseline glucose, insulin and c-peptide were evaluated through blood sample. To evaluate insulin resistance, the oral glucose tolerance test (OGTT) was used before and after exercise training. The disease status was evaluated by International Myositis Assessment and Clinical Studies Group (IMACS) core set measures.
Results. Mean age of the patients was 45.6 years, with mean disease duration of 7.3 years. All patients have a stable disease, according to IMACS core set measures. At least one immunosuppressive drugs was used by all patients and glucocorticoids drugs in low dosage (<5mg) was used by just one patient. After exercise training program, there was no disease relapsing or auto-related events. In addition, there was an important increase in aerobic capacity, muscle strength and function in the patients (P<0.05). The area under curve (AUC) for glucose and baseline glucose has no change (P>0.05), while baseline insulin and baseline c-peptide has a decrease (insulin: 18.7±7.6 vs. 13.5±4.8uU/mL, P=0.104, effect size: 0.82; C-peptide: 4.0±1.0 vs. 3.0±0.4ng/mL, P=0.043, effect size: 1.31) after exercise training program. AUC for insulin and c-peptide has an important decrease after exercise training (P=0.025 and P=0.020, respectively) in the OGTT.
Conclusions. Exercise training was effective in attenuates insulin resistance and improve b-cell function in patients with SAM. This findings contributes to attenuate metabolic impairment and cardiovascular risks in these diseases.
Support by FAPESP #2016/19771-5 (DSO), #2016/23574-0 (RGM), #2016/20371-1 (IBPB), #2017/13109-1 (SKS), CAPES (MGS)
Karolyne Nogueira De Medeiros, Roberta Laís de Souza Bezerra, Ádala Nayana de Sousa Mata, Rafael BArros Gomes da Câmara
UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE, CAICÓ, RIO GRANDE DO NORTE, Brasil
Background: APS is a chronic disease characterized by thrombotic events, which can cause recurrent abortions. Being a chronic disease, there may be some impact on the lives of its patients. Thus, this study sought to evaluate the experience of a patient with APS, regarding their experience with the disease and its biological/psychological/social repercussions.
Methods: The research was developed through an interview with a SAF carrier. The interview method chosen was the McGill Illness Narrative Interview, and was done after approval of the Ethics Committee and signing of the TCLE.
Results And Conclusions: The difficulty of the diagnostic/therapeutic itinerary for rare diseases generates feelings of anguish, fear and doubt: “When I was hospitalized, I knew very little about my problem … I felt worried … I was afraid that was something recurring … The doctor even told me not to ask too many questions because even he did not know how to answer everything. Many do not even know which remedies I can take.” In addition to the better knowledge about APS, it is also important to take into account the patient’s longings: “He wrote the APS acronym on a paper, and said that I had it. He said that I would do the treatment for the rest of my life, which would have a normal life, but with restrictions … just told me that. My restrictions! I believe the treatment works, but I think the doctor should be something more present in my life.” According to data, chronic diseases have an impact on both subjectivity and their way of life. These repercussions can be alleviated in the face of social support, in the sense of knowing other people with the same health problem, and help in a greater coping capacity: “I would like to have more contact with people who have APS as a group, to share things.” It is observed as resources of support/confrontation cited by the patient, references to the family and spiritual support. The concept of health/illness is produced from the subjects’ experiences in knowledge and ways of thinking, which incorporate aspects related to pain, suffering, life and death. Thus, interpersonal relationships, such as the support of friends, family, health team, and faith, are important coping resources.
Consent for publication
P190 FAMILY HISTORY OF AUTOIMMUNE AND NON-AUTOIMMUNE DISEASES FROM A BRAZILIAN COHORT OF INITIAL RHEUMATOID ARTHRITS
Ana Paula Monteiro Gomides1, Ana Paula Faria de Carvalho2, Licia Maria Henrique da Mota2, Luciana Feitosa Muniz2, Talita Yokoy de Souza2, Andressa Junqueira Osório2, Luciana Teófilo Lourençoni2, Isabela de Sousa Russo2, Tassiane Raquel Cunha Martins de Moraes2
1UNB/UNICEUB, BRASILIA, DF, Brasil; 2UNB, BRASÍLIA, DF, Brasil
Iintroduction: Rheumatoid arthritis (RA) is a chronic and systemic disease in which genetic and environmental factors are involved in its etiology. In the literature we find epidemiological and genetic studies that suggest the familial aggregation of autoimmune diseases. In addition, the comorbidities commonly found in RA, such as arterial hypertension for example, may be common in first-degree relatives. The aim of this study was to evaluate family history in first-degree relatives of patients with RA.
Methods: Patients from an initial RA cohort were analyzed in a Brazilian university hospital. For the present study, a cross-sectional study was performed and the patients’ charts were analyzed from December 2016 to December 2017. Participants underwent routine clinical evaluation. The work was approved by the local ethics committee.
Results And Conclusions: We included 107 RA patients, 101 women and 5 men. The mean age was 62 years and 43% of the white race. The median time to illness was 12 years.
When we analyzed the first-degree relatives of the patients we verified that the non-autoimmune disease most common was hypertension (n=56, 52,33%), that was more prevalent in the mothers of patients with RA (n=31, 28,97%). The second most found non-autoimmune disease was diabetes mellitus (n=22, 20,56%), was also more common in the mothers of patients with RA (n=13, 12,14%).
A personal family history of rheumatoid arthritis (n=17, 15,88%) was the most prevalent data in this cohort for an autoimmune disease. It was more present in sisters of patients with RA.
The full evaluation can be seen in Table 1
This result, reasures the relevance of inquiring about RA family history, specially at the suspected diagnosis of RA. Environmental factors might contribute toward increased familial aggregation. The results for non-autoimmune diseases prevalences in family history, sugests the need for cardiovascular risk acessment in the RA patients.
Vívian Garcia Moreira, Rayla Felizardo Oliveira Marques, Fernando de Almeida Marques, Nayara Ramos Antelo, Caroline Kauscher Santa Rita, Fernando Henrique Souza, Flavio Ribeiro Pereira, Isabella Matias Ribeiro
SEMUSA, MACAÉ, RJ, Brasil
Background: Behçet’s disease (DB) is a multisystemic condition characterized by vasculitic lesions, affecting venous and arterial vessels of varying caliber. It may be associated with genetic factors with the presence of HLA-B51. It is manifested by recurrent oral and genital ulcers, cutaneous lesions, arthritis, uveitis, thrombophlebitis, and gastrointestinal and central nervous system implication. Vascular lesions may be associated with high morbidity and mortality, especially when associated with the existence of thrombi and aneurysms.
Case Report: MP, 55 years old, female, presenting weight loss, left knee arthritis, dislocating lumbosacral pain in the right knee, painful oral ulcer, prolonged fever, cicatricial lesions on the legs suggestive of folliculitis, in addition to normocytic and normochromic anemia and increased HSV. During the investigation, we discarded differential diagnoses such as chronic infections, neoplasms and other chronic inflammatory diseases, such as diffuse collagen diseases and inflammatory bowel disease. Patient evolved deep venous thrombosis in right lower limb and single genital ulcer. She was submitted to High Digestive Endoscopy which revealed multiple ulcers in gastric antrum. The paternal test was positive. Thus, Behçet’s disease was the main diagnostic hypothesis. Anticoagulation with rivaroxaban was initiated and immunomodulation with steroid and colchicine. She then evolved bilateral DVT associated with a 7 cm right femoral artery saccular aneurysm (Fig. 1), and then was submitted to immunosuppression with cyclophosphamide pulses. EcoDoppler and Cineangiocoronariography were performed and discarded evidence of aneurysms or thrombi in pulmonary artery and/or coronary arteries. Then she was submitted to surgical procedure, femoral bypass femoral vein with reversed major saphenous vein technique, evidencing the presence of ruptured aneurysm, with a satisfactory evolution on the postoperative period.
Conclusion: DB is a rare condition, with chronic evolution, acute outbreaks, an essentially clinical diagnosis, and no predilection for gender. It is important to point out that there is no evidence of the benefit of using anticoagulants for the management of venous or arterial thrombotic events in patients with this disease, since thrombi adhered to the vessel hardly result in embolic events. Pulmonary embolism is rare despite the high prevalence of DVT. Another reason for not recommending such drugs would be the high risk of fatal bleeding, given the high rate of pulmonary artery aneurysm; besides not reducing the recurrence of new thrombotic events. Thus, the best strategy for disease control is immunosuppression.
Consent for publication
Maira Sant Anna Genaro, Matheus Yung Perin
UNIVERSIDADE DE CUIABÁ, CUIABÁ, MT, Brasil
Background: Baggio-Yoshinari syndrome, also called Lyme-like disease (DL-S), is an infectious disease caused by spirochetes of the Borrelia burgdorferi complex and transmitted by ticks of the genera Amblyomma and Rhipicephalus. It is considered an emerging zoonosis in Brazil that shares clinical similarities with Lyme Disease (DL) found in North America and Eurasia. In Brazil, the first case of DL-simile was described in the 1990s and to date it has not been possible to isolate the spirochete from atypical morphology, even with the use of enriched culture media.
Case Report: A 29-year-old woman, previously living in Cuiabá, Mato Grosso, Brazil, with a history of pruritic cutaneous lesion of centrifugal growth on the left thigh, fatigue, and non cicatricial alopecia for more than fifteen days. At the afebrile physical examination, macular lesion with erythematous borders and light center, on the lateral side of the left thigh. The complementary tests showed antibodies against Borrelia burgdorfer IgM 3,1 and IgG 95, positive according to the reference. The patient presented complete response to systemic therapy after 12 weeks of the treatment, without reporting constitutional symptoms in this period.
Conclusion: Characterization according to LIM-17 HCMUSP criteria are higher criteria: clinical manifestations (erythema migrans or systemic symptoms), epidemiological evidence (tick bite, endemic region, contact with animals or rural area) and positive serology; the minor criteria are: recurrent episodes, fatigue, arthralgia, myalgia, paresthesia and cognitive disorders, and identification of the spirochete in the dark field. For diagnosis it is considered 3 major criteria or 2 major and 2 minor.
The patient presented, according to LIM-17 protocol, three major criteria: reactive serology, migratory erythema and epidemiological data.
Thus, the first case of Boggio-Yoshinari syndrome occurred in the State of Mato Grosso and the sequence of clinical reasoning necessary for the diagnostic elucidation was presented.
Consent for publication
P194 FOLATE SUPPLEMENTATION ASSOCIATED WITH METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS: SYSTEMATIC REVIEW
Debora P Souza, Ana Carolina Londe, Antonio de Azevedo Barros Filho, Simone Appenzeller
UNICAMP, SP, SP, Brasil
Background: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in childhood, with a prevalence ranging from 7 to 150/100,000 children. It is defined by onset of disease before age 16 and persistent arthritis for more than six weeks after exclusion of other causes. The main characteristic of the disease is chronic arthritis, and may also present systemic involvement and lead to permanent functional disability outcomes. Patients with JIA commonly use Anti-Rheumatic Disease Modifying Drugs (DMARDs), capable of attenuating clinical evolution and leading to remission of the disease. Methotrexate is a DMARD, analogue of folic acid. Folate supplementation is indicated to decrease the gastrointestinal and hepatotoxic adverse effects of methotrexate, but its efficacy in JIA is not well defined. The aim of this study was to perform a systematic literature review whether supplementation of folic or folinic acid may decrease the efficacy of MTX and whether it is able to reduce or ameliorate the adverse effects caused by MTX in JIA.
Methods: We conducted the systematic review in the literature, through the sensitive search strategy, in the Pubmed, BVS, Cochrane and Embase databases, from September to October 2017, searching for published studies in the last 22 years, including MESH terms: folic acid; arthritis, juvenile; methotrexate and their synonyms.
Results and conclusions: We identified 108 studies, after removal of the duplicates, 90 were sorted through the abstract, 87 were excluded because they did not meet the objective of the study, and 3 were considered eligible. The Hunt et al (1997) was a randomized double blind study conducted in a short period of 13 weeks including only 18 patients, being considered a moderate quality study due to unknown selection and allocation bias; the study of Ravelli et al (1999), uncontrolled retrospective included 43 patients and was not controlled, featuring a study with high risk of bias; and the study of Modesto et al (1996), case report with 3 patients, considered a low level of scientific evidence. It was concluded that despite the widespread use of folate supplementation to prevent adverse effects related to the use of MTX in JIA, there is a lack of evidence to support this practice, so it is necessary to conduct a well-designed clinical trial to support a regimen of supplementation.
Roberta Lais De Souza Bezerra, Karolyne Nogueira de Medeiros
UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE, CAICO, RN, Brasil
Background: APS corresponds to the association of thrombotic events with repetitive abortions and/or thrombocytopenia, in the presence of specific antibodies. The pathogenesis of APS has not been fully elucidated yet, however, it is known that autoantibodies when interacting with negatively charged phospholipids from membranes generate immune complexes that are deposited in vessels and predispose to formation of clots, generating a prothrombotic condition. The diagnosis is given through the association of clinical and laboratory criteria, but there are cases that not have clinical or laboratory evidence, or associated with other autoimmune diseases. Even today, there is a lack of information about APS, both in the literature and in clinical practice, causing their diagnosis to be postponed and favoring the development of complications in the patient. In this way, the search for a deeper understanding of the disease contributes to its early diagnosis and better management of the patients. Thus, this work sought to make a case report of a patient with APS, highlighting the main events from the onset of symptoms to the implementation of appropriate treatment.
Case Report: R.F.S, 35-year-old female, from Currais Novos-RN, started with epigastric pain, 10/10 intensity associated with dyspnea, with irradiation to the cervical region, investigated with endoscopy. It was evidenced gastritis, which had its treatment initiated. Subsequently, with the maintenance and progression of the condition, an abdominal ultrasonography was performed which showed an echogenic image in the splenic vein, suggestive of thrombus, leading to the patient's hospitalization for treatment and better investigation by computed tomography (CT). CT scan (Fig. 1) revealed tomographic signs of thrombosis of the splenic vein and the intrahepatic portion of the portal vein, as well as of its main and peripheral branches. In addition, serology was positive for IgM-ACL on two occasions, confirming the diagnosis of APS, and treatment with warfarin, food care and indication of physical exercise.
Conclusion: Although the incidence of APS has grown since its description, its diagnosis is still difficult to achieve. Thus, the more detailed knowledge about its clinical manifestations and pathogenesis end up favoring the diagnosis, treatment and quality of life of the affected patients.
Consent for publication
P196 GIANT CELL ARTERITIS ASSOCIATED WITH MYOPERICARDITIS AS A PARANEOPLASIC MANIFESTATION OF COLON ADENOCARCINOMA
Jeane Oliveira Da Silva, Igor da Fonseca Rangel, Lionete Gall Acosta Filha, Marília Daniela Silveira da Silva, Beatriz Gonçalves Batista Lamounier, Belisia Vasconcelos de Barros, Maria Isabel Dutra Souto, Laura Hoffmann de Segadas Soares, Afonso Celso de Oliveira Senos
UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, RIO DE JANEIRO, RJ, Brasil
Backgroud: Giant cell arteritis (GCA) is a chronic inflammation vasculitis of large and medium arteries wall, mainly affecting extracranial branches of the carotid artery. It is the most common vasculitis in people over 50 years, with a peak incidence in the 70-80 year age group. A few case reports have described rare myopericarditis manifestations in temporal arteritis disease. In addiction, rheumatic diseases can be associated with malignant diseases characterizing a paraneoplastic syndrome and concurrent malignancy in GCA is observed in up to 7,4% of cases. The objective of this case report is to describe an illustrative rare case about an elderly man with temporal arteritis evolving with myopericarditis and associated with colon tubular adenocarcinoma.
Case Report: A 79-year-old black m